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ABSTRACT	  
Increasing	   evidence	   highlights	   that	   term	   labour	   is	   an	   inflammatory	   event	   associated	  
with	  increased	  production	  of	  pro-­‐inflammatory	  mediators	  and	  leukocyte	  influx	  into	  the	  
intrauterine	   tissues.	   	   Preterm	   labour	   (PTL),	   defined	   as	   labour	   before	   37	   weeks	  
gestation,	  is	  a	  major	  clinical	  problem,	  and	  preterm	  birth	  is	  the	  leading	  cause	  of	  neonatal	  
mortality	   and	   morbidity	   worldwide.	   	   The	   causes	   of	   PTL	   are	   poorly	   understood,	   but	  
intrauterine	   infection	   and	   inflammation	   have	   been	   shown	   to	   be	   important	   factors.	  	  
Therefore,	  there	  is	  growing	  interest	  in	  the	  hypothesis	  that	  preterm	  labour	  may	  occur	  as	  
a	   result	  of	   the	  premature	  activation	  of	   the	   inflammatory	  pathways	  normally	   initiated	  
with	  labour	  at	  term,	  either	  idiopathically,	  or	  in	  response	  to	  a	  pathological	  intrauterine	  
infection.	  	  	  
	  
The	   aim	   of	   this	   thesis	   was	   to	   use	   a	   mouse	   model	   of	   infection-­‐induced	   PTL	   to:	  
characterise	  the	  local	  inflammatory	  and	  immune	  response	  to	  an	  intrauterine	  infection;	  
investigate	   the	  potential	  of	  anti-­‐inflammatory	  agents	   to	  delay	  delivery	  of	  pups	  and	   to	  
improve	  their	  survival;	  and	  to	  investigate	  the	  role	  of	  specific	  immune	  cell	  populations	  
in	  infection-­‐induced	  preterm	  labour.	  	  	  	  	  
	  
To	  characterise	  the	  inflammatory	  and	  immune	  response	  to	  intrauterine	  infection,	  CD1	  
mice	  received	  an	  intrauterine	  injection	  of	  PBS	  vehicle	  or	  increasing	  doses	  of	  bacterial-­‐
derived	   lipopolysaccharide	   (LPS)	   on	   day	   17	   of	   gestation.	   	   Time	   to	   delivery,	   and	   the	  
number	  of	   live	  born	  pups	  were	  determined.	   Intrauterine	  administration	  of	   increasing	  
doses	  of	  LPS	  dose-­‐dependently	  induced	  preterm	  labour	  and	  reduced	  the	  proportion	  of	  
live	  born	  pups.	  	  Analysis	  of	  tissues	  harvested	  six	  hours	  post-­‐surgery	  demonstrated	  that	  
in	   response	   to	   intrauterine	   LPS	   administration,	   there	   was	   increased	   expression	   of	  
inflammatory	   cytokines	   and	   chemokines	   within	   the	   utero-­‐placental	   tissues,	   amniotic	  
fluid	  and	  maternal	  serum;	  and	  an	   influx	  of	  neutrophils	   into	   the	  decidua,	   compared	   to	  
mice	  receiving	  PBS.	  
	  
Given	   these	   results,	   the	   potential	   of	   anti-­‐inflammatory	   agents	   to	   delay	   LPS-­‐induced	  
preterm	   delivery	   and	   improve	   pup	   survival	   was	   then	   investigated	   using	   the	   same	  
mouse	  model.	   	   Prior	   to	   intrauterine	   LPS	   administration,	  mice	  were	   pre-­‐treated	  with	  
epi-­‐lipoxin,	   BML-­‐111	   (a	   stable	   lipoxin	   analogue),	   or	   IL-­‐10.	   	   Time	   to	   delivery	   was	  
unaffected	   by	   pre-­‐treatment	   with	   the	   anti-­‐inflammatory	   agents,	   however	   epi-­‐lipoxin	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significantly	   increased	   the	   proportion	   of	   live	   born	   pups	   in	   mice	   delivering	   preterm,	  
compared	  to	  mice	  receiving	  only	  LPS.	  	  	  
	  
To	   further	   investigate	   the	   role	   of	   immune	   cells	   in	   infection-­‐induced	   PTL,	   antibody-­‐
based	   depletion	   strategies	   were	   used	   to	   selectively	   deplete	   specific	   immune	   cell	  
populations	  to	  determine	  whether	  they	  played	  a	  causative	  role	  in	  LPS-­‐induced	  preterm	  
delivery.	  	  Despite	  successful	  depletion	  of	  macrophages	  or	  neutrophils,	  it	  was	  not	  found	  
to	  significantly	  affect	  LPS-­‐induced	  preterm	  delivery,	  suggesting	  these	  immune	  cells	  are	  
not	  required	  for	  the	  induction	  of	  preterm	  labour	  in	  response	  to	  intrauterine	  infection.	  	  
However,	  it	  is	  likely	  that	  they	  contribute	  to	  the	  intrauterine	  inflammatory	  response	  as	  
depletion	  resulted	  in	  altered	  inflammatory	  signalling	  within	  the	  intrauterine	  tissues.	  	  	  
	  
Collectively,	   this	   work	   has	   demonstrated	   that	   the	   presence	   of	   intrauterine	   bacterial	  
LPS,	   as	   a	   surrogate	   model	   of	   infection,	   induces	   a	   robust	   inflammatory	   and	   immune	  
response	  within	   the	  utero-­‐placental	   tissues	   that	   involves	   the	   increased	  production	  of	  
inflammatory	   mediators	   and	   the	   influx	   of	   immune	   cells	   into	   the	   decidua,	   which	  
ultimately	   leads	   to	  PTL.	   	  Whilst	   the	  anti-­‐inflammatory	   treatments	   tested	  here	  did	  not	  
delay	   LPS-­‐induced	   PTL,	   epi-­‐lipoxin	   attenuated	   LPS-­‐induced	   mortality	   in	   pups	   born	  
preterm,	  suggesting	  this	  anti-­‐inflammatory	  agent	  may	  be	  useful	  in	  protecting	  the	  fetus	  
from	  the	  adverse	  effects	  of	  infection-­‐induced	  preterm	  birth.	  	  Using	  models	  such	  as	  the	  
one	  described	  here,	  are	  vital	  to	   improving	  our	  understanding	  of	  the	  events	  regulating	  
the	  induction	  of	  PTL	  and	  will	  ultimately	  aid	  the	  search	  for	  novel	  therapeutic	  options	  for	  
the	  treatment	  of	  PTL.	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1.1 INTRODUCTION	  
Although	  the	  exact	  mechanisms	  controlling	  the	  onset	  of	  parturition	  in	  humans	  remain	  
incompletely	  understood,	  there	  is	  now	  strong	  evidence	  that	  labour	  is	  an	  inflammatory	  
process	  associated	  with	  increased	  production	  of	  inflammatory	  cytokines	  and	  leukocyte	  
influx	  into	  the	  utero-­‐placental	  tissues.	  	  The	  timing	  of	  the	  initiation	  of	  this	  inflammatory	  
cascade	  must	  be	  tightly	  regulated	  as	  the	  premature	  activation	  of	  these	  events	  can	  result	  
in	  preterm	  labour.	   	   In	  contrast,	  delayed	  activation	  results	   in	  post-­‐term	  pregnancy	  and	  
increased	   perinatal	  mortality.	   	   Preterm	   labour	   (defined	   as	   labour	   prior	   to	   37	  weeks	  
gestation)	   is	  a	  major	  clinical	  problem	  worldwide	  and	   is	   the	   leading	  cause	  of	  neonatal	  
mortality	  and	  morbidity.	  	  Although	  the	  causes	  of	  preterm	  labour	  are	  poorly	  understood,	  
intrauterine	   infection	   and	   inflammation	   are	   important	   causal	   factors	   in	   many	   cases.	  	  
This	  chapter	  introduces	  the	  concept	  that	  labour	  is	  an	  inflammatory	  event	  and	  discusses	  
the	  role	  of	   intrauterine	   infection	  as	  a	  cause	  of	  preterm	  labour.	   	  The	   ineffectiveness	  of	  
currently	  available	  treatments	  for	  preterm	  labour	  is	  discussed	  and	  the	  potential	  use	  of	  
anti-­‐inflammatory	  agents	  as	  novel	  therapeutic	  agents	  is	  then	  considered.	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1.2 LABOUR:	  AN	  INFLAMMATORY	  EVENT	  
The	   physiological	   process	   of	   parturition	   involves	   three	   main	   processes:	   cervical	  
ripening	   and	   dilation,	   rupture	   of	   the	   fetal	   membranes,	   and	   the	   development	   of	  
synchronous	  myometrial	  contractions,	  resulting	  in	  successful	  delivery	  of	  the	  fetus.	  	  It	  is	  
clear	   that	   the	   timing	   of	   the	   initiation	   of	   labour	   must	   be	   tightly	   controlled,	   as	   the	  
premature	   onset	   of	   labour	   can	   result	   in	   preterm	   birth	   (delivery	   prior	   to	   37	   weeks	  
gestation),	  which	   is	   the	   leading	  cause	  of	  neonatal	  mortality	  and	  morbidity	  worldwide	  
(Goldenberg	  et	  al.	  2008).	  	  However,	  despite	  intensive	  research	  over	  recent	  decades,	  the	  
molecular	   mechanisms	   responsible	   for	   regulating	   the	   initiation	   of	   labour	   remain	  
relatively	  poorly	  understood.	  	  Over	  recent	  years,	  strong	  evidence	  has	  emerged	  that	  the	  
process	   of	   parturition	   shares	   many	   characteristics	   with	   a	   classical	   inflammatory	  
response,	   including	   leukocyte	   influx	   and	   increased	   production	   of	   pro-­‐inflammatory	  
mediators	   in	   the	   intrauterine	   tissues,	   leading	   to	   the	   now	  well-­‐accepted	   concept	   that	  
labour	  is	  an	  inflammatory	  event.	  	  	  
	  
1.2.1 Immune	  cells	  and	  parturition	  
Some	   of	   the	   earliest	   evidence	   associating	   labour	   and	   inflammation	   came	   from	  work	  
examining	  the	  process	  of	  cervical	  ripening	  more	  than	  30	  years	  ago,	  where	  it	  was	  shown	  
that	   cervical	   ripening	  was	   characterised	   by	   an	   influx	   of	   neutrophils	   into	   the	   cervical	  
stroma	   (Junqueira	   et	  al.	   1980,	   Liggins	   1981).	   	   Since	   these	   early	   studies,	  more	   recent	  
work	  has	  confirmed	  that	  both	  neutrophils	  and	  macrophages	  infiltrate	  the	  cervix	  either	  
just	   prior	   to,	   or	   at	   the	   onset	   of	   labour	   (Bokström	   et	  al.	   1997,	   Osman	   et	  al.	   2003).	   	   A	  
similar	   leukocyte	   influx	   during	   labour	   at	   term	   has	   also	   been	   reported	   in	   the	  
myometrium,	   fetal	  membranes	   and	   decidua	   (Thomson	   et	  al.	   1999,	   Keski-­‐Nisula	   et	  al.	  
2000,	  Osman	  et	  al.	   2003,	  Osman	  et	  al.	   2006,	  Gomez-­‐Lopez	  et	  al.	   2009,	  Hamilton	  et	  al.	  
2012).	   	  Additionally,	  Yuan	  et	  al.	  also	  reported	  increased	  activation	  of	  peripheral	  blood	  
leukocytes	  at	  onset	  of	  labour	  (Yuan	  et	  al.	  2009).	  	  	  
The	   recruitment	   of	   leukocytes	   from	   peripheral	   blood	   into	   tissues	   involves	   two	  main	  
processes,	   the	   production	   of	   chemotactic	   signals,	   and	   increased	   expression	   of	   cell	  
adhesion	  molecules.	   	   Chemokines	   are	   a	   subfamily	   of	   cytokines	  which	   are	   involved	   in	  
directing	  leukocyte	  migration	  to	  the	  site	  of	  tissue	  injury/inflammation	  and	  promoting	  
their	   activation	   (Simon	   et	   al.	   1998).	   	   Leukocytes	   are	   recruited	   to	   the	   intrauterine	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tissues	  in	  response	  to	  chemotactic	  signals	  released	  by	  the	  gestational	  tissues	  (Gomez-­‐
Lopez	   et	   al.	   2009,	   Gomez-­‐Lopez	   et	   al.	   2010).	   	   Cell	   adhesion	   molecules	   are	   proteins	  
expressed	  on	  the	  cell	  surface	  of	  circulating	  immune	  cells	  and	  the	  vascular	  endothelium,	  
which	  are	  involved	  in	  the	  recruitment,	  adhesion	  and	  migration	  of	  leukocytes	  from	  the	  
circulation	   into	   target	   tissues	   during	   an	   inflammatory	   response	   (Bevilacqua	   1993).	  	  
During	   labour,	   increased	   expression	   of	   several	   cell	   adhesion	   molecules,	   such	   as	  
intercellular	   cell	   adhesion	   molecule-­‐1	   (ICAM-­‐1),	   platelet	   endothelial	   cell	   adhesion	  
molecule	   (PECAM),	   vascular	   cell	   adhesion	  molecule	   (VCAM)	   and	   e-­‐selectin	   has	   been	  
reported	   in	   the	   cervix,	   myometrium	   and	   fetal	   membranes	   (Thomson	   et	   al.	   1999,	  
Ledingham	   et	   al.	   2001,	   Osman	   et	   al.	   2004),	   suggesting	   that	   these	   molecules	   are	  
involved	  in	  regulating	  the	  labour-­‐associated	  immune	  cell	  influx	  into	  the	  utero-­‐placental	  
tissues.	  	  
These	   infiltrating	   leukocytes	   contribute	   to	   the	   local	   intrauterine	   inflammatory	  
environment	  by	  producing	  a	  number	  of	  pro-­‐inflammatory	  mediators	  (Roh	  et	  al.	  2000,	  
Helmig	  et	  al.	  2002,	  Young	  et	  al.	  2002),	  which	  can	  stimulate	   labour	  progression	  (these	  
will	   be	   discussed	   in	   greater	   detail	   in	   the	   next	   section).	   	   Although	   neutrophils	   and	  
macrophages	  are	  the	  predominant	  immune	  cells	  infiltrating	  the	  intrauterine	  tissues	  in	  
association	   with	   labour,	   there	   are	   other	   immune	   cell	   populations	   present	   at	   the	  
maternal-­‐fetal	  interface	  which	  could	  contribute	  to	  the	  labour-­‐associated	  inflammatory	  
response,	  including	  T	  cells,	  uterine	  NK	  cells	  and	  mast	  cells	  (Gomez-­‐Lopez	  et	  al.	  2010).	  	  	  
	  
1.2.1.1 Neutrophils	  
Neutrophils	   are	   one	   of	   three	   leukocyte	   subtypes	   collectively	   known	   as	   granulocytes	  
(which	  also	  include	  eosinophils	  and	  basophils)	  characterised	  by	  a	  distinct	  multi-­‐lobed	  
nucleus	   and	   numerous	   granules	   (there	   are	   at	   least	   four	   types	   of	   granules	   in	   human	  
neutrophils).	   	   They	   are	   synthesised	   continuously	   from	  myeloid	  precursor	   cells	   in	   the	  
bone	   marrow	   and	   are	   usually	   released	   into	   the	   circulation	   as	   mature	   terminally	  
differentiated	  cells.	  	  They	  are	  the	  most	  abundant	  population	  of	  leukocytes	  in	  circulating	  
human	   blood	   (approximately	   70%	   of	   total	   circulating	   leukocytes	   are	   neutrophils)	  
(Leitch	  et	  al.	   2008).	   	  Neutrophils	   play	   important	   roles	   in	   acute	   inflammation	   and	   are	  
usually	  the	  first	   leukocytes	  to	  be	  recruited	  to	  an	  inflammatory	  site.	   	   In	  response	  to	  an	  
infection,	   they	   have	   multiple	   effector	   mechanisms	   to	   neutralise	   and	   eliminate	  
pathogens,	   these	   include:	   phagocytosis,	   degranulation	   and	   release	   of	   antibacterial	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proteins	  (e.g.	  defensins	  and	  cathespins);	  production	  of	  reactive	  oxygen	  species	  (e.g.	  O2-­‐
);	  and	  formation	  of	  neutrophil	  extracellular	  traps	  (NETS),	  which	  can	  immobilise	  and	  kill	  
pathogens	   extracellularly.	   Additionally,	   neutrophils	   are	   an	   important	   source	   of	   pro-­‐
inflammatory	  mediators,	  (e.g.	  leukotriene	  B4),	  cytokines	  (e.g.	  IL-­‐1),	  chemokines	  (e.g.	  IL-­‐
8)	   and	   matrix	   metalloproteinases	   (MMPs,	   particularly	   MMP-­‐9)	   (Kolaczkowska	   and	  
Kubes	   2013).	   	   Many	   of	   these	   factors	   can	   exacerbate	   the	   inflammatory	   response	   by	  
causing	  the	  recruitment,	  activation	  and	  increased	  longevity	  of	  neutrophils	  (Leitch	  et	  al.	  
2008,	   Fox	   et	  al.	   2010)	   and	   other	   inflammatory	   cells,	   including	  macrophages	   (Nathan	  
2006).	  	  
	  
1.2.1.2 Macrophages	  	  
Macrophages,	   which	   are	   usually	   derived	   from	   circulating	   monocytes,	   are	   found	   in	  
almost	  all	  tissues	  of	  the	  body,	  where	  they	  have	  important	  roles	  in	  a	  diverse	  number	  of	  
processes,	   including	  development,	  homeostasis,	   repair	  and	   immune	  responses	   (Wynn	  
et	  al.	  2013).	  	  Macrophages	  can	  be	  divided	  based	  on	  the	  tissue	  in	  which	  they	  are	  located	  
in	   the	   body,	   for	   example	   lung	   macrophages	   are	   termed	   alveolar	   macrophages,	  
macrophages	   in	   the	  bone	  are	  termed	  osteoblasts,	  and	  macrophages	   found	   in	  the	   liver	  
are	   called	   Kupffer	   cells.	   	   These	   tissue-­‐resident	   macrophages	   are	   involved	   in	  
maintaining	   normal	   tissue	   homeostasis	   by	   constantly	   monitoring	   for	   signs	   of	   tissue	  
damage	  and	  phagocytosing	  dead	  or	  dying	  cells	  (Murray	  and	  Wynn	  2011).	  	  Macrophages	  
can	   have	   important	   pro-­‐	   and	   anti-­‐inflammatory	   actions.	   	   In	   response	   to	   a	   pathogen,	  
macrophages	   phagocytose	   the	   invading	   organism	   and	   release	   a	   number	   of	   pro-­‐
inflammatory	  mediators	   (e.g.	   TNF-­‐α	   and	   IL-­‐1β)	   that	   can	   activate	   other	   immune	   cells	  
and	  drive	   the	   inflammatory	  response;	   these	  pro-­‐inflammatory	  activated	  macrophages	  
have	  been	  previously	  classified	  as	  M1	  macrophages.	   	  However,	  macrophages	  are	  also	  
important	   in	   driving	   the	   resolution	   of	   inflammation	   and	   tissue	   repair,	   by	   producing	  
anti-­‐inflammatory	  cytokines	  (e.g.	  IL-­‐10)	  and	  growth	  factors	  (e.g.	  TGF-­‐β)	  and	  removing	  
apoptotic	   cells	   from	   the	   tissue,	   these	   have	   been	   classically	   termed	  M2	  macrophages	  
(Murray	  and	  Wynn	  2011).	   	   	   Interestingly,	   specialised	   ‘resolution-­‐phase	  macrophages’	  
have	  been	   identified	   in	  mice,	  which	   generally	   have	   an	  M2	  phenotype,	   but	  which	   also	  
express	  classical	  M1	  markers,	  such	  as	  COX-­‐2,	  alongside	  other	  markers	  which	  promote	  
the	  resolution	  of	  inflammation	  (Bystrom	  et	  al.	  2008,	  Stables	  et	  al.	  2011).	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1.2.2 Inflammatory	  mediator	  production	  and	  parturition	  
Further	  evidence	  that	   labour	   is	  an	   inflammatory	  event	  comes	  from	  data	  showing	  that	  
co-­‐incident	  with	  the	  onset	  of	  parturition	  and	  the	  influx	  of	  immune	  cells	  into	  the	  utero-­‐
placental	  tissues,	  there	  is	  also	  increased	  production	  of	  inflammatory	  mediators	  in	  these	  
tissues	  which	   are	   proposed	   to	   have	  multiple	   actions	   in	   stimulating	   cervical	   ripening	  
and	   dilation,	   fetal	   membrane	   rupture	   and	   myometrial	   contractility,	   the	   three	  
fundamental	   processes	   of	   labour.	   	   The	   inflammatory	   mediators	   that	   play	   important	  
roles	   in	   the	   onset	   and	   progression	   of	   parturition	   include	   cytokines	   and	   chemokines,	  
prostaglandins,	  and	  MMPs.	  	  	  
	  
1.2.2.1 Cytokines	  and	  chemokines	  
Cytokines	  are	  a	  family	  of	  small	  glycoprotein	  signalling	  molecules	  that	  are	  produced	  by	  
both	   immune	   and	   non-­‐immune	   cells	   in	   the	   body	   and	   act	   locally	   to	   regulate	  multiple	  
biological	   processes	   (Saito	   2000).	   	   Most	   focus	   is	   on	   their	   role	   in	   regulating	  
inflammatory/immune	   responses;	   indeed	   there	   is	   strong	   evidence	   that	   cytokines	   are	  
important	   in	   regulating	   many	   reproductive	   processes	   associated	   with	   inflammation,	  
particularly	  during	  pregnancy.	   	  As	  previously	  described,	   chemokines	  are	  a	  sub-­‐family	  
of	  cytokines	  which	  have	  specific	  chemoattractant	  activities.	  	  Chemokines	  mediate	  their	  
effects	  via	  binding	   to	  specific	  G-­‐protein-­‐coupled	  receptors	   that	  are	  expressed	  on	  both	  
immune	   cells	   and	   many	   other	   cell	   types	   in	   the	   body.	   	   Cytokines	   work	   together	   in	  
complex	   networks,	   where	   they	   can	   work	   synergistically	   together,	   or	   antagonise	   the	  
actions	   of	   other	   cytokines.	   	   Two	   other	   unique	   properties	   of	   cytokines	   include	  
pleiotropism,	   that	   is	   they	   can	   act	   on	   multiple	   target	   cells	   to	   produce	   different	  
responses;	   and	   functional	   redundancy,	  where	  multiple	   cytokines	   can	  act	  on	   the	   same	  
cell	   to	   produce	   the	   same	   effect	   (Paulesu	   et	   al.	   2010).	   	   	   The	   roles	   of	   a	   number	   of	  
chemokines	  and	  cytokines	  in	  pregnancy	  and	  parturition	  have	  been	  well	  reviewed	  (Orsi	  
and	  Tribe	  2008,	  Gomez-­‐Lopez	  et	  al.	  2010,	  Paulesu	  et	  al.	  2010).	  	  	  
The	   onset	   of	   labour	   is	   associated	   with	   increased	   expression	   of	   pro-­‐inflammatory	  
cytokines	  and	  chemokines,	  including	  the	  pro-­‐inflammatory	  cytokines,	  tumour	  necrosis	  
factor	   alpha	   (TNF-­‐α),	   interleukin	   (IL)-­‐1β,	   IL-­‐6,	   and	   the	   chemokine,	   IL-­‐8	   in	   the	   cervix,	  
decidua,	   fetal	  membranes	  myometrium	  and	  placenta	  (Elliott	  et	  al.	  2000,	  Sennstrom	  et	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al.	   2000,	   Young	   et	   al.	   2002,	   Osman	   et	   al.	   2003).	   	   Additionally,	   recent	   microarray	  
analysis	   comparing	   gene	   expression	   in	   myometrium,	   cervix	   and	   fetal	   membranes	  
obtained	   from	   labouring	  and	  non-­‐labouring	  women	  at	   term,	   confirmed	   that	   labour	   is	  
associated	  with	  a	  core	  inflammatory	  response	  in	  these	  tissues,	  with	  chemokines	  being	  
some	  of	  the	  most	  highly	  up-­‐regulated	  genes	  associated	  with	  labour	  (Haddad	  et	  al.	  2006,	  
Bollapragada	  et	  al.	  2009).	   	   Increased	  production	  of	  inflammatory	  mediators,	   including	  
IL-­‐6,	   TNF-­‐α,	   chemokine	   (C-­‐C	   motif)	   ligand	   2	   (CCL2,	   also	   known	   as	   MCP-­‐1),	   and	  
chemokine	   (C-­‐X-­‐C	   motif)	   ligand	   5	   (CXCL5,	   also	   known	   as	   ENA-­‐78),	   has	   also	   been	  
described	   in	   the	   amniotic	   fluid	   of	   women	   in	   spontaneous	   labour	   at	   term,	   compared	  
with	   non-­‐labouring	  women	   (Olah	   et	  al.	   1996,	  Maymon	   et	  al.	   1999,	   Esplin	   et	  al.	   2003,	  
Keelan	  et	  al.	  2004).	  	  
These	   cytokines	   and	   chemokines	   can	   further	   perpetuate	   the	   local	   inflammatory	  
environment	   by	   further	   promoting	   leukocyte	   recruitment,	   activating	   inflammatory	  
signalling	   pathways,	   such	   as	   the	   NF-­‐κB	   pathway,	   and	   by	   inducing	   the	   production	   of	  
other	   inflammatory	  mediators	  which	   can	   stimulate	   the	   processes	   of	   fetal	  membrane	  
rupture,	  cervical	  ripening	  and	  dilation,	  and	  myometrial	  contractions.	   	  In	  vitro,	  both	  IL-­‐
1β	  and	  TNF-­‐α	  increase	  expression	  of	  the	  proteases,	  MMPs	  (So	  et	  al.	  1992,	  Arechavaleta-­‐
Velasco	  et	  al.	  2002),	  while	  decreasing	  expression	  of	  their	  inhibitors,	  tissue	  inhibitor	  of	  
metalloproteinases	  (TIMP)	  (So	  et	  al.	  1992).	  	  The	  expression	  of	  MMPs	  and	  TIMPs	  in	  the	  
cervix	   is	  similarly	  affected	  by	  pro-­‐inflammatory	  cytokines	   in	  vitro	   (Watari	  et	  al.	  1999,	  
Yoshida	  et	  al.	  2002).	   	   IL-­‐1β	   and	  TNF-­‐α	   can	  also	  stimulate	  myometrial	   contractility	  by	  
increasing	  calcium	  entry	  and	  concentration	   in	  myometrial	  smooth	  muscle	  cells	  (Tribe	  
et	   al.	   2003,	   Barata	   et	   al.	   2004)	   and	   by	   up-­‐regulating	   the	   production	   and	   activity	   of	  
prostaglandins	  in	  the	  myometrium,	  by	  increasing	  expression	  of	  cyclooxygenase	  (COX)-­‐
2,	   and	   their	   receptors	   (Pollard	   and	  Mitchell	   1996,	   Rauk	   and	   Chiao	   2000,	   Olson	   et	  al.	  
2003,	  Sooranna	  et	  al.	  2006,	  Duggan	  et	  al.	  2007).	  	  
	  
1.2.2.2 Prostaglandins	  
Prostaglandins	   are	   another	   class	   of	   important	   inflammatory	   mediators	   involved	   in	  
parturition.	   	   	  They	  are	  arachidonic	  acid-­‐derived	   lipid	  mediators	   that	  are	  produced	  by	  
most	  cell	  types	  in	  the	  body.	  	  Phospholipase	  enzymes	  release	  arachidonic	  acid	  from	  the	  
phospholipid	   cell	   membrane,	   allowing	   it	   to	   be	   converted	   to	   the	   intermediate	  
prostaglandin,	   prostaglandin	   endoperoxide	   H2	   (PGH2)	   by	   the	   actions	   of	   the	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prostaglandin	   endoperoxidase	   synthase	   (PTGS)	   enzymes	   1	   and	   2	   (more	   commonly	  
known	  as	  COX-­‐1	  and	  COX-­‐2).	   	  COX-­‐1	   is	  constitutively	  expressed	   in	  tissues	  throughout	  
the	  body,	  whereas	  COX-­‐2	  expression	   is	  up-­‐regulated	  by	  cytokines	  and	  growth	  factors.	  	  
This	   intermediate	   prostaglandin	   is	   then	   converted	   by	   the	   action	   of	   specific	  
prostaglandin	   synthases	   into	   active	   prostaglandins,	   such	   as	   PGE2,	   PGF2α	   and	   PGD2.	  	  
Prostaglandins	   are	   produced	   and	   act	   locally,	   and	   are	   rapidly	   metabolised	   by	   the	  
enzyme	   15-­‐hydroxyprostaglandin	   dehydrogenase	   (15-­‐HPGD),	   which	   breaks	   them	  
down	  into	  inactive	  15-­‐keto	  metabolites	  (Olson	  2003).	  	  	  	  
The	  expression	  of	  COX-­‐2	  increases	  with	  the	  onset	  of	  spontaneous	  labour	  at	  term	  in	  the	  
fetal	  membranes,	  decidua	  and	  myometrium	  (Hirst	  et	  al.	  1995,	  Slater	  et	  al.	  1995,	  Hirst	  et	  
al.	   1998,	   Slater	   et	   al.	   1999);	   and	   the	   production	   of	   PGE2	  and	   PGF2α	   from	   the	   amnion,	  
myometrium,	  decidua	  and	  amniotic	  fluid	  is	  increased	  during	  spontaneous	  term	  labour	  
(Willman	  and	  Collins	  1976,	  Bennett	  et	  al.	  1993,	  Erkinheimo	  et	  al.	  2000,	  Lee	  et	  al.	  2008).	  	  
In	  addition,	  increased	  expression	  of	  the	  specific	  PGE2	  and	  PGF2α	  receptors	  has	  also	  been	  
reported	   during	   term	   labour	   in	   the	   fetal	   membranes	   and	   decidua	   (Unlugedik	   et	   al.	  
2010).	   	   Several	   studies	   have	   demonstrated	   that	   prostaglandins	   can	   simulate	  
myometrial	   contractions	   (Dyal	   and	   Crankshaw	   1988,	   Senior	   et	   al.	   1993),	   fetal	  
membrane	   rupture	   (McLaren	   et	   al.	   2000,	   Keelan	   et	   al.	   2001)	   and	   cervical	   ripening	  
(Fletcher	  et	  al.	  1993,	  Kelly	  et	  al.	  2009).	  
	  
1.2.2.3 MMPs	  
MMPs	   are	   a	   family	   of	   zinc-­‐dependent	   protease	   enzymes	   that	   are	   involved	   in	  
degradation	   of	   extracellular	  matrix	   proteins.	   	  MMPs	   affect	   a	  wide	   range	   of	   biological	  
processes,	   including	   tissue	  morphogenesis,	  wound	  repair	  and	   inflammation.	  They	  are	  
secreted	  by	  a	  wide	  range	  of	  tissues	  and	  their	  production	  can	  be	   induced	  by	  cytokines	  
and	  growth	  factors.	   	  The	  production	  of	  MMPs	  is	  tightly	  regulated	  by	  the	  production	  of	  
their	  endogenous	   inhibitor	  proteins,	  TIMPs	   (Sternlicht	  and	  Werb	  2001).	   	   	  Given	   their	  
well-­‐defined	  role	  in	  tissue	  breakdown	  and	  remodelling,	  MMPs	  play	  important	  roles	  in	  
the	  processes	  of	  cervical	  ripening	  and	  fetal	  membrane	  rupture.	   	   	  Several	  studies	  have	  
reported	   increased	   MMP	   expression,	   particularly	   MMP-­‐2	   and	   MMP-­‐9,	   in	   association	  
with	   spontaneous	   labour	   at	   term	   in	   the	  myometrium,	   fetal	  membranes,	   placenta	   and	  
cervix	   (Stygar	   et	   al.	   2002,	   Xu	   et	   al.	   2002,	   Yoshida	   et	   al.	   2002,	   Choi	   et	   al.	   2007);	   co-­‐
incident	  with	  decreased	  TIMP	  expression	  (Riley	  et	  al.	  1999).	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1.2.3 Role	  of	  NF-­‐κB	  activation	  in	  parturition	  
Central	   to	   the	   dramatic	   increase	   in	   pro-­‐inflammatory	   mediator	   production	   with	   the	  
onset	  of	  parturition,	   is	  the	  transcription	  factor,	  nuclear	  factor-­‐κB	  (NF-­‐κB).	   	  NF-­‐κB	  is	  a	  
key	   transcription	   factor	   involved	   in	   regulating	   the	   transcription	  of	   a	  wide	  number	  of	  
genes,	   but	   is	   classically	   linked	   to	   inflammation	   and	   immune	   responses	   (Hayden	   and	  
Ghosh	   2004).	   There	   are	   five	   different	   transcription	   factors	   involved	   in	   the	   NF-­‐κB	  
pathway,	  these	  are	  p50,	  p52,	  p65,	  c-­‐REL	  and	  RELB;	  these	  transcription	  factors	  interact	  
with	  one	  another	  to	  form	  either	  homo-­‐	  or	  hetero-­‐dimers	  which	  can	  bind	  to	  specific	  κB	  
sequences	   on	   target	   genes	   to	   regulate	   their	   transcription.	   	  Normally,	   in	   unstimulated	  
cells,	   NF-­‐κB	   is	   held	   inactive	   in	   the	   cell	   cytoplasm	   by	   the	   actions	   of	   its	   endogenous	  
inhibitor	  proteins,	  the	  IκB	  proteins.	   	  In	  response	  to	  an	  inflammatory	  stimulus,	  such	  as	  
IL-­‐1β,	   TNF-­‐α,	   or	   bacterial	   lipopolysaccharide	   (LPS),	   the	   IκB	   inhibitor	   protein	   is	  
phosphorylated	   by	   the	   actions	   of	   the	   IκB	   kinase	   enzymes,	   usually	   IKKβ,	   leading	   to	  
subsequent	   ubiquitination	   and	   proteosomal	   degradation	   of	   the	   IκB	   inhibitor	   protein,	  
thus	  freeing	  the	  NFκB	  dimer	  to	  translocate	  to	  the	  nucleus	  of	  the	  cell	  where	  it	  can	  bind	  
to	   specific	   NF-­‐κB	   DNA	   binding	   sites	   to	   regulate	   the	   transcription	   of	   target	   genes	  
(Hayden	  and	  Ghosh	  2004).	  	  	  
Two	   recent	   reviews	  have	  discussed	   the	   role	  of	  NF-­‐κB	   in	   regulating	   the	   inflammatory	  
events	   surrounding	   the	   onset	   of	   human	   parturition	   (Lindstrom	   and	   Bennett	   2005,	  
Lappas	   and	   Rice	   2007).	   	   There	   are	   conflicting	   reports	   regarding	   changes	   in	   NF-­‐κB	  
activity	   in	   the	   intrauterine	   tissues	   in	   association	   with	   labour.	   	   There	   have	   been	   a	  
number	   of	   studies	   which	   have	   reported	   increased	   NF-­‐κB	   activity	   and	   nuclear	  
localisation	   of	   p65	   in	   amnion	   (Allport	   et	   al.	   2001,	   Lee	   et	   al.	   2003,	   Lim	   et	   al.	   2012),	  
decidua	  (Yan	  et	  al.	  2002,	  Vora	  et	  al.	  2010)	  and	  myometrium	  (Condon	  et	  al.	  2006,	  Vora	  
et	   al.	   2010)	   collected	   from	   women	   in	   labour,	   compared	   to	   non-­‐labouring	   women;	  
however,	   other	   studies	   have	   not	   observed	   any	   significant	   changes	   in	   NF-­‐κB	   activity	  
when	  comparing	  amnion	  and	  myometrial	  tissues	  obtained	  from	  women	  pre-­‐	  and	  post-­‐
labour	   (Yan	  et	  al.	   2002,	  Vora	  et	  al.	   2010,	  Khanjani	  et	  al.	   2011),	   although	  nuclear	   p65	  
staining	  was	  observed,	  suggesting	  activation	  of	  NF-­‐κB	  prior	   to	   labour	  onset.	   	  There	   is	  
considerable	   in	  vitro	  evidence	  that	  demonstrates	  a	  role	   for	  NF-­‐κB	  in	   the	  regulation	  of	  
several	   key	   pro-­‐inflammatory	   genes	   associated	  with	   labour.	   	   Blocking	  NF-­‐κB	   activity	  
has	   been	   reported	   to:	   inhibit	   inflammatory	   cytokine	   expression,	   including	   IL-­‐8,	   IL-­‐6	  
and	  TNF-­‐α	   in	  amnion	  and	  cervical	  epithelial	  cells	  (Elliott	  et	  al.	  2001)	  and	  amnion	  and	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chorio-­‐decidua	  tissue	  (Lappas	  et	  al.	  2003);	  inhibit	  COX-­‐2	  expression	  and	  prostaglandin	  
production	   in	   amnion	   and	   myometrial	   cells	   (Lindstrom	   and	   Bennett	   2005);	   and	  
decrease	   MMP	   activity	   in	   amnion	   and	   chorio-­‐decidual	   tissues	   (Lappas	   et	   al.	   2003)	  
Additionally,	   a	   recent	   study	   using	   a	   cDNA	   microarray	   to	   examine	   NF-­‐κB-­‐regulated	  
genes	  in	  myocytes	  obtained	  from	  women	  at	  term	  demonstrated	  that	  NF-­‐κB	  activation	  
up-­‐regulated	   the	   expression	   of	   a	   number	   of	   genes	   related	   to	   inflammation	   and	  
immunity	   in	  pregnant	  myometrium	   (Khanjani	  et	  al.	   2011).	   	   Collectively	   these	   studies	  
demonstrate	  an	  important	  role	  for	  NF-­‐κB	  in	  regulating	  the	  production	  of	  inflammatory	  
mediators	  within	  the	  utero-­‐placental	  tissues	  in	  association	  with	  parturition.	  	  	  
	  	  
	  
1.2.4 Steroid	  hormones	  and	  parturition	  	  
1.2.4.1 Progesterone	  
Progesterone	  is	  the	  main	  steroid	  hormone	  produced	  throughout	  pregnancy	  in	  humans,	  
initially	   by	   the	   corpus	   luteum,	   and	   then	   by	   the	   placenta,	   and	   plays	   a	   crucial	   role	   in	  
maintaining	   uterine	   quiescence	   throughout	   gestation.	   	   Evidence	   that	   progesterone	   is	  
required	  for	  the	  maintenance	  of	  pregnancy	  comes	  from	  studies	  which	  demonstrate	  that	  
removal	   of	   the	   corpus	   luteum	   or	   administration	   of	   progesterone	   receptor	   (PR)	  
antagonists	   during	   the	   first	   trimester	   of	   pregnancy	   led	   to	   pregnancy	   loss	   (Csapo	   and	  
Pulkkinen	   1978,	   Peyron	   et	   al.	   1993).	   	   It	   is	   proposed	   that	   progesterone	   maintains	  
uterine	   quiescence	   during	   pregnancy	   via	   anti-­‐inflammatory	   actions,	   which	   will	   be	  
discussed	   in	   greater	   detail	   later.	   	   The	   exact	   mechanisms	   by	   which	   progesterone	  
maintains	   uterine	   quiescence	   are	   still	   being	   investigated,	   but	   are	   thought	   to	   include:	  
inhibiting	  the	  expression	  of	  contraction-­‐associated	  proteins	  (CAPs),	  such	  as	  connexin-­‐
43	   and	   oxytocin	   receptors;	   inhibiting	   prostaglandin	   production	   by	   inhibiting	   COX-­‐2	  
expression;	   and	   inhibiting	   inflammatory	   signalling,	   via	   blocking	   of	   NF-­‐κB	   activity	  
(Loudon	  et	  al.	  2003,	  Renthal	  et	  al.	  2010,	  Mesiano	  et	  al.	  2011,	  Tan	  et	  al.	  2012).	  	  
In	  most	  species,	  labour	  is	  preceded	  by	  a	  sharp	  drop	  in	  circulating	  progesterone	  levels,	  
which	  is	  not	  observed	  in	  humans,	  suggesting	  that	  a	  decline	  in	  progesterone	  levels	  is	  not	  
required	   for	   the	   onset	   of	   labour	   in	   humans.	   	   However,	   as	   administration	   of	   the	   PR	  
antagonist,	  mifepristone	   (or	  RU486)	  can	  be	  used	   to	   ripen	   the	  cervix	  and	   increase	   the	  
responsiveness	  of	  the	  uterus	  to	  contractile	  agents	  (Chwalisz	  et	  al.	  1991,	  Frydman	  et	  al.	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1992,	   Elliott	   et	   al.	   1998),	   this	   suggests	   that	   some	   form	   of	   progesterone	   withdrawal,	  
locally	  within	  the	  uterus,	  is	  important	  to	  the	  initiation	  of	  parturition.	  	  This	  has	  led	  to	  the	  
hypothesis	   that	   in	   humans	   at	   term	   there	   is	   a	   functional	   progesterone	   withdrawal,	  
which	   results	   in	   a	   local	   reduction	   in	   responsiveness	   of	   the	   uterus	   to	   the	   actions	   of	  
progesterone.	   	   The	  mechanisms	  by	  which	   this	   functional	   progesterone	  withdrawal	   is	  
proposed	   to	   come	   about	   include:	   changes	   in	   PR	   isoform	   ratios	   in	   the	   myometrium,	  
where	   there	   is	   increased	   expression	   of	   the	   inhibitory	   PR-­‐A	   isoform,	   resulting	   in	   an	  
increase	  in	  the	  PR-­‐A/PR-­‐B	  ratio	  (Pieber	  et	  al.	  2001,	  Mesiano	  et	  al.	  2002,	  Merlino	  et	  al.	  
2007);	  increased	  local	  progesterone	  metabolism	  (Mitchell	  and	  Wong	  1993,	  Williams	  et	  
al.	  2012);	  negative	  interactions	  between	  NF-­‐κB	  and	  the	  PR	  (Allport	  et	  al.	  2001);	  and	  a	  
decline	  in	  the	  expression	  of	  PR	  co-­‐activators,	  cAMP-­‐response	  element-­‐binding	  protein	  
(CREB),	  and	  steroid	  receptor	  co-­‐activators,	  which	  may	  impair	  PR	  function	  (Condon	  et	  al.	  
2003).	  	  	  
	  
1.2.4.2 Estrogen	  
The	   role	   of	   estrogens	   in	   regulating	   the	   inflammatory	   cascade	   associated	   with	  
parturition	  is	  less	  clear.	  	  Estrogen	  can	  stimulate	  myometrial	  contractility	  by	  increasing	  
the	  expression	  of	  CAPs,	  such	  as	  COX-­‐2,	  connexin-­‐43	  and	  oxytocin	  receptor	  (Pinto	  et	  al.	  
1966,	  Petrocelli	  and	  Lye	  1993,	  Mesiano	  et	  al.	  2002).	  	  Estrogen	  is	  produced	  throughout	  
gestation,	  with	  circulating	  estrogen	  levels	  gradually	  increasing	  from	  mid-­‐gestation	  until	  
birth,	  but	  there	  is	  no	  evidence	  of	  increased	  circulating	  estrogen	  in	  association	  with	  the	  
initiation	  of	  labour	  in	  women	  (Tulchinsky	  et	  al.	  1972,	  Boroditsky	  et	  al.	  1978);	  however,	  
it	   has	   been	   proposed	   that	   similar	   to	   the	   functional	   progesterone	   withdrawal,	  
parturition	   involves	   functional	   estrogen	   activation	   (Mesiano	   and	   Welsh	   2007).	  	  
Estrogen	   receptor	   α	   (ERα)	   expression	   is	   increased	   in	   labouring	   myometrium,	  
compared	   to	   non-­‐labouring,	   co-­‐incident	   with	   decreased	   PR-­‐B	   expression,	   suggesting	  
that	   during	   pregnancy	   progesterone	   attenuates	   the	   actions	   of	   estrogen	   by	   inhibiting	  
ERα	  expression,	  and	  at	  the	  time	  of	  functional	  progesterone	  withdrawal,	  increased	  ERα	  
expression	  allows	  estrogen	  to	  act	  on	  the	  uterus	  to	  stimulate	  contractions	  (Mesiano	  et	  al.	  
2002).	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1.2.5 Initiation	  of	  the	  inflammatory	  response	  at	  term	  
Therefore,	  whilst	   there	   is	   now	   strong	   evidence	   that	   labour	   is	   an	   inflammatory	   event,	  
the	  mechanisms	  responsible	   for	   initiating	   the	   inflammatory	  cascade	  normally	  at	   term	  
remain	  unclear.	  	  Mechanical	  stretch	  of	  the	  uterus,	  which	  occurs	  at	  the	  end	  of	  gestation,	  
is	   one	   mechanism	   that	   has	   been	   proposed	   to	   initiate	   labour.	   	   In	   vitro	   studies	   have	  
demonstrated	   that	   myometrial	   cells	   respond	   to	   stretch	   by	   increasing	   chemokine	  
expression	   and	   expression	   of	   COX-­‐2	   via	   activation	   of	   both	   the	   NF-­‐κB	   and	   MAPK	  
signalling	   pathways	   (Loudon	   et	   al.	   2004,	   Sooranna	   et	   al.	   2004,	   Hua	   et	   al.	   2012);	   and	  
similar	  effects	  of	  stretch	  have	  been	  reported	  in	  amnion	  epithelial	  cells	  in	  vitro	  (Mohan	  
et	  al.	  2007).	  	  	  The	  effect	  of	  stretch	  on	  myometrial	  chemokine	  production	  has	  also	  been	  
confirmed	   in	   vivo,	  where	   Shynlova	   et	   al.,	   reported	   that	   in	   a	   unilateral	   pregnant	   rat	  
model,	  expression	  of	  Ccl2	  was	  much	  greater	  in	  uterine	  tissue	  taken	  from	  the	  pregnant	  
uterine	   horn,	   which	   had	   been	   stretched	   as	   the	   implanted	   fetuses	   grew	   through	  
gestation,	  compared	  to	  the	  empty,	  non-­‐pregnant	  horn	  (Shynlova	  et	  al.	  2008).	  	  	  
Another	   hypothesis	   to	   explain	   how	   the	   inflammatory	   cascade	   of	   labour	   is	   normally	  
initiated	   involves	   the	  production	  of	  a	   signal	   from	  the	  maturing	   fetus	   that	   triggers	   the	  
onset	   of	   parturition.	   	   Surfactant,	   a	   protein	   produced	   by	   the	   maturing	   fetal	   lung,	   is	  
proposed	  to	  be	  an	  important	  fetal	  trigger	  for	   labour.	   	  Condon	  et	  al.,	  reported	  that	   in	  a	  
mouse	  model,	  surfactant	  protein	  secretion	  into	  the	  amniotic	  fluid	  by	  the	  maturing	  fetal	  
lung	  from	  day	  17	  of	  gestation	  onwards,	  was	  associated	  with	  increased	  IL-­‐1β	  expression	  
in	   amniotic	   fluid	  macrophages	   and	   NF-­‐κB	   activation	   in	   the	   uterus;	   and	   showed	   that	  
injection	  of	  surfactant	  protein	  A	  into	  the	  amniotic	  fluid	  of	  mice	  on	  day	  15	  of	  gestation	  
induced	   preterm	   labour	   (Condon	   et	   al.	   2004).	   	   Additionally,	   amniotic	   fluid-­‐derived	  
surfactant	   protein	   has	   been	   reported	   to	   increase	   PGE2	   release	   from	   cultured	   amnion	  
discs	   in	   vitro,	   suggesting	   that	   surfactant	   can	   be	   a	   source	   of	   arachidonic	   acid	   for	  
prostaglandin	  synthesis,	  which	  may	  also	  initiate	  labour	  in	  humans	  (Lopez	  Bernal	  et	  al.	  
1988).	  	  However,	  the	  importance	  of	  surfactant	  in	  inducing	  labour	  has	  been	  questioned,	  
as	   over-­‐expression	   of	   surfactant	   protein	   in	   mice	   was	   not	   found	   to	   induce	   labour	  
(Salminen	   et	   al.	   2011);	   and	   other	   studies	   have	   questioned	   the	   	   role	   of	   surfactant	   in	  
inducing	  labour	  in	  humans	  (Lee	  et	  al.	  2010).	  
Interestingly,	  a	  recent	  study	  investigating	  whether	  mice	  deficient	  in	  surfactant	  proteins	  
had	   delayed	   onset	   of	   parturition	   highlighted	   the	   complexity	   in	   understanding	   the	  
mechanisms	   responsible	   for	   initiating	   labour.	   	   Montalbano	   et	   al.,	   reported	   that	   mice	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deficient	   in	   surfactant	   proteins	   A	   and	   D	   delivered	   normally	   during	   their	   first	  
pregnancies,	   but	   demonstrated	   a	   significant	   delay	   in	   delivery	   in	   their	   second	  
pregnancies,	   suggesting	   that	   the	   initiation	   of	   labour	   is	   likely	   to	   be	   a	   multifactorial	  
process,	  which	  may	  also	  be	  affected	  by	  parity	  (Montalbano	  et	  al.	  2013).	  	  	  
	  	  
	  
1.3 PRETERM	  LABOUR	  
1.3.1 The	  incidence	  and	  consequences	  of	  preterm	  labour	  
Preterm	  labour,	  defined	  as	  the	   initiation	  of	   labour	  prior	  to	  37	  weeks	  of	  gestation,	   is	  a	  
major	  clinical	  problem	  which	  is	  estimated	  to	  affect	  between	  5	  and	  18%	  of	  pregnancies	  
annually	   across	   the	   world,	   resulting	   in	   around	   15	   million	   preterm	   births	   each	   year	  
(March	  of	  Dimes	  2012).	   	  In	  Scotland,	  in	  2011,	  around	  7.3%	  of	  all	  births	  were	  preterm	  
(ISD	  Scotland	  2012).	   	  The	   incidence	  of	  preterm	  birth	   in	  recent	  decades	  has	  remained	  
relatively	  unchanged,	  with	  some	  studies	  actually	  demonstrating	  an	  increase	  in	  the	  rate	  
of	  preterm	  birth	  in	  many	  developed	  countries	  including	  the	  USA	  and	  the	  UK	  (Norman	  et	  
al.	   2009,	   Blencowe	   et	   al.	   2012).	   	   Despite	   advances	   in	   the	   medical	   care	   of	   preterm	  
infants,	  preterm	  birth	   remains	   the	   leading	   cause	  of	  neonatal	  mortality	   and	  morbidity	  
worldwide,	   and	   has	   been	   estimated	   to	   account	   for	   up	   to	   75%	   of	   neonatal	   deaths	  
(Goldenberg	  et	  al.	  2008),	  with	  more	  than	  one	  million	  babies	  dying	  each	  year	  due	  to	  the	  
complications	   of	   their	   premature	   birth	   (March	   of	   Dimes	   2012).	   	   Indeed,	   although	   a	  
greater	   number	   of	   premature	   infants	   now	   survive,	   with	   77%	   of	   babies	   born	   at	   26	  
weeks	   of	   gestation	   in	   the	   UK	   now	   leaving	   hospital	   (Costeloe	   et	   al.	   2012),	   premature	  
birth	  is	  also	  associated	  with	  an	  increased	  risk	  of	  both	  short-­‐term	  morbidities	  and	  long-­‐
term	  disabilities,	  including	  cerebral	  palsy,	  bronchopulmonary	  dysplasia,	  retinopathy	  of	  
prematurity	  and	  learning	  difficulties	  (Saigal	  and	  Doyle	  2008).	  	  	  
In	   addition	   to	   the	   huge	   emotional	   burden	   premature	   birth	   can	   place	   on	   families,	   the	  
economic	  burden	  that	  premature	  birth	  places	  on	  public	  sector	  resources	  is	  vast.	  	  Taking	  
into	  consideration	  not	  only	  the	  immediate	  costs	  of	  caring	  for	  a	  newborn	  preterm	  infant,	  
but	  also	  the	  continuing	  costs	  of	  dealing	  with	  the	  long-­‐term	  morbidities	  associated	  with	  
premature	  birth	  until	  the	  age	  of	  18,	  Mangham	  et	  al.	  estimate	  that	  the	  total	  annual	  cost	  
of	  preterm	  birth	  to	  the	  public	  sector	  in	  England	  and	  Wales	  was	  £2.946	  billion	  (at	  2006	  
prices)(Mangham	   et	  al.	   2009).	   	   This	   translates	   into	   an	   additional	   incremental	   cost	   of	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£22,885	  throughout	  childhood	  required	  for	  every	  preterm	  child	  surviving	  to	  18	  years	  
of	  age,	  compared	  with	  costs	  associated	  with	  the	  care	  of	  babies	  born	  at	  term	  (Mangham	  
et	  al.	  2009).	  	  	  
	  
1.3.2 Causes	  of	  preterm	  labour	  
Preterm	   labour	  can	  be	  categorised	   into	   three	  groups.	   	  The	   first	   is	  medically	   indicated	  
preterm	   labour,	   where	   labour	   is	   induced	   or	   the	   baby	   is	   delivered	   prematurely	   by	  
caesarean	  section	   to	   reduce	   the	  risk	  of	   significant	  harm	  to	  either	   the	  mother	  or	   fetus	  
(or	  both);	  this	  accounts	  for	  30-­‐35%	  of	  preterm	  births.	  	  The	  second	  category	  of	  preterm	  
labour	  occurs	  following	  preterm	  premature	  rupture	  of	  the	  membranes	  (PPROM),	  which	  
accounts	   for	   25-­‐30%	   of	   preterm	   births.	   	   The	   third,	   and	   largest,	   category	   of	   preterm	  
labour	  is	  spontaneous	  preterm	  labour,	  which	  accounts	  for	  40-­‐45%	  of	  all	  preterm	  births	  
(Goldenberg	  et	  al.	  2008).	   	  Whilst	  preterm	  births	  have	  been	  categorised	  in	  this	  manner	  
for	  many	  years,	  interestingly,	  a	  recent	  paper	  has	  suggested	  that	  a	  more	  comprehensive	  
classification	   system	   is	   required	   to	   better	   define	   the	   variable	   complex	   phenotypes	   of	  
preterm	   birth.	   	   Villar	   et	  al.	  suggest	   that	   preterm	   birth	   classification	   should	   take	   into	  
account	  maternal	  and	  fetal	  conditions,	  placental	  pathology,	  whether	  there	  are	  any	  signs	  
of	  the	  initiation	  of	  parturition,	  and	  the	  pathway	  to	  delivery	  (Villar	  et	  al.	  2012).	  
The	  causes	  of	  spontaneous	  preterm	  labour	  are	  poorly	  understood	  and	  in	  the	  majority	  
of	  cases,	  the	  underlying	  reasons	  why	  a	  woman	  has	  delivered	  prematurely	  are	  unknown.	  	  
Intensive	  research	  into	  this	  area	  has	  suggested	  a	  number	  of	  pathological	  processes	  that	  
are	  associated	  with	  preterm	  birth	  including,	  uterine	  overdistention,	  cervical	  deficiency,	  
abnormal	   allograft	   reaction,	   utero-­‐placental	   ischemia,	   endocrine	   disorders	   and	   an	  
allergic	   reaction	   (Romero	  et	  al.	   2006).	   	  However,	   to	   date,	   the	   only	   factor	   for	  which	   a	  
firm	   causal	   link	   as	   been	   proven	   is	   the	   presence	   of	   intrauterine	   infection	   and/or	  
inflammation	   (Goldenberg	   et	   al.	   2000,	   Romero	   et	   al.	   2006).	   	   	   Therefore,	   there	   is	  
growing	   interest	   in	   the	   hypothesis	   that	   in	   many	   cases,	   preterm	   labour	   may	   occur	  
because	   of	   the	   premature	   activation	   of	   the	   same	   inflammatory	   pathways	   normally	  
initiated	   with	   labour	   at	   term,	   either	   idiopathically,	   or	   in	   response	   to	   a	   pathological	  
intrauterine	   infection.	   	   The	   inflammatory	   events	   proposed	   to	   be	   involved	   in	   the	  
initiation	   of	   physiological	   term	   labour	   and	   pathological	   infection-­‐induced	   preterm	  
labour	  are	  summarised	  in	  Figure	  1.1.	  	  	  	  
Chapter	  1	  	  
	   15	  
	  
	  
Figure	   1.1	   -­‐	   Inflammatory	   events	   associated	   with	   term	   labour	   and	   infection-­‐
induced	  preterm	   labour.	   	   	  The	  inflammatory	  cascade	  associated	  with	  term	  labour	  is	  
shown	  on	  the	  left,	  and	  the	  events	  of	  infection-­‐induced	  preterm	  labour	  on	  the	  right.	   	  In	  
response	   to	   an	   intrauterine	   infection,	   which	   is	   recognised	   via	   TLRs	   present	   at	   the	  
maternal-­‐fetal	   interface,	   a	   similar	   inflammatory	   cascade	   to	   that	   proposed	   to	   occur	  
during	  normal	  physiological	  term	  labour	  is	  prematurely	  initiated,	  resulting	  in	  preterm	  
birth.	  	  Adapted	  from	  Rinaldi	  et	  al.,	  (2011).	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1.3.3 Intrauterine	  infection	  as	  a	  major	  cause	  of	  preterm	  labour	  
Up	   to	   40%	  of	   preterm	  deliveries	   are	   associated	  with	   the	   presence	   of	   an	   intrauterine	  
infection	   (Agrawal	   and	   Hirsch	   2012),	   with	   early	   preterm	   deliveries	   (i.e.	   before	   30	  
weeks	  gestation),	  being	  more	  strongly	  associated	  with	  infection	  (Mueller-­‐Heubach	  et	  al.	  
1990,	  Lahra	  and	  Jeffery	  2004).	   	  A	  diverse	  range	  of	  bacteria	  is	  associated	  with	  preterm	  
labour,	  including	  Ureaplasma	  urealyticum,	  Mycoplamsma	  hominis,	  Gardnerella	  vaginalis,	  
Escherichia	  coli,	  and	  group	  B	  streptococci	  (Goldenberg	  et	  al.	  2000).	  	  The	  most	  common	  
route	   that	  microorganisms	   are	   thought	   to	   gain	   access	   to	   the	   usually	   sterile	   amniotic	  
cavity	   is	   via	   ascension	   from	   the	   vagina	   and	   cervix,	   although	   other	   proposed	   routes	  
include:	  haematogenous	  dissemination	  through	  the	  placenta;	  retrograde	  invasion	  from	  
the	  abdominal	  cavity	  via	  the	  fallopian	  tubes;	  and	  accidental	  contamination	  at	  the	  time	  
of	  invasive	  obstetric	  procedures	  such	  as	  amniocentesis	  (Goldenberg	  et	  al.	  2008).	  	  	  
Supporting	   evidence	   that	   intrauterine	   infection	   causes	   preterm	   labour	   includes	   data	  
showing	  that	  women	  delivering	  preterm	  have:	  a	  higher	  incidence	  of	  positive	  amniotic	  
fluid	  cultures	  (Romero	  et	  al.	  1989),	  a	  higher	  incidence	  of	  chorioamnionitis	  (infection	  of	  
the	   fetal	   membranes)	   (Mueller-­‐Heubach	   et	   al.	   1990),	   and	   higher	   levels	   of	   pro-­‐
inflammatory	  mediators	  in	  their	  amniotic	  fluid,	  including	  IL-­‐1β,	  TNF-­‐α,	  IL-­‐6	  and	  MMP-­‐8,	  
compared	   to	   women	   delivering	   at	   term	   (Yoon	   et	   al.	   2001,	   Thomakos	   et	   al.	   2010,	  
Marconi	   et	   al.	   2011).	   	   Additionally,	   studies	   in	   animal	   models	   demonstrate	   that	   the	  
intrauterine	   or	   systemic	   administration	   of	   bacteria,	   or	   bacterial	   products,	   effectively	  
induces	  preterm	  labour	  in	  mice	  (Hirsch	  and	  Muhle	  2002,	  Elovitz	  et	  al.	  2003,	  Wang	  and	  
Hirsch	  2003,	  Pirianov	  et	  al.	  2009,	  Sykes	  et	  al.	  2013),	  rats	  (Bennett	  et	  al.	  2000,	  Terrone	  
et	   al.	   2001),	   rabbits	   (McDuffie	   et	   al.	   1992,	   Davies	   et	   al.	   2000)	   and	   rhesus	   monkeys	  
(Gravett	  et	  al.	  1994,	  Adams	  Waldorf	  et	  al.	  2008).	  	  Interestingly,	  administration	  of	  either	  
IL-­‐1β	   or	   TNF-­‐α	   to	   pregnant	   animals	   has	   also	   been	   shown	   to	   induce	   preterm	   labour	  
(Romero	   et	   al.	   1991,	   Silver	   et	   al.	   1994,	   Sadowsky	   et	   al.	   2003,	   Yoshimura	   and	   Hirsch	  
2005,	   Sadowsky	   et	   al.	   2006);	   highlighting	   that	   the	   inflammatory	   response	   to	  
intrauterine	  infection	  is	  likely	  to	  be	  key	  to	  the	  induction	  of	  preterm	  labour,	  as	  even	  in	  
the	  absence	  of	  infection	  pro-­‐inflammatory	  mediators	  can	  induce	  preterm	  labour.	  	  	  
The	  presence	  of	  an	   intrauterine	   infection	   is	  also	  associated	  with	  a	  number	  of	  adverse	  
effects	  on	  the	  fetus.	  	  Exposure	  of	  the	  fetus	  to	  an	  intrauterine	  infection	  can	  result	  in	  the	  
development	   of	   a	   systemic	   inflammatory	   response,	   known	   as	   the	   fetal	   inflammatory	  
response	   syndrome	   (FIRS),	  which	   can	   result	   in	   damage	   to	  multiple	   organs,	   including	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the	  heart,	  lungs,	  eyes	  and	  kidneys	  (Gomez	  et	  al.	  1998,	  Gotsch	  et	  al.	  2007).	  	  In	  particular,	  
perinatal	   brain	   damage,	   a	   major	   consequence	   of	   preterm	   birth,	   has	   been	   strongly	  
linked	  to	  the	  presence	  of	  intrauterine	  inflammation	  and	  infection	  (Galinsky	  et	  al.	  2013).	  	  
Indeed	   Shatrov	   et	   al.	   reported	   in	   a	   recent	   meta-­‐analysis	   study	   that	   the	   presence	   of	  
histological	   chorioamnionitis	   was	   associated	   with	   an	   80%	   increase	   in	   the	   risk	   of	  
development	  of	  cerebral	  palsy	  (Shatrov	  et	  al.	  2010).	  	  
	  
1.3.3.1 Molecular	   mechanisms	   of	   infection-­‐induced	   preterm	   labour:	   role	   of	   toll-­‐like	  
receptors	  
The	  mechanism	  by	  which	  intrauterine	  infection	  is	  proposed	  to	  induce	  preterm	  labour	  is	  
via	  Toll-­‐like	  receptor	  (TLR)	  recognition	  of	  bacterial	  products	  resulting	  in	  the	  activation	  
of	   an	   innate	   immune	   response.	   	   TLRs	   are	   a	   family	   of	   pattern	   recognition	   receptors	  
which	   play	   a	   key	   role	   in	   activating	   the	   innate	   immune	   response	   to	   pathogens	   by	  
recognising	  pathogen-­‐associated	  molecular	   patterns	   expressed	  by	  microbes.	   	   To	  date	  
10	  TLRs	  and	  their	  respective	  ligands	  have	  been	  identified	  in	  humans,	  including:	  TLR-­‐4,	  
which	   is	   involved	   in	   binding	   LPS,	   a	   cell	   wall	   component	   of	   Gram-­‐negative	   bacteria;	  
TLR-­‐2	   which	   is	   involved	   in	   the	   recognition	   of	   Gram-­‐positive	   bacterial	   components	  
including	  peptidoglycan	  and	  lipoteichoic	  acid;	  TLR-­‐3	  which	  is	  involved	  in	  co-­‐ordinating	  
the	   immune	   response	   to	   viruses	   by	   binding	   viral	   double-­‐stranded	   RNA;	   and	   TLR-­‐9	  
which	   is	   required	   for	   the	   recognition	   of	   specific	   unmethylated	  CpG	  motifs	   present	   in	  
bacterial	  DNA	  (Takeda	  and	  Akira	  2001,	  Koga	  et	  al.	  2009).	  	  	  	  
Upon	   ligand	  binding,	  TLR-­‐signalling	   is	  mediated	  via	  either	  the	  myeloid	  differentiation	  
factor	   88	   (MyD88)-­‐dependent	   pathway	   or	   MyD88-­‐independent	   pathway.	   	   In	   the	  
MyD88-­‐dependent	   pathway,	   ligand	   binding	   to	   the	   TLR	   results	   in	   recruitment	   of	   the	  
adapter	   protein	   MyD88	   which	   in	   turn	   recruits	   and	   activates	   other	   intracellular	  
signalling	   molecules,	   IL-­‐1	   receptor-­‐associated	   kinases	   (IRAK),	   and	   TNF	   receptor	  
associated	   factor	   6	   (TRAF-­‐6),	  which	  ultimately	   results	   in	   activation	  of	   two	   important	  
inflammatory	   signalling	   pathways,	   the	   JNK	   and	   NF-­‐κB	   signalling	   pathways.	   	   In	   the	  
MyD88-­‐independent	   pathway,	   TLR	   signalling	   is	   mediated	   via	   the	   adaptor	   protein	  
Toll/IL-­‐1	  receptor	  domain-­‐containing	  adapter-­‐inducing	  interferon-­‐β	  (TRIF)	  which	  can	  
in	   turn	   result	   in	   activation	   of	   the	   NF-­‐κB	   signalling	   pathway,	   and	   is	   also	   involved	   in	  
inducing	   transcription	   of	   type-­‐1	   interferons	   via	   activation	   of	   the	   transcription	   factor	  
interferon	  regulatory	  factor	  3	  (IRF3).	   	  The	  MyD88-­‐dependent	  pathway	  is	  the	  common	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pathway	  of	  TLR	  signalling	  for	  all	  TLRs,	  while	  TLR-­‐3	  and	  TLR-­‐4	  have	  also	  been	  shown	  to	  
be	  capable	  of	  signalling	  via	  the	  MyD88-­‐independent	  pathway	  (Takeda	  and	  Akira	  2001,	  
Koga	  et	  al.	  2009).	  	  An	  overview	  of	  the	  LPS-­‐TLR-­‐4	  signalling	  pathway	  resulting	  in	  NF-­‐κB	  
activation	  is	  given	  in	  Figure	  1.2.	  	  
At	   the	   maternal-­‐fetal	   interface	   TLR	   expression	   has	   been	   reported	   in	   the	   decidua	  
(Canavan	   and	   Simhan	   2007,	   Krikun	   et	   al.	   2007,	   Schatz	   et	   al.	   2012),	   myometrium	  
(Youssef	  et	  al.	  2009,	  Thota	  et	  al.	  2013),	  placenta	  (Holmlund	  et	  al.	  2002,	  Kumazaki	  et	  al.	  
2004,	  Pineda	  et	  al.	  2011,	  Chatterjee	  et	  al.	  2012),	  and	  fetal	  membranes	  (Kim	  et	  al.	  2004,	  
Choi	   et	   al.	   2012,	   Abrahams	   et	   al.	   2013).	   	   Some	   of	   these	   studies	   reported	   increased	  
expression	   of	   TLR-­‐2	   and	   TLR-­‐4	   in	   term	   labouring	   samples,	   compared	   with	   non-­‐
labouring	  (Kim	  et	  al.	  2004,	  Youssef	  et	  al.	  2009);	  and	  TLR	  expression	  was	  also	  increased	  
in	   placenta	   and	   fetal	   membranes	   obtained	   from	   women	   with	   evidence	   of	  
chorioamnionitis	  (Kim	  et	  al.	  2004,	  Kumazaki	  et	  al.	  2004),	  and	  in	  response	  to	  bacterial	  
treatment	  of	  fetal	  membrane	  explants	  in	  vitro	  (Abrahams	  et	  al.	  2013,	  Thota	  et	  al.	  2013).	  	  
Animal	  models	  have	  confirmed	  the	  role	  of	  TLR-­‐4	  in	  infection-­‐induced	  preterm	  labour,	  
where	   studies	   using	   TLR-­‐4	   deficient	   mice	   demonstrated	   that	   TLR-­‐4	   signalling	   is	  
required	   for	   LPS-­‐	   or	   E.coli-­‐induced	   preterm	   delivery	   (Elovitz	   et	   al.	   2003,	   Wang	   and	  
Hirsch	   2003).	   	   Additionally,	   blocking	   TLR-­‐4	   signalling	   inhibited	   uterine	   contractions	  
and	   amniotic	   pro-­‐inflammatory	   mediator	   production	   in	   a	   model	   of	   LPS-­‐induced	  
preterm	  labour	  in	  rhesus	  monkeys	  (Adams	  Waldorf	  et	  al.	  2008);	  and	  reduced	  the	  rate	  
of	   preterm	   delivery	   and	   improved	   pup	   survival	   in	   a	   mouse	   model	   of	   LPS-­‐induced	  
preterm	  labour	  (Li	  et	  al.	  2010).	  	  
Therefore,	  taken	  together	  this	  evidence	  suggests	  that	  TLR	  signalling	  in	  response	  to	  an	  
intrauterine	   infection	   is	   likely	   to	   activate	   inflammatory	   signalling	   pathways,	   such	   as	  
NF-­‐κB,	   inducing	   the	   premature	   activation	   of	   the	   inflammatory	   cascade	   proposed	   to	  
occur	  at	  term,	  resulting	  in	  preterm	  labour.	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Figure	  1.2	  –	  Overview	  of	  NF-­‐κB	  activation	  in	  response	  to	  LPS	  signalling	  via	  TLR-­‐4.	  	  	  
LPS	  binding	  to	  TLR-­‐4	  can	  induce	  an	  inflammatory	  response	  via	  NF-­‐κB	  activation	  which	  
can	  occur	  as	  a	   result	  of	  a	  MyD88-­‐dependent	  or	  MyD88-­‐independent	  pathway.	   	   In	   the	  
MyD88-­‐dependent	  pathway,	  LPS	  binding	  to	  TLR-­‐4	  results	  in	  MyD88	  recruitment	  which	  
in	   turn	   recruits	   and	   activates	   other	   intracellular	   signalling	  molecules	   including	   IRAK	  
and	  TRAF-­‐6,	   leading	  to	  the	  release	  of	  NF-­‐κB	  molecules	   from	  their	   inhibitor	  protein	   in	  
the	  cytoplasm,	  allowing	  NF-­‐κB	  to	  translocate	  to	  the	  nucleus	  where	  it	  can	  bind	  to	  target	  
genes	   and	   promote	   pro-­‐inflammatory	   gene	   expression.	   	   In	   the	   MyD88-­‐independent	  
pathway,	  NF-­‐κB	  activation	  can	  occur	   through	  activation	  of	   the	   intracellular	   signalling	  
molecule,	  TRIF.	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1.3.4 Current	  therapeutic	  options	  for	  the	  treatment	  of	  preterm	  labour	  
Despite	   considerable	   medical	   advances	   over	   recent	   decades	   resulting	   in	   more	  
premature	  babies	  surviving,	  preterm	  birth	  remains	  the	  single	  biggest	  cause	  of	  neonatal	  
mortality	  worldwide	  and	  the	  second	  leading	  cause	  of	  death	  in	  children	  under	  five	  years	  
of	  age	  (March	  of	  Dimes	  2012).	  	  	  A	  major	  reason	  why	  preterm	  birth	  remains	  such	  a	  huge	  
clinical	   problem	   is	   because	   current	   treatment	   options	   are	   limited	   and	   largely	  
ineffective	  at	  improving	  neonatal	  outcome,	  which	  is	  the	  ultimate	  goal	  of	  preterm	  birth	  
prevention.	  	  The	  following	  section	  briefly	  discusses	  the	  currently	  available	  therapeutic	  
options	  to	  treat	  preterm	  labour.	  	  
	  
1.3.4.1 Tocolytics	  
Current	   treatments	   for	   preterm	   labour	   focus	   on	   using	   tocolytic	   drugs	   to	   stop	  
myometrial	   contractions.	   	   Drugs	   used	   for	   this	   purpose	   include	   calcium	   channel	  
blockers,	  β-­‐mimetics	  and	  nitric	  oxide	  donors,	  which	  act	  to	  directly	   inhibit	  myometrial	  
smooth	  muscle	  contractions;	  and	  oxytocin	  receptor	  antagonists	  and	  non-­‐steroidal	  anti-­‐
inflammatory	   agents	   (NSAIDs),	   which	   target	   the	   production	   and	   action	   of	   two	   pro-­‐
contractile	  agents,	  prostaglandins	  and	  oxytocin	  (Hubinont	  and	  Debieve	  2011).	  	  Whilst	  a	  
number	   of	   these	   commonly	  used	   tocolytic	   agents	   have	  been	   shown	   to	  delay	  preterm	  
labour	  for	  48	  hours	  up	  to	  7	  days	  (King	  et	  al.	  2003,	  Smith	  et	  al.	  2009,	  Haas	  et	  al.	  2012),	  
there	  is	  little	  evidence	  that	  these	  drugs	  actually	  improve	  neonatal	  outcome.	  	  Indeed,	  the	  
latest	  guidelines	  published	  by	  the	  Royal	  College	  of	  Obstetricians	  and	  Gynaecologists	  on	  
the	  topic	  of	  tocolysis	  for	  women	  in	  preterm	  labour	  state	  that	  “there	  is	  no	  clear	  evidence	  
that	   tocolytic	  drugs	   improve	  outcome	  and	  therefore	   it	   is	   reasonable	  not	   to	  use	   them”	  
(RCOG	  2011);	  and	  a	  recent	  review	  article	  questions	  the	  continued	  use	  of	   tocolytics	   in	  
clinical	   practice	   today	   (Kenyon	   and	   Peebles	   2011).	   The	   limited	   effectiveness	   of	  
tocolytic	  drugs	  in	  delaying	  preterm	  delivery	  rates	  and	  improving	  neonatal	  outcome,	  is	  
likely	   due	   to	   the	   fact	   that	   these	   drugs	   do	  not	   target	   the	   underlying	   cause	   of	   preterm	  
labour,	   instead	   focussing	   on	   the	   inhibition	   of	  myometrial	   contractions,	   which	   are	   an	  
end-­‐point	   in	   the	   inflammatory	   cascade	   of	   labour,	   therefore	   it	   is	   possible	   that	   at	   this	  
point	  in	  the	  inflammatory	  cascade,	  the	  physiological	  process	  of	  labour	  may	  be	  hard	  to	  
reverse.	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1.3.4.2 Antibiotics	  
Given	   the	   strong	   link	   between	   intrauterine	   infection	   and	   preterm	   labour,	   the	   use	   of	  
broad-­‐spectrum	   antibiotic	   therapy	   for	   the	   treatment	   of	   spontaneous	   preterm	   labour	  
was	   trialled	   in	   a	   large	   randomised	   multicentre	   trial.	   	   Whilst	   initial	   results	   of	   the	  
ORACLE	   I	   trial	   appeared	   promising,	   where	   erythromycin	   treatment	   was	   associated	  
with	  prolongation	  of	  pregnancy	  and	  a	  reduction	  in	  neonatal	  morbidities	  in	  women	  with	  
PPROM,	   compared	   to	   the	  placebo	   group	   (Kenyon	  et	  al.	   2001);	   in	   the	  ORACLE	   II	   trial,	  
women	  who	  were	   in	   spontaneous	  preterm	   labour	  with	   intact	  membranes	  showed	  no	  
benefit	   of	   antibiotic	   treatment	   (Kenyon	   et	   al.	   2001).	   	   Furthermore,	   follow-­‐up	   of	   the	  
babies	  treated	  with	  antibiotics	  in	  ORACLE	  I	  and	  II	  at	  7	  years	  of	  age	  revealed	  the	  short-­‐
term	  benefits	  observed	  in	  the	  initial	  ORACLE	  I	  study	  were	  no	  longer	  apparent,	  with	  no	  
difference	  in	  terms	  of	  the	  rates	  of	  functional	  impairment	  between	  children	  treated	  with	  
erythromycin	   and	   those	   that	  were	   not	   (Kenyon	   et	   al.	   2008);	   and	   of	  more	   concern,	   a	  
greater	   proportion	   of	   children	   in	   the	   ORACLE	   II	   trial	   whose	   mothers	   received	  
erythromycin	  treatment	  had	  functional	  impairment	  compared	  with	  the	  placebo	  group;	  
and	  antibiotic	   treatment	  was	   also	   associated	  with	   an	   increased	   risk	  of	   cerebral	  palsy	  
(Kenyon	  et	  al.	  2008).	   	  These	   findings	  highlight	   the	   importance	  of	   long-­‐term	  follow-­‐up	  
studies	   to	   fully	   investigate	   whether	   delaying	   preterm	   delivery	   results	   in	   improved	  
neonatal	   outcome.	   	   Particularly	   in	   the	   context	   of	   intrauterine	   infection,	   delaying	  
delivery	   could	   result	   in	   prolonged	   exposure	   of	   the	   fetus	   to	   a	   hostile	   inflammatory	  
environment,	  which	  may	  ultimately	  lead	  to	  adverse,	  rather	  than	  improved,	  outcomes.	  	  	  
	  
1.3.4.3 Progesterone	  
The	  use	  of	  progesterone	  treatment	  to	  delay	  preterm	  delivery	  has	  been	  considered	  for	  
many	  decades,	  with	   the	   first	   report	   investigating	  progesterone	  administration	   for	   the	  
treatment	   of	   threatened	   preterm	   labour	   published	   in	   1960	   (Fuchs	   and	   Stakemann	  
1960),	   however	   it	   is	   only	   in	   the	   last	   decade,	   following	   the	   publication	   of	   two	  
randomised	  controlled	  trials	  (da	  Fonseca	  et	  al.	  2003,	  Meis	  et	  al.	  2003),	   	   that	  there	  has	  
been	   renewed	   interest	   in	   investigating	   the	  potential	  of	  progesterone	  as	  a	   therapeutic	  
option	  to	  treat	  preterm	  labour.	  	  As	  already	  discussed,	  progesterone	  plays	  a	  key	  role	  in	  
maintaining	   uterine	   quiescence	   throughout	   pregnancy	   and	   progesterone	  withdrawal,	  
or	  reduced	  local	  action	  of	  progesterone,	  is	  thought	  to	  be	  an	  important	  regulator	  of	  the	  
initiation	   of	   parturition;	   alongside	   evidence	   that	   progesterone	   receptor	   antagonists	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(such	  as	  mifepristone,	  RU486)	  can	  induce	  the	  onset	  of	   labour	  and	  cervical	  ripening	  in	  
women	   and	   animal	   models	   (Clark	   et	   al.	   2006,	   Hapangama	   and	   Neilson	   2009),	  
progesterone	  treatment	  seems	  to	  be	  a	  logical	  option	  in	  the	  treatment	  of	  preterm	  labour.	  	  	  
There	   are	   a	   number	   of	   clinical	   trials	   still	   on-­‐going	   evaluating	   the	   effectiveness	   of	  
different	   progesterone	   derivatives,	   dosage	   regimes	   and	   optimal	   routes	   of	  
administration,	  but	  to	  date	  progesterone	  supplementation	  has	  been	  reported	  to	  reduce	  
preterm	   delivery	   rates	   in	   high-­‐risk	   women,	   that	   is	   those	   with	   a	   previous	   preterm	  
delivery	  or	  with	  a	  short	  cervix	  (Mackenzie	  et	  al.	  2006,	  Dodd	  et	  al.	  2008,	  Conde-­‐Agudelo	  
et	  al.	  2013,	  Schmouder	  et	  al.	  2013).	   	  However	   in	  contrast,	  O’Brien	  et	  al.,	  reported	  that	  
although	   progesterone	   treatment	   was	   associated	   with	   less	   cervical	   shortening,	  
compared	  to	  the	  placebo	  group	  in	  a	  randomised	  double	  blind	  placebo	  controlled	  trial,	  
this	  did	  not	  significantly	  affect	  the	  rate	  of	  recurrent	  preterm	  birth	  (O'Brien	  et	  al.	  2007,	  
O'Brien	   et	   al.	   2009).	   	   Additionally,	   progesterone	   prophylaxis	   does	   not	   appear	   to	   be	  
effective	   in	  reducing	  preterm	  birth	  rates	   in	  women	  with	  multiple	  pregnancies	  (Briery	  
et	  al.	  2009,	  Norman	  et	  al.	  2009,	  Combs	  et	  al.	  2010,	  Wood	  et	  al.	  2012);	  or	  in	  those	  with	  
PPROM	  (Briery	  et	  al.	  2011),	  highlighting	   that	  whilst	  progesterone	   is	  a	  promising	  new	  
treatment	   option,	   it	   only	   appears	   to	   be	   effective	   in	   a	   specific	   sub-­‐group	   of	   high-­‐risk	  
women	   with	   a	   singleton	   pregnancy.	   	   Furthermore,	   although	   progesterone	   treatment	  
has	   delayed	   delivery	   in	   some	   cases,	   there	   is	   still	   little	   convincing	   evidence	   that	  
progesterone	   prophylaxis	   ultimately	   improves	   neonatal	   outcome	   (Smith	   et	   al.	   2009,	  
Dodd	   and	   Crowther	   2010).	   	   Results	   of	   the	   OPPTIMUM	   trial,	   a	   UK-­‐based	   randomised	  
double	  blind	  placebo	  controlled	  trial	  examining	  the	  effect	  of	  progesterone	  prophylaxis	  
on	   neonatal	   outcome	   at	   2	   years	   of	   age,	  will	   provide	  more	   information	   regarding	   the	  
benefits	  of	  progesterone	  treatment.	  	  	  	  
Therefore,	  clinicians	  face	  a	  difficult	  task	  when	  attempting	  to	  treat	  preterm	  labour,	  they	  
have	   few	   treatment	   options	   to	   choose	   from,	   and	   of	   those	   that	   are	   available,	   there	   is	  
insufficient	   evidence	   that	   they	   actually	   improve	   neonatal	   outcome.	   	   The	   limited	  
effectiveness	  of	  the	  currently	  available	  treatments	  is	  likely	  due	  to	  poor	  understanding	  
of	   the	   varied	   underlying	  mechanisms	   causing	   preterm	   labour	   and	   the	   fact	   that	  most	  
focus	  on	  blocking	  myometrial	  contractions,	  an	  end-­‐point	   in	   the	   inflammatory	  cascade	  
proposed	   to	   initiate	   labour	   normally.	   	   The	   limited	  number	   of	   treatment	   options	   is	   in	  
part	   due	   to	   under-­‐investment	   by	   the	   pharmaceutical	   industry	   in	   the	   development	   of	  
new	   drugs	   to	   treat	   pregnancy-­‐related	   disorders.	   	   Due	   to	   the	   risks	   associated	   with	  
administering	  drugs	  to	  pregnant	  women,	  where	  there	  are	  possible	  fetal	  side-­‐effects	  to	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consider,	   long-­‐term	   follow-­‐up	   studies	   are	   required	   to	   confirm	   any	   adverse	   effects	   on	  
the	   children;	   and	   the	   fact	   that	   pregnant	   women	   represent	   a	   relatively	   small	   target	  
market,	   where	   pregnancy	   and	   pregnancy-­‐related	   pathologies	   are	   considered	   ‘short-­‐
term’,	   there	   is	   very	   little	   interest	   from	   the	   pharmaceutical	   industry	   to	   develop	   new	  
drugs	   to	   treat	   pregnancy-­‐related	   disorders.	   	   Indeed,	   a	   recent	   study	   highlighted	   that	  
only	   17	   drugs	   were	   currently	   under	   development	   for	   treating	   obstetric-­‐related	  
problems,	   compared	   with	   660	   drugs	   being	   investigated	   for	   cardiovascular	   diseases;	  
and	  in	  the	  last	  20	  years,	  only	  one	  new	  class	  of	  drug	  (oxytocin	  receptor	  antagonists)	  has	  
been	  licensed	  to	  treat	  pregnancy-­‐related	  conditions	  in	  Europe	  (Fisk	  and	  Atun	  2008).	  	  	  
Preterm	   labour	   is	   a	   multi-­‐factorial	   condition,	   and	   as	   demonstrated	   in	   the	   case	   of	  
progesterone	   treatment,	   one	   treatment	   is	   not	   going	   to	   be	   applicable	   or	   effective	   for	  
each	  woman.	  	  Improving	  our	  understanding	  of	  the	  underlying	  causes	  of	  preterm	  labour	  
and	  improved	  identification	  of	  ‘high-­‐risk’	  women	  will	  hopefully	  lead	  to	  novel	  and	  more	  
targeted	  treatments.	  	  As	  mentioned	  earlier,	  a	  further	  complication	  in	  attempting	  to	  stop	  
preterm	  delivery	  is	  that	  in	  the	  presence	  of	  an	  intrauterine	  infection,	  delaying	  delivery	  
could	   potentially	   leave	   the	   fetus	   in	   a	   hostile	   inflammatory	   environment,	   which	   may	  
ultimately	  cause	  more	  harm.	  	  Therefore,	  if	  the	  primary	  aim	  of	  therapeutics	  for	  preterm	  
labour	  is	  to	  improve	  outcome	  for	  the	  baby,	  then	  novel	  treatment	  options	  must	  focus	  not	  
only	   on	   blocking	   myometrial	   contractions,	   but	   also	   resolve	   the	   inflammatory	  
environment	   of	   the	   uterus	   to	   limit	   damage	   to	   the	   fetus.	   	   Taking	   these	   factors	   into	  
consideration,	  and	  the	  hypothesis	  that	  many	  cases	  of	  preterm	  labour	  occur	  as	  a	  result	  
of	  the	  premature	  activation	  of	  the	  inflammatory	  cascade	  proposed	  to	  occur	  normally	  at	  
term,	   there	   is	   now	   growing	   interest	   in	   examining	   the	   potential	   of	   anti-­‐inflammatory	  
agents	  as	  a	  novel	  treatment	  option	  for	  preterm	  labour.	  	  	  	  
	  
	  
1.3.5 Novel	   therapeutic	   options	   to	   treat	   preterm	   labour:	   the	   potential	   of	   anti-­‐
inflammatory	  agents	  
Anti-­‐inflammatory	  agents	  are	  used	   to	   treat	  a	  vast	  number	  of	   inflammation-­‐associated	  
pathologies,	   including	   rheumatoid	   arthritis,	   inflammatory	   bowel	   diseases,	   airway	  
inflammation,	   cardiovascular	   disease	   and	   some	   cancers;	   and	   in	   recent	   years	  
investigating	   the	   potential	   of	   anti-­‐inflammatory	   agents	   as	   exciting	   novel	   therapeutic	  
options	  to	  treat	  preterm	  labour	  has	  become	  a	  major	  focus	  of	  premature	  birth	  research.	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Interestingly,	  support	   for	   the	  hypothesis	   that	  anti-­‐inflammatory	  agents	  may	  be	  useful	  
novel	  therapeutic	  agents	  comes	  from	  two	  treatments	  already	  in	  use	  for	  preterm	  labour,	  
NSAIDs	   and	   progesterone,	   both	   of	   which	   are	   proposed	   to	   mediate	   their	   effects	   by	  
blocking	  inflammatory	  signalling.	  	  	  
Indomethacin	  is	  a	  non-­‐selective	  COX	  inhibitor	  and	  is	  the	  most	  common	  NSAID	  used	  as	  a	  
tocolytic	   agent	   in	   the	   treatment	   of	   preterm	   labour.	   The	   first	   reported	   use	   of	  
indomethacin	  as	  a	  tocolytic	  drug	  was	  in	  1974	  (Zuckerman	  et	  al.	  1974),	  and	  subsequent	  
studies	   reported	   a	   promising	   reduction	   in	   preterm	   birth	   rates	   following	   the	   use	   of	  
indomethacin,	   compared	   to	   placebo	   (Niebyl	   et	   al.	   1980,	   Panter	   et	   al.	   1999)	   and	  
compared	  to	  other	  tocolytic	  drugs	  (King	  et	  al.	  2005).	   	  However,	  these	  trials	  have	  been	  
small,	   and	   the	   data	   is	   not	   conclusive.	   	   Furthermore,	   there	   are	   safety	   concerns	  
associated	  with	  the	  use	  of	  indomethacin,	  as	  it	  has	  been	  associated	  with	  adverse	  effects	  
on	   the	   fetus,	   including	   premature	   closure	   of	   the	   ductus	   arteriosus	   and	   necrotizing	  
enterocolitis	   (Norton	   et	   al.	   1993,	   Koren	   et	   al.	   2006).	   	   Although	   a	   recent	   systematic	  
review	  assessing	  the	  safety	  of	  indomethacin	  as	  a	  tocolytic	  agent	  did	  not	  find	  increased	  
risk	  of	  adverse	  neonatal	  outcomes,	  again	  this	  study	  emphasised	  that	  the	  small	  number	  
of	  randomised	  trials	  with	  limited	  statistical	  power	  that	  have	  been	  carried	  out	  to	  date	  do	  
not	   allow	   firm	   conclusions	   to	   be	   made	   on	   the	   safety	   of	   indomethacin	   as	   a	   tocolytic	  
agent	  (Loe	  et	  al.	  2005).	   	  As	  previously	  discussed,	  prostaglandins	  are	  key	  regulators	  of	  
myometrial	   contractility,	   therefore	   inhibition	  of	  COX	  enzymes	  using	  NSAIDs	   resulting	  
in	  inhibition	  of	  prostaglandin	  synthesis,	   is	  thought	  to	  be	  the	  key	  mechanism	  by	  which	  
NSAID	  treatment	  reduces	  preterm	  labour.	   	  However,	   there	   is	  also	  some	  evidence	  that	  
they	   can	   act	   directly	   to	   inhibit	   calcium	   channel	   currents	   in	   human	  myometrial	   cells	  
(Sawdy	  et	  al.	  1998),	  and	   they	  may	  also	  be	  capable	  of	   inhibiting	  NF-­‐κB	  activity,	  as	  has	  
been	  shown	  in	  other	  systems	  (Yin	  et	  al.	  1998,	  Loudon	  et	  al.	  2003).	  	  Therefore,	  although	  
the	  use	  of	  indomethacin	  demonstrates	  some	  success	  of	  using	  anti-­‐inflammatory	  agents	  
to	  delay	  preterm	  delivery,	  the	  risk	  of	  adverse	  neonatal	  outcomes	  associated	  with	  its	  use	  
suggest	  that	  continued	  research	  is	  required	  into	  more	  suitable	  alternatives.	  	  	  
As	   discussed	   above,	   progesterone	   is	   currently	   being	   intensively	   investigated	   as	   a	  
promising	   treatment	   option	   for	   preterm	   labour.	   	   Interestingly,	   although	   it	   has	   been	  
used	   clinically	   for	   a	   number	   of	   years,	   the	  mechanisms	  by	  which	  progesterone	  delays	  
preterm	  delivery	  are	  relatively	  poorly	  understood.	  	  Animal	  models	  and	  in	  vitro	  studies	  
are	   now	   being	   used	   to	   elucidate	   the	   underlying	  mechanisms	   of	   progesterone	   action,	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many	  of	  which	  appear	  to	  be	  related	  to	  anti-­‐inflammatory	  actions	  of	  progesterone	  in	  the	  
utero-­‐placental	  tissues.	  	  Using	  a	  mouse	  model	  of	  LPS-­‐induced	  preterm	  labour,	  Elovitz	  et	  
al.	  demonstrated	   that	  pre-­‐treatment	  with	   the	  progestin	  medroxyprogesterone	  acetate	  
(MPA),	   delayed	   preterm	   delivery.	   	   MPA	   treatment	   significantly	   reduced	   the	   LPS-­‐
induced	   expression	   of	   several	   inflammatory	   genes	   which	   are	   normally	   up-­‐regulated	  
with	   labour,	   Cox-­‐2,	   Il-­‐1β	  and	   Tnf-­‐α	   in	   the	   uterus	   and	   cervix,	   and	   connexin-­‐43	  mRNA	  
expression	   in	   the	  uterus;	   and	  MPA	   treatment	   inhibited	   cervical	   ripening	   (Elovitz	   and	  
Wang	  2004).	   	  Using	  the	  same	  model,	   they	  also	  reported	  that	  MPA	  decreased	  the	  LPS-­‐
induced	  expression	  of	  Tlr-­‐2	  and	  Tlr-­‐4	  in	  the	  cervix	  and	  placenta	  (Elovitz	  and	  Mrinalini	  
2005),	  highlighting	  that	   in	   the	  presence	  of	  an	   intrauterine	   infection,	  MPA	  may	  reduce	  
the	   rate	   of	   preterm	  birth	   by	   decreasing	   inflammatory	  mediator	   production,	   reducing	  
expression	  of	  contraction-­‐associated	  genes	  and	  inhibiting	  cervical	  ripening.	  	  These	  anti-­‐
inflammatory	   actions	   of	   MPA	   on	   utero-­‐placental	   inflammation	   and	   cervical	   ripening	  
have	  been	  confirmed	  in	  subsequent	  studies	  using	  the	  same	  animal	  model	  (Elovitz	  and	  
Mrinalini	  2006,	  Elovitz	  and	  Gonzalez	  2008,	  Xu	  et	  al.	  2008,	  Yellon	  et	  al.	  2009).	  	  	  	  
MPA	   has	   also	   been	   reported	   to	   have	   anti-­‐inflammatory	   actions	   in	   vitro	  where	   MPA	  
treatment	   of	   human	   myometrial	   samples	   significantly	   suppressed	   LPS-­‐induced	  
production	  of	  IL-­‐1β,	  IL-­‐6	  and	  IL-­‐8	  (Youssef	  et	  al.	  2009).	  	  A	  recent	  study	  by	  Norman	  et	  al,	  
reported	   that	   prolonged	   progesterone	   administration	   in	   vivo	   to	   women	   from	   24-­‐34	  
weeks	  of	  pregnancy	  resulted	  in	  decreased	  myometrial	  expression	  of	  connexin	  proteins,	  
and	  down-­‐regulated	  expression	  of	  CD11b	  on	  neutrophils,	  thus	  altering	  the	  ability	  of	  the	  
myometrium	  to	  efficiently	  contract,	  and	  possibly	  attenuating	  neutrophil	  recruitment	  to	  
the	  uterus	   (Norman	  et	  al.	   2011).	   	  Additionally,	  progesterone	   treatment	  has	  also	  been	  
shown	   to	   significantly	   attenuate	   IL-­‐1β–induced	   IL-­‐8	   and	   PGE2	   production	   and	   COX-­‐2	  
expression	  in	  lower	  segment	  fibroblast	  cells	  and	  amnion	  cells	  collected	  from	  pre-­‐labour	  
biopsies	  at	  term	  (Loudon	  et	  al.	  2003).	  	  These	  anti-­‐inflammatory	  actions	  of	  progesterone	  
may	   involve	   negative	   interactions	   between	   the	   progesterone	   receptor	   and	   NF-­‐κB,	  
which	  have	  been	  previously	  reported	  in	  other	  cell	  systems	  (Kalkhoven	  et	  al.	  1996),	  and	  
in	  human	  amnion	   cells	   in	  vitro	  (Allport	  et	  al.	   2001).	   	  Interestingly,	   there	   is	   also	   some	  
evidence	   that	   progesterone	   treatment	   may	   be	   capable	   of	   modulating	   FIRS,	   where	  
progesterone	   pre-­‐treatment	   has	   been	   reported	   to	   decrease	   IL-­‐6	   production	   in	   feto-­‐
placental	  arteries	  (Shields	  et	  al.	  2005,	  Gotkin	  et	  al.	  2006)	  and	  in	  fetal	  mononuclear	  cells	  
in	  vitro	  (Schwartz	  et	  al.	  2009);	  this	  would	  be	  of	  particular	  importance	  in	  the	  context	  of	  
intrauterine	   infection.	   	   Whilst	   further	   work	   is	   required	   to	   elucidate	   fully	   how	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progesterone	  treatment	  delays	  preterm	  delivery,	  taken	  together	  these	  studies	  highlight,	  
anti-­‐inflammatory	   actions	   appear	   to	   be	   important	   underlying	   mechanisms	   of	  
progesterone	  action	  in	  the	  utero-­‐placental	  tissues,	  suggesting	  that	  progesterone	  can	  be	  
considered	  as	  an	  anti-­‐inflammatory	  agent	  in	  the	  context	  of	  preterm	  labour.	  	  	  
Therefore,	   although	   indomethacin	   and	   progesterone	   are	   two	   treatments	  with	   strong	  
anti-­‐inflammatory	   actions,	   neither	   treatment	   have	   yet	   made	   a	   significant	   impact	   on	  
improving	   neonatal	   outcome.	   	   So,	   as	   previously	  mentioned,	   given	   the	   current	   lack	   of	  
effective	  treatment	  options	  to	  delay	  preterm	  delivery	  and	   improve	  neonatal	  outcome,	  
there	   has	   been	   intensive	   research	   over	   the	   last	   decade	   examining	   a	   large	   number	   of	  
anti-­‐inflammatory	   agents	   as	   novel	   therapeutic	   options.	   	   The	   reason	  why	   these	   drugs	  
are	   thought	   to	   have	   greater	   potential	   to	   treat	   preterm	   delivery	   is	   that	   they	   focus	   on	  
targeting	  the	  underlying	  cause	  of	  the	  premature	  initiation	  of	  labour	  (the	  inflammatory	  
cascade),	   rather	   than	   the	   end-­‐point	   (myometrial	   contractions).	   	   The	   use	   of	   animal	  
models	   has	   been	   invaluable	   in	   investigating	   the	   potential	   of	   anti-­‐inflammatory	  
treatments	  to	  delay	  delivery	  in	  vivo,	  and	  many	  promising	  treatments	  options	  have	  been	  
proposed.	   	   These	   can	   be	   broadly	   categorised	   into	   two	   groups:	   the	   administration	   of	  
agents	   that	   aim	   to	   directly	   block	   or	   antagonise	   pro-­‐inflammatory	   signalling;	   and	   the	  
administration	  of	  endogenous	  anti-­‐inflammatory	  agents.	   	  Evidence	  demonstrating	   the	  
potential	   of	   anti-­‐inflammatory	   mediators	   as	   novel	   therapeutic	   options	   for	   the	  
treatment	   of	   preterm	   labour	   has	   recently	   been	   comprehensively	   reviewed	   (Keelan	  
2011,	   Rinaldi	   et	   al.	   2011,	   MacIntyre	   et	   al.	   2012).	   	   The	   following	   section	   will	   briefly	  
detail	   a	   number	   of	   the	   anti-­‐inflammatory	   interventions	   investigated	   to	   date,	   with	  
particular	  focus	  on	  two	  endogenous	  anti-­‐inflammatory	  agents,	  IL-­‐10	  and	  lipoxins.	  	  	  
	  
1.3.5.1 Blocking	  IL-­‐1β 	  and	  TNF-­‐α 	  
Given	  the	  evidence	  that	  expression	  of	  both	  IL-­‐1β	  and	  TNF-­‐α	  is	  increased	  in	  gestational	  
tissues	  and	  amniotic	  fluid	  at	  both	  term	  and	  preterm	  labour	  (Maymon	  et	  al.	  1999,	  Young	  
et	   al.	   2002,	   Osman	   et	   al.	   2003,	   Marconi	   et	   al.	   2011);	   and	   administration	   of	   either	  
cytokine	  can	  induce	  preterm	  labour	  in	  animal	  models	  (Romero	  et	  al.	  1991,	  Silver	  et	  al.	  
1994,	   Yoshimura	   and	   Hirsch	   2005,	   Sadowsky	   et	   al.	   2006),	   studies	   have	   investigated	  
whether	   blocking	   IL-­‐1β	   or	   TNF-­‐α	   signalling	   can	   attenuate	   inflammatory	   signalling	   in	  
gestational	  tissues	  in	  vitro,	  and	  preterm	  delivery	  rates	  in	  vivo.	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Anti-­‐TNF-­‐α	  therapy	  has	  been	  used	  clinically	  as	  a	  therapeutic	  option	  to	  treat	  a	  number	  
of	   chronic	   inflammatory	   conditions,	   including	   inflammatory	   bowel	   disease	   and	  
rheumatoid	   arthritis	   (Ali	   et	   al.	   2013).	   	   Studies	   in	   animal	   models	   have	   reported	   that	  
blocking	   TNF-­‐α,	   either	   using	   anti-­‐TNF-­‐α	   antibodies,	   soluble	   TNF	   receptors,	   or	  
pentoxifylline	   (an	   inhibitor	   of	   TNF-­‐α	   synthesis),	   improved	   LPS-­‐mediated	   adverse	  
pregnancy	  outcomes	  in	  mice,	  including	  fetal	  resorption,	  intrauterine	  growth	  restriction	  
and	   fetal	   mortality	   (Gendron	   et	   al.	   1990,	   Silver	   et	   al.	   1994,	   Xu	   et	   al.	   2006).	   	   In	   the	  
context	   of	   preterm	   labour	   there	  have	  been	   conflicting	   reports	   on	   the	   effectiveness	  of	  
anti-­‐TNF-­‐α	   treatment	  to	  delay	  delivery.	   	  Blocking	  TNF-­‐α	  action	  using	  a	  soluble	  TNF-­‐α	  
receptor	   Fc	   fusion	  protein	  did	  not	   prevent	   LPS-­‐induced	  preterm	  delivery	   in	   a	  mouse	  
model	   (Fidel	   et	   al.	   1997);	   whereas	  more	   recently,	   pre-­‐treatment	  with	   an	   anti-­‐TNF-­‐α	  
antibody	   has	   been	   reported	   to	   significantly	   decrease	   the	   number	   of	   LPS-­‐induced	  
preterm	  deliveries,	   improve	  pup	  survival	  and	  decrease	   the	  expression	  of	  several	  pro-­‐
inflammatory	  mediators	  in	  the	  uterus	  (Holmgren	  et	  al.	  2008).	  
Similarly,	  blocking	  IL-­‐1β	  signalling	  has	  also	  been	  used	  therapeutically	  in	  the	  treatment	  
of	   inflammatory	   conditions	   and	   the	   endogenous	   IL-­‐1	   receptor	   antagonist	   (IL-­‐1Ra)	   is	  
clinically	   approved	   for	   the	   treatment	  of	   rheumatoid	   arthritis	   (Dinarello	  2011).	   	   Early	  
studies	   by	   Romero	   et	   al.	   demonstrated	   that	   IL-­‐1Ra	   decreased	   IL-­‐1β-­‐induced	   PGE2	  
production	   in	   amnion	   and	   chorion	   explant	   culture	   in	  vitro	  (Romero	   et	  al.	   1992);	  and	  
prevented	   IL-­‐1-­‐induced	   preterm	   birth	   in	   a	   mouse	   model	   (Romero	   and	   Tartakovsky	  
1992).	   	   However,	   subsequent	   studies	   have	   proved	   less	   successful,	   where	   IL-­‐1Ra	  
administration	  did	  not	  prevent	  LPS-­‐induced	  preterm	  labour	  in	  a	  mouse	  model	  (Fidel	  et	  
al.	   1997);	   LPS-­‐induced	   preterm	   delivery	   rates	   were	   unaffected	   in	   transgenic	   mice	  
overexpressing	   IL-­‐1Ra	  (Yoshimura	  and	  Hirsch	  2005);	  and	  similarly,	   infection-­‐induced	  
preterm	   delivery	   rates	   were	   unaffected	   in	   IL-­‐1β	   and	   IL-­‐1	   receptor	   knockout	   mice	  
(Reznikov	   et	   al.	   1999,	   Hirsch	   et	   al.	   2002),	   suggesting	   that	   IL-­‐1β	   signalling	   is	   not	  
required	   for	   the	   induction	   of	   preterm	   labour	   in	   response	   to	   intrauterine	   infection.	  	  	  	  
Interestingly,	   the	   rate	  of	   infection-­‐induced	  preterm	  delivery	   in	  double	  knockout	  mice	  
lacking	   both	   the	   type	   1	   receptors	   for	   IL-­‐1	   and	   TNF	   was	   found	   to	   be	   significantly	  
reduced	   compared	   to	   the	   wild-­‐type	   control	   mice;	   and	   the	   knockout	   mice	   also	   had	  
significantly	  lower	  myometrial	  expression	  of	  COX-­‐2	  (Hirsch	  et	  al.	  2006).	  	  These	  studies	  
highlight	   the	   complexity	   of	   the	   cytokine	   interactions	   associated	  with	  preterm	   labour,	  
and	  suggest	  that	  due	  to	  the	  redundancy	  of	  the	  cytokine	  network,	  simply	  attempting	  to	  
Chapter	  1	  	  
	   28	  
block	   one	   cytokine	   is	   unlikely	   to	   be	   a	   useful	   therapeutic	   strategy	   in	   the	   treatment	   of	  
preterm	  labour.	  	  
	  
1.3.5.2 NF-­‐κB	  inhibitors	  
As	   discussed	   earlier,	   the	   NF-­‐κB	   signalling	   pathway	   has	   a	   key	   role	   in	   regulating	   the	  
inflammatory	  response	  associated	  with	  the	  onset	  of	  parturition,	  therefore	  making	  it	  an	  
attractive	   therapeutic	   target	   in	   the	   search	   for	   novel	   treatments	   for	   inflammation-­‐
associated	   preterm	   labour.	   	   To	   date,	   more	   than	   700	   NF-­‐κB	   inhibitors	   have	   been	  
described	  which	  target	  the	  signalling	  pathway	  at	  various	  points	  (Gupta	  et	  al.	  2010);	  and	  
NF-­‐κB	  inhibitors	  have	  been	  investigated	  as	  novel	  therapeutic	  options	  in	  the	  treatment	  
of	   rheumatoid	  arthritis	   (Okamoto	  2006),	   inflammatory	   lung	  diseases	   (Decramer	  et	  al.	  
2005,	  Demedts	  et	  al.	  2005)	  and	  inflammatory	  bowel	  disease	  (Egan	  and	  Sandborn	  1998,	  
Atreya	  et	  al.	  2008).	   	  The	  potential	  of	  a	  number	  of	  different	  NF-­‐κB	  inhibitors	  to	  control	  
inflammatory	   signalling	   in	   human	   gestational	   tissues	   and	   to	   delay	   delivery	   in	   animal	  
models	   has	   been	   investigated;	   this	   section	   shall	   discuss	   the	   evidence	   regarding	   N-­‐
acetylcysteine	  (NAC)	  and	  sulfasalazine	  (SSZ)	  as	  potential	  novel	   therapeutic	  options	  to	  
treat	  inflammation-­‐induced	  preterm	  labour.	  	  	  
NAC	  is	  an	  antioxidant	  and	  anti-­‐inflammatory	  mediator	  involved	  in	  regulating	  oxidative	  
stress	  by	  increasing	  glutathione	  levels	  (Millea	  2009).	   	  NAC	  treatment	  has	  been	  shown	  
to	   inhibit	   nuclear	   translocation	   of	  NF-­‐κB	   in	   a	   number	   of	   cell	   systems	   (Origuchi	   et	  al.	  
2000,	  Martinez-­‐Losa	  et	  al.	  2007).	   	  NAC	  has	  been	  used	  therapeutically	  in	  the	  treatment	  
of	   a	   variety	   of	   inflammation-­‐related	   pathologies,	   including	   chronic	   obstructive	  
pulmonary	   disease	   (Decramer	   et	   al.	   2005),	   influenza	   (De	   Flora	   et	   al.	   1997),	   and	  
pulmonary	  fibrosis	  (Demedts	  et	  al.	  2005);	  and	  has	  been	  investigated	  as	  a	  treatment	  for	  
a	  number	  of	   reproductive	  pathologies	   including	  polycystic	  ovarian	  syndrome	  (Rizk	  et	  
al.	  2005),	  recurrent	  pregnancy	  loss	  (Amin	  et	  al.	  2008)	  and	  pre-­‐eclampsia	  (Rumiris	  et	  al.	  
2006).	   	   In	   vitro,	   NAC	   treatment	   of	   human	   fetal	   membranes	   inhibited	   NF-­‐κB	   DNA-­‐
binding	   activity,	   which	   subsequently	   attenuated	   the	   LPS-­‐induced	   pro-­‐inflammatory	  
cytokine	  and	  prostaglandin	  release	  and	  MMP-­‐9	  activity	  in	  the	  fetal	  membranes	  (Lappas	  
et	  al.	  2003).	  	  In	  animal	  models	  in	  vivo,	  NAC	  pre-­‐treatment	  delayed	  LPS-­‐induced	  preterm	  
labour	   and	   improved	   pup	   survival	   (Buhimschi	   et	   al.	   2003,	   Chang	   et	   al.	   2011);	  
attenuated	   the	   LPS-­‐induced	   inflammatory	   response	   in	   fetal	   plasma	   and	  myometrium	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(Beloosesky	   et	   al.	   2006,	   Chang	   et	   al.	   2011);	   and	   protected	   the	   fetal	   brain	   from	  
inflammation-­‐induced	  injury	  (Chang	  et	  al.	  2011).	  	  These	  studies	  highlight	  the	  potential	  
of	   NAC	   to	   not	   only	   delay	   preterm	   delivery,	   but	   also	   suggest	   it	   may	   be	   useful	   in	  
protecting	   the	   fetus	   from	   infection-­‐associated	   brain	   injury.	   	   Interestingly,	   a	   recently	  
published	   study	   reported	   that	   administration	   of	   NAC	   (in	   conjunction	   with	  
metronidazole	   and	   17-­‐hydroxyprogestrone	   caproate)	   to	   women	   with	   a	   history	   of	  
preterm	  labour	  and	  bacterial	  vaginosis	  improved	  outcome.	  	  Gestational	  age	  at	  delivery,	  
and	   fetal	   weight	   were	   both	   significantly	   increased	   in	   the	   NAC	   treatment	   group,	  
compared	  to	  the	  placebo	  group,	  and	  there	  were	  also	  significantly	  fewer	  neonatal	  deaths	  
in	  the	  NAC	  group	  (Shahin	  et	  al.	  2009).	  	  Although	  this	  was	  a	  relatively	  small	  study,	  this	  is	  
the	   first	   clinical	   study	   to	   demonstrate	   an	   effect	   of	   NAC	   in	   delaying	   preterm	   labour,	  
suggesting	  it	  could	  be	  a	  useful	  treatment	  option	  to	  use	  along-­‐side	  other	  agents,	  such	  as	  
progesterone.	  	  	  
Sulfasalazine	   is	  a	  5-­‐aminosalicylic	  acid	  drug	   that	  has	  been	  used	   for	  many	  years	  as	  an	  
anti-­‐inflammatory	   treatment	   for	   inflammatory	   bowel	   disease	   (Egan	   and	   Sandborn	  
1998)	   and	   rheumatoid	   arthritis	   (Box	   and	   Pullar	   1997).	   	   Sulfasalazine	   was	   first	  
identified	  as	  a	  potent	  and	  specific	  NF-­‐κB	  inhibitor	  in	  1998	  (Wahl	  et	  al.	  1998),	  and	  has	  
subsequently	  been	  shown	  to	  act	  by	  directly	  inhibiting	  the	  IKK	  kinases,	  IKKα	  and	  IKKβ	  
(Weber	  et	  al.	  2000).	  	  The	  anti-­‐inflammatory	  actions	  of	  SSZ	  have	  been	  demonstrated	  in	  
human	  gestational	  tissues	  in	  vitro,	  where	  SSZ	  treatment	  inhibited	  NF-­‐κB	  translocation	  
to	   the	   nucleus	   and	   subsequently	   attenuated	   LPS-­‐induced	   pro-­‐inflammatory	   cytokine	  
and	  prostaglandin	  release	  in	  placenta,	  amnion	  and	  choriodecidua	  explants	  (Lappas	  et	  al.	  
2002,	   Keelan	   et	   al.	   2009).	   	   In	   addition	   SSZ	   treatment	   inhibited	   IL-­‐8	   production	   by	  
endocervical	  epithelial	  cells	  in	  response	  to	  a	  variety	  of	  bacterial	  pathogens	  (Peltier	  et	  al.	  
2009).	   	   In	  a	  mouse	  model	  of	  preterm	   labour,	   SSZ	  pre-­‐treatment	   significantly	   reduced	  
the	   rate	   of	   E.coli-­‐induced	   preterm	   labour	   and	   was	   associated	   with	   a	   modest	   (non-­‐
significant)	  increase	  in	  pup	  survival,	  compared	  with	  mice	  receiving	  E.coli	  alone	  (Nath	  et	  
al.	  2010).	  	  	  
Taken	  together,	  these	  studies	  demonstrate	  the	  potential	  of	  drugs	  such	  as	  NAC	  and	  SSZ	  
to	  target	  the	  NF-­‐κB	  signalling	  pathway	  as	  a	  potential	  novel	  therapeutic	  strategy	  in	  the	  
treatment	  of	  preterm	  labour.	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1.3.5.3 15d-­‐PGJ2	  
15-­‐deoxy-­‐Δ12,14-­‐prostaglandin-­‐J2	   (15d-­‐PGJ2)	   is	   a	   metabolite	   of	   PGD2	   that	   has	   been	  
shown	  to	  have	  potent	  anti-­‐inflammatory	  actions	  in	  a	  variety	  of	  cell	  systems	  (Scher	  and	  
Pillinger	  2005).	  	  15d-­‐PGJ2	  is	  produced	  in	  the	  later	  phase	  of	  an	  inflammatory	  response	  in	  
vivo	   and	   is	   therefore	   postulated	   to	   play	   an	   important	   role	   in	   the	   resolution	   of	  
inflammatory	   responses	   (Gilroy	   et	   al.	   1999),	   as	   it	   has	   been	   shown	   to	   stimulate	  
granulocyte	  apoptosis	  (Ward	  et	  al.	  2002)	  and	  promote	  macrophage	  clearance	  from	  the	  
site	   of	   inflammation	   (Rajakariar	   et	   al.	   2007).	   	   The	   mechanisms	   underlying	   15d-­‐PGJ2	  
action	  are	  not	  clear.	  	  15d-­‐PGJ2	  has	  been	  reported	  to	  act	  via	  a	  prostaglandin	  D	  receptor,	  
chemoattractant	   receptor-­‐homologous	   molecule	   expressed	   on	   TH2	   cells	   (CRTH2)	  
(Monneret	  et	  al.	  2002);	  and	  it	  has	  been	  proposed	  that	  15d-­‐PGJ2	  may	  exert	  its	  actions	  via	  
interactions	   with	   intracellular	   targets,	   such	   as	   the	   transcription	   factors,	   peroxisome	  
proliferator-­‐activated	   receptors	   (PPARs)	   and	   	   NF-­‐κB	   (Scher	   and	   Pillinger	   2005).	   	   A	  
major	  anti-­‐inflammatory	  mechanism	  of	  15d-­‐PGJ2	  action	  is	  through	  inhibition	  of	  NF-­‐κB,	  
either	  directly	  by	  inhibiting	  IKKβ	  activity	  (Rossi	  et	  al.	  2000);	  or	  indirectly	  via	  activation	  
of	   PPAR-­‐γ,	   which	   has	   been	   shown	   to	   antagonise	   the	   activity	   of	   transcription	   factors	  
involved	   in	   pro-­‐inflammatory	   gene	   transcription,	   such	   as	   NF-­‐κB	   (Ricote	   et	   al.	   1998).	  	  
Research	  into	  the	  use	  of	  15d-­‐PGJ2	  as	  an	  anti-­‐inflammatory	  therapeutic	  agent	  is	  still	  at	  a	  
relatively	   early	   stage,	   but	   several	   in	   vivo	   studies	   have	   now	   reported	   that	   15d-­‐PGJ2	  
administration	   was	   associated	   with	   reduced	   disease	   severity	   in	   animal	   models	   of	   a	  
number	  of	  inflammation-­‐associated	  pathologies,	  including	  chronic	  lung	  injury	  (Wang	  et	  
al.	  2009)	  and	  arthritis	  (Kawahito	  et	  al.	  2000).	  	  
During	  pregnancy,	  PGD2	  is	  produced	  by	  the	  placenta	  and	  decidua	  (Mitchell	  et	  al.	  1982,	  
Norwitz	  et	  al.	   1992)	   and	  both	  PGD2	  and	  15d-­‐PGJ2	  have	  been	  detected	   in	   the	   amniotic	  
fluid	  of	  women	  at	   term	  (Helliwell	  et	  al.	  2006).	   	  The	  anti-­‐inflammatory	  actions	  of	  15d-­‐
PGJ2	  have	  been	  demonstrated	  in	  human	  gestational	  tissue	  culture	   in	  vitro,	  where	  15d-­‐
PGJ2	   treatment	   has	   been	   reported	   to	   down-­‐regulate	   inflammatory	   gene	   expression,	  
PGE2	   release,	   and	   inhibit	  NF-­‐κB	   in	   human	   amnion,	  myometrial	   and	   trophoblast	   cells,	  
and	  amnion-­‐derived	  WISH	  cells	  (Ackerman	  et	  al.	  2005,	  Berry	  et	  al.	  2005,	  Lindstrom	  and	  
Bennett	   2005,	   Helliwell	   et	   al.	   2006);	   and	   in	   placenta,	   amnion	   and	   choriodecidua	  
explants	  (Lappas	  et	  al.	  2006).	  	  Additionally,	  a	  recent	  study	  demonstrated	  that	  15d-­‐PGJ2	  
treatment	  down-­‐regulated	  production	  of	  IFN-­‐γ,	  TNF-­‐α	  and	  reduced	  NF-­‐κB	  activation	  in	  
peripheral	  blood	  mononuclear	  cells	  obtained	  from	  pregnant	  women	  (Sykes	  et	  al.	  2012).	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In	  a	  mouse	  model	  of	  LPS-­‐induced	  preterm	  labour,	  Pirianov	  et	  al.	  recently	  demonstrated	  
that	  treatment	  with	  15d-­‐PGJ2	  significantly	  delayed	  preterm	  delivery	  and	  improved	  pup	  
survival	  rates.	  	  15d-­‐PGJ2	  treatment	  was	  associated	  with:	  decreased	  IKKβ	  activity	  in	  the	  
myometrium	  and	   fetal	  brain;	   inhibition	  of	  LPS-­‐induced	  myometrial	  pro-­‐inflammatory	  
cytokine	  production;	  and	  inhibition	  of	  cPLA2	  and	  COX-­‐2	  expression	  in	  the	  myometrium,	  
suggesting	  a	  negative	   feedback	  mechanism	  on	  prostaglandin	  synthesis	  (Pirianov	  et	  al.	  
2009).	  	  In	  a	  follow-­‐up	  study,	  Sykes	  et	  al.	  recently	  reported	  that	  these	  anti-­‐inflammatory	  
actions	  of	  15d-­‐PGJ2	  in	  the	  mouse	  model	  of	  LPS-­‐induced	  preterm	  labour	  do	  not	  appear	  
to	  be	  mediated	  via	  CRTH2	  (Sykes	  et	  al.	  2013)	  	  
Overall,	   the	   in	   vitro	   and	   in	   vivo	   evidence	   to	   date	   suggests	   that	   15d-­‐PGJ2	   could	   be	   an	  
exciting	  novel	   therapeutic	  agent	   to	   treat	   inflammation-­‐induced	  preterm	   labour	  which	  
ultimately	   may	   improve	   neonatal	   outcome	   by	   protecting	   the	   fetal	   brain	   from	  
inflammation-­‐induced	   damage.	   	   Further	   research	   is	   required	   to	   elucidate	   the	  
underlying	   mechanisms	   of	   15d-­‐PGJ2	   actions	   in	   the	   gestational	   tissues	   and	   fully	  
investigate	  its	  potential	  as	  a	  therapeutic	  option.	  	  	  	  
	  
1.3.5.4 IL-­‐10	  
IL-­‐10	  was	   initially	   discovered	   in	   1989	   as	   a	   novel	   product	   of	  mouse	   Th2	   cells	   which	  
suppressed	   inflammatory	   cytokine	   production	   from	   Th1	   cells,	   and	   was	   originally	  
named	   ‘cytokine	   synthesis	   inhibitory	   factor’	   (Fiorentino	   et	   al.	   1989).	   	   Subsequent	  
studies	   confirmed	   these	   inhibitory	   actions	   of	   IL-­‐10,	   and	   it	   is	   now	   considered	   as	   the	  
classical	   anti-­‐inflammatory	   cytokine.	   	   IL-­‐10	   is	   primarily	   produced	   by	   monocytes,	  
macrophages	   and	   some	   T-­‐cell	   subsets	   in	   vivo,	   but	   other	   immune	   cells	   including	  
dendritic	  cells,	  B-­‐cells,	  NK	  cells,	  mast	  cells	  and	  neutrophils	  have	  also	  been	  reported	  to	  
produce	  IL-­‐10	  (Sabat	  et	  al.	  2010).	  	  	  Monocytes	  and	  macrophages	  are	  proposed	  to	  be	  the	  
main	  target	  cells	  of	  immuno-­‐modulatory	  IL-­‐10	  signalling,	  although	  IL-­‐10	  has	  also	  been	  
shown	  to	  act	  on	  other	  immune	  cell	  populations,	  including	  T	  cells,	  B	  cells,	  NK	  cells	  and	  
neutrophils	   via	   activation	   of	   its	   specific	   IL-­‐10	   receptor	   (Sabat	   et	   al.	   2010).	   	   The	   key	  
actions	   of	   IL-­‐10	   on	   monocytes	   and	   macrophages	   include:	   inhibition	   of	   pro-­‐
inflammatory	  cytokine	  production	  (de	  Waal	  Malefyt	  et	  al.	  1991,	  Fiorentino	  et	  al.	  1991);	  
promoting	   the	   release	   of	   anti-­‐inflammatory	   mediators	   such	   as	   IL-­‐1Ra	   (Jenkins	   et	   al.	  
1994);	  and	  enhancing	  the	  phagocytic	  ability	  of	  monocytes/macrophages	  (Buchwald	  et	  
al.	  1999).	   	  Upon	   IL-­‐10	  binding	   to	   the	   IL-­‐10	  receptor,	   the	  anti-­‐inflammatory	  actions	  of	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IL-­‐10	  are	  largely	  mediated	  through	  the	  activation	  of	  the	  signal	  transducer	  and	  activator	  
of	   transcription	  (STAT)	  transcription	  factors,	  particularly	  STAT3.	   	  The	  activated	  STAT	  
transcription	  factors	  translocate	  to	  the	  cell	  nucleus	  and	  bind	  to	  STAT-­‐binding	  elements	  
in	  the	  promoter	  regions	  of	  target	  genes,	  such	  as	  the	  suppressor	  of	  cytokine	  signalling	  3	  
(SOCS3),	  which	  can	  act	  to	  inhibit	   further	  cytokine	  synthesis	  (Sabat	  et	  al.	  2010).	   	   IL-­‐10	  
signalling	  has	  also	  been	  shown	  to	  inhibit	  NF-­‐κB	  activation	  in	  a	  number	  of	  different	  cell	  
systems	   (Wang	   et	   al.	   1995,	   Yoshidome	   et	   al.	   1999,	   Al-­‐Ashy	   et	   al.	   2006).	   	   Given	   the	  
potent	  anti-­‐inflammatory	  actions	  of	  IL-­‐10,	  it	  has	  been	  investigated	  clinically	  as	  a	  novel	  
therapeutic	   option	   in	   the	   treatment	   of	   a	   number	   of	   inflammation-­‐associated	  
pathologies	   including	   Crohn’s	   disease	   (Buruiana	   et	  al.	   2010),	   psoriasis	   (Kimball	   et	  al.	  
2002)	   and	   chronic	   hepatitis	   C	   infection	   (Nelson	   et	   al.	   2000);	   however	   the	   results	   of	  
these	   trials	   have	   been	   mixed,	   suggesting	   that	   further	   studies	   are	   required	   to	   fully	  
elucidate	  the	  therapeutic	  potential	  of	  IL-­‐10	  therapy	  (Asadullah	  et	  al.	  2003).	  	  	  
Although	  much	   research	  has	   focussed	  on	   identifying	   the	  pro-­‐inflammatory	  mediators	  
associated	  with	   the	  onset	  of	  parturition,	  both	  at	   term	  and	  preterm,	  over	  recent	  years	  
there	   has	   been	   a	   growing	   interest	   in	   understanding	   how	   these	   pro-­‐inflammatory	  
signals	   may	   be	   regulated	   in	   vivo,	   and	   what	   role	   IL-­‐10	   may	   play	   in	   controlling	   the	  
inflammation	   surrounding	   parturition.	   	   	   The	   important	   role	   of	   IL-­‐10	   signalling	   in	  
pregnancy	   has	   been	   recently	   reviewed	   (Thaxton	   and	   Sharma	   2010,	   Kalkunte	   et	   al.	  
2011).	   	   During	   pregnancy,	   IL-­‐10	   expression	   and	   secretion	   has	   been	   reported	   in	  
placental	   villous	   cytotrophoblasts,	   decidua,	   chorion,	   uterine	   NK	   cells	   and	   decidual	  
macrophages	  (Roth	  et	  al.	  1996,	  Trautman	  et	  al.	  1997,	  Denison	  et	  al.	  1998,	  Hanna	  et	  al.	  
2000,	  Lidstrom	  et	  al.	  2003);	  and	  IL-­‐10	  has	  been	  detected	  in	  amniotic	  fluid	  (Greig	  et	  al.	  
1995,	  Dudley	  et	  al.	  1997,	  Gotsch	  et	  al.	  2008).	   	  There	  are	  conflicting	  reports	  of	  changes	  
in	   IL-­‐10	  expression	   through	  pregnancy	  and	  with	   the	  onset	  of	   labour.	   	  Placental	   IL-­‐10	  
expression	   was	   found	   to	   be	   higher	   in	   first	   and	   second	   trimester	   placental	   tissue,	  
compared	   to	   term	   placenta	   (Hanna	   et	   al.	   2000);	   and	   IL-­‐10	   production	   from	  
choriodecidual	  tissue	  was	  reported	  to	  be	  decreased	  with	  labour,	  compared	  with	  tissue	  
obtained	  before	  labour	  (Simpson	  et	  al.	  1998).	  	  Whilst	  in	  the	  amniotic	  fluid	  some	  studies	  
have	  reported	  increased	  amniotic	  fluid	  IL-­‐10	  in	  the	  third	  trimester,	  compared	  to	  earlier	  
stages	  of	  gestation	  (Greig	  et	  al.	  1995);	  others	  have	  reported	  no	  change	  across	  gestation	  
(Dudley	  et	  al.	  1997,	  Gotsch	  et	  al.	  2008).	   	   Increased	  amniotic	   fluid	   IL-­‐10	  has	  also	  been	  
reported	  in	  association	  with	  spontaneous	  term	  and	  preterm	  labour	  (Greig	  et	  al.	  1995,	  
Gotsch	   et	   al.	   2008).	   	   IL-­‐10	   deficiency	   has	   been	   associated	  with	   a	   number	   of	   adverse	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pregnancy	   outcomes	   including,	   pre-­‐eclampsia,	   recurrent	   spontaneous	   abortions	   and	  
preterm	   labour	   (Hill	   et	   al.	   1995,	   Hennessy	   et	   al.	   1999,	   Makhseed	   et	   al.	   2003);	  
highlighting	   that	   IL-­‐10	   plays	   a	   key	   role	   in	  maintaining	   the	   balance	   between	   pro-­‐and	  
anti-­‐inflammatory	  signalling	  throughout	  pregnancy.	  	  
Evidence	   that	   IL-­‐10	   can	   regulate	   inflammatory	   signalling	   in	   the	   gestational	   tissues	  
comes	   from	   in	   vitro	   studies	   which	   have	   demonstrated	   that	   treatment	   with	   IL-­‐10	  
attenuated	   the	   LPS-­‐induced	   production	   of	   IL-­‐6,	   TNF-­‐α,	   IL-­‐1β,	  MMPs	   and	   PGE2	   in	   the	  
fetal	   membranes	   (Fortunato	   et	   al.	   1996,	   Brown	   et	   al.	   2000,	   Fortunato	   et	   al.	   2001);	  
inhibited	  LPS-­‐induced	  TNF-­‐α	  and	  IL-­‐1β	  expression	  in	  choriodecidual	  explants	  (Sato	  et	  
al.	  2003);	  and	  reduced	  IL-­‐1β-­‐induced	  COX-­‐2	  and	  PGE2	  and	  basal	  MMP-­‐9	  production	  in	  
cultured	  placental	  trophoblasts	  	  (Pomini	  et	  al.	  1999,	  Roth	  and	  Fisher	  1999).	  	  	  	  	  
In	   addition	   to	   these	   in	   vitro	   studies,	   animal	   models	   have	   been	   utilised	   to	   further	  
investigate	  the	  effect	  of	  IL-­‐10	  administration	  on	  preterm	  labour.	  	  Using	  Il-­‐10	  knockout	  
mice,	  Robertson	  et	  al.	  demonstrated	  that	  IL-­‐10	  played	  an	  essential	  role	  in	  response	  to	  
intrauterine	  infection	  (Robertson	  et	  al.	  2006).	  	  The	  Il-­‐10	  knockout	  mice	  required	  a	  10-­‐
fold	  lower	  dose	  of	  LPS	  to	  induce	  50%	  fetal	  loss	  compared	  with	  wild-­‐type	  controls,	  and	  
LPS-­‐treatment	   induced	   greater	   pro-­‐inflammatory	   cytokine	   production	   in	   the	   serum,	  
uterus	  and	  placenta,	  compared	  to	  the	  wild-­‐type	  animals;	  these	  differences	  between	  the	  
Il-­‐10	   knockout	   mice	   and	   wild-­‐type	   mice	   were	   attenuated	   by	   the	   administration	   of	  
recombinant	  IL-­‐10.	  	  	  Interestingly,	  the	  administration	  of	  exogenous	  IL-­‐10	  to	  both	  wild-­‐
type	  and	  Il-­‐10	  knockout	  animals	  significantly	  reduced	  the	  number	  of	  LPS-­‐induced	  fetal	  
losses	  and	  down-­‐regulated	  inflammatory	  cytokine	  synthesis	  (Robertson	  et	  al.	  2006).	  	  In	  
a	  rat	  model	  of	  LPS-­‐induced	  preterm	  labour,	  administration	  of	  IL-­‐10,	  either	  at	  the	  same	  
time	  as	  LPS,	  or	  24	  hours	  later,	  significantly	  delayed	  the	  time	  to	  delivery	  and	  improved	  
pup	  survival	  rates	  (Terrone	  et	  al.	  2001).	  Also	  using	  a	  similar	  rat	  model,	  IL-­‐10	  was	  found	  
to	  inhibit	  E.coli-­‐induced	  white	  matter	  damage	  in	  rat	  pup	  brains	  by	  inhibiting	  microglial	  
activation	  (Rodts-­‐Palenik	  et	  al.	  2004,	  Pang	  et	  al.	  2005).	   	   	  Additionally,	   in	  a	  non-­‐human	  
primate	   model,	   treatment	   with	   IL-­‐10	   attenuated	   IL-­‐1β-­‐induced	   uterine	   contractions,	  
reduced	   the	   levels	   of	   TNF-­‐α	   and	   prostaglandins	   in	   the	   amniotic	   fluid	   and	   reduced	  
leukocyte	  influx	  into	  the	  amniotic	  fluid	  (Sadowsky	  et	  al.	  2003).	  	  	  	  
Collectively,	  these	  studies	  highlight	  the	  potential	  of	  IL-­‐10	  as	  a	  novel	  anti-­‐inflammatory	  
treatment	   for	   preterm	   labour,	   which	   can	   block	   the	   inflammatory	   signalling	   cascade	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associated	  with	   the	   initiation	   of	   parturition,	   and	  more	   importantly	   could	   protect	   the	  
fetal	  brain	  from	  the	  adverse	  effects	  of	  intrauterine	  infection	  and/or	  inflammation.	  	  	  
	  
1.3.5.5 Lipoxins	  
To	   prevent	   chronic	   inflammation,	   which	   can	   often	   lead	   to	   tissue	   injury,	   acute	  
inflammation	   must	   be	   halted	   once	   the	   original	   stimulus	   or	   infection	   has	   been	  
neutralised.	   	   This	   phase	   is	   referred	   to	   as	   the	   resolution	   of	   inflammation,	   and	   was	  
previously	   believed	   to	   be	   a	   passive	   process,	   which	   occurred	   as	   pro-­‐inflammatory	  
signals	   gradually	   fizzled	   out.	   	  However,	   in	   recent	   decades	   it	   has	   become	   increasingly	  
clear	   that	   the	   resolution	  of	   an	   inflammatory	   response	   is	   a	  highly	   co-­‐ordinated,	   active	  
process	   involving	   the	   production	   of	  mediators	  with	   specific	   pro-­‐resolution	   and	   anti-­‐
inflammatory	   actions	   (Gilroy	  et	  al.	   2004,	   Serhan	  et	  al.	   2008).	   	   Lipoxins	  were	   the	   first	  
family	   of	   lipid	   mediators	   recognised	   to	   have	   dual-­‐acting	   anti-­‐inflammatory	   and	   pro-­‐
resolution	   actions.	   	   Lipoxins,	   which	   are	   trihydroxy	   tetraene-­‐containing	   eicosanoids,	  
were	   first	   identified	   in	   1984	   as	   novel	   derivatives	   of	   arachidonic	   acid	   that	   were	  
proposed	  to	  be	  involved	  in	  regulating	  specific	  cellular	  responses	  in	  neutrophils	  (Serhan	  
et	  al.	  1984,	  Serhan	  et	  al.	  1984).	   	  Subsequent	  studies	  have	   identified	  a	  number	  of	  anti-­‐
inflammatory	  and	  pro-­‐resolution	  actions	  lipoxins	  have	  on	  a	  range	  of	  cell	  types	  	  	  
Lipoxins	  are	  derived	  from	  arachidonic	  acid	  via	  the	  action	  of	  their	  specific	  lipoxygenase	  
enzymes,	  5-­‐lipoxygenase	  (5-­‐LOX),	  12-­‐lipoxygenase	  (12-­‐LOX)	  and	  15-­‐lipoxygenase	  (15-­‐
LOX).	  	  In	  humans	  two	  main	  pathways	  of	  lipoxin	  synthesis	  have	  been	  identified,	  both	  of	  
which	  involve	  transcellular	  interactions	  between	  leukocytes	  and	  other	  cell	  types.	  	  	  The	  
first	   pathway,	   which	   was	   identified	   in	   blood	   vessels,	   involves	   platelet-­‐leukocyte	  
interactions,	  where	  arachidonic	  acid	  is	  oxygenated	  by	  5-­‐LOX	  in	  leukocytes	  resulting	  in	  
the	  production	  of	  leukotriene	  A4,	  which	  can	  then	  be	  rapidly	  converted	  by	  the	  actions	  of	  
12-­‐LOX	   in	   platelets	   into	   lipoxin	   A4	  and	   lipoxin	   B4.	   The	   second	   pathway,	   identified	   in	  
mucosal	  tissues,	  involves	  epithelial	  cell-­‐leukocyte	  interactions,	  where	  arachidonic	  acid	  
is	   oxygenated	   by	   15-­‐LOX	   in	   epithelial	   cells,	   resulting	   in	   the	   formation	   of	   the	  
intermediate	   lipid	   15S-­‐HETE,	  which	   can	   then	   be	   rapidly	   converted	   to	   lipoxin	   A4	   and	  
lipoxin	  B4	  by	  5-­‐LOX	  in	  leukocytes.	  	  A	  third	  pathway	  of	  lipoxin	  occurs	  in	  the	  presence	  of	  
aspirin,	  which	   results	   in	   the	  production	  of	  aspirin-­‐triggered	  or	  15-­‐epi-­‐lipoxins,	  which	  
are	  epimers	  of	  native	   lipoxin.	   	   In	   the	  presence	  of	  aspirin,	  COX-­‐2	  becomes	   irreversibly	  
acetylated,	   and	   drives	   arachidonic	   acid	   down	   the	   lipoxin	   synthesis	   pathway,	   rather	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than	   the	  prostaglandin	   synthesis	  pathway	  by	  producing	  15R-­‐HETE,	   this	   intermediate	  
can	  then	  be	  rapidly	  converted	  by	  5-­‐LOX	  in	  activated	  leukocytes	  to	  15-­‐epi-­‐lipoxin	  A4	  and	  
15-­‐epi-­‐lipoxin	   B4	   (Chiang	   et	   al.	   2005).	   	   	   Epi-­‐lipoxins	   have	   many	   of	   the	   same	   anti-­‐
inflammatory	  and	  pro-­‐resolution	  actions	  as	  lipoxins	  and	  it	  has	  been	  proposed	  that	  the	  
generation	  of	  epi-­‐lipoxins	  in	  the	  presence	  aspirin	  may	  underlie	  many	  of	  its	  therapeutic	  
actions	   (Claria	  and	  Serhan	  1995,	  Chiang	  et	  al.	  2005).	   	  The	   lipoxin	  synthesis	  pathways	  




Figure	   1.3	   -­‐	   Schematic	   representation	   of	   the	   three	   pathways	   of	   lipoxin	  
biosynthesis.	   	   	   Lipoxins	   are	   synthesised	   from	   arachidonic	   acid	   via	   the	   actions	   of	  
specific	  lipoxygenase	  enzymes,	  5-­‐LOX,	  12-­‐LOX	  and	  15-­‐LOX,	  during	  cell-­‐cell	  interactions.	  	  	  
A	   third	   pathway	   of	   lipoxin	   synthesis	   occurs	   in	   the	   presence	   of	   aspirin	   where	   COX-­‐2	  
becomes	  acetylated	  and	  drives	  arachidonic	  acid	  synthesis	  down	  the	  lipoxin-­‐generating	  
pathway,	  rather	  than	  the	  prostaglandin	  pathway,	  resulting	  in	  the	  production	  of	  aspirin-­‐
triggered,	  or	  15-­‐epi-­‐lipoxins.	  	  Adapted	  from	  Chiang	  et	  al.,	  2006.	  	  	  
	  
The	   actions	   of	   lipoxin	   A4	   are	   mediated	   via	   binding	   to	   a	   specific	   G-­‐protein	   coupled	  
receptor,	  FPR2/ALX,	  which	  is	  a	  member	  of	  the	  formyl	  peptide	  receptor	  family	  (Ye	  et	  al.	  
2009);	  although	  there	  is	  evidence	  that	  lipoxin	  A4	  can	  bind	  to	  other	  receptors	  including	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the	  cysteinyl	  leukotriene	  receptors	  (Badr	  et	  al.	  1989,	  McMahon	  et	  al.	  2000)	  and	  nuclear	  
aryl	  carbon	  receptor	  (Schaldach	  et	  al.	  1999,	  Machado	  et	  al.	  2006,	  McBerry	  et	  al.	  2012),	  
the	  anti-­‐inflammatory	  and	  pro-­‐resolution	  actions	  of	   lipoxins	  acting	  via	  FPR2/ALX	  are	  
the	  best	  characterised.	   	  FPR2/ALX	  is	  expressed	  on	  a	  wide	  number	  of	  cell	   types	   in	  the	  
body,	   including	   monocytes,	   macrophages,	   neutrophils,	   lymphocytes,	   microglial	   cells,	  
epithelial	  cells	  and	  fibroblasts	  in	  a	  variety	  of	  tissues	  (Migeotte	  et	  al.	  2006).	  	  During	  the	  
course	   of	   an	   inflammatory	   response,	   binding	   of	   lipoxin	   A4	   to	   FPR2/ALX	   elicits	   cell	  
specific	  actions	  to	  promote	  resolution.	  	  Lipoxins	  have	  been	  shown	  to	  inhibit	  neutrophil	  
activation,	  adhesion	  and	  chemotaxis	  (Lee	  et	  al.	  1989,	  Colgan	  et	  al.	  1993,	  Papayianni	  et	  
al.	  1996,	  Filep	  et	  al.	  2005),	  while	  increasing	  neutrophil	  apoptosis	  (El	  Kebir	  et	  al.	  2007);	  
in	  contrast	  lipoxins	  have	  been	  reported	  to	  stimulate	  monocyte	  adhesion	  and	  migration	  
(Maddox	  and	  Serhan	  1996,	  Maddox	  et	  al.	  1997),	  inhibit	  monocyte	  apoptosis	  (Simoes	  et	  
al.	   2010),	   and	   stimulate	   the	   non-­‐phlogistic	   phagocytosis	   of	   apoptotic	   neutrophils	   by	  
macrophages	   (Godson	  et	  al.	   2000).	   	   Additionally,	   lipoxins	   have	   also	   been	   reported	   to	  
down-­‐regulate	  the	  production	  of	  a	  number	  of	  pro-­‐inflammatory	  mediators,	  such	  as	  IL-­‐
1β,	   TNF-­‐α	   IL-­‐6,	   IL-­‐8	   and	   MMPs	   in	   synovial	   fibroblasts	   (Sodin-­‐Semrl	   et	   al.	   2000),	  
endothelial	   cells	   (Wu	   et	   al.	   2008),	   astrocytes	   (Decker	   et	   al.	   2009)	   and	   intestinal	  
epithelial	   cells	   in	   vitro	   (Kure	   et	   al.	   2009).	   	   The	   mechanisms	   by	   which	   lipoxins	   are	  
thought	   to	  regulate	   inflammatory	  mediator	  production	  have	  been	  reported	  to	   include	  
inhibition	  of	  the	  NF-­‐κB	  pathway	  (Gewirtz	  et	  al.	  2002,	  Wu	  et	  al.	  2008,	  Kure	  et	  al.	  2009,	  
Wang	  et	  al.	  2011);	  activation	  of	  PPAR-­‐γ	  (Sobrado	  et	  al.	  2009);	  and	  activation	  of	  STAT3,	  
resulting	  in	  increased	  SOCS3	  expression	  (Li	  et	  al.	  2011).	  	  	  
In	   vivo,	   lipoxin	   administration	   has	   been	   associated	  with	   decreased	   pro-­‐inflammatory	  
mediator	   production	   and	   reduced	   disease	   severity	   in	   animal	  models	   of	   a	   number	   of	  
inflammation-­‐associated	  pathologies	  including	  asthma	  (Levy	  et	  al.	  2002,	  El	  Kebir	  et	  al.	  
2009),	   arthritis	   (Conte	   et	   al.	   2010),	   Alzheimer’s	   disease	   (Medeiros	   et	   al.	   2013)	   and	  
inflammatory	   bowel	   disease	   (Gewirtz	   et	   al.	   2002),	   among	   others.	   	   These	   studies	  
demonstrate	   the	   therapeutic	   potential	   of	   lipoxins	   as	   a	   novel	   treatment	   for	  
inflammation-­‐associated	  pathologies.	  	  	  
The	  role	  of	   lipoxins	   in	  regulating	   inflammatory	  events	   in	  the	  reproductive	  tissues	  has	  
been	   less	   well	   explored.	   	   Given	   that	   many	   reproductive	   events,	   including	   ovulation,	  
menstruation,	  implantation	  and	  the	  initiation	  labour,	  are	  associated	  with	  inflammation	  
(Jabbour	  et	  al.	  2009),	  it	  is	  possible	  that	  lipoxins	  are	  important	  mediators	  in	  controlling	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these	   inflammatory	   events	   and	   driving	   the	   resolution	   and	   repair	   of	   these	   tissues	  
following	   inflammation.	   	   Evidence	   demonstrating	   the	   potential	   role	   of	   lipoxins	   in	  
regulating	   these	   inflammatory	   reproductive	   events	   has	   been	   recently	   reviewed	  
(Hutchinson	   et	   al.	   2011).	   	   Several	   studies	   have	   examined	   the	   role	   of	   lipoxins	   in	  
regulating	  inflammatory	  signalling	  in	  the	  endometrium.	  	  Macdonald	  et	  al.	  reported	  that	  
FPR2/ALX	  expression	  is	  increased	  in	  glandular	  epithelial	  cells	  and	  stromal	  cells	  in	  the	  
menstrual	   endometrium	   and	   first-­‐trimester	   decidua;	   and	   showed	   the	   lipoxin	   A4	  
suppressed	   phorbol	  myristate	   acetate-­‐induced	   expression	   of	   IL-­‐6	   and	   IL-­‐8	   in	   human	  
endometrial	  and	  decidual	  tissue	  explants	  (Macdonald	  et	  al.	  2011).	   	  Lipoxins	  have	  also	  
been	  investigated	  therapeutically	  in	  animal	  models	  of	  endometriosis	  (Chen	  et	  al.	  2010,	  
Xu	   et	   al.	   2012).	   	   Additionally,	   lipoxins	   have	   recently	   been	   identified	   as	   novel	   ERα	  
modulators	   (Russell	   et	   al.	   2011),	   and	   Xiong	   et	   al.	   reported	   that	   lipoxin	   A4	   blocked	  
embryo	  implantation	  in	  a	  mouse	  model	  by	  controlling	  ERα	  activity	  (Xiong	  et	  al.	  2013).	  	  	  
In	  gestational	  tissues,	  lipoxygenase	  enzyme	  expression	  has	  been	  detected.	  	  Expression	  
of	  5-­‐LOX	  has	  been	   reported	   throughout	  pregnancy	   in	   the	  human	  amnion	  and	   chorio-­‐
decidua	   tissue,	   with	   increased	   5-­‐LOX	   mRNA	   and	   protein	   in	   chorio-­‐decidual	   tissue	  
collected	  after	   labour	  at	   term,	   compared	  with	  before	   labour	   (Brown	  et	  al.	   1999);	  and	  
decreased	  15-­‐LOX	  has	  been	   reported	   in	  myometrial	   smooth	  muscle	   cells	   at	   term	  and	  
during	   labour	   (Lei	   and	   Rao	   1992).	   	   Additionally,	   5-­‐LOX	   and	   12-­‐LOX	   have	   also	   been	  
detected	   in	   baboon	   myometrium,	   cervix,	   chorion	   and	   decidua	   at	   term	   (Smith	   et	   al.	  
2001).	   	  Taken	  together,	  these	  studies	  demonstrate	  that	  the	  utero-­‐placental	  tissues	  are	  
capable	   of	   lipoxin	   synthesis,	   suggesting	   lipoxins	   may	   play	   a	   role	   in	   regulating	   the	  
inflammatory	   events	   surrounding	   parturition.	   	   Indeed,	   a	   recent	   study	   from	   our	  
laboratory	  has	  provided	  further	  evidence	  that	  lipoxins	  may	  be	  important	  mediators	  in	  
parturition.	  	  Maldonado-­‐Perez	  et	  al.	  reported	  that	  circulating	  serum	  lipoxin	  levels	  were	  
elevated	   in	   pregnant	   women,	   compared	   with	   non-­‐pregnant	   women,	   and	   FPR2/ALX	  
expression	   was	   increased	   in	   myometrial	   tissue	   obtained	   from	   women	   during	   term	  
labour,	   compared	   to	   non-­‐labouring	   women	   (Maldonado-­‐Perez	   et	   al.	   2010).	  	  
Additionally,	   the	   same	   study	   demonstrated	   that	   lipoxin	   A4	   is	   capable	   of	   regulating	  
inflammatory	  signalling	  in	  myometrium,	  where	  pre-­‐treatment	  with	  lipoxin	  A4	  was	  able	  
to	  significantly	  attenuate	  LPS-­‐induced	  IL-­‐6	  and	  IL-­‐8	  expression	  in	  cultured	  myometrial	  
explants	  in	  vitro	  (Maldonado-­‐Perez	  et	  al.	  2010).	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Collectively,	   these	   preliminary	   data	   showing	   lipoxins	   can	   regulate	   inflammation	   in	  
myometrial	   tissue	   obtained	   at	   term,	   alongside	   evidence	   from	   animal	   models	  
demonstrating	   lipoxins	   are	   useful	   in	   treating	   other	   inflammation-­‐associated	  
pathologies,	  suggest	   that	   lipoxins	  could	  be	  an	  exciting	  novel	   therapeutic	  option	   in	  the	  
treatment	  of	   inflammation-­‐induced	  preterm	  labour.	   	  Lipoxins	  have	  the	  potential	  to	  be	  
more	  useful	  than	  simple	  anti-­‐inflammatory	  agents	  alone	  due	  to	  their	  ability	  to	  promote	  
the	   resolution	   of	   inflammation,	   suggesting	   that	   rather	   than	   simply	   stopping	   the	  
inflammatory	  cascade	  associated	  with	  labour,	  they	  could	  also	  act	  to	  resolve	  the	  hostile	  
inflammatory	   intrauterine	   environment,	   thereby	   limiting	   inflammation-­‐induced	  
neonatal	   injury.	   	   Indeed	   studies	   have	   demonstrated	   the	   potential	   for	   lipoxins	   to	  
regulate	  inflammatory	  signalling	  in	  a	  human	  astrocytoma	  cell	  line	  in	  vitro	  (Decker	  et	  al.	  
2009)	  and	  also	  in	  a	  rat	  model	  of	  brain	  injury	  in	  vivo	  (Ye	  et	  al.	  2010),	  therefore	  lipoxins	  
may	  be	  able	  to	  protect	  the	  fetal	  brain	  from	  inflammation-­‐induced	  injury.	  	  
	  
1.3.6 Animal	  models	  of	  preterm	  labour	  
Animal	   models	   have	   been	   extensively	   used	   in	   the	   field	   of	   premature	   birth	   research,	  
both	   to	   investigate	   the	   underlying	   mechanisms	   surrounding	   the	   onset	   of	   preterm	  
labour	   and	   to	   test	   interventions	   to	   stop	   preterm	   delivery.	   	   The	   pros	   and	   cons	   of	   the	  
various	  animal	  models	  of	  preterm	  labour	  have	  been	  extensively	  reviewed	  (Elovitz	  and	  
Mrinalini	   2004,	   Mitchell	   and	   Taggart	   2009,	   Ratajczak	   et	   al.	   2010).	   Obviously	   due	   to	  
species	  differences,	  animal	  models	  can	  never	  fully	  recapitulate	  the	  clinical	  scenario	  of	  
preterm	   labour	   in	  women,	   but	   given	   the	  practical	   and	   ethical	   issues	   surrounding	   the	  
collection	   of	   tissues	   from	   pregnant	   women	   and	   the	   concerns	   about	   testing	   novel	  
therapies	  in	  pregnant	  women,	  animal	  models	  have	  been	  invaluable	  in	  providing	  insight	  
into	   the	   molecular	   events	   surrounding	   the	   onset	   of	   labour	   and	   providing	   proof	   of	  
principle	   of	   therapeutic	   strategies.	   	   	   Several	   species	   have	   been	   used	   as	   models	   of	  
preterm	   labour,	   including	   sheep,	   rodents	   and	   non-­‐human	   primates.	   	   The	   advantages	  
and	  disadvantages	  of	  each	  model	  will	  be	  briefly	  discussed.	  	  	  
Sheep	   have	   been	   primarily	   used	   to	   study	   the	   mechanisms	   surrounding	   the	   onset	   of	  
parturition	  at	  term,	  and	  the	  use	  of	  this	  animal	  model	  demonstrated	  a	  role	  for	  the	  fetus	  
in	  regulating	  the	  timing	  of	  parturition.	   	  Work	  by	  Liggins	  et	  al.	  more	  than	  40	  years	  ago	  
identified	   a	   role	   for	   the	   fetal	   hypothalamic-­‐pituitary	   axis	   in	   triggering	   the	   onset	   of	  
parturition	   (Liggins	   1968,	   Liggins	   et	   al.	   1973).	   	   As	   the	   fetus	   matures	   during	   late	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gestation,	  there	  is	  increased	  production	  of	  adrenocorticotropic	  hormone	  (ACTH)	  in	  the	  
fetal	  circulation,	  which	  stimulates	  the	  fetal	  adrenal	  gland	  to	  produce	  increased	  levels	  of	  
cortisol.	   	   This	   cortisol	   acts	   to	   promote	   maturation	   of	   the	   fetal	   lungs	   and	   stimulates	  
progesterone	  metabolism	   by	   the	   placenta,	   resulting	   in	   a	   drop	   in	   progesterone	   levels	  
and	  an	  increase	  in	  estrogen	  levels,	  which	  leads	  to	  the	  onset	  of	  parturition	  (Mitchell	  and	  
Taggart	  2009).	  	  The	  importance	  of	  ACTH	  and	  cortisol	  in	  initiating	  parturition	  in	  sheep	  
was	  demonstrated	  by	  studies	  showing	  infusion	  of	  either	  of	  these	  hormones	  successfully	  
induced	  preterm	  labour	  (Liggins	  1968).	  	   	  The	  main	  advantage	  of	  the	  sheep	  as	  a	  model	  
to	   study	   human	   parturition	   is	   the	   large	   size,	   which	   enables	   surgical	  manipulation	   of	  
both	   the	   fetus	   and	   the	   mother,	   allowing	   for	   longitudinal	   sampling	   of	   both	   across	  
gestation.	   	  Additionally,	   there	  are	  a	  number	  of	  similarities	  between	  human	  and	  sheep	  
pregnancy	  which	   include:	   the	   placenta	   being	   the	   source	   of	   progesterone	   throughout	  
most	  of	  pregnancy;	  a	  small	  number	  of	  fetuses;	  and	  the	  relatively	  long	  gestational	  period,	  
which	   is	   more	   similar	   to	   humans	   than	   other	   models.	   	   However,	   compared	   to	   other	  
models,	  sheep	  are	  relatively	  expensive	  and	  take	  longer	  to	  breed.	   	  Furthermore,	  unlike	  
in	   humans,	   the	   onset	   of	   parturition	   is	   dependent	   upon	   systemic	   progesterone	  
withdrawal;	   and	   the	   role	   of	   ACTH	   and	   cortisol	   in	   triggering	   the	   onset	   of	   parturition	  
appears	   not	   to	   apply	   to	   humans,	   as	   glucocorticoids	   do	   not	   induce	   labour	   in	   women	  
(Elovitz	   and	   Mrinalini	   2004,	   Mitchell	   and	   Taggart	   2009,	   Ratajczak	   et	   al.	   2010).	  	  
Nevertheless,	  the	  sheep	  provides	  a	  useful	  model	  system	  to	  study	  the	  fetal	  response	  to	  
intrauterine	  infection	  and	  the	  events	  surrounding	  fetal	  maturation	  (Schlafer	  et	  al.	  1994,	  
Kallapur	  et	  al.	  2001,	  Grigsby	  et	  al.	  2003,	  Westover	  et	  al.	  2012).	  	  	  
Non-­‐human	  primates	  have	  also	  been	  used	  in	  premature	  birth	  research.	  	  Intra-­‐amniotic	  
injection	   of	   bacteria	   or	   bacterial	   products	   such	   as	   LPS,	   and	   the	   pro-­‐inflammatory	  
cytokines	   IL-­‐1β	   or	   TNF-­‐α	   have	   been	   shown	   to	   induce	   preterm	   labour	   in	   rhesus	  
monkeys	   (Gravett	   et	   al.	   1994,	   Sadowsky	   et	   al.	   2006),	   thus	   confirming	   the	   role	   of	  
intrauterine	   infection	   and/or	   inflammation	   in	   the	   induction	   of	   preterm	   labour.	   	   	   The	  
non-­‐human	  primate	  model	  has	  also	  been	  used	  to	  test	  therapeutic	  interventions	  to	  delay	  
preterm	   delivery,	   including	   TLR-­‐4	   antagonists	   (Adams	   Waldorf	   et	   al.	   2008),	   IL-­‐10	  
(Sadowsky	   et	   al.	   2003)	   and	   oxytocin	   receptor	   antagonists	   (Reinheimer	   2007).	   	   The	  
main	  advantage	  of	   the	  non-­‐human	  primate	  as	  a	  model	   for	  studying	  preterm	  labour	   is	  
that	  it	  shares	  many	  similarities	  with	  human	  pregnancy,	  including:	  similar	  reproductive	  
physiology;	  no	  requirement	  for	  systemic	  progesterone	  withdrawal;	  similar	  gestational	  
length;	   and	   similar	   number	   of	   fetuses.	   	   Additionally,	   like	   the	   sheep,	   the	   non-­‐human	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primate	  model	  is	  amenable	  to	  chronic	  instrumentation	  and	  surgical	  interventions,	  thus	  
allowing	   for	   longitudinal	   sampling	   of	   both	   mother	   and	   fetus	   and	   monitoring	   of	  
myometrial	   contractions	   (Elovitz	   and	   Mrinalini	   2004,	   Mitchell	   and	   Taggart	   2009).	  	  	  
However,	   the	   high	   cost	   of	   using	   non-­‐human	   primates	   and	   the	   ethical	   considerations	  
associated	  with	  their	  use	  has	  limited	  the	  widespread	  use	  of	  non-­‐human	  primate	  models	  
in	  the	  study	  of	  preterm	  labour.	  	  	  
Another	  commonly	  used	  animal	  model	  in	  the	  field	  of	  parturition	  research	  is	  the	  rodent	  
model.	   	  Both	  mice	  and	  rats	  have	  been	  used,	  with	  mice	  being	  the	  most	  commonly	  used	  
animal	  model	  in	  this	  field.	  	  The	  administration	  of	  both	  bacterial	  products	  and	  the	  pro-­‐
inflammatory	  cytokines	   IL-­‐1β	  or	  TNF-­‐α	  have	  been	   found	   to	   induce	  preterm	   labour	   in	  
mice	  (Romero	  et	  al.	  1991,	  Silver	  et	  al.	  1994,	  Elovitz	  et	  al.	  2003,	  Yoshimura	  and	  Hirsch	  
2005),	   making	   the	   mouse	   a	   useful	   model	   with	   which	   to	   study	   the	   mechanisms	  
surrounding	   infection-­‐induced	   preterm	   labour	   and	   to	   test	   novel	   therapeutic	  
interventions	   for	   the	   treatment	   of	   preterm	   labour.	   	   Indeed,	   the	   mouse	   has	   been	  
extensively	  used	  to	  test	  a	  number	  of	  therapeutic	  agents,	  as	  detailed	  earlier.	   	  Using	  the	  
mouse	   as	   a	   model	   of	   preterm	   labour	   has	   several	   advantages	   over	   the	   other	   models	  
already	   described,	   these	   include:	   a	   short	   gestational	   period;	   ease	   of	   breeding;	   their	  
immune	   system	   has	   been	   relatively	   well	   characterised;	   and	   they	   can	   be	   genetically	  
manipulated	   such	   that	   specific	   genes	   can	  be	  either	  knocked	  out	  or	  over-­‐expressed	   to	  
examine	  the	  role	  of	  particular	  genes	  in	  preterm	  labour	  (Hirsch	  and	  Wang	  2005);	  thus	  
making	  them	  a	  useful	  cost-­‐effective	  model	   for	  the	  study	  of	  preterm	  labour.	   	  However,	  
there	  are	  clearly	  physiological	  differences	  between	  human	  and	  mouse	  pregnancy	  which	  
limit	   the	   usefulness	   of	   the	   mouse	   as	   a	   model	   of	   preterm	   labour,	   including:	   multiple	  
fetuses,	   very	   short	   gestational	   period	   compared	   to	   the	   human;	   and	   dependence	   on	  
systemic	   progesterone	   withdrawal	   for	   the	   initiation	   of	   term	   labour	   (Elovitz	   and	  
Mrinalini	   2004).	   	   Despite	   these	   physiological	   differences	   the	   requirement	   for	  
progesterone	  withdrawal	  for	  the	  onset	  of	  preterm	  labour	  in	  the	  context	  of	  intrauterine	  
infection	   has	   recently	   been	   questioned	   (Hirsch	   and	  Muhle	   2002,	  Murphy	   et	  al.	   2009,	  
Gonzalez	  et	  al.	  2011);	  suggesting	  that	  the	  mouse	  may	  be	  more	  relevant	  to	  study	  in	  this	  
context,	  rather	  than	  in	  spontaneous	  term	  labour.	  	  	  	  
The	   guinea	   pig	   has	   also	   been	   recently	   proposed	   as	   a	   more	   suitable	   model	   for	  
parturition	  research	   for	  a	  number	  of	  reasons,	   including:	   they	  do	  not	  require	  systemic	  
progesterone	   withdrawal	   prior	   to	   the	   onset	   of	   parturition;	   they	   have	   a	   longer	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gestational	   period	   compared	  with	   other	   rodents,	  which	   allows	  more	   opportunity	   for	  
longitudinal	  sampling;	  and	  the	  guinea	  pig	  fetus	  born	  at	  term	  is	  more	  developmentally	  
competent	   compared	   to	   other	   rodent	   species,	   making	   it	   more	   similar	   to	   the	   human	  
(Mitchell	   and	   Taggart	   2009).	   	   However,	   although	   the	   guinea	   pig	   could	   prove	   to	   be	   a	  
more	  applicable	  model	  for	  future	  studies	  of	  preterm	  labour,	  the	  genome	  of	  the	  guinea	  
pig	   is	   currently	   less	   well	   established	   than	   that	   of	   the	   mouse,	   which	   is	   limiting	   its	  
widespread	  use	  as	  model	  of	  preterm	  labour.	  	  
Aside	  from	  the	  choice	  of	  which	  animal	  model	  to	  use	  to	  study	  preterm	  labour,	  in	  models	  
of	   infection-­‐induced	  preterm	   labour,	   consideration	  must	  also	  be	  given	   to	   the	  route	  of	  
administration	   of	   the	   infectious	   agent,	   as	   each	   route	   of	   administration	   can	   model	   a	  
different	  clinical	  scenario	  in	  women.	  	  Systemic	  administration	  of	  bacterial	  products	  via	  
intra-­‐peritoneal	   (i.p.)	   injection	   has	   been	   carried	   out	   in	   a	   number	   of	   animal	   models	  
(Fidel	  et	  al.	  1994,	  Schlafer	  et	  al.	  1994,	  Kaga	  et	  al.	  1996,	  Robertson	  et	  al.	  2006);	  however,	  
systemic	  infection	  is	  rare	  in	  women	  in	  preterm	  labour,	  limiting	  the	  applicability	  of	  i.p.	  
administration	  as	  a	  model	  of	   infection-­‐induced	  preterm	   labour	   (Elovitz	  and	  Mrinalini	  
2004).	   	   	   Therefore,	   since	   the	   majority	   of	   women	   with	   infection-­‐associated	   preterm	  
labour	   actually	   present	   with	   a	   subclinical,	   local	   intrauterine	   infection,	   the	   local	  
administration	   of	   bacterial	   products	   is	   perhaps	   more	   appropriate.	   	   This	   has	   been	  
carried	  out	  in	  a	  number	  of	  ways	  including	  intra-­‐amniotic	  injection	  (Gravett	  et	  al.	  1994),	  
intrauterine	  administration	  (Elovitz	  et	  al.	  2003),	  intracervical	  injection	  (Reznikov	  et	  al.	  
1999)	   and	   intravaginal	   administration	   (Gonzalez	   et	   al.	   2011).	   	   Elovitz	   et	   al.	   have	  
discussed	  the	  pros	  and	  cons	  of	  each	  method	  (Elovitz	  and	  Mrinalini	  2004);	  it	  is	  clear	  that,	  
whichever	  method	  is	  chosen,	  a	  model	  of	  a	  localised	  infection	  within	  the	  uterus	  is	  more	  
applicable	  and	  more	  relevant	  to	  the	  scenario	  in	  women.	  	  	  
Therefore,	   although	   there	   are	   considerable	   inter-­‐species	   variations	   meaning	   that	  
discoveries	   in	   animal	  models	   are	  not	   always	   easily	   translatable	   to	  humans,	   given	   the	  
considerable	   practical	   and	   ethical	   limitations	   surrounding	   the	   collection	   of	   gestation	  
tissues	  throughout	  pregnancy	   in	  humans,	  animal	  models	  continue	  to	  be	  an	   invaluable	  
resource	  to	  this	   field	  of	  research.	   	  They	  have	  provided	  a	  greater	  understanding	  of	   the	  
molecular	   mechanisms	   responsible	   for	   the	   onset	   of	   parturition	   both	   at	   term	   and	  
preterm,	   and	   have	   been	   useful	   tools	   with	   which	   to	   investigate	   potential	   novel	  
therapeutic	  interventions.	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1.4 SUMMARY	  
This	   chapter	   has	   discussed	   the	   evidence	   that	   in	   humans	   the	   onset	   of	   labour	   is	  
associated	   with	   a	   core	   inflammatory	   response	   at	   the	   maternal-­‐fetal	   interface	  
culminating	  in	  fetal	  membrane	  rupture,	  cervical	  ripening	  and	  dilation	  and	  myometrial	  
contractions,	   which	   results	   in	   delivery	   of	   the	   fetus.	   	   The	   inappropriately	   timed	  
initiation	   of	   these	   inflammatory	   pathways,	   often	   in	   response	   to	   a	   pathological	  
intrauterine	   infection,	   can	   result	   in	   preterm	   birth.	   	   Despite	   decades	   of	   research,	  
preterm	   birth	   remains	   the	   leading	   cause	   of	   neonatal	   mortality	   and	   morbidity	  
worldwide	  and	  the	  currently	  available	  treatments	  have	  made	  little	  impact	  on	  reducing	  
the	   incidence	   of	   preterm	   labour	   and	   there	   is	   limited	   evidence	   that	   they	   improve	  
neonatal	  outcome.	  	  	  
Given	  the	  causal	  link	  between	  intrauterine	  infection	  and/or	  inflammation	  and	  preterm	  
labour,	   there	   is	   growing	   interest	   in	   examining	   whether	   using	   anti-­‐inflammatory	  
treatments	  may	  prove	  more	  successful.	  	  Animal	  models	  have	  proved	  invaluable	  in	  this	  
research,	   as	   they	   have	   provided	   a	   powerful	   tool	   to	   understand	   the	   mechanisms	  
underlying	   infection-­‐induced	   preterm	   labour	   and	   therefore	   have	   helped	   in	   the	  
identification	   of	   appropriate	   targets	   for	   novel	   treatment	   options.	   	   Anti-­‐inflammatory	  
agents	  have	  the	  potential	  to	  be	  more	  effective	  than	  the	  currently	  used	  tocolytic	  drugs,	  
as	  rather	  than	  simply	  targeting	  myometrial	  contractions,	  which	  are	  likely	  the	  physical	  
endpoint	  of	  a	  complex	  biological	   inflammatory	  cascade,	  anti-­‐inflammatory	  agents	  can	  
target	  the	  underlying	  mechanisms	  occurring	  much	  earlier	  in	  the	  cascade	  and	  hopefully	  
halt	   its	   progress	   before	   contractions	   are	   induced.	   	   Furthermore,	   anti-­‐inflammatory	  
agents	  which	  can	  also	  act	  to	  promote	  the	  resolution	  of	  inflammation,	  such	  as	  lipoxins,	  
may	   have	   the	   added	   benefit	   of	   being	   capable	   of	   resolving	   the	   inflammatory	   in	   utero	  
environment,	   thereby	   limiting	   exposure	  of	   the	   fetus	   to	  harmful	   inflammatory	   signals,	  
which	  are	  associated	  with	  adverse	  outcomes.	  	  
Therefore,	  as	  preterm	  birth	  continues	  to	  affect	  millions	  of	  babies	  worldwide	  each	  year	  
causing	  significant	  neonatal	  death	  and	   long-­‐term	  morbidities,	   research	  must	  continue	  
into	  improving	  our	  understanding	  of	  the	  multiple	  causes	  to	  enable	  the	  identification	  of	  
novel	   treatment	   options	   which	   will	   be	   effective	   in	   delaying	   preterm	   labour	   and	  
ultimately	  improving	  the	  long-­‐term	  health	  prospects	  of	  the	  baby.	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1.5 HYPOTHESIS	  AND	  AIMS	  
The	  work	   presented	   in	   this	   thesis	  was	   based	   on	   the	   hypothesis	   that	   preterm	   labour	  
occurs	   as	   a	   result	   of	   a	   local	   intrauterine	   infection	  which	   stimulates	   an	   inflammatory	  
and	  immune	  response	  in	  the	  utero-­‐placental	  tissues,	  and	  that	  using	  anti-­‐inflammatory	  
treatments	   or	   directly	   targeting	   immune	   cells	   would	   successfully	   delay	   delivery	   and	  
improve	   neonatal	   outcome.	   	   Therefore,	   the	   specific	   aims	   of	   the	  work	   presented	   here	  
were	  to	  use	  a	  mouse	  model	  of	  infection-­‐induced	  preterm	  labour	  to:	  
-­‐ Characterise	   the	   local	   inflammatory	   and	   immune	   response	   to	   a	   bacterial	  
intrauterine	  infection.	  
-­‐ Investigate	   the	   potential	   of	   anti-­‐inflammatory	   agents	   to	   delay	   delivery	   and	  
improve	  pup	  survival.	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Details	  for	  all	  the	  materials	  and	  reagents	  used	  are	  given	  in	  Appendix	  1.	  	  
	  
2.1 MOUSE	  MODEL	  OF	  PRETERM	  LABOUR	  
All	  animal	  experiments	  were	  conducted	  under	  a	  UK	  Home	  Office	  licence	  in	  line	  with	  the	  
Animals	   Scientific	   Procedure	   Act	   (1986).	   	   Timed-­‐pregnant	   CD1	   mice	   were	   obtained	  
from	   Charles	   River	   Laboratories	   on	   day	   9-­‐11	   of	   gestation	   (the	   day	   vaginal	   plug	  was	  
found	   was	   designated	   day	   1	   of	   gestation),	   and	   were	   allowed	   to	   acclimatise	   for	   a	  
minimum	  of	  6	  days	  prior	  to	  surgery.	  	  	  
On	   day	   17	   (D17)	   of	   gestation	   mice	   were	   anaesthetised	   with	   isoflurane	   (5%	   for	  
induction,	   2.5%	   for	   maintenance)	   in	   oxygen,	   and	   a	   mini-­‐laparotomy	   procedure	   was	  
performed,	  exposing	  the	  two	  uterine	  horns	  (Figure	  2.1A).	  	  The	  number	  of	  viable	  fetuses	  
in	  each	  horn	  was	  recorded.	  	  Using	  a	  33-­‐gauge	  Hamilton	  syringe,	  the	  mice	  then	  received	  
an	   intrauterine	   injection	  of	  either	  LPS	  (from	  E.Coli	  O111:B4)	  or	  PBS	   in	  a	  25µl	  volume	  
between	   the	   first	   and	   second	   anterior	   fetuses	   directly	   into	   the	   uterine	   lumen	   of	   the	  
horn	  with	  the	  most	  viable	  fetuses.	  	  Care	  was	  taken	  not	  to	  inject	  into	  the	  amniotic	  cavity	  
(Figure	  2.1B).	  	  The	  uterine	  horns	  were	  then	  carefully	  returned	  to	  the	  peritoneal	  cavity	  
(Figure	   2.1C)	   and	   the	   abdominal	  wall	   incision	  was	   then	   closed	  with	   a	   running	   stitch	  
using	  5/0	  sutures,	  and	  the	  skin	  was	  closed	  using	  interrupted	  double	  and	  single	  stitches	  
with	   4/0	   sutures	   (Figure	   2.1D).	   	   Immediately	   following	   surgery	   mice	   received	   a	  
subcutaneous	   injection	  of	   vetergesic	   analgesia,	   at	   a	  dose	  of	  0.03mg/ml	   in	  60µl.	   	  Mice	  
were	   kept	   at	   30oC	   while	   they	   recovered	   from	   surgery,	   before	   being	   transferred	   to	  
individual	  cages	  for	  monitoring.	  	  	  
Mice	  with	   fewer	   than	   seven	   viable	   fetuses	   at	   the	   time	   of	   intrauterine	   injection	  were	  
excluded,	  because	  this	  was	  considered	  an	  abnormal	  pregnancy	  for	  CD1	  mice	  due	  to	  the	  
small	   number	   of	   fetuses	   and	   early	   experiments	   indicated	   that	   these	   mice	   did	   not	  
respond	   to	   treatment	   normally.	   	   Following	   delivery	   mice	   were	   culled	   by	   cervical	  
dislocation.	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Figure	   2.1	   -­‐	   Mouse	  model	   of	   infection-­‐induced	   preterm	   labour.	   	   	   (A)	   CD-­‐1	  mice	  
were	   anaesthetised	   on	  D17	  of	   gestation	   and	   a	  mini	   laparotomy	  performed	   to	   expose	  
the	   uterine	   horns.	   	   (B)	   Mice	   received	   an	   intrauterine	   injection	   of	   either	   PBS	   or	   LPS	  
between	   the	   first	   and	   second	   anterior	   fetuses	   directly	   into	   the	   uterine	   lumen	   of	   the	  
horn	  with	  the	  most	  viable	  fetuses.	  	  (C)	  The	  uterine	  horns	  were	  carefully	  returned	  to	  the	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2.1.1 Time	  to	  delivery	  
Following	  surgery,	   individual	   cameras	  were	  attached	   to	   the	  end	  of	  each	  cage	  and	   the	  
mice	  were	  recorded	  using	  a	  digital	  video	  recorder.	   	  Time	  to	  delivery	  was	  recorded	  as	  
the	  number	  of	  hours	  from	  the	  time	  of	  intrauterine	  injection,	  to	  delivery	  of	  the	  first	  pup.	  	  
Preterm	   delivery	   was	   defined	   as	   delivery	   of	   the	   first	   pup	   within	   36	   hours	   of	  
intrauterine	  injection,	  with	  the	  preterm	  delivery	  rate	  calculated	  by	  dividing	  the	  number	  
of	  mice	  that	  delivered	  within	  36	  hours	  by	  the	  total	  number	  of	  mice	  in	  each	  treatment	  
group.	  
	  
2.1.2 Proportion	  of	  live	  born	  pups	  
Following	   delivery,	   the	   number	   of	   live	   pups	   present	   in	   the	   cage	   was	   recorded.	   	   The	  
proportion	  of	  live	  pups	  per	  dam	  was	  then	  calculated	  by	  taking	  the	  number	  of	  live	  pups	  
delivered	  and	  dividing	  this	  by	  the	  number	  of	  pups	  recorded	  at	  the	  time	  of	  intrauterine	  
injection.	  	  The	  proportion	  of	  live	  pups	  was	  determined	  within	  24	  hours	  of	  delivery.	  	  Any	  
live	  pups	   still	  within	   the	  uterine	  horns	   at	   this	   time	  were	  not	   considered	   as	   live	  born	  
pups	  as	  they	  had	  not	  been	  through	  labour.	  	  
	  
2.1.3 Tissue	  collection	  
Mice	   were	   culled	   by	   lethal	   exposure	   to	   CO2	   6	   hours	   post-­‐surgery	   and	   the	   utero-­‐
placental	  tissues	  were	  collected	  and	  fixed	  in	  three	  separate	  ways:	  RNAlater®	   for	  RNA	  
extraction;	  frozen	  on	  dry	  ice	  for	  protein	  extraction;	  and	  fixed	  in	  4%	  NBF	  for	  histological	  
analysis.	  	  	  RNAlater®	  samples	  were	  stored	  overnight	  at	  4oC	  and	  then	  transferred	  to	  an	  	  	  	  	  
-­‐80oC	   freezer.	   	   Samples	   frozen	   in	  dry	   ice	  were	   stored	   immediately	   at	   -­‐80oC.	   	   Samples	  
collected	  in	  4%	  NBF	  were	  left	  for	  24	  hours	  and	  then	  transferred	  to	  70%	  ethanol	  prior	  
to	  embedding	  in	  paraffin	  blocks.	  Additionally	  fetal	  brains	  were	  collected	  in	  RNAlater®.	  	  
Amniotic	  fluid	  and	  maternal	  serum	  were	  also	  collected	  for	  analysis.	  	  
2.1.3.1 Uterus	  
Samples	   of	   uterine	   horn	  were	   collected	   from	   three	   separate	   sites	   within	   the	   uterus:	  
from	  the	  top	  of	  the	  injected	  uterine	  horn;	  the	  lower	  part	  of	  the	  uterine	  horn,	  close	  to	  the	  
cervix;	  and	  from	  the	  top	  of	  the	  un-­‐injected	  uterine	  horn.	  	  One	  piece	  of	  uterus	  collected	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from	  each	  site	  was	  fixed	  in	  RNAlater®,	  frozen	  on	  dry	  ice	  and	  fixed	  in	  4%	  NBF,	  resulting	  
in	  a	  total	  of	  nine	  pieces	  of	  uterus	  taken	  from	  each	  mouse.	  	  
2.1.3.2 Fetal	  membranes	  
Fetal	   membranes	   were	   dissected	   free	   from	   the	   placenta	   and	   collected	   from	   nine	  
separate	  gestational	  sacs.	   	  Fetal	  membranes	  from	  the	  three	  pups	  surrounding	  the	  site	  
of	  injection	  were	  collected	  in	  RNAlater®.	  	  The	  following	  three	  sets	  of	  fetal	  membranes	  
from	   adjacent	   pups	  were	   frozen	   in	   dry	   ice.	   	   The	   final	   three	   sets	   of	   fetal	  membranes	  
were	  collected	  into	  NBF.	  	  
2.1.3.3 Placenta	  
Placental	   tissue	  was	   collected	   from	   six	   separate	   gestational	   sacs.	   	   Placentas	   from	   the	  
three	  pups	  surrounding	  the	  site	  of	  injection	  were	  collected	  and	  halved,	  with	  half	  stored	  
in	  RNAlater®,	  and	  half	   frozen	   in	  dry	   ice.	   	  The	  placentas	   from	  the	  adjacent	  three	  pups	  
were	  stored	  in	  NBF.	  	  	  
2.1.3.4 Fetal	  brains	  
Fetal	   brains	  were	   collected	   from	   the	   three	   pups	   surrounding	   the	   site	   of	   intrauterine	  
injection.	  	  Whole	  brains	  were	  dissected	  free	  from	  the	  skull	  and	  fixed	  in	  RNAlater®.	  	  
2.1.3.5 Amniotic	  fluid	  
Amniotic	   fluid	   was	   collected	   from	   each	   gestational	   sac	   and	   pooled	   for	   each	   horn,	  
resulting	   in	   two	   amniotic	   fluid	   samples	   per	  mouse.	   	   Amniotic	   fluid	   was	   kept	   on	   ice,	  
centrifuged	  at	  8000	  g	  for	  10	  minutes	  at	  4oC	  and	  aliquoted	  in	  0.5ml	  volumes	  for	  storage	  
at	  -­‐80oC.	  	  
2.1.3.6 Serum	  
Immediately	  after	  mice	  were	  culled,	  blood	  was	  collected	  from	  the	  vena	  cava	  using	  a	  25-­‐
gauge	   needle	   and	   1ml	   syringe.	   	   Blood	   samples	  were	   allowed	   to	   clot	   for	   1-­‐2	   hours	   at	  
room	   temperature,	   prior	   to	   being	   centrifuged	   at	   2000	  g	   for	   20	  minutes.	   	   Serum	  was	  
then	  aliquoted	  in	  25µl	  volumes	  and	  stored	  at	  -­‐80oC.	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2.2 RNA	  EXTRACTION	  AND	  REVERSE	  TRANSCRIPTION	  
2.2.1 RNA	  extraction	  
Two	  similar	  methods	  of	  RNA	  extraction	  were	  used,	  depending	  on	   the	   tissue	   the	  RNA	  
was	  to	  be	  extracted	  from.	  	  Both	  methods	  were	  based	  on	  homogenisation	  of	  tissue	  in	  a	  
phenol-­‐guanidine	   thyiocyanate	   solution,	   followed	   by	   isolation	   of	   the	   RNA	   using	  
RNeasy®	  mini	   columns.	   	  The	  spin	  columns	  contain	  a	   silica-­‐based	  membrane	   that	   can	  
selectively	  bind	  the	  RNA	  and	  the	  RNA	  is	  then	  eluted	  in	  nuclease-­‐free	  water.	  	  	  
2.2.1.1 RNA	  extraction	  from	  utero-­‐placental	  tissues	  
Utero-­‐placental	  tissue	  samples	  stored	  in	  RNAlater®	  were	  thawed	  and	  transferred	  to	  a	  
2ml	  Eppendorf	  tube	  containing	  1ml	  TRI	  Reagent®	  and	  a	  stainless	  steel	  bead.	  	  Samples	  
were	   then	   homogenised	   using	   a	   tissue	   lyser	   for	   two	   3	   minutes	   cycles	   at	   25	   Hz	   and	  
incubated	   at	   room	   temperature	   for	   15	   minutes.	   	   Following	   this,	   samples	   were	  
centrifuged	  at	  8000g	   for	  10	  minutes	   in	  order	   to	   remove	  any	   insoluble	  material.	   	   The	  
resulting	  supernatant	  was	  transferred	  to	  phase-­‐lock	  tubes	  and	  to	  precipitate	  the	  RNA,	  
200µl	   bromochloropropane	   (BCP)	   added	   to	   each	   tube	   and	   the	   samples	   were	   left	   to	  
incubate	  for	  15	  minutes	  before	  being	  centrifuged	  at	  maximum	  speed	  for	  15	  minutes	  at	  
4oC	  to	   isolate	  the	  RNA	  in	  the	  aqueous	  phase.	  The	  aqueous	  phase	  was	  transferred	  to	  a	  
fresh	  1.5ml	  Eppendorf	   tube	   and	   an	   equal	   volume	  of	   70%	  ethanol	  was	   added	   to	   each	  
sample	  and	  mixed	  by	  pipetting.	  	  	  
To	   isolate	   the	   RNA,	   samples	  were	   then	   added	   to	   the	   RNeasy	  mini	   spin	   columns	   and	  
manufacturer’s	   guidelines	   were	   followed.	   	   Briefly,	   columns	   were	   centrifuged	   for	   15	  
seconds	   at	   8000g	   at	   room	   temperature.	   	   	   The	   resultant	   flow	   through	  was	   discarded,	  
350µl	  of	  RW1	  buffer	  was	  then	  added	  to	  each	  column	  and	  they	  were	  centrifuged	  again.	  	  
On	  column	  DNA	  digestion	  was	  then	  performed	  by	  the	  addition	  of	  80µl	  DNase	  1	  solution	  
directly	  onto	  the	  column	  membrane.	  	  Samples	  were	  incubated	  for	  15	  minutes	  at	  room	  
temperature.	   	   The	   columns	   were	   then	   washed	   with	   350µl	   RW1	   buffer.	   	   This	   was	  
followed	  by	  a	   further	  2	  washes	  with	  500µl	  of	  RPE	  buffer.	   	  To	  ensure	  no	  carry	  over	  of	  
ethanol,	   the	  columns	  were	  placed	   in	  clean	  collection	  tubes	  and	  centrifuged	  at	  12000g	  
for	  1	  minute.	  	  Finally,	  RNA	  was	  eluted	  in	  30-­‐50µl	  of	  nuclease-­‐free	  water.	  	  The	  RNA	  was	  
stored	  at	  -­‐80oC.	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2.2.1.2 RNA	  extraction	  from	  fetal	  brains	  
A	  slightly	  different	  protocol	  was	  used	  to	  extract	  RNA	  from	  fetal	  brains	  due	  to	  the	  fact	  
that	   brain	   tissue	   is	   rich	   in	   fat,	   therefore	   the	   protocol	   in	   the	   RNeasy®	   Lipid	   Kit	   was	  
followed.	   	   Fetal	   brains	   stored	   in	   RNAlater®	   were	   thawed	   and	   transferred	   to	   a	   2ml	  
Eppendorf	   tube	   containing	   1ml	   QIAzol®	   Lysis	   Reagent	   and	   a	   stainless	   steel	   bead.	  
Samples	  were	  then	  homogenised	  using	  a	  tissue	  lyser	  for	  two	  3	  minute	  cycles	  at	  25	  Hz	  
and	  incubated	  at	  room	  temperature	  for	  5	  minutes.	   	  200µl	  of	  chloroform	  was	  added	  to	  
each	   sample	   to	   precipitate	   the	   RNA	   and	   the	   samples	   were	   incubated	   at	   room	  
temperature	  for	  2-­‐3	  minutes	  before	  being	  centrifuged	  at	  12000g	  for	  15	  minutes	  at	  4oC.	  	  
The	   aqueous	   phase	   was	   transferred	   to	   a	   fresh	   1.5ml	   Eppendorf	   tube	   and	   an	   equal	  
volume	  of	  70%	  ethanol	  was	  added	  to	  each	  sample	  and	  mixed	  by	  pipetting.	  	  	  
Samples	  were	  then	  added	  to	  the	  RNeasy®	  mini	  columns	  and	  the	  protocol	  followed,	  as	  
detailed	  above.	  	  	  
2.2.1.3 RNA	  quantification	  	  
The	  RNA	  concentration	  was	  calculated	  by	  measuring	  the	  absorbance	  of	  the	  RNA	  sample	  
at	  260	  and	  280nm	  on	  the	  Nanodrop	  ND-­‐1000.	  	  The	  260:280	  absorbance	  ratio	  was	  used	  
as	  an	  indicator	  of	  RNA	  purity,	  with	  ratios	  of	  1.8-­‐2.1	  considered	  acceptable.	  
	  
2.2.2 Reverse	  transcription	  
300ng	   of	   RNA	   was	   reverse	   transcribed	   using	   the	   High	   Capacity	   cDNA	   Reverse	  
Transcription	   kit.	   	   A	   2X	   mastermix	   containing	   RT	   buffer,	   dNTPs,	   random	   primers,	  
RNase	  inhibitor	  and	  reverse	  transcriptase,	  was	  prepared	  for	  each	  sample,	  see	  Table	  2.1.	  	  
10µl	  of	   the	  mastermix	  was	  mixed	  with	  10µl	  of	  RNA	  diluted	   to	  30ng/µl	   in	  RNase-­‐free	  
water.	   	   Samples	  were	   incubated	   for	   10	  minutes	   at	   25oC,	   followed	   by	   120	  minutes	   at	  
37oC	  and	  5	  minutes	  at	  85oC.	  	  Two	  controls	  were	  included	  in	  each	  cDNA	  experiment:	  RT	  
negative	   (template	  RNA	  but	  no	   reverse	   transcriptase)	   and	  RT	  H20	   (including	   reverse	  
transcriptase,	   but	  with	   nuclease	   free	  water	   instead	   of	   template	   RNA).	   	   The	   resultant	  
cDNA	  was	   stored	  at	   -­‐20oC	   for	  use	   in	  quantitative	   real-­‐time	  PCR	  reactions,	   as	  detailed	  
below.	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RT-­‐PCR	  mastermix	  component	   Volume	  per	  sample	  (µl)	  
10x	  RT	  Buffer	   2	  
25x	  dNTP	  Mix	  (100mM)	   0.8	  
10x	  RT	  Random	  Primers	   2	  
Multiscribe	  Reverse	  Transcriptase	   1	  
RNase	  Inhibitor	   1	  
Nuclease-­‐free	  H20	   3.2	  
Table	  2.1	  -­‐	  Reverse	  transcription	  mastermix	  
	  
	  
2.3 QUANTITATIVE	  REAL-­‐TIME	  PCR	  
Quantitative	   real-­‐time	   PCR	   (qRT-­‐PCR)	   was	   carried	   out	   to	   quantify	   the	   expression	   of	  
specific	   genes.	   	   The	   addition	   of	   a	   fluorescently	   labelled	   probe,	   in	   addition	   to	   specific	  
forward	   and	   reverse	   primers,	   allows	   for	   quantification	   of	   the	   abundance	   of	   a	   target	  
gene,	   relative	   to	   the	   levels	   of	   a	   housekeeping	   gene.	   	   	   The	   probe	   is	   labelled	   with	   a	  
fluorescent	   reporter	   dye	   at	   the	   5’-­‐end	   and	   a	   quencher	   dye	   at	   the	   3’-­‐end.	   	   The	   probe	  
anneals	   to	   the	   target	  DNA	  sequence	  between	  the	   forward	  and	  reverse	  primers.	  When	  
the	   probe	   is	   intact	   and	   annealed	   to	   the	   DNA	   sequence,	   very	   little	   fluorescence	   is	  
emitted	  due	  to	  the	  close	  proximity	  to	  the	  quencher.	  	  During	  amplification	  of	  the	  target	  
sequence,	   the	  5’	   to	  3’	   exonuclease	  activity	  of	   the	  enzyme	  Taq	  polymerase	  cleaves	   the	  
probe,	  resulting	  in	  the	  fluorescent	  reporter	  dye	  being	  released	  from	  the	  quencher,	  thus	  
fluorescent	   light	   is	   then	   emitted	   from	   the	   reporter	   dye	   upon	   excitation	  with	   a	   laser.	  	  
The	   amount	   of	   fluorescence	   measured	   is	   directly	   proportional	   to	   the	   amount	   of	  
template	  present	  in	  the	  PCR.	  	  
The	  use	  of	  different	  reporter	  dyes	  allows	  the	  expression	  of	  both	  target	  and	  endogenous	  
control	  genes	  to	  be	  measured	  in	  each	  sample	  at	  the	  same	  time.	  	  Expression	  of	  the	  gene,	  
β-­‐actin	   was	   found	   to	   be	   consistent	   during	   late	   pregnancy	   and	   between	   different	  
treatment	   groups,	   therefore	   this	   was	   used	   as	   the	   endogenous	   control	   gene	   in	   all	  
experiments.	  	  The	  amount	  of	  target	  gene	  measured	  was	  normalised	  to	  the	  amount	  of	  β-­‐
actin	  present.	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2.3.1 Primers	  and	  probes	  
The	  expression	  of	   the	  majority	  of	   genes	  was	  measured	  using	  pre-­‐designed	  Taqman®	  	  
gene	  expression	  assays	  from	  Applied	  Biosystems,	  which	  are	  optimised	  for	  use	  in	  qRT-­‐
PCR.	  	  The	  gene	  names	  and	  corresponding	  assay	  IDs	  are	  given	  in	  Table	  2.2.	  
	  
Gene	  	   Taqman®	  	  Gene	  expression	  Assay	  ID	  
15-­‐Hpgd	   Mm00515121_m1	  
Ccl2	   Mm00441242_m1	  
Cxcl1	   Mm04207460_m1	  
Cxcl2	   Mm00436450_m1	  
Cxcl5	   Mm00436451_g1	  
Emr1	   Mm00802529_m1	  
Fpr2	   Mm00484464_s1	  
Gfap	   Mm01253033_m1	  
Il-­‐1β	   Mm00434228_m1	  
Il-­‐10	   Mm00439614_m1	  
Mtap2	   Mm00485231_m1	  
Ngp	   Mm01250218_m1	  
TNF-­‐α	   Mm99999068_m1	  
Table	  2.2	  -­‐	  Taqman®	  	  gene	  expression	  assay	  IDs	  used	  in	  qRT-­‐PCR	  experiments.	  
	  
Primers	   and	   probes	   for	   β-­‐actin,	   Cox-­‐2	   and	   Il-­‐6	  were	   designed	   using	   Primer	   Express	  
Software	   Version	   3	   (Applied	   Biosystems).	   	   To	   avoid	   amplification	   of	   genomic	   DNA,	  
probes	  were	  designed	   to	  span	  an	  exon-­‐exon	   junction.	   	  The	  specificity	  of	   the	  designed	  
primers	  was	  then	  checked	  using	  BLAST	  (Basic	  Local	  Alignment	  Tool).	   	  The	  sequences	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Gene	   Primer/Probe	   Sequence	  
β-­‐actin	   Forward	   5’-­‐GCTTCTTTGCAGCTCCTTCGT-­‐3’	  
Reverse	   5’-­‐GCGCAGCGATATCGTCATC-­‐3’	  
Probe	   5’-­‐CACCCGCCACCAGTTCGCCAT-­‐3’	  
Cox-­‐2	   Forward	   5’-­‐GCTTCGGGAGCACAACAG-­‐3’	  
Reverse	   5’-­‐TGGTTTGGAATAGTTGCTC-­‐3’	  
Probe	   5’-­‐TGTGCGACATACTCAAGCA-­‐3’	  
Il-­‐6	   Forward	   5’-­‐CCACGGCCTTCCCTACTTC-­‐3’	  
Reverse	   5’-­‐TGCACAACTCTTTTCTCATTCCA-­‐3’	  
Probe	   5’-­‐TCACAGAGGATACCACTCCCAACAGACCTG-­‐3’	  
Table	  2.3	  -­‐	  Primer	  and	  probe	  sequences	  designed	  using	  Primer	  Express	  Software.	  
	  
The	   designed	   primer	   and	   probe	   sets	   were	   validated	   to	   ensure	   that	   the	   endogenous	  
control	  gene	  and	  target	  gene	  had	  similar	  amplification	  efficiencies,	  as	  is	  required	  when	  
using	  the	  comparative	  Ct	  method	  of	  analysis	  (discussed	  below).	  	  Serially	  diluted	  cDNA	  
samples	   were	   used	   to	   determine	   the	   amplification	   efficiencies	   of	   each	   gene,	   both	   in	  
singleplex	  and	  multiplex	  reactions	  (i.e.	  target	  gene	  with	  the	  endogenous	  control	  gene	  in	  
the	  same	  well).	  	  	  The	  amplification	  efficiency	  of	  each	  gene	  was	  calculated	  by	  plotting	  the	  
Ct	  against	  the	  log	  input	  of	  RNA	  (ng),	  to	  give	  a	  semi-­‐log	  regression	  line.	  	  The	  slope	  of	  the	  
line	  indicates	  the	  efficiency	  of	  the	  reaction,	  with	  a	  slope	  value	  of	  around	  -­‐3.3	  indicating	  
100%	   amplification	   efficiency.	   	   Plotting	   the	   ΔCT	   value	   (Ct	   of	   target	   gene	   –	   Ct	   of	  
endogenous	  control	  gene)	  against	  the	  log	  input	  of	  RNA	  and	  calculating	  the	  slope	  of	  the	  
semi-­‐log	   regression	   line	   was	   also	   used	   to	   check	   the	   amplification	   efficiencies	   of	   the	  
genes	  would	  not	  be	  affected	  by	  running	  in	  multiplex.	  	  In	  this	  case,	  the	  absolute	  value	  of	  
the	  slope	  was	  to	  be	  <0.1.	  	  Representative	  data	  from	  a	  validation	  experiment	  are	  shown	  
in	  Figure	  2.2.	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Figure	  2.2	  -­‐	  Cox-­‐2	  and	  β-­‐actin	  primer	  and	  probe	  validation.	  	  	  Log	  RNA	  input	  plotted	  
against	  ΔCt	  value.	  	  Absolute	  value	  of	  slope	  <0.1.	  	  	  
	  
2.3.2 Method	  
Details	  of	   the	  reaction	  mix	  prepared	  for	  each	  duplicate	  sample	  are	  given	   in	  Table	  2.4,	  
including	   the	   final	   concentration	  of	   each	   component.	   	  Either	   target	   gene	  primers	  and	  
probes	  or	  a	  Taqman®	  gene	  expression	  assay	  were	  used	  in	  each	  reaction,	  depending	  on	  
the	   gene	   of	   interest,	   as	   detailed	   in	   Table	   2.2.	   and	   Table	   2.3.	   above.	   	   Reactions	   were	  
made	  up	  to	  30µl	  with	  nuclease-­‐free	  water.	  	  In	  addition	  to	  the	  two	  controls	  made	  during	  
reverse	  transcription,	  RT	  negative	  and	  RT	  H20,	  a	  negative	  control	  was	  included	  which	  
consisted	  of	  reaction	  mixture	  plus	  nuclease-­‐free	  water	  in	  place	  of	  cDNA.	  	  On	  each	  plate	  
a	  calibrator	  sample	  was	  also	  included,	  this	  was	  cDNA	  from	  an	  untreated	  tissue,	  which	  
expressed	   the	   gene	   of	   interest.	   	   Calibrators	   used	   are	   detailed	   in	   the	   relevant	   results	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qRT-­‐PCR	  Mix	  component	   Volume	  (µ l)	   Final	  Concentration	  
2X	  Taqman®	  	  mastermix	   15	   1X	  
β-­‐actin	  forward	  and	  reverse	  primers	   0.72	   60nM	  
β-­‐actin	  probe	   1.2	   200nM	  
Target	  gene	  forward	  and	  reverse	  primers	   0.72	   300nM	  
Target	  gene	  probe	   1.2	   200nM	  
20x	  Taqman®	  	  Gene	  Expression	  Assay	   1.5	   900nM	  (primers)	  
250nM	  (probe)	  
cDNA	   1.5	   -­‐	  
Table	  2.4	  -­‐	  qRT-­‐PCR	  reaction	  mix.	  
	  
2.3.3 Analysis	  
Analysis	  of	  qRT-­‐PCR	  data	  was	   carried	  out	  using	   the	   comparative	  Ct	  method.	   	   	   In	   this	  
method	   of	   analysis,	   after	   normalising	   Ct	   values	   to	   the	   endogenous	   control	   gene,	   all	  
samples	  are	  compared	  to	  a	  control	  or	  calibrator	  sample,	  resulting	  in	  the	  calculation	  of	  
the	  fold	  change	  in	  expression	  of	  the	  target	  gene	  relative	  to	  the	  control	  sample,	  using	  the	  
formula	   2-­‐ΔΔCt.	   	   	   The	   Ct	   value	   is	   the	   cycle	   at	   which	   expression	   of	   the	   gene	   crosses	   a	  
threshold;	   ΔCt	   is	   the	   Ct	   of	   target	   gene	   –	   Ct	   of	   β-­‐actin;	   and	   ΔΔCt	   is	   the	   difference	  
between	  the	  ΔCt	  of	  the	  sample	  and	  that	  of	  the	  calibrator	  or	  control.	  	  	  
Each	  sample	  is	  representative	  of	  one	  dam,	  where	  RNA	  was	  extracted	  from	  three	  pieces	  
of	  tissue	  per	  dam	  (i.e.,	  three	  pieces	  of	  uterus,	  three	  fetal	  membranes,	  three	  placentas	  or	  
three	  fetal	  brains	  per	  dam)	  and	  analysed	  by	  qRT-­‐PCR	  and	  the	  average	  ΔΔCt	  value	  of	  the	  
three	  pieces	  of	  tissue	  was	  then	  used	  for	  calculation	  of	  the	  fold	  change.	  	  
	  
	  
2.4 ENZYME-­‐LINKED	  IMMUNOSORBENT	  ASSAY	  (ELISA)	  
ELISAs	  were	  used	  to	  quantify	  the	  amount	  of	  particular	  proteins	  in	  serum	  and	  amniotic	  
fluid	  samples.	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2.4.1 Sandwich	  ELISAs	  
In	  a	  sandwich	  ELISA,	  plates	  are	  pre-­‐coated	  with	  a	  monoclonal	  antibody	  that	  is	  specific	  
to	  the	  protein	  of	  interest.	  	  Standards,	  samples	  and	  controls	  are	  then	  added	  to	  the	  plate	  
and	  any	  protein	  of	   interest	  present	   in	  the	  sample	  will	  be	  bound	  by	  the	  antibody.	   	  The	  
plate	  is	  washed	  to	  remove	  any	  unbound	  proteins,	  prior	  to	  the	  addition	  of	  a	  secondary	  
antibody,	  specific	  to	  a	  different	  epitope	  on	  the	  protein	  of	  interest.	  	  This	  second	  antibody	  
is	  conjugated	  to	  the	  enzyme	  horseradish	  peroxidase	  (HRP).	   	  A	  further	  wash	  is	  carried	  
out	   to	   remove	   any	   unbound	   antibody-­‐enzyme	   conjugates	   and	   a	   substrate	   solution	   of	  
hydrogen	   peroxide	   and	   tetramethylbenzidine	   (TMB)	   is	   added	   to	   detect	   peroxidase	  
activity.	   	   The	   enzyme	   reaction	   results	   in	   a	   colour	   change	  which	   can	   be	  measured	   by	  
spectrophotometry.	  	  The	  intensity	  of	  colour	  measured	  is	  proportional	  to	  the	  amount	  of	  
the	  specific	  protein	  of	  interest	  in	  the	  sample.	   	  The	  standard	  curve	  can	  then	  be	  used	  to	  
extrapolate	  protein	  concentration.	  	  	  
All	  sandwich	  ELISA	  plates	  were	  read	  at	  450nm	  with	  wavelength	  correction	  at	  570nm	  
using	  a	  spectrophotometer	  and	  Softmax	  Pro	  software.	  	  	  
2.4.1.1 TNF-­‐α 	  ELISA	  
A	  Quantikine®	  ELISA	  kit	  was	  used	  for	  the	  quantification	  of	  TNF-­‐α	  in	  amniotic	  fluid	  and	  
serum.	  	  The	  standard	  curve	  allowed	  for	  detection	  of	  700	  to	  10.9	  pg/ml	  of	  TNF-­‐α.	  	  	  50µl	  
of	  assay	  diluent	  was	  added	  to	  each	  well,	  followed	  by	  50µl	  of	  standards	  and	  samples	  and	  
the	   plate	   was	   then	   incubated	   for	   2	   hours	   at	   room	   temperature.	   	   All	   samples	   were	  
assayed	   neat.	   	   The	   plate	  was	   then	  washed	   four	   times	  with	  wash	   buffer	   and	   100µl	   of	  
TNF-­‐α	  conjugate	  (polyclonal	  antibody	  against	  mouse	  TNF-­‐α	  conjugated	  to	  horseradish	  
peroxidase)	   added	   to	   each	   well.	   	   The	   plate	   was	   incubated	   for	   2	   hours	   at	   room	  
temperature.	  	  Following	  a	  further	  wash,	  100µl	  of	  substrate	  solution	  was	  added	  to	  each	  
well	   and	   the	   plate	   incubated	   at	   room	   temperature	   for	   30	   minutes.	   	   100µl	   of	   stop	  
solution	  was	  then	  added	  to	  quench	  the	  reaction	  and	  the	  plate	  read	  as	  described	  above.	  	  
2.4.1.2 	  IL-­‐1β 	  ELISA	  	  
As	  with	   TNF-­‐α,	   a	   Quantikine®	   ELISA	   kit	   was	   used	   for	   the	   quantification	   of	   IL-­‐1β	   in	  
amniotic	  fluid.	  	  The	  standard	  curve	  allowed	  for	  detection	  of	  800	  to	  12.5pg/ml	  of	  IL-­‐1β.	  	  
All	  samples	  were	  assayed	  neat.	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2.4.1.3 IL-­‐6	  ELISA	  
As	  with	  TNF-­‐α	  and	  IL-­‐1β	  a	  Quantikine®	  ELISA	  kit	  was	  used	  for	  the	  quantification	  of	  IL-­‐
6	  in	  amniotic	  fluid.	  	  The	  standard	  curve	  allowed	  for	  detection	  of	  500	  to	  7.8pg/ml	  of	  IL-­‐6.	  	  
Samples	  were	  diluted	  1	  in	  10	  before	  being	  assayed.	  	  	  
2.4.1.4 IL-­‐10	  ELISA	  
A	  Quantikine®	  ELISA	  kit	  was	  used	  for	  the	  quantification	  of	  IL-­‐10	  in	  both	  amniotic	  fluid	  
and	   serum.	   	   The	   standard	   curve	   allowed	   for	   detection	   of	   1000	   to	   15.6pg/ml	   IL-­‐10.	  	  
Serum	  samples	  were	  diluted	  1	  in	  2	  and	  amniotic	  fluid	  samples	  were	  assayed	  neat.	  	  	  
	  
2.4.2 Competitive	  binding	  ELISA	  	  
A	  competitive	  binding	  ELISA	  is	  based	  on	  labelled	  and	  unlabelled	  ligand	  competing	  for	  a	  
limited	   number	   of	   antibody	   binding	   sites.	   	   A	   defined	   amount	   of	   labelled	   ligand	   is	  
incubated	   with	   the	   sample	   and	   both	   the	   labelled	   ligand	   and	   any	   unlabelled	   ligand	  
present	   in	   the	   sample	   compete	   to	   bind	   to	   the	   antibody	   binding	   sites	   on	   the	   plate.	  	  
Substrate	   is	   then	   added	   and	   the	   resultant	   colour	   change	   can	   be	   measured	   by	   a	  
spectrophotometer.	   	   If	   there	   is	  a	  high	  concentration	  of	   ligand	   in	   the	  sample	   then	   less	  
labelled	  ligand	  will	  be	  bound	  and	  the	  colour	  change	  will	  be	  low,	  therefore	  in	  this	  ELISA	  
the	  concentration	  of	   the	  protein	  of	   interest	   in	   the	  sample	   is	   inversely	  proportional	   to	  
the	   optical	   density	   measured.	   	   As	   with	   the	   sandwich	   ELISA	   described	   above,	   plates	  
were	   read	  using	  a	  plate	   reader	  and	  Softmax	  Pro	   software	  which	  automatically	  draws	  
the	  standard	  curve	  and	  extrapolates	  protein	  concentrations.	  	  	  
2.4.2.1 Progesterone	  ELISA	  
A	   progesterone	   rat/mouse	   ELISA	   kit	   was	   used	   to	   quantify	   serum	   progesterone	  
concentrations.	   	   	   The	   standard	   curve	   allowed	   for	   the	   detection	   of	   100	   to	   0.4ng/ml	  
progesterone.	  	  25µl	  of	  standard	  and	  sample	  were	  added	  to	  the	  appropriate	  wells	  on	  the	  
plate.	   	   50µl	   of	   incubation	   buffer	   and	   100µl	   of	   enzyme	   conjugate	   (progesterone	  
conjugated	   to	   HRP)	   were	   also	   added	   to	   each	   well	   and	   the	   plate	   incubated	   at	   room	  
temperature	   for	  1	  hour.	   	  The	  wells	  were	   then	  washed	  with	  300µl	  of	  wash	  buffer	  and	  
200µl	   substrate	   solution	   (TMB	   and	   hydrogen	   peroxide	   solution)	   was	   added	   to	   each	  
well	  and	  the	  plate	  incubated	  for	  30	  minutes	  at	  room	  temperature.	  	  50µl	  of	  stop	  solution	  
Chapter	  2	  
	   58	  
was	  then	  added	  to	  quench	  the	  colour	  change	  reaction	  and	  the	  absorbance	  of	  each	  well	  




Immunohistochemical	   staining	   was	   used	   to	   localise	   immune	   cells	   within	   the	   uterus.	  	  	  
Details	  of	  solutions	  used	  are	  given	  in	  Table	  2.6.	  	  	  
2.5.1 Paraffin	  embedding	  and	  slide	  cutting	  
Uterus	  samples	  were	  collected	  as	  detailed	  in	  section	  2.1.3.1	  and	  fixed	  overnight	  in	  4%	  
NBF	  before	  being	  transferred	  to	  70%	  ethanol	  and	  embedded	  in	  paraffin	  blocks.	  	  Using	  a	  
microtome,	   5µm	   sections	  were	   cut	   and	  mounted	   onto	   slides.	   	  When	   cut,	   slides	  were	  
incubated	   at	   37oC	   for	   24	   hours	   to	   ensure	   sections	  were	   adhered	   to	   the	   slides	   before	  
being	  used	  in	  immunhistochemistry	  experiments.	  	  	  	  
2.5.2 Staining	  protocol	  
Some	   staining	   was	   carried	   out	   using	   the	   automated	   Bond	   immunostaining	   robot	  
service,	   where	   this	   was	   not	   used,	   the	   same	   conditions	   were	   used	   to	   achieve	   similar	  
staining	  quality.	   	  Neutrophils	  were	  localised	  using	  either	  an	  anti-­‐Gr-­‐1	  antibody,	  or	  the	  
more	   specific	   anti-­‐Ly-­‐6G	   antibody;	   macrophages	   were	   localised	   using	   an	   anti-­‐F4/80	  
antibody.	  	  Details	  of	  the	  source,	  dilution	  and	  antigen	  retrieval	  method	  for	  the	  different	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Antibody	  name	   Source	   Dilution	  	   Antigen	  retrieval	  method	  
Mouse	  Gr-­‐1/Ly-­‐6G,	  	  
clone	  RB6-­‐8C5	  	  
R&D	  Systems	  
(MAB1037)	  
1:1000	   None	  




1:500	   None	  
Anti-­‐mouse	  F4/80	  	   eBioscience	  
(14-­‐4801)	  
1:250	   0.5	  mg/ml	  Trypsin	  for	  10	  minutes	  
at	  37oC	  
Table	   2.5	   -­‐	   Antibody	   information	   for	   specific	   antibodies	   used	   in	  
immunohistochemistry	  experiments.	  
	  
Briefly,	  slides	  were	  dewaxed	  in	  xylene	  for	  5	  minutes,	  rehydrated	  in	  ethanol	  (absolute,	  
90%,	  80%	  and	  then	  70%),	  and	  washed	  in	  H20.	   	   If	  required	  antigen	  retrieval	  was	  then	  
performed.	   	   Slides	   were	   washed	   twice	   in	   PBS	   for	   5	   minutes.	   	   Following	   this,	  
endogenous	  peroxidase	  activity	  was	  blocked	  by	  incubating	  the	  slides	  for	  15	  minutes	  in	  
3%	  H202	  in	  PBS.	  	  The	  two	  5	  minutes	  PBS	  washes	  were	  repeated	  prior	  to	  incubating	  the	  
sections	   for	  30	  minutes	   in	  normal	  goat	  serum	  to	  block	  any	  non-­‐specific	  binding.	   	  The	  
primary	   antibody	   specific	   to	   the	   immune	   cell	   of	   interest	   was	   diluted	   in	   normal	   goat	  
serum,	  added	  to	  the	  sections	  and	  the	  slides	  were	  incubated	  in	  a	  humidified	  chamber	  at	  
4oC	   overnight.	   	   A	   negative	   control,	   where	   the	   primary	   antibody	   was	   replaced	   with	  
normal	  goat	  serum,	  was	  included	  in	  each	  run.	  	  	  	  
The	   following	   day	   the	   slides	   underwent	   two	   5	   minutes	   PBS	   washes	   and	   were	   then	  
incubated	   with	   the	   secondary	   antibody	   (ImmPRESS	   anti-­‐Rat	   IgG	   reagent)	   for	   30	  
minutes	  at	  room	  temperature.	  	  This	  reagent	  is	  a	  polymerized	  reporter	  enzyme	  staining	  
system	  that	  conjugates	  a	  peroxidase	  micropolymer	  to	  the	  secondary	  antibody,	  allowing	  
one-­‐step	  detection.	   	   	  Following	  two	  further	  PBS	  washes,	  slides	  were	  incubated	  with	  3,	  
3’-­‐diaminobenzidine	   (DAB)	   substrate	   for	   peroxidase	   for	   a	   maximum	   of	   5	   minutes	  
resulting	  in	  positive	  brown	  staining.	  	  Slides	  were	  then	  counterstained	  in	  haematoxylin,	  
dehydrated	  in	  increasing	  concentrations	  of	  ethanol,	   incubated	  in	  xylene	  for	  5	  minutes	  
and	  coverslips	  were	  mounted	  using	  pertex	  mounting	  medium.	  	  
Images	  of	  stained	  sections	  were	  obtained	  using	  the	  PROVIS	  microscope	  and	  AxioVision	  
Rel	  4.8	  software.	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Solution	   Recipe	  
NBF	  fixative	   100	  ml	  40%	  formaldehyde	  
4	  g	  sodium	  dihydrogen	  phosphate	  monohydrate	  
6.5	  g	  disodium	  hydrogen	  phosphate	  anhydrous	  
900	  ml	  distilled	  H20	  
Trypsin	  antigen	  retrieval	  solution	   0.5	  g	  trypsin	  
0.37g	  EDTA	  
1	  L	  distilled	  H20	  
pH	  8	  
Normal	  goat	  serum	  	   2ml	  non-­‐immune	  goat	  serum	  
8	  ml	  PBS	  
0.5	  g	  BSA	  
Table	   2.6	   -­‐	   Solutions	   used	   for	   tissue	   fixation	   and	   immunohistochemistry	  
experiments.	  
	  
2.5.3 Quantification	  of	  positively	  stained	  cells	  	  
Immune	  cell	  influx	  into	  the	  uterus	  six	  hours	  post-­‐surgery	  was	  quantified	  stereologically.	  	  
The	  myometrium	  and	  decidua	  of	  each	  uterus	  section	  were	  analysed	  separately.	   	  Each	  
uterus	   section	  was	   tiled	   using	   a	   x5	   objective	   and	   using	   Image-­‐Pro	   Plus	   software,	   the	  
area	   of	   interest	   (i.e.,	   myometrium	   or	   decidua)	   was	   selected	   by	   drawing	   round	   the	  
appropriate	   structure	   in	   the	   uterus.	   	   Using	   a	   x40	   objective	   lens,	   a	   total	   of	   10	  
randomised	  fields	  of	  view	  were	  visualised	  and	  the	  positive	  cells	  counted	  per	  section	  of	  
myometrium	   or	   decidua,	   with	   9	   sections	   counted	   in	   total	   per	   mouse.	   	   The	   average	  
number	   of	   positive	   cells	   counted	   per	   area	   was	   then	   calculated	   for	   each	   mouse	   and	  
averaged	  across	  treatments	  for	  both	  the	  decidua	  and	  myometrium.	  	  	  	  
	  
	  
2.6 WESTERN	  BLOTTING	  
Western	   blotting	   was	   used	   to	   detect	   TNF-­‐α	   protein	   in	   uterus,	   fetal	   membranes	   and	  
placental	  tissue	  collected	  from	  mice	  as	  described	  in	  section	  2.1.3.	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2.6.1 Protein	  Extraction	  
0.5ml	  lysis	  buffer	  (Table	  2.7)	  and	  a	  stainless	  steel	  bead	  were	  added	  to	  2ml	  Eppendorfs	  
tubes	  containing	  frozen	  tissue	  samples	  (collected	  as	  detailed	  in	  section	  2.1.3.).	  	  Samples	  
were	  homogenised	  at	  25Hz	  for	  5	  minutes	  using	  a	  tissue	  lyser.	  	  The	  homogenates	  were	  
then	   centrifuged	   at	   8000g	   for	   10	   minutes	   at	   4oC.	   	   Following	   this	   the	   clear	   aqueous	  
phase	  was	   transferred	   to	   a	   fresh	  2ml	  Eppendorf	   tube	  and	   stored	  at	   -­‐80oC.	   	   Extracted	  
protein	  from	  three	  pieces	  of	  the	  same	  tissue	  were	  pooled	  for	  each	  mouse.	  	  	  
2.6.1.1 Protein	  Quantification	  
The	  Bio-­‐Rad	  DC	  Protein	  Assay	  was	  used	  to	  quantify	  the	  protein	  concentration	  in	  each	  
sample.	   	  This	  protein	  assay	  is	  a	  colorimetric	  assay	  similar	  to	  the	  Lowry	  protein	  assay.	  	  
The	  colour	  change	  results	   from	  the	  reaction	  of	  protein	  present	   in	   the	  sample	  with	  an	  
alkaline	  copper	  tartrate	  solution	  and	  Folin	  reagent.	   	  The	  reaction	  between	  the	  protein	  
and	   copper	   in	   the	   alkaline	   solution	   reduces	   the	   Folin	   reagent,	   resulting	   in	   a	  
characteristic	   blue	   colour.	   	   The	   intensity	   of	   the	   blue	   colour	   is	   proportional	   to	   the	  
amount	   of	   protein	   present	   in	   the	   sample	   and	   can	   be	   quantified	   by	   measuring	   the	  
absorbance	  at	  650	  nm.	  	  	  
A	  standard	  curve	  of	  bovine	  serum	  albumin	  (BSA)	  was	  made	  up	  in	  lysis	  buffer	  (0,	  2.5,	  5,	  
10,	  20	  and	  40	  mg/ml	  of	  BSA).	  	  2µl	  of	  standards	  or	  sample	  were	  added	  to	  wells	  in	  a	  96-­‐
well	   plate,	   followed	   by	   25µl	   Reagent	   A	   (alkaline	   copper	   tartrate	   solution)	   and	   200µl	  
Reagent	  B	  (dilute	  Folin	  reagent).	   	  The	  plate	  was	   then	   incubated	  at	   room	  temperature	  
for	   15	  minutes.	   	   The	   plate	  was	   then	   read	   at	   650	   nm	   and	   the	   protein	   concentrations	  
were	  extrapolated	  from	  the	  standard	  curve.	  	  	  
2.6.2 Method	  
Details	  of	  the	  solutions	  used	  for	  western	  blotting	  are	  given	  in	  Table	  2.7.	  	  
A	  total	  of	  100µg	  of	  protein	  was	  run	  in	  each	  lane.	  	  Loading	  buffer,	  in	  a	  volume	  of	  5µl,	  was	  
added	  to	  each	  sample	  and	  samples	  were	  denatured	  by	  heating	  at	  100oC	  for	  10	  minutes,	  
cooled	  on	  ice	  and	  quickly	  centrifuged	  at	  full	  speed	  for	  10	  seconds	  before	  being	  loaded	  
onto	  the	  gel.	  	  Aliquots	  (15	  or	  20µl)	  of	  sample	  and	  10µl	  of	  molecular	  weight	  marker	  (See	  
Blue®	  Plus	  2	  Pre-­‐Stained	  Standard)	  were	  loaded	  on	  to	  NuPAGE	  4%-­‐12%	  Bis-­‐Tris	  Mini	  
Gels	   (1mm,	  15	  well).	   	  The	  gel	  was	  run	  using	  MES	  running	  buffer	  at	  200V	   for	  30	  –	  45	  
minutes	  to	  separate	  out	  the	  proteins.	  	  The	  proteins	  were	  then	  transferred	  from	  the	  gel	  
to	  a	  PVDF	  membrane	  in	  transfer	  buffer	  at	  200mA	  for	  2	  hours.	   	   	  Following	  transfer,	   to	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reduce	   the	   chance	   of	   non-­‐specific	   binding,	   the	   membranes	   were	   blocked	   in	   5%	   dry	  
skimmed	  milk	  in	  TBST	  for	  1	  hour	  at	  room	  temperature.	  	  Membranes	  were	  then	  washed	  
for	   5	   minutes	   in	   TBST,	   this	   step	   was	   repeated	   for	   a	   total	   of	   three	   washes.	   	   	   The	  
membranes	  were	   then	   incubated	   overnight	   at	   4oC	  with	   rabbit	   polyclonal	   anti-­‐TNF-­‐α	  
antibody	  (1:800;	  Catalogue	  no.	  3707,	  Cell	  Signaling)	  in	  5%	  BSA	  in	  TBST.	  	  	  
The	  following	  day	  membranes	  were	  washed	  for	  5	  minutes	  in	  TBST	  for	  a	  total	  of	  three	  
washes	   and	   incubated	   at	   room	   temperature	   for	   1	   hour	   with	   a	   goat-­‐anti-­‐rabbit	   IgG	  
secondary	   antibody,	   which	   is	   conjugated	   to	   HRP,	   in	   5%	   milk	   in	   TBST	   (1:1000).	  	  
Following	   three	   final	  5	  minute	  washes	   in	  TBST,	   the	  membranes	  were	   incubated	  with	  
1ml	  chemiluminescent	  developing	  solution	  (ECL	  Western	  Blot	  Analysis	  System)	  for	  30	  
seconds,	  placed	  in	  cassette	  and	  exposed	  to	  X-­‐Ray	  film	  in	  the	  dark	  room	  for	  5	  seconds	  to	  
3	  minutes,	  depending	  on	  the	  signal	  strength.	  	  The	  film	  was	  then	  exposed	  using	  an	  X-­‐Ray	  
developer.	  	  Following	  development	  of	  the	  TNF-­‐α	  signal,	  membranes	  were	  then	  washed	  
for	  20	  minutes	   in	  TBST	  for	  a	  total	  of	  3	  washes,	  and	  incubated	  overnight	  at	  4oC	  with	  a	  
rabbit	   polyclonal	   anti-­‐β-­‐Tubulin	   antibody	   (1:1000)	   in	   5%	   BSA	   in	   TBST,	   as	   a	   protein	  
loading	  control.	  	  The	  β-­‐Tubulin	  signal	  was	  developed	  as	  described	  above	  for	  TNF-­‐α.	  	  	  
2.6.3 Analysis	  
Image	  J	  software	  was	  used	  to	  quantify	  the	  intensity	  of	  the	  bands.	   	  The	  intensity	  of	  the	  
TNF-­‐α	   bands	   were	   then	   made	   relative	   to	   the	   intensity	   of	   the	   β-­‐Tubulin	   bands,	   as	   a	  
loading	  control	  for	  the	  amount	  of	  protein	  present	  in	  each	  lane.	  	  The	  seven	  PBS	  sample	  
and	  LPS	  samples	  were	  analysed	  individually	  and	  then	  an	  average	  for	  PBS	  and	  LPS	  was	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Solution	   Recipe	  
Lysis	  Buffer	   50	  mmol/l	  Tris	  (pH	  7.4)	  
0.27	  mol/l	  sucrose	  
1	  mmol/l	  sodium	  orthovanadate	  (pH	  10)	  
1	  mmol/l	  EDTA	  
1	  mmol/l	  EGTA	  
10	  mmol/l	  sodium	  β-­‐glycerophosphate	  
50	  mmol/l	  NaF	  
5	  mmol/l	  sodium	  pyrophosphate	  
1%	  [w/v]	  Triton	  X-­‐100	  
0.1%	  [v/v]	  2-­‐mercaptoethanol	  
protease	  inhibitors	  EDTA	  free	  tablets	  (Roche)	  
Loading	  Buffer	  (5x)	   1.8	  ml	  2M	  Tris	  (pH	  6.8)	  
3	  ml	  Glycerol	  
0.3	  ml	  0.5%	  Bromophenol	  Blue	  
1.8	  g	  SDS	  
925	  mg	  DTT	  
Made	  up	  to	  10	  ml	  with	  dH20	  
Transfer	  Buffer	  (10x)	   24.2	  g	  Tris	  
112.3	  g	  glycine	  
Made	  up	  to	  1	  L	  with	  dH20	  
Transfer	  Buffer	  (1x)	   100	  ml	  transfer	  buffer	  (10x)	  
800	  ml	  dH20	  
100	  ml	  methanol	  
TBS	  (10x)	   12.11	  g	  Tris	  HCL	  
87.66g	  NaCl	  
Made	  up	  to	  1	  L	  with	  dH20	  
pH	  7.6	  
TBST	   1	  L	  TBS	  	  
1	  ml	  Tween-­‐20	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2.7 FLOW	  CYTOMETRY	  	  
Flow	   cytometry	   is	   a	   technique	   used	   to	   analyse	   and	   count	   cell	   populations	   based	   on	  
their	   size,	   granularity	   and,	   if	   labelled	   with	   a	   specific	   fluorophore-­‐labelled	   antibody,	  
their	  fluorescent	  emissions.	  	  	  
Flow	   cytometry	   was	   used	   to	   quantify	   the	   number	   of	   neutrophils	   present	   in	   mouse	  
serum	  following	  neutrophil	  depletion	  experiments.	  	  	  
2.7.1 Sample	  preparation	  
Blood	  was	   collected	   6	   hours	   after	   surgery	   from	   the	   vena	   cava,	   as	   detailed	   in	   section	  
2.1.3.6.	   	   	   Following	   collection	   20µl	   of	   whole	   blood	   was	   immediately	   mixed	   with	   an	  
equal	  volume	  of	  the	  anticoagulant,	  sodium	  citrate	  and	  placed	  on	  ice.	   	   	  Aliquots	  of	  20µl	  
of	  the	  blood	  samples	  were	  then	  incubated	  with	  specific	  fluorophore-­‐labelled	  antibodies	  
diluted	   1:100	   in	   PBS	   for	   30	  minutes	   on	   ice,	   protected	   from	   the	   light	   (PE-­‐labelled	   rat	  
anti-­‐mouse	   CD45	   antibody;	   Pacific	   Blue-­‐labelled	   rat	   anti-­‐mouse	   Ly-­‐6G	   antibody).	  	  
Blood	  samples	  from	  each	  animal	  were	  incubated	  with	  both	  antibodies	  together	  (double	  
stain).	   	   Single	   stains	   and	   an	   unstained	   control	   samples	   were	   incubated	   with	   pooled	  
blood	  samples	  from	  multiple	  mice	  in	  order	  to	  check	  the	  specificity	  of	  the	  antibodies	  and	  
control	   for	  basal	   fluorescence	  of	   the	  samples.	   	  After	  30	  minutes,	  1ml	  of	  BD	  FACSLyse	  
solution	  was	   added	   to	   each	   sample,	   to	   lyse	   red	   blood	   cells	   and	   fix	   the	   cells,	   and	   the	  
samples	  were	  stored	  at	  4oC	  until	   they	  were	  analysed	  on	   the	   flow	  cytometer.	   	  Prior	   to	  
flow	   analysis,	   samples	   were	   centrifuged	   for	   5	   minutes	   at	   350	   g,	   the	   supernatant	  
removed	  and	  the	  samples	  re-­‐suspended	  in	  200µl	  of	  PBS.	  	  	  
2.7.2 Flow	  cytometric	  analysis	  
Flow	   cytometry	   analysis	   was	   carried	   out	   using	   the	   BD	   LSR	   Fortessa.	   	   Immediately	  
before	  analysis,	  50µl	  of	  Flow-­‐check	  bead	  suspension	  (approximately	  50000	  beads)	  was	  
added	  to	  each	  sample	  to	  allow	  subsequent	  calculation	  of	  the	  absolute	  number	  of	  cells	  
counted.	   	   The	   samples	   were	   then	   run	   on	   the	   flow	   cytometer	   and	   5000-­‐10000	   bead	  
events	  were	   counted.	   	   	   Cells	  were	   initially	   analysed	   based	   on	   their	   forward	   and	   side	  
scatter	  characteristics,	  and	  the	  neutrophil	  population	  was	  gated	  based	  on	  expression	  of	  
both	  CD45	  and	  Ly-­‐6G	   for	  comparison	  between	  blood	  collected	   from	  control	  mice	  and	  
neutrophil	  depleted	  mice.	  	  Representative	  flow	  plots	  from	  a	  mouse	  treated	  with	  an	  IgG	  
control	   antibody	   (Figure	   2.3A)	   and	   a	  mouse	   treated	  with	   anti-­‐Gr-­‐1	   (Figure	   2.3B)	   are	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shown	   below.	   	   Data	  were	   collected	   using	   BD	   FACSDiva	   software	   and	   analysed	   using	  




Figure	   2.3	   -­‐	   Representative	   flow	   cytometry	   plots	   to	   measure	   circulating	  
neutrophils	   in	  blood.	   	   	  Left	  panel	  of	  each	  shows	  FSC	  vs.	  SSC	  plots	  and	  gating	  on	  live	  
cells.	   	  Right	  panel	  of	  each	  shows	  Ly-­‐6G	  vs.	  CD45	  staining	  of	  neutrophils	   in	  peripheral	  
blood.	   (A)	   Representative	   flow	   plot	   from	   control	   mouse	   with	   high	   circulating	  
neutrophil	  numbers.	   	  (B)	  Representative	   flow	  plot	   from	  a	  neutrophil	  depleted	  mouse	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2.8 STATISTICAL	  ANALYSIS	  
Unless	   otherwise	   stated	   data	   are	   presented	   as	   mean	   ±	   standard	   error	   of	   the	   mean	  
(SEM).	   	   Statistical	   analysis	   was	   carried	   out	   using	   GraphPad	   Prism	   version	   6.0	  
(GraphPad	  Software,	  San	  Diego,	  California,	  USA).	  	  The	  specific	  statistical	  tests	  used	  are	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3.1 INTRODUCTION	   	  
There	   is	  now	  strong	  evidence	   that	   labour	   is	  an	   inflammatory	  event,	  with	   the	  onset	  of	  
labour	  at	  term	  being	  associated	  with	  increased	  production	  of	  inflammatory	  mediators,	  
such	   as	   TNF-­‐α,	   IL-­‐1β	   and	   IL-­‐6	   at	   the	   maternal-­‐fetal	   interface,	   as	   well	   as	   increased	  
immune	   cells,	   particularly	   neutrophils	   and	   macrophages	   in	   the	   cervix,	   myometrium	  
and	   fetal	  membranes	   (Denison	   et	  al.	   1998,	   Sennstrom	   et	  al.	   2000,	   Young	   et	  al.	   2002,	  
Osman	   et	  al.	   2003).	   	   	   It	   is	   now	  widely	   accepted	   that	   intrauterine	   infection	   results	   in	  
early	  activation	  of	  these	  inflammatory	  pathways	  normally	  initiated	  at	  term,	  resulting	  in	  
preterm	   labour	   (Goldenberg	   et	   al.	   2000).	   	   Indeed,	   intrauterine	   infection	   and	  
inflammation	   are	   known	   to	   be	   an	   important	   cause	   of	   preterm	   labour,	   with	   studies	  
estimating	   that	  up	   to	  40%	  of	  preterm	  births	  occur	   in	   the	  presence	  of	   an	   intrauterine	  
infection	   (Goldenberg	   et	   al.	   2008).	   	   Furthermore,	   intrauterine	   infection	   and	  
inflammation	   are	   strongly	   associated	  with	   adverse	   neonatal	   outcomes,	   such	   as	   brain	  
injury	  (Shatrov	  et	  al.	  2010).	  	  	  
Animal	   models	   have	   confirmed	   the	   role	   of	   infection	   and	   inflammation	   in	   preterm	  
labour,	  where	  administration	  of	  bacterial	  products	  such	  as	  LPS	  have	  effectively	  induced	  
preterm	  labour	  in	  mice	  (Elovitz	  et	  al.	  2003,	  Pirianov	  et	  al.	  2009),	  rabbits	  (McDuffie	  et	  al.	  
1992)	  and	  rhesus	  monkeys	  (Gravett	  et	  al.	  1994).	  	  The	  use	  of	  animal	  models,	  which	  can	  
be	  manipulated	  and	  studied	  at	  various	   time	  points	  during	  pregnancy,	   is	   invaluable	   to	  
improve	  our	  understanding	  of	  the	  sequence	  of	  events	  that	  lead	  to	  preterm	  labour.	  	  	  	  
Using	   a	   mouse	   model	   of	   LPS-­‐induced	   preterm	   labour,	   to	   mimic	   the	   presence	   of	   an	  
intrauterine	   bacterial	   infection,	   this	   chapter	   aimed	   to	   characterise	   the	   local	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3.2 METHODS	  
3.2.1 Mouse	  model	  of	  PTL	  
Mice	   underwent	   surgery	   as	   detailed	   in	   section	   2.1.	   	   Mice	   received	   an	   intrauterine	  
injection	  of	   either	  1µg	   (n=5),	   5µg,	   (n=6)	  10µg	   (n=11),	   15µg	   (n=8)	  or	  20µg	   (n=42)	  of	  
LPS	  or	  PBS	  (n=35),	  as	  a	  control.	  	  Time	  to	  delivery	  and	  the	  proportion	  of	  live	  born	  pups	  
was	  then	  monitored	  as	  detailed	  in	  sections	  2.1.1	  and	  2.1.2.	   	  Time	  to	  delivery	  was	  also	  
recorded	  in	  a	  second	  cohort	  of	  mice	  that	  did	  not	  undergo	  surgery	  (n=8),	  to	  determine	  if	  
the	  surgery	   itself	  affected	  time	  to	  delivery.	   	  These	  mice	  were	  monitored	  from	  midday	  
on	   D17	   of	   gestation	   until	   delivery	   of	   the	   first	   pup	   to	   determine	   an	   average	   time	   to	  
delivery	  for	  untreated	  mice.	  	  	  
	  
3.2.2 Tissue	  collection	  
In	   a	   separate	   cohort	  of	  mice	   receiving	   intrauterine	   injection	  of	  1µg	   (n=6),	  5µg	   (n=5),	  
10µg	   (n=5),	   15µg	   (n=5)	  or	  20µg	  of	   LPS	   (n=11)	  or	  PBS	   (n=8),	  utero-­‐placental	   tissues,	  
maternal	  serum,	  amniotic	  fluid	  and	  fetal	  brains	  were	  collected	  6	  hours	  post-­‐surgery	  as	  
detailed	  in	  section	  2.1.3,	  for	  analysis	  of	  the	  inflammatory	  and	  immune	  response.	  
	  
3.2.3 qRT-­‐PCR	  
The	  mRNA	   expression	   of	   several	   inflammatory	   genes	   and	   immune	   cell	   markers	   was	  
examined	  using	  qRT-­‐PCR	  as	  described	  in	  section	  2.3.	   	  The	  expression	  of	  the	  following	  
genes	   were	   measured	   in	   the	   uterus,	   fetal	   membranes	   and	   placenta	   of	   mice	   6	   hours	  
post-­‐surgery:	   Cxcl1,	   Cxcl2,	   Cxcl5,	   Ccl2,	   Il-­‐1β,	   Tnf-­‐α,	   Il-­‐6,	   Il-­‐10,	   Cox-­‐2,	   15-­‐Hpgd,	  Ngp	  and	  
Emr1.	   	  Expression	  of	   two	  genes	  associated	  with	  brain	  damage	  were	  also	  measured	   in	  
the	   fetal	   brains	   6	   hours	   post-­‐surgery,	   glial	   fibrillary	   associated	   protein	   (Gfap),	   and	  
microtubule-­‐associated	  protein	  (Mtap2).	  	  	  
As	  described	   in	  section	  2.3.3,	  expression	  of	   the	  gene	  of	   interest	  was	  normalised	   to	  β-­‐
actin	   as	   the	   endogenous	   control	   gene	   in	   each	   sample	   and	   all	   samples	   were	   then	  
compared	   relative	   to	   either	   a	   calibrator	   tissue	   or	   control	   sample.	   	   Analysis	   of	   all	   the	  
genes	  examined	  in	  the	  uterus,	  fetal	  membranes	  and	  placenta	  was	  carried	  out	  relative	  to	  
untreated	  D18	  uterus	  as	  a	  calibrator.	   	   	  Analysis	  of	   the	  expression	  of	  genes	  within	   the	  
brain	  was	  made	  relative	  to	  the	  PBS	  control	  group.	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3.2.4 ELISA	  
ELISAs	   were	   used	   to	   quantify	   the	   concentration	   of	   inflammatory	   markers	   in	   both	  
serum	   and	   amniotic	   fluid	   collected	   6	   hours	   post-­‐surgery,	   as	   described	   in	   section	   2.4.	  	  
Briefly,	  the	  specific	  ELISAs	  performed	  were	  TNF-­‐α,	  IL-­‐10	  and	  progesterone	  in	  maternal	  
serum;	   and	   TNF-­‐α,	   IL-­‐1β,	   IL-­‐6	   and	   IL-­‐10	   in	   amniotic	   fluid.	   	   Details	   of	   each	   assay	   are	  
given	  in	  section	  2.4.	  	  
	  
3.2.5 Western	  Blotting	  
Western	  blotting	  was	  used	  to	  detect	  TNF-­‐α	  protein	  in	  the	  uterus,	  fetal	  membranes	  and	  
placenta	  of	  mice	  harvested	  6	  hours	  post-­‐surgery.	  	  Protein	  was	  extracted	  from	  mice	  who	  
received	  an	  intrauterine	  injection	  of	  PBS	  (n=7)	  or	  20µg	  LPS	  (n=7),	  as	  detailed	  in	  section	  
2.6.1.	   	  The	  protocol	  used	   for	   the	  western	  blotting	  experiments	   is	  described	   in	  section	  
2.6.2.	  	  The	  intensity	  of	  each	  band	  was	  normalised	  to	  β-­‐tubulin	  as	  a	  loading	  control	  and	  
then	  quantified	  using	  Image	  J	  software	  to	  measure	  the	  density	  of	  the	  bands,	  as	  detailed	  
in	  section	  2.6.3.	  	  	  	  
	  
3.2.6 Immunohistochemistry	  
Immunohistochemistry	  was	  used	   to	   localise	  neutrophils	   and	  macrophages	  within	   the	  
uterus	  of	  mice,	  as	  detailed	  in	  section	  2.5.	  	  Neutrophils	  were	  localised	  using	  an	  anti-­‐Gr-­‐1	  
antibody.	   	   Macrophages	   were	   localised	   using	   an	   anti-­‐F4/80	   antibody.	   	   	   Staining	  
protocols	  are	  detailed	  in	  section	  2.5.2.	  	  	  
The	  three	  pieces	  of	  uterus	  collected	  from	  each	  mouse	  were	  fixed	  together	  in	  one	  block	  
and	  a	  total	  of	  3	  slides	  were	  stained	  from	  each	  mouse.	  	  	  The	  number	  of	  positive	  cells	  was	  
quantified	  as	  detailed	  in	  section	  2.5.3	  and	  compared	  between	  PBS	  (n=4)	  and	  20µg	  LPS	  
(n=5)	  treatment	  groups,	  with	  comparisons	  also	  made	  between	  the	  location	  of	  the	  cells	  
within	  the	  uterus,	  whether	  they	  resided	  in	  the	  myometrium	  or	  decidua.	  	  	  
3.2.7 Statistical	  analysis	  
Data	  are	  presented	  as	  mean	  ±	  SEM.	  	  	  Where	  data	  were	  not	  normally	  distributed,	  it	  was	  
transformed	  prior	   to	  analysis.	   	  Time	  to	  delivery	  data,	  and	  serum	  ELISA	  data	  were	   log	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transformed	   before	   analysis;	   and	   the	   proportion	   of	   live	   pups	   born	   was	   arc-­‐sin	  
transformed	  prior	   to	  analysis.	   	  Normally	  distributed	  data	  were	  then	  analysed	  by	  one-­‐
way	  ANOVA	  to	  compare	  treatment	  groups,	  followed	  by	  Dunnett’s	  multiple	  comparison	  
tests	   to	   identify	   significant	   differences	   compared	   to	   the	   PBS	   control	   group.	   Preterm	  
delivery	  rates	  were	  analysed	  by	  Fisher’s	  exact	  test.	  	  Amniotic	  fluid	  cytokine	  levels	  were	  
analysed	   non-­‐parametrically	   using	   a	   Kruskal-­‐Wallis	   test	   followed	   by	  Dunn’s	  multiple	  
comparison	  test	  to	  identify	  significant	  differences	  between	  treatment	  groups	  compared	  
with	  the	  PBS	  control	  group.	  	  Comparisons	  between	  just	  PBS	  and	  20µg	  LPS	  treated	  mice	  
in	  western	   blot	   analysis	  were	   compared	   using	   unpaired	   t-­‐tests.	   	   Immune	   cell	   counts	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3.3 RESULTS	  
3.3.1 Intrauterine	  administration	  of	  LPS	  induced	  PTL	  in	  a	  dose-­‐dependent	  manner	  
To	  investigate	  the	  ability	  of	  intrauterine	  LPS	  administration	  to	  induce	  preterm	  labour,	  a	  
dose	   response	   experiment	   was	   carried	   out	   to	   identify	   the	   dose	   of	   LPS	   that	   reliably	  
induced	  preterm	  labour	  with	  minimal	  variation.	  	  	  	  
3.3.1.1 Time	  to	  delivery	  
The	   time	   to	   delivery	   of	   mice	   that	   did	   not	   undergo	   surgery	   or	   treatment	   was	   not	  
significantly	   different	   to	   the	   PBS	   control	   group,	   in	   which	   PBS	   was	   injected	   into	   the	  
uterine	  horn	  (mean	  time	  to	  delivery	  of	  no	  surgery	  control	  51.34	  hours	  ±	  SEM	  1.13	  vs.	  
PBS	   mean	   time	   to	   delivery	   49.58	   hours	   ±	   SEM	   3.71;	   Figure	   3.1).	   	   Mice	   receiving	  
intrauterine	   LPS	   delivered	   earlier	   than	   those	   receiving	   PBS,	   in	   a	   dose-­‐responsive	  
manner.	   	  Administration	  of	  both	  15µg	  and	  20µg	  of	  LPS	   induced	  delivery	   significantly	  
earlier	   than	   the	   PBS	   control	   group	   (15µg	  mean	   time	   to	   delivery	   26.44	   hours	   ±	   SEM	  
13.09,	  p<0.001	  compared	  to	  PBS	  control;	  20µg	  mean	  time	  to	  delivery	  27.23	  hours	  ±	  SE	  
3.37;	  p<0.001	  compared	  to	  PBS	  control;	  Figure	  3.1).	  	  
To	   analyse	   further	   the	   effect	   of	   LPS	   treatment	   on	   preterm	   delivery,	   the	   preterm	  
delivery	   rate	   was	   calculated.	   	   This	   was	   defined	   as	   the	   proportion	   of	   dams	   in	   which	  
there	  was	  delivery	  of	   the	   first	  pup	  within	  36	  hours	  of	   intrauterine	   injection.	   	  Preterm	  
delivery	   rates	   for	   each	   treatment	   group	   are	   given	   in	   Table	   3.1.	   	   The	   rate	   of	   preterm	  
delivery	  in	  the	  PBS	  control	  group	  was	  40%;	  higher	  preterm	  delivery	  rates	  were	  present	  
in	   groups	   receiving	   doses	   of	   LPS	   at	   5µg	   and	   higher.	   	   Mice	   receiving	   20µg	   LPS	   were	  
twice	  as	  likely	  to	  deliver	  preterm	  compared	  with	  the	  PBS	  control	  group,	  with	  a	  preterm	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Figure	  3.1	  -­‐	  Effect	  of	  intrauterine	  LPS	  administration	  on	  time	  to	  delivery.	  	  	  Time	  to	  
delivery	  was	  monitored	  in	  mice	  receiving	  an	  intrauterine	  injection	  of	  PBS	  (n=35),	  1µg	  
LPS	  (n=5),	  5µg	  LPS	  (n=6),	  10µg	  LPS	  (n=11),	  15µg	  (n=8)	  or	  20µg	  LPS	  (n=42).	   	  Time	  to	  
delivery	  was	  also	  monitored	  in	  a	  group	  of	  mice	  receiving	  no	  surgery	  as	  a	  control	  (n=8).	  
Data	  are	  presented	  as	  mean	  ±	  SEM	  (error	  bars);	  ***p<0.001,	  compared	  to	  PBS	  
	  
	  
Table	   3.1	   -­‐	   Effect	   of	   intrauterine	   LPS	   administration	   on	   preterm	   delivery	   rate.	  	  
Time	  to	  delivery	  was	  monitored	  in	  mice	  receiving	  an	  intrauterine	  injection	  of	  PBS,	  1µg,	  
5µg,	   10µg,	   15µg	   and	   20µg	   LPS.	   	   Preterm	   delivery	  was	   defined	   as	   delivery	  within	   36	  
hours	   of	   intrauterine	   injection	   to	   calculate	   the	   preterm	   delivery	   rate	   in	   each	   group.	  
Relative	  risk	  ratios	  calculated	  using	  Fisher’s	  exact	  test.	  ***p<0.001,	  compared	  to	  PBS.	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3.3.1.2 Proportion	  of	  live	  born	  pups	  
The	  proportion	  of	  live	  born	  pups	  reduced	  in	  response	  to	  increasing	  doses	  of	  LPS,	  with	  a	  
significantly	  lower	  proportion	  of	  live	  pups	  born	  to	  mice	  receiving	  15µg	  and	  20µg	  of	  LPS,	  
compared	   to	   the	   PBS	   control	   group	   (15µg	  mean	  proportion	   of	   live	   born	   pups	   0.13	   ±	  
SEM	  0.08,	  p<0.01;	  20µg	  mean	  proportion	  of	   live	  born	  pups	  0.25	  ±	  SEM	  0.05,	  p<0.001;	  
compared	  with	  PBS	  mean	  proportion	  of	  live	  born	  pups	  0.56	  ±	  SEM	  0.06;	  Figure	  3.2A).	  	  
To	   investigate	   further	  whether	   the	  observed	   reduction	   in	   the	  proportion	  of	   live	  born	  
pups	   in	   the	   15µg	   and	   20µg	   LPS	   treatment	   groups	   was	   simply	   due	   to	   a	   higher	  
proportion	  of	  mice	  in	  these	  groups	  being	  born	  prematurely,	  rather	  than	  an	  effect	  of	  the	  
LPS	  treatment,	  the	  proportion	  of	  live	  born	  pups	  was	  also	  examined	  in	  mice	  delivering	  
preterm.	  	  Mice	  delivering	  preterm	  in	  the	  PBS	  group	  had	  a	  mean	  proportion	  of	  live	  born	  
pups	   of	   0.42	   ±	   SEM	   0.12,	   which	  was	   still	   significantly	   higher	  when	   compared	   to	   the	  
proportion	  of	  live	  born	  pups	  in	  mice	  that	  delivered	  preterm	  in	  the	  15µg	  LPS	  treatment	  
group	   (mean	   proportion	   of	   live	   born	   pups	   0;	   p<0.05);	   and	   the	   20µg	   LPS	   treatment	  
group	  (mean	  proportion	  of	  live	  born	  pups	  0.14	  ±	  0.04;	  p<0.05;	  Figure	  3.2B).	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Figure	   3.2	   -­‐	   Effect	   of	   intrauterine	   LPS	   administration	   on	   the	   proportion	   of	   live	  
born	   pups.	   	   	  The	  proportion	  of	   live	  born	  pups	  was	  determined	   in	  mice	   receiving	  an	  
intrauterine	   injection	  of	  PBS	  (n=35),	  1µg	  LPS	  (n=5),	  5µg	  LPS	  (n=6),	  10µg	  LPS	  (n=11),	  
15µg	  (n=8)	  and	  20µg	  LPS	  (n=42).	  (A)	  Proportion	  of	  live	  born	  pups	  in	  all	  mice.	  	  (B)	  The	  
proportion	  of	  pups	  delivered	  prematurely	  (within	  36	  hours	  of	  surgery)	  who	  were	  born	  
live;	   [PBS	  (n=14),	  5µg	  LPS	  (n=3),	  10µg	  LPS	  (n=6),	  15µg	  LPS	  (n=6),	  20µg	  LPS	  (n=35)].	  	  
Data	  presented	  as	  mean	  ±	  SEM	  (error	  bars);	  *p<0.05,	  **p<0.01,	  ***p<0.001,	  compared	  
to	  PBS.	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3.3.2 Expression	  of	  inflammatory	  mediators	  in	  the	  utero-­‐placental	  tissues	  in	  response	  to	  
intrauterine	  LPS	  
Utero-­‐placental	   tissues	   were	   analysed	   for	   the	   expression	   of	   several	   inflammatory	  
mediators	   6	   hours	   post-­‐intrauterine	   injection	   using	   qRT-­‐PCR.	   	   The	   genes	   measured	  
were:	   the	   pro-­‐inflammatory	   cytokines	   Tnf-­‐α,	   Il-­‐1β	   and	   Il-­‐6;	   the	   major	   enzyme	  
responsible	   for	   initiating	   prostaglandin	   synthesis,	   Cox-­‐2;	   the	   enzyme	   responsible	   for	  
the	  breakdown	  of	   prostaglandins,	  15-­‐Hpgd;	   the	   anti-­‐inflammatory	   cytokine,	   Il-­‐10;	   the	  
neutrophil	  chemokines	  Cxcl1,	  Cxcl2	  and	  Cxcl5;	  and	  the	  macrophage	  chemokine,	  Ccl2.	  	  	  
	  
3.3.2.1 Inflammatory	  gene	  expression	  in	  the	  uterus	  
Uterine	   Tnf-­‐α	   expression	   was	   significantly	   elevated	   in	   response	   to	   all	   doses	   of	   LPS	  
administered	  compared	  to	  the	  PBS	  control	  (p<0.001;	  Figure	  3.3A).	  	  In	  response	  to	  20µg	  
LPS,	   there	   was	   a	   5.1-­‐fold	   increase	   in	   Tnf-­‐α	   expression	   compared	   to	   the	   PBS	   control	  
group	  (p<0.001).	  	  	  
Il-­‐1β	  expression	  was	  significantly	  elevated	  in	  response	  to	  all	  doses	  of	  LPS	  administered	  
compared	  to	  the	  PBS	  control	  group	  (p<0.001;	  Figure	  3.3B),	  with	  a	  2.7-­‐fold	  increase	  in	  
uterine	   Il-­‐1β	   expression	   in	   mice	   receiving	   20µg	   of	   LPS	   compared	   to	   the	   control	  
(p<0.001).	  
Il-­‐6	   expression	  was	   significantly	   increased	   in	   response	   to	   LPS	   treatment	   at	   all	   doses	  
administered,	  with	  a	  mean	  6.3-­‐fold	  increase	  in	  Il-­‐6	  expression	  in	  response	  to	  20µg	  LPS	  
compared	  to	  the	  PBS	  group	  (p<0.001;	  Figure	  3.3C).	  
Expression	   of	   the	   anti-­‐inflammatory	   cytokine,	   Il-­‐10	   was	   also	   significantly	   elevated	   in	  
response	  to	  intrauterine	  LPS	  administration	  in	  a	  dose-­‐responsive	  manner,	  with	  a	  2-­‐fold	  
increase	   in	   Il-­‐10	   expression	   in	   the	   uterus	   of	  mice	   given	   20µg	   of	   LPS,	   compared	  with	  
mice	  receiving	  PBS	  (p<0.001;	  Figure	  3.3D).	  	  	  
Given	  the	  important	  role	  of	  prostaglandins	  in	  the	  initiation	  of	  labour,	  the	  levels	  of	  Cox-­‐2	  
and	   15-­‐Hpgd	   were	   also	   measured.	   	   Expression	   of	   Cox-­‐2	   increased	   in	   response	   to	  
increasing	  doses	  of	  LPS,	  with	  significantly	  elevated	  expression	  at	  10µg	  (p<0.05),	  15µg	  
(p<0.001)	  and	  20µg	  (p<0.001)	  of	  LPS,	   compared	   to	   the	  PBS	  control	   (Figure	  3.3E).	   	   In	  
contrast	   there	  was	  no	   significant	   change	   in	   the	  mRNA	  expression	   level	  of	  15-­‐Hpgd	   in	  
response	  to	  LPS	  treatment	  (PBS	  vs.	  20µg	  LPS	  p=0.38;	  Figure	  3.3F).	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The	   expression	   of	   Cxcl1,	   Cxcl2	   and	   Cxcl5,	   all	   of	   which	   are	   potent	   murine	   neutrophil	  
chemoattractants	  and	  activators	  was	  significantly	  elevated	  in	  the	  uterus	  in	  response	  to	  
all	   doses	   of	   LPS	   administered	   compared	   to	   the	   PBS	   control	   group	   (p<0.01).	   	   In	  
comparison	  to	  the	  PBS	  control	  group,	  administration	  of	  20µg	  of	  LPS	  induced	  a	  17.5-­‐fold	  
increase	   in	   Cxcl1	   expression	   (p<0.001;	   Figure	   3.4A);	   a	   14.7-­‐fold	   increase	   in	   uterine	  
Cxcl2	   expression	   (p<0.001;	   Figure	   3.4B);	   and	   a	   9.8-­‐fold	   increase	   in	   Cxcl5	   expression	  
(p<0.001;	  Figure	  3.4C).	  	  	  
Expression	   of	   the	   macrophage	   chemokine,	   Ccl2,	   was	   also	   elevated	   in	   response	   to	  
increasing	   doses	   of	   LPS,	   with	   significantly	   higher	   levels	   at	   15µg	   and	   20µg	   of	   LPS,	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Figure	   3.3	   -­‐	   Effect	   of	   intrauterine	   LPS	   administration	   on	   inflammatory	   gene	  
expression	   in	   the	   uterus.	   	   	  Uterine	   tissue	  was	   collected	  6	   hours	   post-­‐surgery	   from	  
mice	   receiving	   PBS	   (n=8),	   1µg	   LPS	   (n=5),	   5µg	   LPS	   (n=5),	   10µg	   LPS	   (n=5),	   15µg	   LPS	  
(n=5)	   or	   20µg	   LPS	   (n=11)	   and	   the	  mRNA	   expression	   of	   several	   inflammatory	   genes	  
assessed	  by	  qRT-­‐PCR.	   	   (A)	  Tnf-­‐α	  expression.	   (B)	   Il-­‐1β	   expression.	   (C)	   Il-­‐6	  expression	  
(D)	  Il-­‐10	  expression.	  	  (E)	  Cox-­‐2	  expression	  	  (F)	  15-­‐Hpgd	  expression.	  	  Data	  presented	  as	  
mean	  fold	  change	  ±	  SEM	  (error	  bars);	  *p<0.05,	  **p<0.01,	  ***p<0.001,	  compared	  to	  PBS.	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Figure	  3.4	  -­‐	  Effect	  of	  intrauterine	  LPS	  administration	  on	  inflammatory	  chemokine	  
expression	   in	   the	   uterus.	   	   Uterine	   tissue	   was	   collected	   6	   hours	   post-­‐surgery	   from	  
mice	   receiving	   PBS	   (n=8),	   1µg	   LPS	   (n=5),	   5µg	   LPS	   (n=5),	   10µg	   LPS	   (n=5),	   15µg	   LPS	  
(n=5)	   or	   20µg	   LPS	   (n=11)	   and	   the	  mRNA	   expression	   of	   several	   inflammatory	   genes	  
assessed	  by	  qRT-­‐PCR.	   (A)	  Cxcl1	  expression.	   (B)	  Cxcl2	  expression	   (C)	  Cxcl5	  expression.	  
(D)	   Ccl2	   expression.	   	   Data	   presented	   as	   mean	   fold	   fold-­‐change	   ±	   SEM	   (error	   bars);	  







	   	   	   Chapter	  3	  
	   80	  
3.3.2.2 Inflammatory	  gene	  expression	  in	  the	  fetal	  membranes	  
Tnf-­‐α	   expression	   in	   the	   fetal	   membranes	   was	   significantly	   elevated	   in	   response	   to	  
intrauterine	   LPS	   administration,	   at	   all	   doses	   (p<0.001;	   Figure	   3.5A),	   with	   a	   33-­‐fold	  
increase	  in	  expression	  in	  response	  to	  20µg	  of	  LPS,	  compared	  to	  the	  PBS	  control.	  	  	  	  
Similarly	   Il-­‐1β	   expression	   was	   also	   significantly	   elevated	   in	   the	   fetal	   membranes	   in	  
response	  to	  all	  doses	  of	  LPS	  administered	  (p<0.001;	  Figure	  3.5B),	  with	  17.4-­‐fold	  higher	  
expression	  induced	  when	  20µg	  of	  LPS	  was	  administered,	  compared	  to	  PBS.	  	  	  	  
Expression	  of	  Il-­‐6	  was	  increased	  in	  a	  dose-­‐responsive	  manner	  in	  the	  fetal	  membranes	  
in	   response	   to	   increasing	   doses	   of	   LPS,	   with	   a	   3.6-­‐fold	   increase	   in	   expression	   in	  
response	   to	   20µg	   of	   LPS	   compared	   with	   the	   PBS	   control,	   however	   this	   was	   not	  
statistically	  significant	  (PBS	  vs.	  20µg	  LPS	  p=0.96;	  Figure	  3.5C).	  	  	  
In	   response	   to	   increasing	   doses	   of	   LPS	   administered,	   Il-­‐10	   expression	   in	   the	   fetal	  
membranes	  was	   significantly	   increased	   (p<0.01	   at	   1µg,	   p<0.001	   at	   all	   other	   doses	   of	  
LPS;	  Figure	  3.5D).	  	  Expression	  in	  response	  to	  20µg	  of	  LPS	  was	  8.2-­‐fold	  higher	  compared	  
with	  expression	  of	  Il-­‐10	  in	  the	  fetal	  membranes	  of	  mice	  receiving	  PBS.	  	  
There	  was	   no	   significant	   change	   in	  Cox-­‐2	   expression	   in	   the	   fetal	  membranes	   of	  mice	  
receiving	  LPS,	  at	  any	  of	  the	  doses	  administered	  (PBS	  vs.	  20µg	  LPS	  p=0.63;	  Figure	  3.5E).	  	  
In	  contrast,	  expression	  of	  15-­‐Hpgd	  was	  significantly	  decreased	  in	  mice	  receiving	  LPS	  at	  
each	  dose,	  with	  2.5-­‐fold	   lower	  expression	  of	  15-­‐Hpgd	   in	   the	   fetal	  membranes	  of	  mice	  
receiving	  20µg	  LPS,	  compared	  to	  the	  PBS	  control	  (p<0.001;	  Figure	  3.5F).	  
Expression	   of	  Cxcl1	   in	   the	   fetal	  membranes	  was	   significantly	   elevated	   in	   response	   to	  
5µg	   (p<0.01),	  10µg	  (p<0.05),	  15µg	  (p<0.001)	  and	  20µg	  (p<0.01)	  of	  LPS,	  with	  5.7-­‐fold	  
higher	  expression	  in	  response	  to	  20µg	  of	  LPS	  compared	  to	  the	  PBS	  group	  (Figure	  3.6A).	  	  
Cxcl2	  expression	  was	  significantly	  higher	  in	  response	  to	  all	  doses	  of	  LPS	  administered	  
compared	  to	  PBS	  (p<0.01	  at	  1µg,	  p<0.001	  at	  all	  other	  doses	  of	  LPS;	  Figure	  3.6B),	  with	  
8.8-­‐fold	   increased	   expression	   in	   mice	   receiving	   20µg	   of	   LPS,	   compared	   with	   PBS.	  	  
Similarly	  fetal	  membrane	  Cxcl5	  expression	  was	  significantly	  elevated	  in	  response	  to	  all	  
doses	  of	  LPS	  administered	  (p<0.001;	  Figure	  3.6C),	  with	  56.8-­‐fold	  increased	  expression	  
in	  response	  to	  20µg	  of	  LPS,	  compared	  with	  PBS.	  	  In	  response	  to	  increasing	  doses	  of	  LPS	  
administered,	   expression	   of	  Ccl2	   increased	   in	   the	   fetal	  membranes,	  with	   significantly	  
elevated	  expression	  in	  response	  to	  5µg	  (p<0.001),	  10µg	  (p<0.01),	  15µg	  (p<0.001)	  and	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20µg	  (p<0.001)	  of	  LPS	  (Figure	  3.6D).	  	  Expression	  levels	  of	  Ccl2	  in	  the	  fetal	  membranes	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Figure	   3.5	   -­‐	   Effect	   of	   intrauterine	   LPS	   administration	   on	   inflammatory	   gene	  
expression	  in	  the	  fetal	  membranes.	   	   	  Fetal	  membranes	  were	  collected	  6	  hours	  post-­‐
surgery	  from	  mice	  receiving	  PBS	  (n=8),	  1µg	  LPS	  (n=5),	  5µg	  LPS	  (n=5),	  10µg	  LPS	  (n=5),	  
15µg	  LPS	  (n=5)	  or	  20µg	  LPS	  (n=11)	  and	  the	  mRNA	  expression	  of	  several	  inflammatory	  
genes	   assessed	   by	   qRT-­‐PCR.	   	   (A)	   Tnf-­‐α	   expression.	   (B)	   Il-­‐1β	   expression.	   (C)	   Il-­‐6	  
expression	   (D)	   Il-­‐10	  expression.	   	   (E)	  Cox-­‐2	  expression	   	   (F)	  15-­‐Hpgd	  expression.	   	  Data	  
presented	  as	  mean	  fold	  change	  ±	  SEM	  (error	  bars);	  **p<0.01,	  ***p<0.001,	  compared	  to	  
PBS.	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Figure	  3.6	  -­‐	  Effect	  of	  intrauterine	  LPS	  administration	  on	  inflammatory	  chemokine	  
expression	  in	  the	  fetal	  membranes.	   	   	  Fetal	  membranes	  were	  collected	  6	  hours	  post-­‐
surgery	  from	  mice	  receiving	  PBS	  (n=8),	  1µg	  LPS	  (n=5),	  5µg	  LPS	  (n=5),	  10µg	  LPS	  (n=5),	  
15µg	  LPS	  (n=5)	  or	  20µg	  LPS	  (n=11)	  and	  the	  mRNA	  expression	  of	  several	  inflammatory	  
genes	   assessed	   by	   qRT-­‐PCR.	   (A)	   Cxcl1	   expression.	   (B)	   Cxcl2	   expression	   (C)	   Cxcl5	  
expression.	  (D)	  Ccl2	  expression.	  	  Data	  presented	  as	  mean	  fold	  fold-­‐change	  ±	  SEM	  (error	  
bars);	  *p<0.05,	  **p<0.01,	  ***p<0.001,	  compared	  to	  PBS.	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3.3.2.3 Inflammatory	  gene	  expression	  in	  the	  placenta	  
Tnf-­‐α	   in	   the	   placenta	   was	   significantly	   elevated	   in	   response	   to	   all	   doses	   of	   LPS	  
administered	  (p<0.001;	  Figure	  3.7A),	  with	  7-­‐fold	  higher	  expression	   in	   the	  placenta	  of	  
mice	  receiving	  20µg	  of	  LPS,	  compared	  to	  those	  receiving	  PBS.	  	  
Similarly	   placental	   Il-­‐1β	   expression	   was	   significantly	   increased	   at	   all	   doses	   of	   LPS	  
administered,	   compared	   to	   the	   PBS	   control	   (p<0.001;	   Figure	   3.7B),	   with	   10-­‐fold	  
elevated	  expression	  in	  response	  to	  20µg	  of	  LPS	  compared	  to	  the	  control.	  
Il-­‐6	  expression	  was	  also	  significantly	  elevated	  in	  the	  placenta	  in	  response	  to	  all	  doses	  of	  
LPS,	   with	   6.3-­‐fold	   higher	   expression	   in	   response	   to	   20µg	   LPS,	   compared	   to	   the	   PBS	  
control	  (p<0.001;	  Figure	  3.7C)	  
Expression	  of	  Il-­‐10	  was	  significantly	  higher	  in	  the	  placentas	  of	  mice	  receiving	  LPS	  at	  all	  
doses	   administered	   (p<0.01	   at	   10µg,	   p<0.001	   at	   all	   other	   doses	   of	   LPS;	   Figure	  3.7D),	  
with	  a	  3.4-­‐fold	   increase	   in	  expression	  of	   IL-­‐10	  comparing	  the	  20µg	  LPS	  dose	  with	  the	  
PBS	  control.	  	  	  
No	  change	  in	  placental	  Cox-­‐2	  expression	  was	  observed	  in	  response	  to	  intrauterine	  LPS	  
administration	  (PBS	  vs.	  20µg	  LPS	  p=0.99;	  Figure	  3.7E).	   	  Similarly,	  15-­‐Hpgd	  expression	  
in	   the	   placenta	   did	   not	   change	   across	   treatment	   groups	   (PBS	   vs.	   20µg	   LPS	   p=0.24;	  
Figure	  3.7F).	  	  
In	  response	  to	  increasing	  doses	  of	  LPS	  administered,	  expression	  of	  Cxcl1	  in	  the	  placenta	  
was	  elevated.	   	  The	  level	  of	  Cxcl1	  expression	  was	  significantly	  higher	  in	  mice	  receiving	  
5µg,	   10µg,	   15µg	   and	   20µg	   of	   LPS	   (p<0.001;	   Figure	   3.8A),	   with	   4.3-­‐fold	   elevated	  
expression	  at	  20µg	  of	  LPS	  compared	  to	  PBS.	  	  Placental	  Cxcl2	  and	  Cxcl5	  expression	  was	  
significantly	   elevated	   in	   response	   to	   each	   dose	   of	   LPS	   administered	   compared	   to	   the	  
PBS	  control	  (p<0.001).	  	  At	  20µg	  of	  LPS,	  Cxcl2	  expression	  was	  12.7-­‐fold	  higher	  than	  PBS	  
(Figure	  3.8B);	  and	  Cxcl5	  expression	  was	  21.8-­‐fold	  higher	  than	  the	  PBS	  control	  (Figure	  
3.8C).	  	  	  
Placental	   Ccl2	   expression	  was	   significantly	   higher	   in	  mice	   receiving	   all	   doses	   of	   LPS	  
administered	  (p<0.001;	  Figure	  3.8D),	  with	  6.8-­‐fold	  higher	  expression	  in	  mice	  receiving	  
20µg	  of	  LPS,	  compared	  with	  those	  receiving	  PBS.	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Figure	   3.7	   -­‐	   Effect	   of	   intrauterine	   LPS	   administration	   on	   inflammatory	   gene	  
expression	  in	  the	  placenta.	  	  	  Placental	  tissue	  was	  collected	  6	  hours	  post-­‐surgery	  from	  
mice	   receiving	   PBS	   (n=8),	   1µg	   LPS	   (n=5),	   5µg	   LPS	   (n=5),	   10µg	   LPS	   (n=5),	   15µg	   LPS	  
(n=5)	   or	   20µg	   LPS	   (n=11)	   and	   the	  mRNA	   expression	   of	   several	   inflammatory	   genes	  
assessed	  by	  qRT-­‐PCR.	   	   (A)	  Tnf-­‐α	  expression.	   (B)	   Il-­‐1β	  expression.	  (C)	   Il-­‐6	  expression	  
(D)	  Il-­‐10	  expression.	  	  (E)	  Cox-­‐2	  expression	  	  (F)	  15-­‐Hpgd	  expression.	  	  Data	  presented	  as	  
mean	  fold	  change	  ±	  SEM	  (error	  bars);	  **p<0.01,	  ***p<0.001,	  compared	  to	  PBS.	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Figure	  3.8	  -­‐	  Effect	  of	  intrauterine	  LPS	  administration	  on	  inflammatory	  chemokine	  
expression	  in	  the	  placenta.	  	  	  Placental	  tissue	  was	  collected	  6	  hours	  post-­‐surgery	  from	  
mice	   receiving	   PBS	   (n=8),	   1µg	   LPS	   (n=5),	   5µg	   LPS	   (n=5),	   10µg	   LPS	   (n=5),	   15µg	   LPS	  
(n=5)	   or	   20µg	   LPS	   (n=11)	   and	   the	  mRNA	   expression	   of	   several	   inflammatory	   genes	  
assessed	  by	  qRT-­‐PCR.	   (A)	  Cxcl1	  expression.	  (B)	  Cxcl2	  expression	  (C)	  Cxcl5	  expression.	  
(D)	   Ccl2	   expression.	   	   Data	   presented	   as	   mean	   fold	   fold-­‐change	   ±	   SEM	   (error	   bars);	  








	   	   	   Chapter	  3	  
	   87	  
3.3.3 TNF-­‐α 	  protein	  levels	  in	  utero-­‐placental	  tissues	  following	  LPS	  treatment.	  	  
To	   further	   investigate	   the	   inflammatory	   response	   induced	   by	   LPS	   treatment	   in	   the	  
utero-­‐placental	   tissues,	   western	   blotting	   was	   performed	   to	   determine	   whether	   the	  
increased	  inflammatory	  gene	  expression	  measured	  by	  qRT-­‐PCR	  was	  translated	  into	  the	  
increased	   production	   of	   inflammatory	   proteins.	   	   TNF-­‐α	   was	   chosen	   as	   the	   candidate	  
inflammatory	  protein	  to	  examine	  because	  LPS	  treatment	  induced	  large	  fold-­‐changes	  in	  
Tnf-­‐α	  mRNA	  expression	   in	  all	   three	  utero-­‐placental	   tissues	  studied.	   	  TNF-­‐α	   is	   initially	  
produced	  as	  a	  26kDa	  transmembrane	  protein	  that	  is	  then	  cleaved	  by	  tumour	  necrosis	  
factor-­‐alpha	   converting	   enzyme	   (TACE)	   into	   the	  mature	   TNF-­‐α	   cytokine	   that	  weighs	  
17kDa	   (Black	   et	   al.	   1997,	   Moss	   et	   al.	   1997).	   	   Production	   of	   TNF-­‐α	   protein	   was	  
determined	  in	  the	  uterus,	  fetal	  membranes	  and	  placenta	  collected	  6	  hours	  post-­‐surgery	  
from	   mice	   receiving	   either	   intrauterine	   injection	   of	   either	   PBS	   or	   20µg	   LPS,	   the	  
antibody	  used	  should	  identify	  both	  precursor	  and	  mature	  TNF-­‐α.	  	  	  
	  
3.3.3.1 Uterine	  TNF-­‐α 	  protein	  production	  
Western	   blotting	   detected	   a	   protein	  weighing	   around	   25kDa	   in	   the	   uterine	   tissue	   of	  
mice	   receiving	   both	   PBS	   and	   LPS,	   mature	   TNF-­‐α	   was	   not	   detectable	   in	   uterus	   from	  
either	  treatment	  group	  (Figure	  3.9A).	   	  β-­‐tubulin	  was	  used	  as	  a	  loading	  control	  (Figure	  
3.9B).	   	  Densitometric	  analysis	  of	  the	  band	  intensity	  of	  TNF-­‐α	  precursor	  relative	  to	  the	  
amount	  of	  protein	  present	  in	  each	  sample	  showed	  there	  was	  no	  significant	  difference	  in	  
the	  amount	  of	  TNF-­‐α	  present	  in	  the	  uterine	  tissue	  of	  mice	  receiving	  PBS	  or	  LPS	  (Figure	  
3.9C;	  p=0.86).	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Figure	  3.9	   -­‐	  Uterine	  TNF-­‐α 	  production.	   	   	  Uterine	  tissue	  was	  collected	  6	  hours	  post-­‐
surgery	  from	  mice	  receiving	  PBS	  (n=7)	  or	  20µg	  LPS	  (n=7)	  and	  the	  production	  of	  TNF-­‐α	  
was	   examined	   by	   western	   blotting.	   	   (A)	   The	   25kDa	   TNF-­‐α	   	   precursor	   protein	   was	  
detected	  in	  uterine	  tissue	  from	  mice	  receiving	  PBS	  and	  LPS.	  	  	  (B)	  β-­‐tubulin	  was	  used	  as	  
a	  protein	  loading	  control.	   	   (C)	  Densitometric	  analysis	  of	  TNF-­‐α	  band	  intensity	  relative	  
to	   β-­‐tubulin	   showed	   there	   was	   no	   significant	   difference	   between	   PBS	   and	   LPS	  
treatment	  in	  uterine	  TNF-­‐α	  production.	  	  Data	  presented	  as	  mean	  ±	  SEM	  (error	  bars).	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3.3.3.2 Fetal	  membrane	  TNF-­‐α 	  protein	  production	  
Western	  blotting	  detected	  a	  protein	  weighing	  around	  25kDa	  in	  the	  fetal	  membranes	  of	  
mice	  receiving	  both	  PBS	  and	  LPS,	  the	  17kDa	  mature	  TNF-­‐α	  protein	  was	  not	  detected	  in	  
the	  fetal	  membranes	  from	  either	  treatment	  group	  (Figure	  3.10A).	   	  β-­‐tubulin	  was	  used	  
as	   a	   loading	   control	   (Figure	   3.10B).	   	   Densitometric	   analysis	   of	   the	   band	   intensity	   of	  
TNF-­‐α	   precursor	   relative	   to	   the	   amount	   of	   protein	   present	   in	   each	   sample	   showed	  
there	  was	  a	  significant	  reduction	  in	  the	  amount	  of	  TNF-­‐α	  precursor	  protein	  present	  in	  
the	  fetal	  membranes	  of	  mice	  receiving	  LPS	  compared	  to	  the	  PBS	  control	  group	  (Figure	  
3.10C;	  p<0.05).	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Figure	  3.10	  -­‐	  Fetal	  membrane	  TNF-­‐α 	  production.	  	   	  Fetal	  membranes	  were	  collected	  
6	   hours	   post-­‐surgery	   from	   mice	   receiving	   PBS	   (n=7)	   or	   20µg	   LPS	   (n=7)	   and	   the	  
production	   of	   TNF-­‐α	   was	   examined	   by	   western	   blotting.	   	   (A)	   The	   25kDa	   TNF-­‐α	  
precursor	  protein	  was	  detected	  in	  fetal	  membranes	  from	  mice	  receiving	  PBS	  and	  LPS.	  	  	  
(B)	  β-­‐tubulin	  was	  used	  as	  a	  protein	  loading	  control.	  	  (C)	  Densitometric	  analysis	  of	  TNF-­‐
α	  band	   intensity	  relative	  to	  β-­‐tubulin	  showed	  there	  was	  a	  significant	  reduction	   in	   the	  
amount	  of	  TNF-­‐α	  precursor	  in	  the	  fetal	  membranes	  of	  mice	  treated	  with	  LPS,	  compared	  
to	  those	  receiving	  PBS.	  	  Data	  presented	  as	  mean	  ±	  SEM	  (error	  bars);	  *p<0.05.	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3.3.3.3 Placental	  TNF-­‐α 	  protein	  production	  
Western	  blotting	  detected	  a	  protein	  weighing	  around	  25kDa	  in	  the	  placental	   tissue	  of	  
mice	   receiving	   both	   PBS	   and	   LPS.	   	   As	   in	   the	   uterus	   and	   fetal	  membranes,	   the	   17kDa	  
mature	  TNF-­‐α	  protein	  was	  not	  detectable	  in	  the	  placental	  tissue	  from	  either	  treatment	  
group	   (Figure	   3.11A).	   	   β-­‐tubulin	   was	   used	   as	   a	   loading	   control	   (Figure	   3.11B).	  	  
Densitometric	  analysis	  of	  the	  band	  intensity	  of	  TNF-­‐α	  precursor	  relative	  to	  the	  amount	  
of	   protein	   present	   in	   each	   sample	   showed	   there	  was	   no	   significant	   difference	   in	   the	  
amount	   of	   TNF-­‐α	   precursor	   protein	   present	   in	   the	   placental	   tissue	   of	  mice	   in	   either	  
treatment	  group	  (Figure	  3.11C;	  p=0.42).	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Figure	   3.11	   -­‐	   Placental	   TNF-­‐α 	   production.	   	   	  Placental	   tissue	  was	  collected	  6	  hours	  
post-­‐surgery	  from	  mice	  receiving	  PBS	  (n=7)	  or	  20µg	  LPS	  (n=7)	  and	  the	  production	  of	  
TNF-­‐α	   was	   examined	   by	  western	   blotting.	   	   (A)	   The	   25kDa	   TNF-­‐α	   precursor	   protein	  
was	  detected	   in	   the	  placental	   tissue	   from	  mice	  receiving	  PBS	  and	  LPS.	   	   	  (B)	  β-­‐tubulin	  
was	   used	   as	   a	   protein	   loading	   control.	   	   (C)	   Densitometric	   analysis	   of	   TNF-­‐α	   band	  
intensity	  relative	  to	  β-­‐tubulin	  showed	  there	  was	  no	  significant	  difference	  between	  PBS	  
and	   LPS	   treatment	   in	   placental	   TNF-­‐α	   production.	   	   Data	   presented	   as	   mean	   ±	   SEM	  
(error	  bars).	  
	  
	   	   	   Chapter	  3	  
	   93	  
3.3.4 Immune	  cell	  influx	  in	  response	  to	  intrauterine	  LPS	  administration	  
A	   number	   of	   studies	   have	   highlighted	   that	   both	   labour	   and	   preterm	   labour	   are	  
associated	  with	   an	   immune	   cell	   influx	   in	   the	   utero-­‐placental	   tissues	   (Thomson	   et	   al.	  
1999,	   Osman	   et	   al.	   2003,	   Hamilton	   et	   al.	   2012).	   	   Therefore,	   to	   determine	   whether	  
immune	   cells	   played	   a	   role	   in	   our	   model	   of	   LPS-­‐induced	   preterm	   labour,	   utero-­‐
placental	  tissues	  were	  collected	  6	  hours	  post-­‐intrauterine	  injection	  and	  the	  expression	  
of	   specific	   immune	   cell	   markers	   was	  measured	   by	   qRT-­‐PCR	   and	   immune	   cells	   were	  
localised	  in	  the	  uterus	  using	  immunohistochemistry.	  	  
	  
3.3.4.1 Macrophage	  marker	  expression	  in	  the	  utero-­‐placental	  tissues	  
To	   assess	  macrophage	   influx,	   expression	  of	   the	  Emr1	   gene	  was	  measured;	   this	   is	   the	  
gene	   which	   codes	   for	   a	   specific	   antigen	   expressed	   on	  macrophages,	   F4/80.	   	   Uterine	  
expression	  of	  Emr1	  was	  unaffected	  by	   intrauterine	  administration	  of	  LPS	  at	  any	  dose	  
(Figure	  3.12A).	   	  Similarly	  placental	  Emr1	  expression	  was	  unaffected	  by	  LPS	  treatment	  
(Figure	  3.12B).	   	  Expression	  of	  Emr1	   in	  the	  fetal	  membranes	  was	  significantly	  elevated	  
in	  response	  to	  20µg	  LPS,	  with	  1.6-­‐fold	  higher	  expression	  compared	  to	  the	  PBS	  control	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Figure	   3.12	   -­‐	   Expression	   of	   Emr1	   mRNA	   in	   the	   uterus,	   placenta	   and	   fetal	  
membranes.	   	   	   Uterus,	   placenta	   and	   fetal	   membranes	   were	   collected	   6	   hours	   post-­‐
surgery	  from	  mice	  receiving	  PBS	  (n=8),	  1µg	  LPS	  (n=5),	  5µg	  LPS	  (n=5),	  10µg	  LPS	  (n=5),	  
15µg	   LPS	   (n=5)	   or	   20µg	   LPS	   (n=11)	   and	   the	   mRNA	   expression	   of	   Emr1	   was	  
investigated	  using	  qRT-­‐PCR.	   	   (A)	  Emr1	  mRNA	  expression	  in	  the	  uterus.	   	  (B)	  Placental	  
Emr1	   mRNA	   expression.	   (C)	   Emr1	  mRNA	   expression	   in	   the	   fetal	   membranes.	   	   Data	  
presented	   as	   mean	   fold	   change	   ±	   SEM	   (error	   bars);	   *p<0.05,	   compared	   to	   the	   PBS	  
control.	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3.3.4.2 Macrophage	  localisation	  in	  the	  uterus	  
To	   determine	   where	   in	   the	   uterus	   macrophages	   reside	   during	   pregnancy,	   and	  
investigate	   whether	   surgery	   and/or	   LPS	   treatment	   affect	   their	   localisation,	  
immunohistochemistry	  using	  an	  anti-­‐F4/80	  antibody	  was	  performed	  on	  uterine	  tissue	  
collected	   from	  mice	   receiving	   PBS	   or	   20µg	   LPS,	   6	   hours	   post-­‐surgery	   and	   also	   from	  
pregnant	  mice	  on	  D17	  of	  gestation	  who	  had	  no	  surgery	  or	  treatment,	  as	  a	  comparison.	  	  	  
On	   D17	   of	   gestation,	   in	   mice	   receiving	   no	   surgery	   or	   treatment,	   macrophages	   were	  
localised	   to	   the	   myometrium	   (Figure	   3.13A)	   and	   the	   decidua	   of	   these	   mice	   (Figure	  
3.13B).	   	   	   In	  mice	   receiving	   intrauterine	  PBS,	  macrophages	  were	  similarly	   found	   to	  be	  
present	  in	  both	  the	  myometrium	  (Figure	  3.13C)	  and	  decidua	  (Figure	  3.13D),	  with	  more	  
positively	  stained	  cells	  present	  in	  the	  endometrium	  compared	  to	  the	  myometrium.	  	  In	  
mice	  treated	  with	  20µg	  LPS,	  F4/80	  positive	  macrophages	  were	  still	  present	  within	  the	  
myometrium	   (Figure	   3.13E)	   and	   decidua	   (Figure	   3.13F).	   	   No	   positive	   staining	   was	  
observed	   in	   negative	   control	   sections	   of	   myometrium	   (Figure	   3.13G)	   and	   decidua	  
(Figure	  3.13H).	  
There	   were	   no	   clear	   differences	   in	   either	   the	   localisation	   or	   the	   number	   of	  
macrophages	   present	   within	   the	   uterus	   when	   comparing	   PBS	   and	   LPS	   treatment;	  
therefore	   stereological	   analysis	   was	   performed	   to	   further	   investigate	   macrophage	  
localisation	  within	  the	  uterus,	  to	  determine	  if	  LPS	  treatment	  affected	  the	  distribution	  of	  
F4/80	  positive	  cells	  within	   the	  uterus.	   	  Ten	  randomised	   fields	  of	  view	  of	  decidua	  and	  
myometrium	  were	  counted	  in	  each	  uterine	  section	  in	  order	  to	  give	  an	  estimate	  of	  the	  
number	   of	   F4/80	   positive	   cells	   in	   the	   uterus	   of	  mice	   receiving	   PBS	   or	   20µg	   LPS.	   	   In	  
response	   to	   intrauterine	   LPS,	   there	  was	   a	  mean	   1.6-­‐fold	   reduction	   in	   the	   number	   of	  
F4/80	  positive	  cells	  counted	  in	  the	  decidua,	  compared	  to	  the	  PBS	  control,	  however	  this	  
did	   not	   reach	   statistical	   significance	   (p=0.05).	   	   Similarly,	   in	   the	   myometrium,	   LPS	  
treatment	   resulted	   in	  a	  mean	  2.1-­‐fold	  decrease	   in	   the	  number	  of	  F4/80	  positive	   cells	  
counted,	   but	   again	   this	   reduction	   was	   not	   found	   to	   be	   statistically	   significant	   when	  
compared	  with	  mice	  receiving	  PBS	  (p=0.06;Figure	  3.14).	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Figure	  3.13	  -­‐	  Macrophage	  localisation	  in	  the	  uterus.	  	  	  Uterine	  tissue	  was	  collected	  6	  
hours	  post-­‐surgery	  from	  mice	  receiving	  PBS	  (n=4)	  or	  20µg	  LPS	  (n=5).	  	  Representative	  
images	  of	  macrophage	  localisation	  by	  immunohistochemical	  staining	  for	  F4/80.	  	  F4/80	  
positive	   cells	   were	   present	   in	   the	   myometrium	   (A)	   and	   decidua	   (B)	   of	   normal	  
untreated	   D17	   mice.	   	   Intrauterine	   injection	   of	   PBS	   did	   not	   appear	   to	   alter	   the	  
localisation	   of	   F4/80	   positive	   cells	   within	   the	   uterus,	   with	   macrophages	   still	   found	  
within	  the	  myometrial	  tissue	  (C)	  and	  decidua	  tissue	  (D).	  	  Positive	  F4/80	  macrophages	  
were	   similarly	   located	   in	   the	   myometrium	   (E)	   and	   decidua	   (F)	   of	   mice	   receiving	  
intrauterine	  LPS.	  	  No	  positive	  staining	  was	  observed	  in	  the	  negative	  control	  sections	  of	  
myometrium	  (G)	  and	  decidua	  (H).	  	  Scale	  bars	  show	  50µm,	  arrows	  indicate	  example	  of	  
positively	  stained	  cells.	  	  All	  images	  taken	  with	  a	  x20	  objective	  lens	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Figure	   3.14	   -­‐	   Quantification	   of	   F4/80	   positive	   cells	   in	   the	   uterus	   following	  
surgery.	   	   	   	  Uterine	  tissue	  was	  collected	  6	  hours	  post-­‐surgery	  from	  mice	  receiving	  PBS	  
(n=4)	  or	  20µg	  LPS	  (n=5).	  	  Decidua	  and	  myometrium	  were	  analysed	  separately.	  	  A	  total	  
of	  ten	  randomised	  fields	  of	  view	  were	  counted	  per	  section,	  with	  nine	  sections	  of	  uterus	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3.3.4.3 Neutrophil	  marker	  expression	  in	  the	  utero-­‐placental	  tissues	  
To	   assess	   neutrophil	   influx	   into	   the	   utero-­‐placental	   tissues,	   expression	   of	   the	   gene	  
coding	   for	   neutrophilic	   granule	   protein,	   (NGP)	   was	   measured	   by	   qRT-­‐PCR.	  	  
Administration	  of	  LPS	  resulted	  in	  significantly	  elevated	  expression	  of	  Ngp	  in	  the	  uterus	  
at	  all	  doses	  of	  LPS,	   compared	   to	   the	  PBS	  control	   (1µg	  and	  5µg	  vs.	  PBS,	  p<0.01;	  10µg,	  
15µg	  and	  20µg	  vs.	  PBS,	  p<0.001;	  Figure	  3.15A),	  with	  a	  4.7-­‐fold	  increase	  in	  expression	  in	  
response	   to	   20µg	   LPS	   compared	   to	   PBS.	   	   	   Similarly	   expression	   of	   Ngp	   in	   the	   fetal	  
membranes	  was	  also	  significantly	  elevated	  in	  response	  to	  all	  doses	  of	  LPS	  administered	  
(p<0.001;	   Figure	   3.15B),	  with	   5.7-­‐fold	   higher	   expression	   of	  Ngp	   in	   response	   to	   20µg	  
LPS	   compared	   to	  PBS.	   	   Placental	   expression	  of	  Ngp	  was	   also	   significantly	   elevated	   in	  
response	   to	   increasing	   doses	   of	   LPS,	   with	   significantly	   higher	   expression	   in	   the	  
placenta	   in	   response	   to	   15µg	   and	   20µg	   LPS	   (p<0.001;	   Figure	   3.15C),	   with	   a	   2-­‐fold	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Figure	   3.15	   -­‐	   Expression	   of	   Ngp	   mRNA	   in	   the	   uterus,	   fetal	   membranes	   and	  
placenta.	   	   	  Uterus,	  fetal	  membranes	  and	  placenta	  were	  collected	  6	  hours	  post-­‐surgery	  
from	  mice	   receiving	  PBS	   (n=8),	  1µg	  LPS	   (n=5),	  5µg	  LPS	   (n=5),	  10µg	  LPS	   (n=5),	  15µg	  
LPS	  (n=5)	  or	  20µg	  LPS	  (n=11)	  and	  the	  mRNA	  expression	  of	  Ngp	  was	  investigated	  using	  
qRT-­‐PCR.	   	   (A)	  Ngp	  mRNA	  expression	   in	   the	  uterus	   (B)	  Ngp	  mRNA	  expression	   in	   the	  
fetal	   membranes.	   (C)	   Placental	  Ngp	  mRNA	   expression.	   Data	   presented	   as	   mean	   fold	  
change	  ±	  SEM	  (error	  bars);	  **p<0.01,	  ***p<0.001,	  compared	  to	  the	  PBS	  control.	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3.3.4.4 Neutrophil	  localisation	  in	  the	  uterus	  
To	  confirm	  that	  increased	  Ngp	  expression	  was	  due	  to	  neutrophil	  influx	  into	  the	  uterus	  
and	   to	   determine	   where	   in	   the	   uterus	   neutrophils	   were	   being	   recruited	   to,	  
immunohistochemistry	   using	   an	   anti-­‐Gr-­‐1	   antibody	  was	   performed	   on	   uterine	   tissue	  
collected	   from	  mice	   receiving	   PBS	   or	   20µg	   LPS,	   6	   hours	   post-­‐surgery	   and	   also	   from	  
pregnant	  mice	  on	  D17	  of	  gestation	  who	  had	  no	  surgery	  or	  treatment,	  as	  a	  comparison.	  
On	  D17	  of	  gestation,	  in	  mice	  who	  received	  no	  treatment	  and	  who	  did	  not	  undergo	  any	  
surgery,	  there	  were	  no	  neutrophils	  present	  in	  the	  myometrium	  (Figure	  3.16A)	  and	  very	  
few,	  if	  any,	  present	  in	  the	  decidua	  of	  these	  mice	  (Figure	  3.16B).	  	  PBS	  treated	  mice	  had	  
positive	   Gr-­‐1	   staining	   in	   the	   connective	   tissue	   layer	   surrounding	   the	   longitudinal	  
myometrial	   muscle	   bundles,	   and	   within	   blood	   vessels	   of	   the	   myometrium	   (Figure	  
3.16C),	  but	  similarly	  to	  the	  untreated	  controls,	  there	  were	  very	  few,	  if	  any,	  positive	  cells	  
located	   within	   the	   decidua	   (Figure	   3.16D).	   	   Mice	   treated	   with	   LPS,	   still	   had	   Gr-­‐1	  
positive	   cells	   within	   the	   myometrium,	   as	   with	   the	   PBS	   treated	   mice	   (Figure	   3.16E),	  
however	   there	   was	   a	   striking	   difference	   when	   comparing	   the	   decidua	   of	   the	   two	  
treatment	  groups,	  where	  the	  LPS	  treated	  mice	  had	  a	  large	  influx	  of	  neutrophils	  into	  the	  
decidua	  (Figure	  3.16F).	  	  No	  positive	  staining	  was	  observed	  in	  negative	  control	  sections	  
of	  myometrium	  (Figure	  3.16G)	  and	  decidua	  (Figure	  3.16H).	  	  
To	  investigate	  further	  the	  different	  localisation	  of	  neutrophils	  within	  the	  uterus	  of	  mice	  
receiving	  PBS	  and	  LPS,	  stereological	  analysis	  was	  performed.	  Ten	  randomised	  fields	  of	  
view	  of	  decidua	  and	  myometrium	  were	  counted	  in	  each	  uterine	  section	  in	  order	  to	  give	  
an	  estimate	  of	  the	  number	  of	  Gr-­‐1	  positive	  cells	  and	  their	  distribution	  in	  the	  uterus	  of	  
mice	   receiving	   PBS	   or	   20µg	   LPS.	   	   In	   response	   to	   20µg	   LPS,	   there	   was	   a	   significant	  
increase	  in	  the	  number	  of	  Gr-­‐1	  positive	  cells	  present	   in	  the	  sampled	  areas	  of	  decidua,	  
with	   approximately	   7-­‐fold	   more	   neutrophils	   present	   in	   the	   LPS	   treated	   group,	  
compared	  to	  the	  PBS	  control	  group	  (p=0.006).	  	  There	  were	  no	  significant	  differences	  in	  
the	  number	  of	  Gr-­‐1	  cells	  present	  in	  the	  sampled	  areas	  of	  myometrium	  when	  comparing	  
between	  the	  PBS	  and	  LPS	  treated	  groups	  (p=0.57;Figure	  3.17).	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Figure	  3.16	  -­‐	  Neutrophil	   localisation	  in	  the	  uterus.	   	   	  Uterine	  tissue	  was	  collected	  6	  
hours	  post-­‐surgery	  from	  mice	  receiving	  PBS	  (n=4)	  or	  20µg	  LPS	  (n=5).	  	  Representative	  
images	  of	  neutrophil	   localisation	  by	   immunohistochemical	   staining	   for	  Gr-­‐1.	   	  No	  Gr-­‐1	  
positive	   cells	   were	   present	   in	   the	   myometrium	   (A)	   and	   decidua	   (B)	   of	   normal	  
untreated	  D17	  mice.	   	   In	   response	   to	   intrauterine	   injection	   of	   PBS,	   Gr-­‐1	   positive	   cells	  
were	   localised	   to	   the	  myometrium,	  surrounding	   the	   longitudinal	  muscle	  bundles,	  and	  
within	   blood	   vessels	   (C).	   	   	   As	   in	   the	   untreated	   controls,	   there	   were	   no	   neutrophils	  
present	   in	   the	   decidua	   of	   mice	   receiving	   PBS	   (D).	   	   Positive	   Gr-­‐1	   neutrophils	   were	  
similarly	   localised	   to	   the	   myometrium	   in	   mice	   receiving	   LPS	   (E).	   	   An	   influx	   of	  
neutrophils	  into	  the	  decidua	  of	  mice	  was	  observed	  in	  response	  to	  intrauterine	  injection	  
of	  20µg	  of	  LPS	  (F).	   	  No	  positive	  staining	  was	  observed	  in	  the	  negative	  control	  sections	  
of	  myometrium	  (G)	  and	  decidua	  (H).	  	  Scale	  bars	  show	  50µm,	  arrows	  indicate	  examples	  
of	  positively	  stained	  cells.	  	  All	  images	  taken	  with	  a	  x20	  objective	  lens.	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Figure	  3.17	  -­‐	  Quantification	  of	  Gr-­‐1	  positive	  cells	  in	  the	  uterus	  following	  surgery.	  	  	  
Uterine	   tissue	  was	   collected	   6	   hours	   post-­‐surgery	   from	  mice	   receiving	   PBS	   (n=4)	   or	  
20µg	  LPS	   (n=5).	   	  Decidua	   and	  myometrium	  were	   analysed	   separately.	   	   A	   total	   of	   ten	  
randomised	   fields	   of	   view	   were	   counted	   per	   section,	   with	   nine	   sections	   of	   uterus	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3.3.5 Inflammatory	  markers	  in	  the	  amniotic	  fluid	  
Amniotic	  fluid	  was	  collected	  6	  hours	  post-­‐surgery	  to	  examine	  the	  level	  of	  inflammatory	  
cytokine	   production	   in	   the	   amniotic	   fluid	   in	   response	   to	   intrauterine	   LPS	  
administration.	  	  ELISAs	  were	  used	  to	  measure	  the	  concentration	  of	  the	  cytokines	  TNF-­‐
α,	   IL-­‐1β,	   IL-­‐6	   and	   IL-­‐10.	   	   Where	   the	   concentration	   of	   cytokines	   was	   too	   low	   to	   be	  
detected	   by	   the	   ELISAs,	   the	   value	   of	   the	   limit	   of	   detection	   of	   the	   specific	   ELISA	  was	  
entered	   to	   give	   a	   value	   for	   analysis	   and	   the	   data	   were	   analysed	   by	   non-­‐parametric	  
ANOVA	  (Kruskal-­‐Wallis).	  	  	  
TNF-­‐α	   was	   undetectable	   in	   six	   PBS	   control	   samples,	   one	   10µg	   LPS	   sample	   and	   one	  
20µg	   LPS	   sample.	   	   Administration	   of	   LPS	   resulted	   in	   increased	   amniotic	   fluid	   TNF-­‐α	  
levels,	  with	  significantly	  higher	  TNF-­‐α	  production	  in	  response	  to	  5µg	  LPS	  (mean	  106.5	  
pg/ml	  ±	  SEM	  38.23;	  p<0.01),	  15µg	  LPS	  (mean	  75.18	  pg/ml	  ±	  SEM	  30.71;	  p<0.05)	  and	  
20µg	  of	  LPS	  (mean	  91.74	  pg/ml	  ±	  SEM	  28.75;	  p<0.01),	  compared	  with	  the	  PBS	  control	  
group	  (mean	  11.96	  pg/ml	  ±	  SEM	  1.06;	  Figure	  3.18A)	  
IL-­‐1β	  was	  undetectable	   in	  one	  10µg	  LPS	   sample.	   	  Amniotic	   fluid	   levels	  of	   IL-­‐1β	  were	  
unaffected	   by	   intrauterine	   LPS	   administration,	   although	   slightly	   elevated	   IL-­‐1β	   was	  
measured	   in	   the	   amniotic	   fluid	   from	  mice	   receiving	   20µg	   LPS	   (mean	   54.59	   pg/ml	   ±	  
SEM	  10.43)	  compared	  to	  PBS	  (mean	  33.08	  pg/ml	  ±	  SEM	  5.08),	  this	  was	  not	  statistically	  
significant	  (p=	  0.99;	  Figure	  3.18B).	  	  	  
Amniotic	   fluid	   levels	   of	   IL-­‐6	   were	   elevated	   in	   response	   to	   LPS	   treatment,	   with	  
significantly	  higher	  levels	  of	  IL-­‐6	  measured	  in	  the	  amniotic	  fluid	  of	  mice	  receiving	  20µg	  
LPS	  (mean	  2216	  pg/ml	  ±	  SEM	  484.7)	  compared	  with	  those	  receiving	  PBS	  (mean	  473.9	  
pg/ml	  ±	  SEM	  228.2;	  p<0.01;	  Figure	  3.18C).	  	  	  
IL-­‐10	   was	   undetectable	   in	   five	   PBS	   samples,	   two	   1µg	   LPS	   samples,	   three	   10µg	   LPS	  
samples,	  one	  15µg	  LPS	  sample	  and	  four	  20µg	  LPS	  samples.	  	  Intrauterine	  administration	  
of	  LPS	  resulted	  in	  significantly	  elevated	  IL-­‐10	  production	  in	  response	  to	  5µg	  LPS	  (mean	  
20.94	  pg/ml	   ±	   SEM	  15.5;	   p<0.05)	   and	  15µg	   LPS	   (mean	  24.38	  pg/ml	   ±	   4.29;	   p<0.05),	  
compared	  with	  mice	  receiving	  PBS	  (mean	  15.5	  pg/ml	  ±	  SEM	  0.37;	  Figure	  3.18D).	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Figure	   3.18	   -­‐	   Inflammatory	   markers	   in	   the	   amniotic	   fluid.	   	   	   Amniotic	   fluid	  was	  
collected	  6	  hours	  post-­‐surgery	  from	  mice	  receiving	  PBS	  (n=8),	  1µg	  LPS	  (n=5),	  5µg	  LPS	  
(n=5),	  10µg	  LPS	  (n=5),	  15µg	  LPS	  (n=5)	  or	  20µg	  LPS	  (n=11)	  and	  ELISAs	  were	  used	  to	  
quantify	  the	  concentration	  of	  inflammatory	  cytokines	  present	  in	  the	  amniotic	  fluid.	  (A)	  
Amniotic	   fluid	   TNF-­‐α	   concentration	   (B)	   Amniotic	   fluid	   IL-­‐1β	   concentration.	   (C)	  
Amniotic	   fluid	   IL-­‐6	   concentration.	   	   (D)	   Amniotic	   fluid	   IL-­‐10	   concentration.	   	   Data	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3.3.6 Serum	  markers	  in	  response	  to	  intrauterine	  LPS	  administration	  
To	   investigate	   whether	   intrauterine	   LPS	   administration	   resulted	   in	   a	   systemic	  
inflammatory	   response,	   the	   serum	   concentrations	   of	   two	   candidate	   cytokines	  
measured	   in	  3.3.5.	  were	  determined.	   	  The	  pro-­‐inflammatory	  cytokine,	  TNF-­‐α,	  and	  the	  
anti-­‐inflammatory	   cytokine,	   IL-­‐10,	   were	   measured	   by	   ELISA	   in	   maternal	   serum	  
collected	  6	  hours	  post-­‐surgery.	  	  Also	  because	  a	  drop	  in	  circulating	  progesterone	  levels	  
normally	   precedes	   labour	   in	   mice,	   serum	   progesterone	   concentration	   was	   also	  
measured	  by	  ELISA.	  	  	  
Serum	   levels	   of	   TNF-­‐α	   were	   elevated	   in	   response	   to	   increasing	   doses	   of	   LPS,	   with	  
significantly	  higher	  levels	  of	  TNF-­‐α	  measured	  when	  mice	  received	  doses	  of	  10µg	  (mean	  
13.63	  pg/ml	  ±	  SEM	  2.72;	  p<0.01),	  15µg	  (mean	  25.54	  pg/ml	  ±	  SEM	  5.95;	  p<0.001)	  and	  
20µg	   of	   LPS	   (mean	   19.07	   pg/ml	   ±	   SEM	   3.51;	   p<0.01),	   compared	   to	   the	   PBS	   control	  
group	  (mean	  4.06	  pg/ml	  ±	  SEM	  0.74;	  Figure	  3.19A).	  
Intrauterine	   administration	   of	   LPS	   resulted	   in	   increased	   circulating	   levels	   of	   IL-­‐10.	  	  	  
Serum	  IL-­‐10	  was	  significantly	  elevated	  in	  response	  to	  both	  15µg	  (mean	  276.5	  pg/ml	  ±	  
SEM	   59.0;	   p<0.001)	   and	   20µg	   of	   LPS	   (mean	   182.4	   pg/ml	   ±	   SEM	   23.89;	   p<0.01),	  
compared	  to	  the	  PBS	  control	  (mean	  52.04	  pg/ml	  ±	  SEM	  6.53;	  Figure	  3.19B).	  	  	  
Serum	  progesterone	  levels	  were	  unaffected	  by	  intrauterine	  LPS	  administration.	  	  There	  
was	  no	  significant	  difference	  in	  the	  mean	  progesterone	  concentration	  in	  the	  PBS	  group	  
(mean	  19.74	  ng/ml	  ±	  SEM	  1.58)	  compared	  with	  any	  of	  the	  doses	  of	  LPS	  administered	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Figure	   3.19	   -­‐	   Serum	   markers	   in	   response	   to	   intrauterine	   LPS	   administration.	  	  	  
Maternal	  blood	  was	  collected	  6	  hours	  post-­‐surgery	  from	  mice	  receiving	  PBS	  (n=8),	  1µg	  
LPS	   (n=5),	   5µg	   LPS	   (n=5),	   10µg	   LPS	   (n=5),	   15µg	   LPS	   (n=5)	   or	   20µg	   LPS	   (n=11)	   and	  
serum	  concentrations	  of	  TNF-­‐α,	  IL-­‐10	  and	  progesterone	  were	  measured	  by	  ELISA.	   	  (A)	  
Serum	  TNF-­‐α	   concentration.	   (B)	  Serum	  IL-­‐10	  concentration.	   (C)	  Serum	  progesterone	  
concentration.	   	   Data	   presented	   as	   mean	   ±	   SEM	   (error	   bars);	   *p<0.05,	   **p<0.01,	  
***p<0.001,	  compared	  to	  the	  PBS	  control.	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3.3.7 Gene	  expression	  in	  the	  fetal	  brain	  following	  intrauterine	  LPS	  administration	  
The	   presence	   of	   an	   intrauterine	   infection	   is	   often	   associated	   with	   poor	   neonatal	  
outcome	   and	   brain	   injury	   (Shatrov	   et	   al.	   2010).	   	   Previous	   animal	   studies	   of	   preterm	  
labour	   have	   demonstrated	   that	   administration	   of	   LPS	   can	   result	   in	   increased	  
expression	   of	   inflammatory	   cytokines	   in	   the	   fetal	   brain,	   and	   alter	   the	   expression	   of	  
neuronal	   markers,	   suggesting	   possible	   brain	   injury	   (Elovitz	   et	   al.	   2006,	   Burd	   et	   al.	  
2011).	  	  	  
Fetal	   brains	   were	   collected	   6	   hours	   post-­‐intrauterine	   injection	   and	   analysed	   for	   the	  
expression	   of:	   the	   pro-­‐inflammatory	   cytokines	   Tnf-­‐α,	   Il-­‐1β	   and	   Il-­‐6;	   the	   anti-­‐
inflammatory	   cytokine,	   Il-­‐10;	   and	   brain-­‐specific	   markers	   glial	   fibrillary	   associated	  
protein	   (Gfap),	   and	   microtubule-­‐associated	   protein	   (Mtap2),	   to	   assess	   whether	  
intrauterine	  LPS	  administration	  resulted	  in	  an	  increased	  inflammatory	  response	  within	  
the	  fetal	  brain	  or	  any	  early	  signs	  of	  brain	  injury.	  	  
Expression	   of	   Tnf-­‐α	   in	   the	   fetal	   brain	   was	   unaffected	   by	   intrauterine	   LPS	   treatment	  
(Figure	  3.20A).	   	  Similarly,	  LPS	   treatment	  did	  not	   induce	  a	  significant	   increase	   in	   Il-­‐1β	  
expression,	   although	   a	   small	   increase	   was	   observed	   in	   mice	   receiving	   20µg	   LPS	  
compared	  to	  the	  PBS	  control	  group,	  this	  was	  not	  statistically	  significant	  (p=0.69;	  Figure	  
3.20B).	   	  Unexpectedly	   Il-­‐6	   expression	   in	   the	   fetal	  brain	  was	  significantly	  decreased	   in	  
mice	   treated	   with	   1µg	   LPS	   (p<0.05;	   Figure	   3.20C),	   with	   2-­‐fold	   lower	   expression	  
compared	   to	   the	   PBS	   control.	   	   ll-­‐10	   expression	   in	   the	   fetal	   brain	   was	   too	   low	   to	   be	  
detected	  in	  all	  treatment	  groups.	  	  
Expression	   of	   the	   marker	   of	   astrogliosis,	   Gfap,	  was	   not	   significantly	   altered	   in	   fetal	  
brains	  of	  mice	   receiving	  LPS,	   compared	   to	   the	  PBS	   control	   (Figure	  3.20D).	   	   Similarly,	  
expression	   of	   the	   neuronal	   marker,	   Mtap2	   in	   fetal	   brains	   was	   also	   unaffected	   by	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Figure	   3.20	   -­‐	   Gene	   expression	   in	   the	   fetal	   brains	   following	   intrauterine	   LPS	  
administration.	   	   	  Fetal	  brains	  was	  collected	  6	  hours	  post-­‐surgery	  from	  mice	  receiving	  
PBS	  (n=8),	  1µg	  LPS	  (n=5),	  5µg	  LPS	  (n=5),	  10µg	  LPS	  (n=5),	  15µg	  LPS	  (n=5)	  or	  20µg	  LPS	  
(n=11)	  and	  the	  mRNA	  expression	  of	  several	  inflammatory	  genes	  assessed	  by	  qRT-­‐PCR.	  	  
(A)	  Tnf-­‐α	  mRNA	  expression.	   	   (B)	   Il-­‐1β	  mRNA	  expression,	   (C)	   Il-­‐6	  mRNA	  expression.	  
(D)	  Gfap	  mRNA	  expression.	   	   (E)	  Mtap-­‐2	  mRNA	  expression.	   	  Data	  presented	   as	  mean	  
fold	  change	  ±	  SEM	  (error	  bars);	  *p<0.05,	  compared	  to	  the	  PBS	  control.	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3.4 DISCUSSION	  
Mouse	  model	  of	  infection	  induced	  preterm	  labour	  
Animal	   models	   of	   parturition	   have	   been	   used	   for	   many	   years	   to	   elucidate	   the	  
mechanisms	  underlying	  the	  onset	  of	  spontaneous	  labour	  at	  term	  and	  to	  understand	  the	  
causes	  of	  preterm	  labour.	  	  The	  pros	  and	  cons	  of	  various	  animal	  models	  for	  parturition	  
research	   have	   been	   extensively	   discussed	   (Elovitz	   and	   Mrinalini	   2004,	   Mitchell	   and	  
Taggart	  2009,	  Ratajczak	  et	  al.	  2010).	  	  Clearly	  there	  are	  always	  limitations	  in	  the	  use	  of	  
any	  animal	  model,	  as	  they	  can	  rarely	  replicate	  the	  exact	  clinical	  scenario	  in	  humans,	  but	  
given	  the	  fact	  that	  collection	  of	  gestational	  tissues	  from	  women	  at	  various	  time	  points	  
during	  pregnancy	  is	  clearly	  not	  possible,	  animal	  models	  are	  required	  to	  build	  a	  picture	  
of	   the	   sequence	  of	  events	   involved	   in	  parturition	   (Mitchell	   and	  Taggart	  2009).	   	  Aside	  
from	   the	   clear	   physiological	   differences	   in	   the	   reproductive	   tissues,	   the	   main	   issue	  
raised	  regarding	  the	  use	  of	  mice	  in	  parturition	  models,	  is	  that	  progesterone	  withdrawal	  
is	   required	   for	   normal	   term	   labour	   in	   this	   species,	   which	   is	   not	   a	   feature	   of	   human	  
parturition	   (Elovitz	   and	   Mrinalini	   2004).	   	   However,	   recent	   studies	   suggest	   that	   the	  
induction	  of	  preterm	  labour,	  by	  injection	  of	  bacterial	  products	  in	  mice,	  does	  not	  appear	  
to	   rely	   on	   progesterone	   withdrawal	   (Hirsch	   and	   Muhle	   2002,	   Murphy	   et	   al.	   2009,	  
Gonzalez	  et	  al.	  2011),	  which	  may	   improve	   the	  suitability	  of	  mice	   in	   this	   context.	   	  The	  
ability	   of	  mice	   to	   reproduce	   efficiently	   and	   rapidly	  with	   a	   short	   gestation,	   allows	   for	  
studies	   to	   be	   carried	   out	   on	   a	   large	   number	   of	   animals	   over	   a	   short	   space	   of	   time,	  
compared	   with	   studies	   using	   the	   more	   closely	   related	   non-­‐human	   primate	   models	  
(Elovitz	   and	   Mrinalini	   2004,	   Mitchell	   and	   Taggart	   2009,	   Ratajczak	   et	   al.	   2010).	  	  
Furthermore,	  as	  will	  be	  discussed	  in	  detail	  in	  this	  chapter,	  there	  are	  many	  similarities	  
in	   the	   response	   to	   intrauterine	   infection	   between	  mice	   and	   humans,	   making	   them	   a	  
reliable	  and	  cost-­‐effective	  model	  to	  study	  infection-­‐induced	  preterm	  labour.	  	  	  	  
This	  chapter	  aimed	  to	  use	  a	  mouse	  model	  of	  intrauterine	  LPS	  administration	  to	  induce	  
preterm	   labour	   and	   investigate	   the	   associated	   inflammatory	   and	   immune	   responses.	  	  
The	   use	   of	   a	   direct	   intrauterine	   injection	   of	   LPS	   to	   induce	   preterm	   labour	   was	   first	  
described	  by	  Elovitz	  et	  al.	  (Elovitz	  et	  al.	  2003),	  and	  is	  now	  routinely	  used	  as	  a	  model	  of	  
preterm	  labour	  to	  investigate	  the	  role	  of	  inflammation	  and	  infection	  in	  preterm	  labour	  
and	   to	   test	   out	   potential	   therapeutic	   drugs	   to	   delay	   delivery	   and	   improve	   neonatal	  
outcome.	   	  Administration	  of	  bacterial	  products	  directly	   into	  the	  uterus,	  as	  opposed	  to	  
via	  intra-­‐peritoneal	  injection	  (Fidel	  et	  al.	  1994,	  Kaga	  et	  al.	  1996,	  Robertson	  et	  al.	  2006),	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provides	  a	  model	  which	  more	  closely	  reflects	  the	  clinical	  scenario	  in	  women,	  where	  the	  
presence	  of	  an	  intrauterine	  infection	  is	  usually	  subclinical	  and	  results	  in	  a	  local,	  rather	  
than	  a	  systemic,	  inflammatory	  and	  immune	  response	  (Goldenberg	  et	  al.	  2000).	  	  	  
Clearly	  the	  surgical	  nature	  of	  the	  model	  itself	  does	  have	  drawbacks.	  	  Although	  generally	  
the	  mice	  recovered	  well	  from	  the	  surgery,	  it	  is	  to	  be	  expected	  that	  performing	  relatively	  
major	   surgery,	   late	   in	   gestation,	   may	   have	   an	   impact	   on	   time	   to	   delivery.	   	   Indeed,	  
although	   no	   significant	   difference	   was	   observed	   in	   the	   mean	   time	   to	   delivery	   when	  
comparing	   the	  no	  surgery	  control	  group	  with	   the	  PBS	   treated	  group,	  40%	  of	   the	  PBS	  
treated	   mice	   did	   go	   into	   preterm	   labour	   (i.e.	   they	   delivered	   within	   36	   hours	   of	  
intrauterine	   injection),	   whilst	   no	   mice	   in	   the	   no	   surgery	   group	   delivered	   preterm.	  	  
Although	   great	   care	  was	   taken	   during	   surgery,	   this	   rate	   of	   preterm	   birth	   in	   the	   PBS	  
control	  group	  is	   likely	  due	  to	  the	  surgical	  procedures	  of	  pulling	  out	  and	  returning	  the	  
uterine	  horns	  to	  the	  abdominal	  cavity.	  	  	  	  
Despite	  its	  limitations,	  the	  evidence	  described	  in	  this	  chapter	  supports	  that	  the	  model	  
we	   used	   is	   an	   effective	   model	   of	   infection-­‐induced	   preterm	   labour;	   which	   reliably	  
induces	   preterm	   delivery	   and	   which	   can	   be	   used	   to	   analyse	   the	   inflammatory	   and	  
immune	  responses	  occurring	  in	  response	  to	  a	  local	  intrauterine	  infection.	  	  
	  
Intrauterine	   LPS	   administration	   dose-­‐dependently	   induced	   preterm	   labour	   and	   reduced	  
the	  proportion	  of	  live	  born	  pups	  
The	  LPS	  dose	  response	  experiments	  showed	  that	  intrauterine	  administration	  of	  LPS	  at	  
doses	   of	   15µg	   and	   20µg	   induced	   delivery	   significantly	   earlier	   than	   the	   PBS	   control	  
group.	   	   This	   result	   is	   similar	   to	   recently	   published	   data	   by	   Sykes	   et	   al.	   (Sykes	   et	   al.	  
2013),	  where	   they	   use	   the	   same	  mode	   of	   administration,	   same	   serotype	   of	   LPS	   and	  
similar	  doses	  in	  a	  LPS	  dose	  response	  experiment	  measuring	  time	  to	  delivery.	  	  However,	  
they	   show	  a	   significant	  effect	  of	   low	  doses	  of	  LPS	   (2.5µg,	  5µg	  and	  10µg)	  on	   reducing	  
time	  to	  delivery,	  which	  were	  not	  seen	  in	  this	  study.	  	  These	  differences	  are	  possibly	  due	  
to	   the	  potential	  variations	   in	  potency	   that	  can	  be	  associated	  with	  different	  batches	  of	  
LPS.	  	  Whilst	  both	  15µg	  and	  20µg	  LPS	  both	  significantly	  reduced	  time	  to	  delivery,	  it	  was	  
decided	  the	  20µg	  LPS	  was	  the	  most	  appropriate	  dose	  to	  use	   in	   future	  experiments	  as	  
this	   dose	   most	   consistently	   induced	   preterm	   labour	   and	   significantly	   increased	   the	  
preterm	  delivery	  rate.	  	  For	  the	  purpose	  of	  describing	  the	  model	  in	  this	  chapter,	  time	  to	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delivery	  and	   live	  pup	  data	   from	  all	  mice	   that	   received	  20µg	  LPS	  and	   from	  all	   control	  
mice	  that	  received	  PBS	  in	  all	  of	  our	  studies	  were	  pooled	  for	  analysis,	  hence	  the	  large	  n	  
numbers	  in	  these	  groups.	  	  	  
The	   reduction	   in	   the	   proportion	   of	   live	   born	   pups	   associated	   with	   intrauterine	   LPS	  
treatment	  has	  been	  demonstrated	   in	  previous	  studies	   in	  similar	  models	  (Elovitz	  et	  al.	  
2003,	  Pirianov	  et	  al.	  2009,	  Sykes	  et	  al.	  2013).	  	  This	  significant	  reduction	  in	  the	  number	  
of	  live	  pups	  being	  born	  is	  likely	  to	  be	  due	  to	  both	  an	  effect	  of	  the	  LPS	  treatment,	  and	  the	  
premature	  delivery	  of	   the	  pups.	   	   	   If	   the	  mice	  are	  delivered	  on	  D17	  or	  D18,	   it	   is	   likely	  
that	   they	  will	  not	  be	  developmentally	  competent	  to	  survive.	   	  However,	  evidence	   from	  
this	   study	   suggests	   that	   receiving	   LPS	   treatment	   further	   compounds	   the	   negative	  
effects	  of	  being	  born	  prematurely,	  as	  even	  when	  PBS	  control	  mice	  delivered	  preterm,	  
they	   had	   a	   significantly	   greater	   proportion	   of	   live	   born	   pups	   compared	   to	   mice	  
receiving	  15µg	  and	  20µg	  of	  LPS.	  	  	  
	  
Intrauterine	  administration	  of	  LPS	  results	  in	  a	  local	  and	  systemic	  inflammatory	  response	  
Both	   spontaneous	   term	   labour	   and	   infection-­‐associated	   preterm	   labour	   in	   humans	  
have	   been	   associated	   with	   increased	   levels	   of	   pro-­‐inflammatory	   mediators	   in	   the	  
amniotic	   fluid	   (Yoon	  et	  al.	  2001,	  Thomakos	  et	  al.	  2010,	  Marconi	  et	  al.	  2011);	  elevated	  
expression	  of	  inflammatory	  cytokines	  within	  the	  utero-­‐placental	  tissues	  (Denison	  et	  al.	  
1998,	   Sennstrom	   et	   al.	   2000,	   Young	   et	   al.	   2002,	   Osman	   et	   al.	   2003);	   and	   increased	  
activation	  of	  peripheral	  blood	  leukocytes	  (Yuan	  et	  al.	  2009).	  	  In	  parallel,	  work	  in	  animal	  
models	  has	  also	  demonstrated	  a	  similar	  inflammatory	  response	  within	  the	  intrauterine	  
tissues	  both	  at	  term	  and	  in	  models	  of	  preterm	  labour	  (Robertson	  et	  al.	  2010,	  Shynlova	  
et	  al.	  2013,	  Shynlova	  et	  al.	  2013).	  	  	  	  
To	   investigate	  whether	   intrauterine	   LPS	   administration	   induced	   a	   local	   and	   systemic	  
inflammatory	   response	   in	   our	   model,	   the	   expression	   of	   inflammatory	   cytokines	   was	  
measured	  in	  the	  uterus,	  fetal	  membranes,	  placenta,	  amniotic	  fluid	  and	  maternal	  serum	  
6	  hours	  post-­‐surgery.	  	  	  
Expression	   of	   the	   pro-­‐inflammatory	   cytokines	   IL-­‐1β,	   TNF-­‐α	   and	   IL-­‐6	   in	   the	  
myometrium,	  cervix,	  fetal	  membranes	  and	  placenta	  are	  elevated	  in	  women	  during	  term	  
labour,	  compared	  to	  non-­‐labouring	  women	  (Sennstrom	  et	  al.	  2000,	  Young	  et	  al.	  2002,	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Osman	  et	  al.	  2003,	  Osman	  et	  al.	  2006).	   	  These	  cytokines	  are	  thought	  to	  be	   involved	  in	  
stimulating	  the	  local	  production	  of	  other	  inflammatory	  mediators,	  such	  as	  MMPs	  (Riley	  
et	  al.	  1999,	  Xu	  et	  al.	  2002)	  and	  prostaglandins	  (Pollard	  and	  Mitchell	  1996,	  Keelan	  et	  al.	  
2003,	  Olson	  2003);	  which	  can	  then	  go	  on	  to	  stimulate	  the	  processes	  required	  for	  labour	  
progression,	   including	  myometrial	   contractions,	   fetal	  membrane	   rupture	   and	   cervical	  
ripening	  and	  dilation.	  	  The	  role	  of	  these	  pro-­‐inflammatory	  cytokines	  in	  preterm	  labour	  
have	  also	  been	  confirmed	  in	  animal	  studies	  which	  demonstrated	  that	  intra-­‐amniotic	  or	  
intrauterine	   injection	   of	   TNF-­‐α	   and	   IL-­‐1β,	   induced	   preterm	   birth	   in	   animal	   models	  
(Romero	  et	  al.	  1992,	  Silver	  et	  al.	  1994,	  Sadowsky	  et	  al.	  2006);	  and	  that	  the	  rate	  of	  E.coli-­‐
induced	   preterm	   birth	   in	   IL-­‐1	   and	   TNF	   receptor	   double	   knockout	  mice	  was	   reduced	  
when	  compared	   to	  wild-­‐type	  mice	   (Hirsch	  et	  al.	  2006).	   	  Additionally,	   the	   incidence	  of	  
LPS-­‐induced	   preterm	   labour	   was	   also	   significantly	   reduced	   in	   IL-­‐6	   knockout	   mice,	  
compared	  with	  wild-­‐types	  (Robertson	  et	  al.	  2010).	  	  	  	  
Results	   from	  our	  model	  demonstrate	  that	  LPS	  treatment	   induced	  a	  robust	   increase	   in	  
the	   expression	   of	   pro-­‐inflammatory	   cytokines	   within	   6	   hours	   in	   the	   uterus,	   fetal	  
membranes	  and	  placenta,	  with	  elevated	  expression	  of	  Il-­‐1β	  and	  Tnf-­‐α	  at	  all	  doses	  of	  LPS	  
administered,	  when	   compared	  with	   the	   PBS	   control	   group.	   	   Similarly	   Il-­‐6	   expression	  
was	  significantly	  elevated	  at	  all	  doses	  of	  LPS	  administered	  in	  the	  uterus	  and	  placenta,	  
but	  expression	  of	  Il-­‐6	  was	  unchanged	  in	  the	  fetal	  membranes.	   	  In	  line	  with	  these	  data,	  
similar	  models	  of	  LPS-­‐induced	  preterm	   labour	  have	  reported	   increased	  expression	  of	  
Il-­‐1β,	  Tnf-­‐α	  and	  Il-­‐6	  in	  the	  uterus	  and	  placenta	  6	  hours	  after	  intrauterine	  LPS	  (Chang	  et	  
al.	   2011);	   and	   in	   the	  myometrium	   and	   decidua	   of	  mice	   during	   LPS-­‐induced	   preterm	  
labour	  (Shynlova	  et	  al.	  2013,	  Shynlova	  et	  al.	  2013).	  	  
Surprisingly,	   increased	   Tnf-­‐α	   gene	   expression	   was	   not	   found	   to	   correlate	   with	  
increased	   protein	   production	   in	   the	   utero-­‐placental	   tissues,	   as	  measured	   by	  western	  
blotting.	  	  TNF-­‐α	  mRNA	  is	  translated	  into	  a	  26kDa	  membrane-­‐bound	  precursor	  protein,	  
which	  is	  converted	  into	  the	  17kDa	  secreted	  mature	  TNF-­‐α	  protein	  by	  tumour	  necrosis	  
factor-­‐alpha	   converting	   enzyme	   (TACE)	   (Black	   et	   al.	   1997,	   Moss	   et	   al.	   1997).	   	   The	  
western	  blot	  only	  detected	  the	  26kDa	  TNF-­‐α	  precursor	  protein,	  rather	  than	  the	  smaller	  
mature	  protein.	  	  This	  may	  suggest	  a	  lack	  of	  mature	  TNF-­‐α	  protein	  within	  these	  tissues,	  
or	   it	   may	   be	   that	   the	   conditions	   were	   not	   optimised	   to	   identify	   the	   smaller	   mature	  
protein.	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In	  the	  uterus	  and	  placenta,	   there	  was	  no	  difference	   in	  TNF-­‐α	  precursor	  protein	   levels	  
when	   comparing	   tissue	   from	  mice	   receiving	   PBS	  with	   that	   from	  mice	   receiving	   20µg	  
LPS,	  and	  there	  was	  a	  reduction	   in	  the	  amount	  of	  TNF-­‐α	  precursor	  protein	   in	  the	   fetal	  
membranes.	   	   Given	   the	   significant	   increase	   in	  Tnf-­‐α	  mRNA	   expression	   in	   uterus	   and	  
placenta	   observed	   in	   response	   to	   20µg	   LPS,	   compared	   to	   the	   PBS	   controls	   (5-­‐fold	  
increase	   in	   uterus,	   7-­‐fold	   increase	   in	   placenta),	   it	   was	   surprising	   that	   this	   did	   not	  
correlate	  with	   increased	   TNF-­‐α	   protein.	   	   However,	   other	   studies	   have	   reported	   LPS-­‐
induced	   increased	   Tnf-­‐α	   expression	   in	   myometrium	   at	   the	   mRNA	   level	   without	  
associated	  increased	  protein	  expression	  at	  the	  same	  time	  point	  (Shynlova	  et	  al.	  2013).	  	  
It	   could	   be	   that	   increased	   protein	   concentrations	   would	   be	   observed	   at	   a	   later	   time	  
point,	  due	  to	  a	  delay	  in	  translation	  of	  the	  increased	  mRNA.	  	  	  
The	   observed	   reduction	   in	   TNF-­‐α	   precursor	   protein	   levels	   detected	   in	   the	   fetal	  
membranes,	  where	  Tnf-­‐α	  mRNA	  was	  increased	  33-­‐fold	  in	  response	  to	  20µg	  LPS,	  could	  
be	   indicative	  of	   a	  higher	   rate	  of	  TACE	  activity	   in	   the	   fetal	  membranes	   converting	   the	  
precursor	   protein	   into	   mature	   TNF-­‐α	   in	   mice	   receiving	   LPS.	   	   Support	   for	   this	  
hypothesis	  comes	  from	  a	  previous	  study	  by	  Hung	  et	  al.	  (Hung	  et	  al.	  2006)	  which	  found	  
increased	  TACE	  activity	   in	  placenta	  and	   fetal	  membranes	   collected	   from	  women	  who	  
had	   evidence	   of	   chorioamnionitis,	   compared	   with	   tissues	   obtained	   from	   normal	  
pregnancies.	   	  They	  also	  demonstrated	  that	  treatment	  of	  placental	  and	  fetal	  membrane	  
samples	  with	  LPS	  in	  vitro	  increased	  TACE	  mRNA	  and	  protein	  levels	  (Hung	  et	  al.	  2006).	  	  
Additionally,	   a	   recent	   study	   highlights	   the	   importance	   of	   not	   only	   measuring	  
inflammatory	   cytokines,	   but	   also	   their	   receptors	   when	   investigating	   the	   role	   of	  
cytokines	   in	   labour	   (Alexander	   et	   al.	   2012).	   	   They	   demonstrate	   that	   whilst	   there	   is	  
inconsistent	  data	  regarding	  whether	  TNF-­‐α	  levels	  increase	  in	  human	  myometrium	  with	  
preterm	  or	  term	  labour,	  they	  found	  increased	  expression	  of	  the	  two	  TNF-­‐α	  receptors,	  
TNFR1A	  and	  TNFR1B	  with	  term	  and	  preterm	  labour,	  respectively,	  suggesting	  that	  the	  
myometrium	   becomes	  more	   sensitive	   to	   TNF-­‐α	   at	   the	   onset	   of	   labour,	   regardless	   of	  
whether	   the	   levels	   of	   TNF-­‐α	   change.	   	   Investigating	   cytokine	   receptor	   levels	   and	  
quantification	  of	  TACE	  protein	  may	  have	  given	  a	  clearer	  picture	  of	  whether	   increased	  
mRNA	  expression	  is	  translated	  into	  increased	  activity	  of	  the	  cytokines.	  	  
To	   investigate	   further	   the	   local	   inflammatory	   response	   to	   intrauterine	   LPS	  
administration,	   the	   levels	   of	  TNF-­‐α,	   IL-­‐1β	   and	   IL-­‐6	   secreted	   into	   the	   amniotic	   fluid	  6	  
hours	   after	   surgery	  were	  measured.	   	  Women	  who	   deliver	   preterm,	  with	   evidence	   of	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intra-­‐amniotic	  infection,	  have	  elevated	  levels	  of	  IL-­‐1β,	  TNF-­‐α	  and	  IL-­‐6	  in	  their	  amniotic	  
fluid	   (Thomakos	   et	   al.	   2010,	   Marconi	   et	   al.	   2011).	   	   In	   line	   with	   these	   studies,	  
intrauterine	  LPS	  administration	  in	  our	  model	  resulted	  in	  significantly	  elevated	  levels	  of	  
both	  TNF-­‐α	  and	  IL-­‐6	  in	  the	  amniotic	  fluid	  when	  compared	  with	  the	  PBS	  control	  group.	  	  
Although	  the	  concentration	  of	  IL-­‐1β	  was	  elevated	  in	  mice	  receiving	  20µg	  LPS,	  this	  was	  
not	  significantly	  greater	  than	  the	  amniotic	  fluid	  concentrations	  in	  PBS	  mice.	  	  These	  data	  
suggest	   that,	   as	   in	   human	   pregnancy	   associated	   with	   an	   intra-­‐amniotic	   infection,	  
intrauterine	  administration	  of	  LPS	  results	  in	  a	  local	  inflammatory	  response	  within	  the	  
amniotic	  fluid,	  and	  agrees	  with	  other	  reported	  mouse	  studies	  (Xu	  et	  al.	  2005,	  Yang	  et	  al.	  
2009).	  
TNF-­‐α	   levels	   were	   also	   measured	   in	   the	   maternal	   serum	   6	   hours	   post-­‐surgery.	  	  
Although	   in	  women,	   the	   presence	   of	   an	   intrauterine	   infection	   is	   normally	   associated	  
with	  minimal	   clinical	   signs	  of	   systemic	   infection,	  elevated	  serum	  cytokine	   levels	  have	  
been	  reported	  in	  women	  who	  deliver	  preterm	  (Murtha	  et	  al.	  1998).	  	  Similarly,	  previous	  
animal	   studies	   have	   reported	   up-­‐regulation	   of	   serum	   cytokine	   levels	   in	   models	   of	  
infection-­‐induced	  preterm	  labour	  (Xu	  et	  al.	  2005,	  Elovitz	  and	  Mrinalini	  2006,	  Yang	  et	  al.	  
2009).	   	   In	   line	   with	   these	   studies,	   the	   serum	   concentration	   of	   TNF-­‐α	   increased	   in	  
response	  to	  increasing	  doses	  of	  intrauterine	  LPS,	  with	  significantly	  increased	  TNF-­‐α	  in	  
the	  serum	  of	  mice	  receiving	  doses	  of	  10µg	  LPS	  and	  above.	  	  	  
Whilst	   there	   has	   been	   much	   focus	   on	   the	   role	   of	   pro-­‐inflammatory	   signalling	   in	  
initiating	   labour	   at	   term	  and	  preterm,	  more	   recent	   studies	  have	  begun	   to	   investigate	  
the	   role	   of	   the	   classical	   anti-­‐inflammatory	   cytokine,	   IL-­‐10.	   	   IL-­‐10	   is	   expressed	   in	  
gestational	  tissues	  (Roth	  and	  Fisher	  1999,	  Hanna	  et	  al.	  2000,	  Lidstrom	  et	  al.	  2003);	  and	  
whilst	   there	   are	   contrasting	   data	   regarding	   amniotic	   fluid	   concentrations	   across	  
gestation	  (Greig	  et	  al.	  1995,	  Dudley	  et	  al.	  1997,	  Gotsch	  et	  al.	  2008),	  it	  has	  been	  reported	  
that	   IL-­‐10	   concentrations	   in	   the	   amniotic	   fluid	   are	   increased	  with	   spontaneous	   term	  
and	  preterm	   labour	   and	   further	   increased	   in	   the	  presence	  of	   intra-­‐amniotic	   infection	  
(Greig	  et	  al.	   1995,	  Gotsch	  et	  al.	   2008).	   	   It	   is	   likely	   that	   IL-­‐10	  has	  an	   important	   role	   in	  
controlling	  the	   inflammatory	  response	  during	   labour,	  and	  in	  the	  presence	  of	  an	   intra-­‐
amniotic	  infection,	  increased	  IL-­‐10	  in	  the	  amniotic	  fluid	  is	  likely	  a	  protective	  response	  
to	  reduce	  fetal	  exposure	  to	  excess	  inflammation.	  	  Work	  using	  an	  IL-­‐10	  knockout	  mouse	  
has	   confirmed	   that	   IL-­‐10	   plays	   an	   important	   role	   in	   protecting	   mice	   against	   LPS-­‐
induced	   fetal	   loss	   (Robertson	   et	   al.	   2006).	   	   In	   response	   to	   intrauterine	   LPS	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administration	  in	  our	  model,	  IL-­‐10	  expression	  was	  significantly	  elevated	  in	  response	  to	  
all	   doses	   of	   LPS	   administered,	   even	   the	   lowest	   dose	   of	   1µg,	   in	   the	   uterus,	   fetal	  
membranes	   and	   placenta,	   compared	   to	   the	   PBS	   control	   tissues.	   	   Similarly,	   the	  
concentration	   of	   IL-­‐10	   was	   significantly	   elevated	   in	   both	   the	   amniotic	   fluid	   and	  
maternal	  serum	  in	  response	  to	  increasing	  LPS	  doses.	  	  These	  data	  are	  in	  agreement	  with	  
other	  animal	  models	  of	  infection-­‐induced	  preterm	  labour,	  which	  also	  report	  increased	  
IL-­‐10	   expression	   in	   the	   utero-­‐placental	   tissues	   and	   amniotic	   fluid	   (Elovitz	   and	  Wang	  
2004,	  Yang	  et	  al.	  2009,	  Chang	  et	  al.	  2011).	  
Given	   the	   important	   roles	   prostaglandins	   play	   in	   the	   induction	   of	   labour,	   including	  
stimulating:	  myometrial	   contractions	   (Dyal	   and	  Crankshaw	  1988,	   Senior	  et	  al.	   1993);	  
fetal	  membrane	  rupture	  (McLaren	  et	  al.	  2000,	  Keelan	  et	  al.	  2001)	  and	  cervical	  ripening	  
and	   dilation	   (Fletcher	   et	   al.	   1993,	   Keirse	   1993);	   the	   expression	   of	   two	   important	  
enzymes	   involved	   in	  regulating	  prostaglandin	  production	  and	  metabolism,	  COX-­‐2	  and	  
15-­‐HPGD,	   was	   measured	   in	   intrauterine	   tissues	   collected	   from	   mice	   6	   hours	   post-­‐
surgery.	  	  
Intrauterine	   administration	   of	   LPS	   resulted	   in	   a	   dose-­‐dependent	   increase	   in	   Cox-­‐2	  
expression	   in	   the	   uterus,	  with	   no	   change	   in	   the	   fetal	  membranes	   or	   placenta.	   	   Other	  
studies	  in	  similar	  animal	  models	  have	  also	  demonstrated	  up-­‐regulation	  of	  Cox-­‐2	  in	  the	  
myometrium	   following	   LPS	   treatment	   (Swaisgood	   et	   al.	   1997,	   Pirianov	   et	   al.	   2009,	  
Shynlova	  et	  al.	  2013,	  Sykes	  et	  al.	  2013);	  and	  similarly	   following	   intrauterine	   injection	  
with	   heat-­‐killed	   E.Coli	   (Wang	   and	   Hirsch	   2003).	   	   There	   have	   also	   been	   reports	   of	  
increased	  Cox-­‐2	  expression	  in	  the	  fetal	  membranes	  and	  placenta	  of	  mice	  6-­‐8	  hours	  after	  
i.p.	  LPS	  to	  induce	  preterm	  labour,	  which	  was	  not	  observed	  in	  our	  study	  (Swaisgood	  et	  
al.	  1997).	  	  However,	  in	  line	  with	  our	  results,	  other	  studies	  have	  also	  reported	  no	  change	  
in	  Cox-­‐2	  mRNA	  expression	  in	  the	  placenta	  and	  fetal	  membranes	  following	  intrauterine	  
injection	   of	   bacteria	   (Wang	   and	   Hirsch	   2003).	   	   Studies	   in	   humans	   have	   also	  
demonstrated	   different	   expression	   profiles	   of	   COX-­‐2	   in	   the	   intrauterine	   tissues	   with	  
labour	  onset,	  where	  COX-­‐2	  mRNA	  expression	  has	  been	  reported	  to:	  increase	  in	  the	  fetal	  
membranes	  with	  the	  onset	  of	  labour	  (Bennett	  et	  al.	  1993,	  Slater	  et	  al.	  1995);	  not	  change	  
in	   the	  placenta	   (Macchia	  et	  al.	   1997);	   and	   there	  are	   conflicting	   reports	   as	   to	  whether	  
COX-­‐2	   mRNA	   is	   affected	   by	   labour	   in	   the	   myometrium	   (Erkinheimo	   et	   al.	   2000,	  
Giannoulias	  et	  al.	  2002).	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Conversely,	   15-­‐Hpgd	  mRNA	   expression	   was	   unchanged	   in	   uterus	   and	   placenta,	   but	  
significantly	   decreased	   in	   the	   fetal	   membranes	   collected	   from	   mice	   6	   hours	   post-­‐
surgery.	  	  Decreased	  15-­‐HPGD	  expression	  has	  previously	  been	  reported	  in	  mouse	  uterus	  
and	   fetal	  membranes	   following	   intrauterine	   injection	   of	   heat-­‐killed	  E.Coli	   (Wang	   and	  
Hirsch	  2003);	  as	  well	  as	  in	  chorion	  and	  myometrium	  from	  women	  in	  preterm	  and	  term	  
labour	  (VanMeir	  et	  al.	  1996,	  VanMeir	  et	  al.	  1997,	  Giannoulias	  et	  al.	  2002).	  
The	  dose-­‐dependent	   increase	   in	  uterine	  Cox-­‐2	  expression	  and	  decrease	   in	  15-­‐Hpgd	   in	  
the	   fetal	   membranes,	   suggests	   that	   in	   response	   to	   intrauterine	   LPS	   administration,	  
there	   is	   a	   shift	   towards	   increased	  prostaglandin	   synthesis	   and	  decreased	  metabolism	  
within	  the	  intrauterine	  tissues,	  which	  could	  stimulate	  labour.	  	  Although	  the	  expression	  
patterns	  of	  these	  enzymes	  are	  not	  exactly	  the	  same	  as	  in	  human	  utero-­‐placental	  tissues	  
in	   association	  with	   labour,	  where	   the	   amnion	   is	   proposed	   to	   be	   a	  major	   producer	   of	  
prostaglandins	  at	   labour	   (Bennett	  et	  al.	   1993),	   our	   results	   suggest	   there	   is	   an	  overall	  
increase	   in	   prostaglandin	   activity	   in	   response	   to	   LPS,	   which	   is	   likely	   to	   play	   an	  
important	   role	   in	   inducing	   preterm	   labour	   in	   our	  model.	   	   To	   further	   confirm	   this,	   it	  
would	   be	   important	   to	   measure	   local	   prostaglandin	   levels	   within	   the	   intrauterine	  
tissues.	  	  	  
In	   addition	   to	   increased	   cytokine	   production,	   labour	   has	   also	   been	   associated	   with	  
increased	   chemokine	   signalling	   within	   the	   intrauterine	   tissues.	   	   Recent	   microarray	  
analysis	   has	   identified	   that	   some	   of	   the	   most	   highly	   up-­‐regulated	   genes	   in	   human	  
myometrium	  and	  cervix	  during	  labour	  are	  chemokines,	  such	  as	  CXCL1,	  CXCL2,	  CXCL5,	  
CXCL8	  and	  CCL2	  (Bollapragada	  et	  al.	  2009).	   	  To	   investigate	   the	  role	  of	  chemokines	   in	  
our	  mouse	  model	  of	   infection-­‐induced	  preterm	  labour,	   the	  expression	  of	   three	  potent	  
mouse	  neutrophil	  chemoattractants,	  Cxcl1	  (also	  known	  as	  keratinocyte	  chemokine;	  KC),	  
Cxcl2	   (also	   known	   as	   macrophage	   inflammatory	   protein	   2;	   MIP-­‐2)	   and	   Cxcl5	   (also	  
known	  as	  LPS-­‐induced	  CXC	  chemokine;	  LIX)	  was	  measured,	  along	  with	  the	  expression	  
of	   the	   mouse	   macrophage	   chemokine,	   Ccl2	   (also	   known	   as	   monocyte	   chemotactic	  
protein	   1;	  MCP-­‐1).	   	   CXCL1,	   CXCL2	   and	   CXCL5	   have	   been	   proposed	   to	   be	   the	  murine	  
homologs	   of	   human	   IL-­‐8	   (CXCL8)	   (Hol	   et	   al.	   2010).	   	   Mouse	   CCL2	   is	   thought	   to	   be	   a	  
murine	  homolog	  of	  human	  MCP-­‐1	  (Fridlender	  et	  al.	  2011).	  	  	  
In	   line	   with	   human	   data	   showing	   elevated	   neutrophil	   chemokine	   expression	   in	  
association	   with	   labour	   (Keelan	   et	   al.	   2004,	   Bollapragada	   et	   al.	   2009);	   and	   previous	  
mouse	   studies	   of	   LPS-­‐induced	   preterm	   labour	   demonstrating	   up-­‐regulation	   of	   Cxcl1,	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Cxcl2	  and	  Cxcl5	  in	  uterine	  tissue	  (Diamond	  et	  al.	  2007,	  Pirianov	  et	  al.	  2009,	  Shynlova	  et	  
al.	  2013),	  expression	  of	  all	   three	  neutrophil	  chemokines	  in	  the	  utero-­‐placental	  tissues	  
collected	   from	   our	   mice	   was	   significantly	   elevated	   by	   intrauterine	   administration	   of	  
LPS	  at	  doses	  of	  5µg	  and	  above,	  suggesting	   that	  neutrophil	   infiltration	   into	   the	  uterus,	  
fetal	  membranes	  and	  placenta	  of	  mice	  receiving	  LPS	  is	  likely.	  	  Conversely,	  no	  change	  in	  
the	   expression	   of	   either	   Cxcl1	   or	   Cxcl5	   was	   observed	   in	   uterus	   collected	   from	   mice	  
labouring	   at	   term,	   compared	   with	   levels	   on	   D18	   of	   gestation	   (Menzies	   et	   al.	   2012),	  
suggesting	   that	   these	   chemokines	   may	   be	   differentially	   expressed	   depending	   on	   the	  
presence	  of	  an	  intrauterine	  infection.	  	  	  
Similarly,	   expression	  of	   the	  macrophage	  chemokine,	  Ccl2	  was	  elevated	   in	   response	   to	  
increasing	  doses	  of	  intrauterine	  LPS	  in	  the	  uterus,	  fetal	  membranes	  and	  placenta	  tissue	  
6	  hours	  post-­‐surgery,	  suggesting	  potential	  macrophage	  recruitment	  to	  the	  intrauterine	  
tissues.	  	  Previous	  studies	  have	  also	  demonstrated	  up-­‐regulation	  of	  Ccl2	  in	  myometrium	  
and	  decidua	   in	   association	  with	   LPS-­‐induced	   preterm	   labour	   in	  mice	   (Diamond	   et	  al.	  
2007,	  Pirianov	  et	  al.	  2009,	  Shynlova	  et	  al.	  2013,	  Shynlova	  et	  al.	  2013);	  as	  well	  as	  term	  
labour	   in:	   mouse	   uterus	   and	   decidua	   (Diamond	   et	   al.	   2007,	   Menzies	   et	   al.	   2012,	  
Shynlova	   et	  al.	   2013);	   rat	  myometrium	   (Shynlova	   et	  al.	   2008);	   and	   human	   labouring	  
myometrium	   and	   fetal	   membranes	   (Esplin	   et	   al.	   2005).	   	   The	   potential	   impact	   of	  
increased	   expression	   of	   both	   potent	   neutrophil	   and	   macrophage	   chemokines	   in	  
inducing	   immune	   cell	   recruitment	   into	   the	   intrauterine	   tissues	   will	   be	   discussed	   in	  
greater	  detail	  below.	  	  	  
The	   mechanism	   by	   which	   intrauterine	   LPS	   induces	   increased	   production	   of	   these	  
inflammatory	  mediators	  has	  not	  been	  discussed	   in	   this	   chapter.	   	   Studies	   suggest	   that	  
the	  presence	  of	  an	  intrauterine	  infection	  initiates	  a	  maternal	  immune	  response	  via	  TLR	  
recognition	  of	  bacterial	  products	  (Patni	  et	  al.	  2007).	  	  	  Support	  for	  this	  hypothesis	  comes	  
from	  evidence	   that	   increased	  TLR-­‐2	  and	  TLR-­‐4	  expression	  has	  been	   reported	   in	   fetal	  
membranes	   associated	   with	   infection	   (Kim	   et	   al.	   2004);	   and	   TLR-­‐4	   knockout	   mice	  
studies	  demonstrated	  the	  essential	  role	  for	  TLR-­‐4	  in	  inducing	  E.Coli-­‐	  and	  LPS-­‐induced	  
preterm	  labour	  (Elovitz	  et	  al.	  2003,	  Wang	  and	  Hirsch	  2003).	  	  Given	  that	  NF-­‐κB	  is	  a	  key	  
transcription	   factor	  activated	   in	   response	   to	  TLR	  signalling	   (Patni	  et	  al.	   2007),	   and	   is	  
well	   documented	   to	   play	   an	   important	   role	   in	   inflammatory	   signalling	   in	   labour	  
(Lindstrom	  and	  Bennett	  2005,	  Lappas	  and	  Rice	  2007);	  it	  is	  likely	  that	  increased	  NF-­‐κB	  
signalling	   plays	   a	   role	   in	   the	   increased	   pro-­‐inflammatory	   cytokine	   production	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described	   in	   this	   model.	   	   Indeed,	   Pirianov	   et	   al.	   (Pirianov	   et	   al.	   2009)	   reported	  
intrauterine	   LPS	   administration	   activated	   both	   NF-­‐κB	   and	   MAPK	   JNK	   signalling	  
pathways	  in	  mouse	  myometrium	  after	  6	  hours.	  	  	  To	  confirm	  whether	  the	  same	  or	  other	  
inflammatory	   transcription	   factors	   are	   involved	   in	   the	   LPS-­‐induced	   up-­‐regulation	   of	  
pro-­‐inflammatory	   signalling	   in	   our	   model,	   similar	   experiments	   would	   need	   to	   be	  
performed.	  	  	  	  
Overall,	   in	   our	   model,	   intrauterine	   LPS	   administration	   induced	   a	   robust	   local	  
inflammatory	   response	   within	   the	   utero-­‐placental	   tissues,	   resulting	   in	   increased	  
expression	  of	  both	  pro-­‐	  and	  anti-­‐inflammatory	  mediators	  compared	  to	  mice	  receiving	  
PBS.	  	  It	  is	  not	  clear	  whether	  the	  increased	  inflammatory	  cytokine	  production	  is	  a	  result	  
of	   increased	   expression	   by	   the	   utero-­‐placental	   tissues	   themselves,	   or	   primarily	   from	  
both	  resident	  and	  infiltrating	  immune	  cell	  populations.	   	  Whilst	  it	   is	  well	  accepted	  that	  
immune	   cells	   in	   the	   utero-­‐placental	   tissues	   are	   major	   producers	   of	   cytokines	   and	  
chemokines,	   there	   is	   also	   evidence	   from	   women	   that	   extravillous	   trophoblasts,	  
myometrial	   cells	   and	   stromal	   cells	   of	   the	   intrauterine	   tissues	   also	   produce	  
inflammatory	   cytokines	   (Young	   et	   al.	   2002,	   Gomez-­‐Lopez	   et	   al.	   2010,	   Mosher	   et	   al.	  
2012);	  which	   suggests	   that	   the	   increased	  pro-­‐inflammatory	   signalling	   is	   likely	  due	   to	  
both	   increased	   numbers	   of	   infiltrating	   immune	   cells	   and	   stimulation	   of	   non-­‐immune	  
cells.	  	  
Interestingly,	  the	  expression	  of	  many	  of	  the	  cytokines	  and	  chemokines	  measured	  here	  
was	   found	   to	   be	   significantly	   elevated	   at	   the	   lowest	   dose	   of	   LPS	   administered,	   1µg,	  
where	  preterm	  delivery	  was	  not	   induced.	   	   In	  agreement	  with	  these	  data,	  Elovitz	  et	  al.	  
also	   recently	   reported	   that	   administration	   of	   LPS	   at	   a	   dose	   insufficient	   to	   induce	  
preterm	   labour,	   still	   elicited	   an	   inflammatory	   cytokine	   response	   in	   the	   fetal	   brain,	  
amniotic	  fluid	  and	  placenta	  (Elovitz	  et	  al.	  2011);	  and	  in	  a	  study	  investigating	  the	  role	  of	  
TLR-­‐4	   in	   infection-­‐induced	  preterm	   labour,	  Hirsch	  et	  al.	   reported	   that	   in	   response	   to	  
intrauterine	  E.coli	  injection	  both	  TLR-­‐4	  mutant	  mice	  and	  wild-­‐type	  mice	  had	  increased	  
expression	   of	   inflammatory	  mediators	   in	   the	  myometrium	   and	   decidua,	   even	   though	  
none	   of	   the	   TLR-­‐4	  mutant	  mice	   went	   into	   preterm	   labour	   (Hirsch	   and	  Wang	   2005).	  	  
Collectively,	   these	   data	   suggest	   that	   the	   increased	   expression	   of	   these	   inflammatory	  
mediators	  is	  a	  response	  to,	  even	  low	  levels	  of,	   intrauterine	  infection,	  and	  they	  are	  not	  
capable	  of	   inducing	  preterm	  labour	  alone.	   	   It	  may	  be	   that	  other	   factors	  not	  measured	  
here,	  such	  as	  prostaglandins,	  may	  only	  be	  elevated	  in	  response	  to	  higher	  doses	  of	  LPS,	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causing	  mice	  receiving	  20µg	  LPS	  to	  reliably	  go	  into	  preterm	  labour.	  	  Another	  possibility	  
is	  that	  the	  intrauterine	  environment	  is	  able	  to	  withstand	  a	  certain	  level	  of	  inflammation,	  
but	  when	  the	  inflammation	  reaches	  a	  particular	  threshold	  level,	   the	  cascade	  of	  events	  
resulting	   in	   labour	   is	   initiated;	   in	   our	   model	   this	   threshold	   may	   only	   be	   reached	   in	  
response	  to	  the	  higher	  doses	  of	  LPS	  administered.	  	  	  	  
	  
Intrauterine	  LPS	  administration	  induces	  changes	  in	  uterine	  immune	  cell	  populations	  
As	   described	   previously,	   parturition	   both	   at	   term	   and	   preterm	   are	   associated	  with	   a	  
massive	   immune	   cell	   influx	   into	   the	   intrauterine	   tissues,	   particularly	  neutrophils	   and	  
macrophages	   (Gomez-­‐Lopez	   et	  al.	   2010).	   	   There	   remains	  much	  debate	   as	   to	  whether	  
these	  infiltrating	  immune	  cells	  are	  a	  causative	  factor	  in	  the	  initiation	  of	  labour	  or	  if	  the	  
primary	   role	   of	   these	   cells	   is	   in	   the	   repair	   and	   remodelling	   of	   the	   uterus	   and	   cervix	  
following	  parturition	  (Timmons	  et	  al.	  2009,	  Shynlova	  et	  al.	  2013,	  Shynlova	  et	  al.	  2013).	  	  
As	   discussed	   earlier,	   the	   increased	   expression	   of	   neutrophil	   and	   macrophage	  
chemokines,	   suggests	   that	   infiltration	   of	   immune	   cells	   is	   likely	   in	   response	   to	  
intrauterine	  LPS.	  	  In	  order	  to	  investigate	  this	  in	  our	  model,	  the	  expression	  of	  neutrophil	  
and	  macrophage	  markers	  was	   assessed	   in	   the	   uterus,	   fetal	  membranes	   and	   placenta	  
and	  the	  cells	  were	  localised	  in	  the	  uterus.	  
Previous	  studies	  examining	  expression	  of	  the	  macrophage	  marker,	  Emr1	  in	  the	  uterus	  
of	   mice	   demonstrated	   significantly	   increased	   expression	   in	   association	   with	   labour,	  
when	  compared	  to	  non-­‐labouring	  D18	  tissue	  (Menzies	  et	  al.	  2012,	  Menzies	  et	  al.	  2012).	  	  
In	   contrast,	   no	   such	   increase	   in	  Emr1	  expression	  was	   observed	   in	   either	   the	   uterine	  
tissue	   or	   the	   placental	   tissue	   of	   mice	   receiving	   intrauterine	   LPS	   when	   compared	   to	  
those	   receiving	   PBS;	   however	   there	   was	   a	   dose-­‐dependent	   increase	   in	   Emr1	   gene	  
expression	   in	   the	   fetal	  membranes	   in	   response	   to	   LPS	   treatment.	   	   These	   differences	  
suggest	  that	  perhaps	  in	  the	  context	  of	  intrauterine	  infection,	  in	  our	  model,	  macrophage	  
recruitment	  is	  not	  induced	  in	  the	  uterus	  and	  placenta,	  unlike	  at	  term	  labour,	  which	  may	  
support	   the	   hypothesis	   that	   different	  mechanisms	   could	   be	   responsible	   for	   inducing	  
spontaneous	  labour	  at	  term	  and	  infection-­‐induced	  preterm	  labour	  (Gonzalez	  et	  al.	  2009,	  
Holt	  et	  al.	  2011,	  Shynlova	  et	  al.	  2013);	  or	  it	  may	  be	  that	  if	  tissue	  had	  been	  collected	  at	  a	  
later	  time	  point,	  or	  during	  labour	  we	  may	  have	  observed	  increased	  Emr1	  expression.	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To	   further	   investigate	  whether	   the	   increased	  expression	  of	  Ccl2	  observed,	   resulted	   in	  
macrophage	   influx	   into	   the	   uterus,	  macrophages	  were	   localised	   in	   the	   uterine	   tissue	  
using	   F4/80.	   	   F4/80	   is	   a	   glycoprotein	   that	   is	   highly	   expressed	   on	   the	   cell	   surface	   of	  
mature	  macrophages	  and	  is	  commonly	  used	  to	  identify	  tissue-­‐resident	  macrophages	  in	  
mice	   (Austyn	   and	   Gordon	   1981).	   	   Previous	   studies	   have	   reported	   that	   macrophages	  
make	  up	  the	  largest	  immune	  cell	  population	  in	  the	  pregnant	  mouse	  uterus	  (Shynlova	  et	  
al.	  2013,	  Shynlova	  et	  al.	  2013),	  where	  they	  have	  been	  estimated	  to	  account	  for	  around	  
22%	  of	  uterine	  cells	  during	  pregnancy	  (Hunt	  et	  al.	  1985).	  	  There	  are	  conflicting	  reports	  
on	   the	   dynamics	   of	   uterine	   macrophages	   during	   normal	   term	   labour	   in	   different	  
species.	  	  In	  women	  it	  has	  been	  reported	  that	  there	  is	  an	  influx	  of	  macrophages	  into	  the	  
myometrium,	  fetal	  membranes,	  decidua,	  placenta	  and	  cervix	  during	  spontaneous	  term	  
labour	  (Thomson	  et	  al.	  1999,	  Osman	  et	  al.	  2003,	  Gomez-­‐Lopez	  et	  al.	  2009,	  Gomez-­‐Lopez	  
et	  al.	  2010)	  and	  in	  preterm	  labour	  (Hamilton	  et	  al.	  2012).	  	  In	  rats,	  macrophage	  numbers	  
were	   found	   to	   increase:	   at	   term	   (Shynlova	   et	   al.	   2008);	   during	   term	   labour	   in	   the	  
myometrium;	   and	   in	   the	   12	   hours	   prior	   to	   labour	   and	   during	   labour	   in	   the	   decidua,	  
relative	   to	   2	   days	   before	   term,	   with	   a	   significantly	   higher	   number	   of	   macrophages	  
present	   within	   the	   decidua	   at	   term,	   compared	   to	   the	   myometrium	   (Hamilton	   et	   al.	  
2012).	  	  In	  mice	  it	  has	  previously	  been	  reported	  that	  uterine	  macrophage	  numbers	  peak	  
around	   D15	   and	   decrease	   on	   D18,	   before	   labour	   (Mackler	   et	   al.	   1999);	   whilst	   more	  
recent	   studies	   found	   macrophage	   numbers	   were	   increased	   on	   D18	   of	   gestation	  
compared	   to	  D15	  and	  remained	  elevated	  during	   term	   labour	   in	   the	  myometrium	  and	  
decidua	   (Shynlova	   et	   al.	   2013,	   Shynlova	   et	   al.	   2013).	   	   These	   differences	   may	   be	  
explained	   by	   different	   mouse	   strains	   studied.	   	   In	   our	   model,	   we	   found	   that	  
macrophages	   were	   present	   in	   normal	   D17	   uterus,	   in	   both	   the	   myometrium	   and	  
decidua;	   however	   since	   tissue	   was	   not	   collected	   at	   other	   time	   points,	   it	   was	   not	  
possible	   to	   compare	   the	  number	  of	  macrophages	  present	   on	  D17	  with	  different	   time	  
points	  in	  pregnancy.	  	  	  
In	   a	   rat	   model	   of	   mifepristone-­‐induced	   preterm	   labour,	   macrophage	   numbers	   have	  
been	   reported	   to	   increase	   in	   the	  decidua	  during	  active	   labour	   (Hamilton	  et	  al.	   2012).	  	  
Conversely,	  mouse	  models	  of	  mifepristone-­‐	  and	  LPS-­‐induced	  preterm	  labour	  found	  no	  
macrophage	   infiltration	   in	   the	   decidua	   or	  myometrium	   of	  mifepristone-­‐treated	  mice,	  
but	   did	   report	   increased	  macrophage	   numbers	   in	   the	   decidua	   of	  mice	   receiving	   LPS	  
during	  labour	  (Shynlova	  et	  al.	  2013,	  Shynlova	  et	  al.	  2013).	  	  In	  contrast	  to	  these	  results,	  
but	  in	  line	  with	  the	  lack	  of	  change	  in	  Emr1	  expression	  within	  the	  uterus,	  there	  was	  no	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obvious	   increase	   in	   macrophage	   number	   associated	   with	   intrauterine	   LPS	  
administration.	   	   In	   fact,	   when	   the	   number	   of	   F4/80	   positive	   cells	   was	   quantified	  
stereologically,	   there	  was	  a	  surprising	  decrease	   in	  the	  number	  of	  F4/80	  macrophages	  
within	  the	  myometrium	  and	  decidua	  of	  mice	  receiving	  LPS,	  although	  this	  decrease	  did	  
not	  reach	  statistical	  significance.	  	  The	  results	  from	  other	  animal	  models	  refer	  to	  uterine	  
tissues	  collected	  during	  active	  labour,	  as	  opposed	  to	  6	  hours	  post-­‐surgery,	  as	  is	  the	  case	  
in	  our	  model,	  therefore	  it	  is	  possible	  that	  an	  influx	  of	  macrophages	  may	  have	  been	  seen	  
only	   at	   labour,	   as	   has	   been	   reported	   to	   occur	   at	   term	   in	   rats	   (Hamilton	   et	  al.	   2012).	  	  
Also,	  6	  hours	  may	  have	  been	  too	  short	  a	   time	  to	  allow	  for	  monocyte	  recruitment	  and	  
differentiation	   into	   tissue-­‐resident	   macrophages	   expressing	   F4/80.	   	   Additionally	  
Shynlova	   et	   al.	   (Shynlova	   et	   al.	   2013)	   describe	   macrophage	   recruitment	   into	   the	  
decidua	   basalis,	   (which	   is	   the	   decidual	   tissue	   at	   the	   site	   of	   placental	   attachment),	   as	  
opposed	  to	  the	  decidual	  parietalis	  (which	  describes	  the	  decidualised	  endometrial	  tissue	  
lining	   the	   rest	   of	   the	   uterus).	   	   In	   this	   study,	   and	   in	   the	   work	   by	   Hamilton	   et	   al.	  
(Hamilton	   et	   al.	   2012),	   immunohistochemical	   studies	   localised	   macrophages	   in	   the	  
decidua	  parietalis	  (referred	  to	  here	  as	  the	  decidua);	  therefore	  the	  differences	  observed	  
may	  be	  due	  to	  macrophage	  infiltration	  to	  different	  regions	  of	  the	  uterus	  in	  response	  to	  
LPS	  administration.	   	  Leukocyte	   infiltration	   into	   the	   intrauterine	   tissues	  during	  mouse	  
pregnancy	  has	  been	  demonstrated	  to	  be	  a	  highly	  organised	  process	  (Kruse	  et	  al.	  2002);	  
and	  in	  support	  of	  this	  hypothesis,	  Shynlova	  et	  al.	  (Shynlova	  et	  al.	  2013),	  report	  that	  the	  
decidua	   basalis	   provides	   a	   much	   stronger	   chemotactic	   signal	   than	   the	   myometrium	  
during	  term	  labour	  in	  mice.	  	  Detailed	  time-­‐course	  analysis	  in	  all	  the	  areas	  of	  the	  uterus	  
would	   be	   required	   to	   test	   this	   hypothesis.	   	   Even	  without	   infiltration,	   it	   is	   likely	   that	  
macrophages	   already	   resident	   are	   playing	   an	   important	   role	   in	   the	   inflammatory	  
environment	  given	  their	  abundance	  in	  the	  pregnant	  uterus,	  and	  the	  fact	  that	  they	  can	  
be	  potent	  producers	  of	  inflammatory	  cytokines	  (Hunt	  and	  Pollard	  1992).	  	  	  
The	   reason	   for	   the	   slight	   reduction	   in	   F4/80	   cells	   in	   the	   LPS-­‐treated	   decidua	   and	  
myometrium	  observed	  in	  our	  model	  is	  unknown.	   	  As	  previously	  discussed,	  Mackler	  et	  
al.	   described	   a	   reduction	   in	   the	   number	   of	   uterine	  macrophages	   just	   prior	   to	   labour	  
(Mackler	  et	  al.	  1999),	  which	  they	  suggested	  may	  be	  a	  mechanism	  to	  induce	  myometrial	  
contractions,	   given	   that	   macrophages	   can	   produce	   an	   inducible	   form	   of	   nitric	   oxide	  
synthase	   (iNOS),	   which	   has	   been	   shown	   to	   inhibit	   contractions	   and	   was	   found	   to	  
decrease	  at	  term	  in	  the	  rat	  uterus	  (Buhimschi	  et	  al.	  1996).	  	  It	  has	  also	  been	  previously	  
reported	   that	   the	   F4/80	   antigen	   is	   down-­‐regulated	   in	   activated	   macrophages	   in	   the	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presence	   of	   bacillus	   calmette-­‐guerin	   infection	   (Ezekowitz	   and	   Gordon	   1982);	   raising	  
the	  possibility	   that	  LPS	   infection	  may	  also	  affect	  F4/80	  expression.	   	  Whether	   there	   is	  
indeed	  a	   reduction	   in	   the	  number	  of	  F4/80	   cells	   in	   response	   to	  LPS	   in	  our	  model,	   or	  
simply	   a	   reduction	   in	   expression	   of	   F4/80	   needs	   further	   investigation.	  	  
Immunohistochemical	  studies	  using	  a	  different	  antigen,	  such	  as	  CD68,	  may	  be	  useful	  in	  
confirming	  macrophage	  expression	  in	  the	  intrauterine	  tissues.	  	  	  
Given	   the	   significant	   up-­‐regulation	   of	   several	   potent	   neutrophil	   chemoattractants	  
within	   the	   intrauterine	   tissues,	   neutrophil	   infiltration	   was	   examined	   by	   measuring	  
expression	  of	  the	  gene	  Ngp,	  which	  encodes	  a	  neutrophilic	  granule	  protein	  expressed	  in	  
mouse	  neutrophils.	  	  Ngp	  expression	  has	  previously	  been	  reported	  to	  remain	  unchanged	  
in	  labouring	  mouse	  uterus,	  compared	  to	  non-­‐labouring	  D18	  tissue	  (Menzies	  et	  al.	  2012).	  	  
In	   contrast,	   in	   our	   model	   in	   response	   to	   intrauterine	   LPS	   administration	   a	   dose-­‐
dependent	   increase	   in	  Ngp	   expression	  was	   observed	   in	   the	   uterus,	   fetal	  membranes	  
and	  placenta.	   	  Again	   these	  data	  provide	   further	  support	   for	   the	   theory	   that	   infection-­‐
induced	   preterm	   labour	   and	   term	   labour	   may	   occur	   via	   different	   mechanisms	  
(Gonzalez	  et	  al.	  2009,	  Holt	  et	  al.	  2011,	  Shynlova	  et	  al.	  2013).	  	  	  
To	  confirm	  that	  neutrophil	  influx	  was	  indeed	  responsible	  for	  the	  observed	  increase	  in	  
Ngp	  expression	   in	  the	  uterus,	  neutrophils	  were	   localised	  using	  the	  marker,	  Gr-­‐1.	   	  The	  
RB6-­‐8C5	  clone	  of	  the	  Gr-­‐1	  antibody	  used	  in	  this	  chapter	  detects	  two	  antigens	  expressed	  
on	  mouse	  neutrophils,	  Ly-­‐6C	  and	  Ly-­‐6G	  (Fleming	  et	  al.	  1993).	   	   In	  women,	  neutrophils	  
are	  proposed	  to	  play	  a	  role	   in	  cervical	  ripening	  (Bokström	  et	  al.	  1997)	  and	  have	  been	  
shown	   to	   infiltrate	   into	   the	   myometrium	   and	   cervix	   in	   association	   with	   labour	  
(Thomson	  et	  al.	  1999,	  Osman	  et	  al.	  2003).	  	  Furthermore,	  increased	  neutrophil	  numbers	  
have	   been	   reported	   in	   women	   in	   preterm	   labour	   with	   an	   infection,	   compared	   with	  
women	   in	   idiopathic	  preterm	  or	  normal	   term	   labour	   (Hamilton	  et	  al.	  2012).	   	   In	  mice,	  
neutrophils	  make	  up	  a	  much	  smaller	  proportion	  of	   the	   immune	  cell	  population	   in	  the	  
pregnant	   uterus	   compared	   with	   macrophages,	   where	   they	   have	   been	   reported	   to	  
account	   for	   less	   than	  2%	  of	   the	   total	   leukocyte	  population	  on	  D18	  of	  gestation	   in	   the	  
decidua	  and	  myometrium	  (Shynlova	  et	  al.	  2013,	  Shynlova	  et	  al.	  2013).	  	  In	  line	  with	  this,	  
very	  few	  if	  any	  Gr-­‐1	  positive	  neutrophils	  were	  observed	  in	  D17	  uterus	  from	  mice	  that	  
did	  not	  undergo	  surgery	  or	  treatment.	  	  Interestingly,	  when	  this	  normal	  D17	  uterus	  was	  
compared	  with	  uterus	  collected	  from	  PBS	  treated	  mice	  there	  was	  a	  distinct	  pattern	  of	  
neutrophils	   localised	   to	   the	   connective	   tissue	   layer	   surrounding	   the	   longitudinal	  
myometrial	   muscle	   bundles.	   	   This	   finding	   suggests	   that	   the	   surgery	   itself	   induced	   a	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local	   inflammatory	  response	  and	   immune	  cell	   influx	   to	   the	  uterus,	  which	  may	   in	  part	  
explain	  why	  some	  mice	  in	  the	  PBS	  control	  group	  went	  into	  preterm	  labour.	  	  In	  a	  model	  
of	   artificial	   stretch,	   Shynlova	   et	   al.	   (Shynlova	   et	   al.	   2013),	   also	   reported	   neutrophil	  
infiltration	  into	  the	  uterus	  of	  mice	  receiving	  sham	  surgery,	  supporting	  the	  theory	  that	  
uterine	  surgery	  during	  pregnancy	  can	  induce	  a	  rapid	  neutrophil	  response.	  	  	  	  	  	  
Normal	   term	   labour	   in	   mice	   has	   been	   associated	   with	   a	   significant	   neutrophil	  
infiltration	   into	   the	   decidua	   (Shynlova	   et	   al.	   2013);	   but	   not	   into	   the	   myometrium,	  
where	  neutrophil	  numbers	  were	  not	   found	   to	  be	  significantly	  elevated	  until	   the	  post-­‐
partum	  period	  (Shynlova	  et	  al.	  2013).	   	  These	  results	  are	   in	  agreement	  with	  studies	   in	  
the	   mouse	   cervix	   that	   also	   show	   neutrophil	   numbers	   in	   the	   cervix	   are	   significantly	  
greater	  2-­‐4	  hours	  after	  labour,	  compared	  to	  cervical	  tissue	  obtained	  from	  mice	  in	  late	  
gestation	   before	   labour,	   and	   during	   labour	   (Timmons	   et	   al.	   2009).	   	   In	   contrast,	   LPS-­‐
induced	   preterm	   labour	   has	   been	   shown	   to	   induce	   a	   massive	   neutrophil	   influx	   into	  
both	   the	   decidua	   and	  myometrium	   of	   mice;	   which	   was	   not	   present	   in	   mifepristone-­‐
induced	   preterm	   labour	   (Shynlova	   et	   al.	   2013,	   Shynlova	   et	   al.	   2013).	   	   In	   our	   model,	  
intrauterine	   LPS	   administration	   was	   found	   to	   alter	   both	   the	   number	   and	   the	  
localisation	  of	  neutrophils	  present	   in	  the	  uterus	  of	  mice,	  compared	  to	  the	  PBS	  control	  
group.	   	   Where	   previously	   neutrophils	   were	   absent	   from	   the	   decidua,	   LPS	   treatment	  
induced	  a	  massive	  influx	  of	  neutrophils	  into	  the	  decidua,	  which	  was	  quantified	  as	  a	  7-­‐
fold	  increase.	  	  In	  contrast,	  neutrophil	  numbers	  in	  the	  myometrium	  remained	  relatively	  
stable	   between	   LPS	   and	   PBS	   treated	   mice.	   	   Although	   no	   neutrophil	   infiltration	   was	  
observed	   in	   the	  myometrium	   at	   6	   hours,	   the	   influx	  may	   have	   been	  more	   apparent	   if	  
tissues	  had	  been	  collected	  during	  active	  labour,	  as	  in	  other	  studies.	   	  Interestingly,	  this	  
appears	   to	   be	   the	   first	   report	   of	   LPS-­‐induced	   neutrophil	   influx	   into	   the	   decidua,	   as	  
previous	   studies	   have	   focussed	   on	   localising	   neutrophils	   in	   the	   decidua	   basalis	  
(Shynlova	  et	  al.	  2013).	  	  	  
A	  limitation	  of	  the	  immunohistochemistry	  studies	  performed	  here	  is	  the	  use	  of	  Gr-­‐1	  as	  
a	  neutrophil	  marker.	   	  Although	  commonly	  used	  as	  a	  marker	  of	  neutrophils	  in	  mice,	  as	  
this	  antibody	  recognises	  both	  Ly-­‐6G	  and	  Ly-­‐6C	  antigens,	  it	  can	  also	  detect	  other	  Ly-­‐6C	  
expressing	  cells,	  which	   include	  some	  subsets	  of	  monocytes,	  dendritic	  cells	  and	  T-­‐cells	  
(Jutila	  et	  al.	  1988,	  Kung	  et	  al.	  1991,	  Shortman	  and	  Naik	  2007).	   	  Therefore,	   to	  confirm	  
neutrophil	   localisation	   in	   the	  uterine	   tissues,	   the	  more	  specific	  Ly-­‐6G	  antibody	  (clone	  
1A8)	  should	  be	  the	  preferred	  marker	  in	  future	  studies.	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A	  possible	   limitation	  of	   the	  quantification	  of	  F4/80	  and	  Gr-­‐1	  positive	   cells	  within	   the	  
uterus	  is	  that	  whilst	  the	  same	  number	  of	  fields	  of	  view	  were	  counted	  for	  each	  section,	  
resulting	  in	  the	  same	  total	  area	  being	  counted,	  the	  total	  number	  of	  cells	  present	  were	  
not	   accounted	   for.	   	   Hypertrophy	   of	   the	   uterus	   has	   been	   previously	   reported	   in	   late	  
gestation	   (Shynlova	   et	   al.	   2010);	   and	   furthermore,	   studies	   in	   cardiac	   myocytes	  
demonstrate	  that	  LPS	  treatment	  induces	  hypertrophy	  of	  muscle	  cells	  (Liu	  et	  al.	  2008).	  	  	  
Therefore,	  LPS	  treatment	  may	  have	  altered	  the	  total	  number	  of	  cells	  present	  within	  the	  
randomised	   fields.	   	   Although	   given	   the	  massive	   influx	   of	   neutrophils	   observed	   in	   the	  
decidua,	   it	   is	   unlikely	   to	   have	   significantly	   altered	   this	   result,	   but	  may	   have	  masked	  
more	  subtle	  changes.	  	  To	  confirm	  the	  changes	  observed	  in	  this	  study,	  counts	  relative	  to	  
the	  total	  number	  of	  cells	  would	  need	  to	  be	  performed.	  	  
	  
Intrauterine	  LPS	  administration	  induces	  the	  inflammatory	  and	  immune	  response	  without	  
apparent	  progesterone	  withdrawal	  
In	  contrast	  to	  humans,	  the	  onset	  of	  labour	  in	  mice,	  as	  in	  many	  other	  species	  is	  preceded	  
with	  a	  sharp	  drop	  in	  circulating	  serum	  progesterone	  levels;	  this	  decrease	  is	  thought	  to	  
allow	   increased	   expression	   of	   pro-­‐inflammatory	   factors	   and	   contraction-­‐associated	  
genes	  which	  can	  then	  go	  on	  to	  stimulate	  labour	  (Mitchell	  and	  Taggart	  2009).	  	  However	  
there	  have	  been	  conflicting	  reports	  as	  to	  whether	  progesterone	  withdrawal	  is	  required	  
for	   infection-­‐induced	  preterm	   labour	   in	  mice.	   	   Fidel	  et	  al.	  (Fidel	  et	  al.	   1998)	  reported	  
that	   intrauterine	   LPS	   administration	   in	  mice	   resulted	   in	   significantly	   reduced	   serum	  
progesterone	   levels,	   compared	   to	   mice	   receiving	   PBS,	   within	   1	   hour	   of	   LPS	  
administration	  prior	  to	  the	  onset	  of	  labour.	  	  Whereas,	  a	  number	  of	  more	  recent	  studies	  
have	   demonstrated	   infection-­‐induced	   preterm	   labour	   is	   not	   associated	   with	  
progesterone	  withdrawal	  (Hirsch	  and	  Muhle	  2002,	  Murphy	  et	  al.	  2009,	  Gonzalez	  et	  al.	  
2011).	   	   To	   determine	   whether	   preterm	   labour	   in	   our	   model	   involved	   progesterone	  
withdrawal,	   serum	   progesterone	   levels	   were	   measured	   6	   hours	   post-­‐intrauterine	  
injection.	   	   In	   line	  with	   these	  more	  recent	  studies,	  no	  drop	   in	  circulating	  progesterone	  
levels	  were	  observed	  in	  response	  to	  intrauterine	  LPS	  administration,	  compared	  to	  the	  
PBS	  control	  group.	   	  Although	  this	  measurement	  was	  taken	  after	   just	  6	  hours,	  and	  not	  
during	   labour,	   the	   fact	   that	   at	   this	   time	   we	   already	   have	   a	   strong	   inflammatory	  
response	   within	   the	   intrauterine	   tissues,	   suggests	   that	   the	   mechanisms	   involved	   in	  
inducing	   preterm	   labour	   in	   our	   model	   are	   largely	   independent	   of	   the	   actions	   of	  
progesterone.	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Intrauterine	  LPS	  administration	  did	  not	  cause	  an	  inflammatory	  response	  in	  fetal	  brains	  
Premature	  birth	  is	  linked	  to	  adverse	  neonatal	  outcomes,	  in	  particular	  increased	  risk	  of	  
brain	   injury.	   	  A	  recent	  meta-­‐analysis	  highlighted	  the	  association	  between	  intrauterine	  
infection	  and	  cerebral	  palsy,	  where	   they	   found	   the	  presence	  of	   clinical	  or	  histological	  
chorioamnionitis	  was	   associated	  with	   a	   140%	  or	  80%	   increased	   risk	   for	   neonates	   to	  
develop	   cerebral	   palsy,	   respectively	   (Shatrov	   et	   al.	   2010).	   The	   exact	   mechanisms	   by	  
which	   intrauterine	   infection	   results	   in	   neonatal	   brain	   injury	   are	  not	   clear,	   but	   a	   fetal	  
systemic	   inflammatory	   response	   (FIRS)	   has	   been	   described	   in	   the	   presence	   of	   an	  
intrauterine	  infection;	  which	  can	  result	  in	  elevated	  cytokine	  production	  and	  damage	  to	  
neonatal	   organs	   (Gomez	   et	   al.	   1998).	   	   Evidence	   from	   animal	   models	   suggests	   that	  
intrauterine	   LPS	   administration	   results	   in	   rapid	   production	   of	   pro-­‐inflammatory	  
cytokines	  within	   the	   fetal	  brain	   itself	   (Elovitz	  et	  al.	   2006).	   	   It	  has	  been	  proposed	   that	  
these	  pro-­‐inflammatory	  cytokines	  may	  cause	  brain	  damage	  both	  directly,	  by	  damaging	  
oligodendrocytes	  and	  neurons;	  or	  indirectly,	  by	  activating	  microglia	  in	  the	  brain	  which	  
can	  in	  turn	  secrete	  more	  cytokines	  (Burd	  et	  al.	  2012).	  
To	  determine	  whether	  our	  model	  of	  infection-­‐induced	  preterm	  labour	  caused	  adverse	  
effects	  on	  the	  fetal	  brain,	  expression	  of	  pro-­‐inflammatory	  cytokines	  and	  early	  markers	  
of	  brain	  damage	  were	  examined	  6	  hours	  post	   intrauterine	   injection.	   	  Whilst	  previous	  
studies	  have	  demonstrated	  up-­‐regulated	  expression	  of	   inflammatory	  cytokines	  within	  
6	   hours	   of	   intrauterine	   LPS	   administration	   (Elovitz	   et	   al.	   2006,	   Chang	   et	   al.	   2011,	  
Elovitz	  et	  al.	  2011);	  and	  NF-­‐κB	  activation	  (Pirianov	  et	  al.	  2009);	  in	  our	  model	  Il-­‐1β	  and	  
Tnf-­‐α	  expression	  was	  not	  significantly	  altered,	  and	  surprisingly	   there	  was	  a	  small	  but	  
significant	  reduction	  in	  Il-­‐6	  expression	  in	  the	  brains	  of	  mice	  receiving	  the	  lowest	  dose	  
of	  LPS.	   	  Furthermore,	  there	  was	  no	  change	  in	  the	  expression	  of	  the	  neuronal	  markers,	  
Gfap	   or	   Mtap2,	   both	   of	   which	   have	   previously	   demonstrated	   altered	   expression	   in	  
response	   to	   intrauterine	   LPS	   (Elovitz	   et	   al.	   2006,	   Burd	   et	   al.	   2011).	   	   The	   differences	  
observed	  between	  these	  results	  and	  previous	  studies	  may	  relate	  to	  the	  different	  doses	  
and	  serotypes	  of	  LPS	  used,	  which	  may	  elicit	  more	  potent	  responses.	  	  Some	  studies	  have	  
also	  reported	  no	  significant	  effect	  of	  LPS	  administration	  on	  pro-­‐inflammatory	  gene	  and	  
neuronal	  marker	  expression	  after	  6	  hours	  (Burd	  et	  al.	  2010),	  and	  in	  fact	  use	  of	  the	  same	  
dose	   and	   serotype	  of	   LPS	  was	   recently	  not	   found	   to	   activate	  NF-­‐κB	   in	   the	   fetal	   brain	  
(Sykes	  et	  al.	  2013);	  highlighting	  a	  variable	  response	  at	  this	  early	  time	  point.	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The	   results	   presented	   here	   suggest	   that,	   in	   our	   model,	   there	   are	   no	   apparent	   early	  
inflammatory	  effects	  on	  the	  fetal	  brain	  associated	  with	  intrauterine	  LPS	  administration.	  	  
This	  was	   a	   surprising	   result	   and	   in	   contrast	   to	   some	  previously	   published	   studies	   in	  
similar	  models.	   	   Given	   the	   robust	   inflammatory	   response	   induced	   in	   the	   intrauterine	  
tissues,	  and	  in	  particular	  in	  the	  amniotic	  fluid	  surrounding	  the	  fetus,	  it	  seems	  unlikely	  
that	   intrauterine	   LPS	   administration	   in	   our	   model	   will	   not	   induce	   an	   inflammatory	  
response	   in	   the	   fetal	   brain.	   	   To	   further	   investigate	   whether	   this	   model	   would	   be	  
suitable	  to	  examine	  the	  effects	  of	   intrauterine	   infection	  on	  the	  fetal	  brain,	   it	  would	  be	  
interesting	   to	   examine	   both	   inflammatory	   signalling	   and	  markers	   of	   oligodendrocyte	  
and	  neuronal	  damage	  in	  specific	  areas	  of	  the	  fetal	  brain	  using	  immunohistochemistry.	  	  
These	   changes	  may	   be	   subtle	   and	  may	   be	  more	   apparent	   at	   time	   points	   later	   than	   6	  
hours,	   for	   example	   at	   term,	   thus	   sampling	   fetal	   brains	   at	   a	   later	   stage	   may	   provide	  
further	  information	  on	  the	  effects	  of	  intrauterine	  LPS	  on	  the	  fetal	  brain	  in	  our	  model.	  	  	  
	  
Summary	  
This	  chapter	  provides	   further	  evidence	   that	   the	   immune	  and	   inflammatory	  responses	  
of	  mice	  to	  intrauterine	  LPS	  administration,	  which	  ultimately	  results	  in	  preterm	  labour,	  
share	   many	   similarities	   with	   the	   clinical	   scenario	   of	   bacterial	   infection-­‐associated	  
preterm	   labour	   in	   women.	   	   In	   agreement	   with	   previous	   studies,	   intrauterine	  
administration	  of	  LPS	  resulted	   in	  the	   increased	  production	  of	   inflammatory	  cytokines	  
and	  chemokines	  within	  the	  utero-­‐placental	  tissues,	  amniotic	  fluid	  and	  maternal	  serum;	  
however,	  this	  is	  the	  first	  study	  in	  which	  detailed	  analysis	  of	  the	  inflammatory	  response	  
to	  a	  range	  of	  LPS	  doses	  has	  been	  carried	  out	  in	  the	  uterus,	  fetal	  membranes,	  placenta,	  
amniotic	   fluid,	   maternal	   serum	   and	   fetal	   brains.	   	   Interestingly,	   these	   inflammatory	  
responses	   appear	   to	   be	   largely	   independent	   of	   progesterone	   actions.	   The	   role	   of	  
immune	   cells	   in	   inducing	   preterm	   labour	   in	   this	  model	   will	   be	   addressed	   in	   greater	  
detail	   in	   a	   subsequent	   chapter,	   but	   these	   data	   presented	   here	   demonstrate	   that	   LPS	  
administration	  induced	  a	  large	  neutrophil	  influx	  into	  the	  decidua	  of	  mice,	  which	  has	  not	  
previously	  been	   reported.	   	  Using	  models,	   such	  as	   the	  one	  described	  here,	   are	  vital	   to	  
improving	  our	  understanding	  of	  the	  events	  regulating	  the	  induction	  of	  preterm	  labour	  
and	  will	  ultimately	  aid	   the	  search	   for	  novel	   therapeutic	  options	   to	  delay	  delivery	  and	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4.1 INTRODUCTION	  
Despite	  considerable	  medical	  advances	  and	  research,	  preterm	  birth	  remains	  the	  single	  
biggest	   cause	  of	   neonatal	  mortality	  worldwide.	   	   	  A	   recent	  World	  Health	  Organisation	  
report	   has	   estimated	   more	   than	   one	   million	   babies	   die	   each	   year	   due	   to	   the	  
complications	   of	   their	   premature	   birth	   (March	   of	   Dimes	   2012).	   	   Current	   treatment	  
options	  for	  preterm	  labour	  are	  limited,	  and	  focus	  on	  the	  use	  of	  tocolytic	  agents	  such	  as	  
calcium-­‐channel	   blockers,	   oxytocin	   receptor	   antagonists	   and	   β-­‐mimetics,	   to	   block	  
myometrial	   contractions	   (Smith	   et	   al.	   2009).	   	   Whilst	   these	   treatments	   have	   proved	  
effective	   in	   delaying	   preterm	   birth	   for	   up	   to	   7	   days,	   it	   is	   not	   clear	   if	   they	   actually	  
improve	   perinatal	   or	   neonatal	   morbidity	   (RCOG	   2011).	   	   The	   limited	   effectiveness	   of	  
tocolytic	   drugs	   in	   treating	   preterm	   labour	   is	   likely	   because	   they	   target	   myometrial	  
contractions,	  which	  are	  likely	  to	  be	  an	  end-­‐point	  of	  the	  inflammatory	  cascade	  leading	  to	  
delivery.	   	  Attempting	  to	  delay	  preterm	  delivery	  is	  further	  complicated	  in	  the	  presence	  
of	   an	   intrauterine	   infection,	   where	   leaving	   the	   fetus	   in	   a	   potentially	   hostile	  
inflammatory	   environment	   could	   result	   in	   further	   adverse	   outcomes	   for	   the	   baby	  
(Gotsch	  et	  al.	  2007).	  	  Therefore,	  if	  novel	  treatments	  for	  preterm	  labour	  are	  to	  be	  more	  
effective	   than	   the	   current	   options,	   they	   must	   attempt	   to	   block	   the	   inflammatory	  
cascade	   earlier	   and	   have	   the	   potential	   to	   resolve	   the	   inflammatory	   intrauterine	  
environment.	  	  
Given	  that	  many	  cases	  of	  preterm	  labour	  are	  thought	  to	  occur	  because	  of	  the	  premature	  
initiation	  of	   the	   inflammatory	  cascade	  normally	   initiated	  during	   term	   labour,	   there	   is	  
now	   growing	   interest	   in	   investigating	   the	   potential	   of	   anti-­‐inflammatory	   agents	   to	  
delay	  preterm	  delivery	  and	  improve	  neonatal	  outcome.	  	  The	  use	  of	  non-­‐steroidal	  anti-­‐
inflammatory	   drugs	   (NSAIDS),	   such	   as	   indomethacin,	   and	   the	   steroid	   hormone	  
progesterone	   in	   clinical	   practice	   for	   the	   treatment	   of	   preterm	   labour	   in	   women	  
supports	   the	   hypothesis	   that	   targeting	   inflammatory	   pathways	   can	   reduce	   the	  
incidence	  of	  preterm	  labour.	  	  Animal	  models	  of	  preterm	  labour	  have	  proved	  invaluable	  
in	   investigating	   the	   potential	   of	   anti-­‐inflammatory	   treatments	   to	   delay	   infection-­‐
induced	  preterm	  labour	  and	  improve	  pup	  survival.	  	  The	  therapeutic	  options	  examined	  
to	  date	   include	   IL-­‐10	   (Terrone	  et	  al.	   2001,	  Rodts-­‐Palenik	  et	  al.	   2004,	  Robertson	  et	  al.	  
2006),	   blocking	   TLR-­‐4	   signalling	   (Adams	  Waldorf	   et	   al.	   2008,	   Li	   et	   al.	   2010),	   NF-­‐κB	  
inhibitors	  (Buhimschi	  et	  al.	  2003,	  Beloosesky	  et	  al.	  2006,	  Nath	  et	  al.	  2010,	  Chang	  et	  al.	  
2011),	  15d-­‐PGJ2	  (Pirianov	  et	  al.	  2009),	  anti-­‐TNF-­‐α	  therapy	  (Fidel	  et	  al.	  1997,	  Holmgren	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et	  al.	  2008)	  and	  blocking	   IL-­‐1β	   signalling	  (Romero	  and	  Tartakovsky	  1992,	  Yoshimura	  
and	  Hirsch	  2005).	  	  	  
The	  identification	  that	  the	  resolution	  of	  inflammation	  is	  an	  active	  process	  involving	  the	  
production	  of	  mediators	  with	  specific	  anti-­‐inflammatory	  and	  pro-­‐resolution	  actions	  has	  
provided	  new	  pathways	  to	  target	  in	  the	  search	  for	  novel	  treatments	  for	  inflammation-­‐
associated	  pathologies	   (Gilroy	  et	  al.	   2004,	   Serhan	  et	  al.	   2008).	   	   The	   arachidonic	   acid-­‐
derived	  lipid	  mediators,	  lipoxins,	  were	  the	  first	  family	  of	  mediators	  recognised	  to	  have	  
dual	  acting	  anti-­‐inflammatory	  and	  pro-­‐resolution	  actions	  (Serhan	  et	  al.	  1984,	  Serhan	  et	  
al.	   1984).	   	   Since	   their	  discovery	   in	   the	  1980s,	   the	   therapeutic	  potential	   of	   lipoxins	   to	  
treat	   inflammation-­‐associated	   pathologies	   has	   been	   widely	   demonstrated	   in	   animal	  
models	   of	   a	   range	   of	   pathologies	   including,	   asthma	   (Levy	   et	   al.	   2002,	   El	   Kebir	   et	   al.	  
2009),	  arthritis	  (Zhang	  et	  al.	  2008,	  Conte	  et	  al.	  2010),	  and	  inflammatory	  bowel	  diseases	  
(Gewirtz	   et	   al.	   2002).	   	   The	   potential	   of	   lipoxins	   to	   regulate	   inflammation	   in	   the	  
reproductive	  tissues	  has	  been	  less	  well	  explored	  (Hutchinson	  et	  al.	  2011).	  	  	  However,	  a	  
recent	   study	   from	   our	   laboratory	   reported	   that	   expression	   of	   the	   lipoxin	   receptor,	  
FPR2/ALX,	   was	   increased	   in	   myometrial	   tissue	   obtained	   from	   women	   during	   term	  
labour,	   compared	   to	  non-­‐labouring	  women;	   and	  demonstrated	   that	   lipoxin	   treatment	  
down-­‐regulated	   LPS-­‐induced	   inflammatory	   gene	   expression	   in	   myometrial	   explant	  
culture	   in	   vitro	   (Maldonado-­‐Perez	   et	   al.	   2010).	   	   Therefore,	   given	   this	   evidence	   that	  
lipoxins	  could	  be	   involved	   in	  regulating	   the	   inflammation	  associated	  with	   labour,	  and	  
the	   evidence	   from	   a	   range	   of	   animal	   models	   of	   other	   inflammation-­‐associated	  
pathologies,	  we	  hypothesised	  that	  lipoxins	  could	  be	  useful	  novel	  therapeutic	  agents	  for	  
the	  treatment	  of	  preterm	  labour.	  	  
Using	  our	  mouse	  model	  of	  LPS-­‐induced	  preterm	  labour,	   the	  experiments	  described	   in	  
this	   chapter	   aimed	   to	   investigate	   the	   potential	   of	   lipoxins,	   BML-­‐111	   (a	   stable	   lipoxin	  
analogue)	   and	   the	   anti-­‐inflammatory	   cytokine,	   IL-­‐10,	   to	   delay	   LPS-­‐induced	   preterm	  
delivery	  and/or	  improve	  pup	  survival;	  and	  to	  examine	  whether	  lipoxin	  could	  regulate	  
LPS-­‐induced	  inflammatory	  signalling	  in	  the	  utero-­‐placental	  tissues.	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4.2 METHODS	  
4.2.1 Mouse	  model	  of	  PTL	  
Mice	   underwent	   surgery	   as	   detailed	   in	   section	   2.1.	   	   The	   potential	   of	   three	   anti-­‐
inflammatory	   agents	   (epi-­‐lipoxin,	  BML-­‐111	   and	   IL-­‐10)	   to	   delay	  preterm	  delivery	   and	  
improve	  pup	  survival	  were	  investigated.	  	  Based	  on	  the	  LPS	  dose	  response	  experiments	  
described	  in	  chapter	  3,	  all	  further	  experiments	  were	  carried	  out	  using	  20µg	  LPS.	  	  	  
4.2.1.1 Epi-­‐lipoxin	  experiments	  	  
To	  determine	  whether	  lipoxin	  administration	  could	  affect	  LPS-­‐induced	  preterm	  labour,	  
mice	  were	   pre-­‐treated	  with	   15-­‐epi-­‐lipoxin	  A4.	  	  Briefly,	   1-­‐2	   hours	   prior	   to	   intrauterine	  
injection	   of	   LPS	   or	   PBS,	   mice	   received	   an	   intra-­‐peritoneal	   (i.p.)	   injection	   of	   vehicle	  
(PBS+1%	  ethanol)	  or	  epi-­‐lipoxin	  (doses	  of	  12.5ng	  or	  125ng),	  both	  in	  a	  volume	  of	  100µl.	  	  
Therefore,	  there	  were	  five	  treatment	  groups:	  vehicle	  (i.p.	   injection	  of	  vehicle	  followed	  
by	   intrauterine	  PBS,	  n=12);	  epi-­‐lipoxin	  (i.p.	   injection	  of	  125ng	  epi-­‐lipoxin	   followed	  by	  
intrauterine	   PBS,	   n=9);	   LPS	   (i.p.	   injection	   of	   vehicle	   followed	   by	   intrauterine	   LPS,	  
n=12);	   12.5ng	   epi-­‐lipoxin+LPS	   (i.p.	   injection	   of	   12.5ng	   epi-­‐lipoxin	   followed	   by	  
intrauterine	  LPS,	  n=11);	  and	  125ng	  epi-­‐lipoxin+LPS	  (i.p.	  injection	  of	  125ng	  epi-­‐lipoxin	  
followed	  by	  intrauterine	  LPS,	  n=11).	  	  
4.2.1.2 BML-­‐111	  experiments	  	  
In	   BML-­‐111	   experiments,	   to	   determine	   whether	   BML-­‐111	   could	   affect	   LPS-­‐induced	  
preterm	  labour.	   	  Mice	  received	  an	  i.p.	  injection	  of	  vehicle	  (PBS+7%	  methanol)	  or	  BML	  
at	   doses	   of	   1mg/kg	   or	   10mg/kg	   BML-­‐111	   in	   a	   volume	   of	   500µl,	   1-­‐2	   hours	   prior	   to	  
intrauterine	   injection	   of	   LPS	   or	   PBS.	   	   Again	   this	   resulted	   in	   five	   treatment	   groups:	  
vehicle	   (i.p.	   injection	   of	   vehicle	   followed	   by	   intrauterine	   PBS,	   n=10);	   BML-­‐111	   (i.p.	  
injection	   of	   1mg/kg	   or	   10mg/kg	   BML-­‐111	   followed	   by	   intrauterine	   PBS,	   n=11;	  mice	  
receiving	   both	   doses	   were	   pooled	   into	   one	   group	   for	   analysis	   as	   there	   was	   no	  
significant	   difference	   between	   them);	   LPS	   (i.p.	   injection	   of	   vehicle	   followed	   by	  
intrauterine	  LPS,	  n=22);	  1mg/kg	  BML+LPS	  (i.p.	  injection	  of	  1mg/kg	  BML-­‐111	  followed	  
by	  intrauterine	  LPS,	  n=20);	  and	  10mg/kg	  BML+LPS	  (i.p.	  injection	  of	  10mg/kg	  BML-­‐111	  
followed	  by	  intrauterine	  LPS,	  n=9).	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4.2.1.3 IL-­‐10	  experiments	  	  
In	   IL-­‐10	   experiments,	   to	   determine	  whether	   IL-­‐10	   could	   affect	   LPS-­‐induced	   preterm	  
labour,	  mice	  received	  an	  i.p.	  injection	  of	  vehicle	  (PBS+sterile	  H20)	  or	  IL-­‐10	  at	  doses	  of	  
2.5µg	  or	  10µg,	  in	  a	  volume	  of	  200µl,	  1-­‐2	  hours	  prior	  to	  intrauterine	  injection	  of	  LPS	  or	  
PBS.	  	  Again,	  there	  were	  five	  treatment	  groups:	  vehicle	  (i.p.	  injection	  of	  vehicle	  followed	  
by	   intrauterine	   PBS,	   n=11);	   10µg	   IL-­‐10	   (i.p.	   injection	   of	   10µg	   IL-­‐10	   followed	   by	  
intrauterine	  PBS,	  n=10);	  LPS	  (i.p.	   injection	  vehicle	  followed	  by	  intrauterine	  LPS,	  n=6);	  
2.5µg	   IL-­‐10+LPS	   (i.p.	   injection	  of	  2.5µg	   IL-­‐10	   followed	  by	   intrauterine	  LPS,	  n=5);	  and	  
10µg	  IL-­‐10+LPS	  (i.p.	  injection	  of	  10µg	  IL-­‐10	  followed	  by	  intrauterine	  LPS,	  n=6).	  	  
In	   each	   experiment,	   time	   to	   delivery	   and	   the	   proportion	   of	   live	   born	   pups	   were	  
recorded	  following	  surgery,	  as	  detailed	  in	  sections	  2.1.1.	  and	  2.1.2.	  	  	  
	  
4.2.2 Tissue	  collection	  
As	  detailed	  in	  section	  2.1.3,	  utero-­‐placental	  tissues	  and	  amniotic	  fluid	  were	  collected	  6	  
hours	   post-­‐surgery	   for	   analysis	   of	   lipoxin	   receptor	   expression	   in	   the	   utero-­‐placental	  
tissues;	  and	  analysis	  of	  the	  inflammatory	  response	  following	  treatment	  with	  LPS	  ±	  epi-­‐
lipoxin.	  	  	  
For	   analysis	   of	   the	   expression	   of	   the	   lipoxin	   receptor,	   Fpr2,	   uterus,	   fetal	  membranes	  
and	   placental	   tissues	   were	   harvested	   6	   hours	   post-­‐surgery	   from	   mice	   receiving	  
intrauterine	  PBS	  (n=7)	  or	  20µg	  LPS	  (n=10).	  	  	  
For	   analysis	   of	   the	   effect	   of	   epi-­‐lipoxin	   on	   the	   LPS-­‐induced	   inflammatory	   response,	  
utero-­‐placental	  tissues	  were	  collected	  6	  hours	  post-­‐surgery	  from	  two	  separate	  cohorts	  
of	  mice.	  	  In	  the	  first	  cohort,	  mice	  received	  i.p.	  pre-­‐treatment	  with	  epi-­‐lipoxin	  1-­‐2	  hours	  
prior	  to	  intrauterine	  LPS	  or	  PBS	  administration.	  	  Therefore,	  tissues	  were	  collected	  from	  
the	   following	   groups:	   vehicle	   (n=3),	   2.5µg	   epi-­‐lipoxin	   (n=4),	   LPS	   (n=5),	   0.25µg	   epi-­‐
lipoxin+LPS	  (n=5)	  and	  2.5µg	  epi-­‐lipoxin+LPS	  (n=5).	  	  
In	  a	  separate	  cohort	  of	  mice,	  the	  effect	  of	  intrauterine	  administration	  of	  epi-­‐lipoxin	  was	  
investigated.	   	   These	  mice	   received	   two	   25µl	   intrauterine	   injections	  within	   1	  minute,	  
either	   vehicle	   or	   epi-­‐lipoxin,	   followed	   by	   PBS	   or	   20µg	   LPS.	   	   Therefore,	   tissues	   were	  
collected	  from	  mice	  receiving:	  vehicle	  (n=4),	  250ng	  epi-­‐lipoxin	  (n=4),	  LPS	  (n=5),	  25ng	  
epi-­‐lipoxin+LPS	  (n=6)	  and	  250ng	  epi-­‐lipoxin+LPS	  (n=6).	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4.2.3 qRT-­‐PCR	  
The	   mRNA	   expression	   of	   the	   lipoxin	   receptor	   and	   several	   inflammatory	   genes	   was	  
examined	  using	  qRT-­‐PCR	  as	  described	  in	  section	  2.3.	   	  The	  expression	  of	  the	  following	  
genes	   were	   measured	   in	   the	   uterus,	   fetal	   membranes	   and	   placenta	   of	   mice	   6	   hours	  
post-­‐surgery:	  Cxcl1,	  Cxcl2,	  Cxcl5,	  Ccl2,	  Il-­‐1β,	  Tnf-­‐α,	  Il-­‐6,	  Il-­‐10,	  Cox-­‐2,	  15-­‐Hpgd	  and	  Fpr2.	  	  	  
As	  described	   in	  section	  2.3.3,	  expression	  of	   the	  gene	  of	   interest	  was	  normalised	   to	  β-­‐
actin	   as	   the	   endogenous	   control	   gene	   in	   each	   sample	   and	   all	   samples	   were	   then	  
compared	   relative	   to	   a	   calibrator	   tissue.	   	   Analysis	   of	   all	   the	   inflammatory	   genes	  
examined	   in	   the	   uterus,	   fetal	   membranes	   and	   placenta	   was	   carried	   out	   relative	   to	  
untreated	  D18	  uterus	  as	  a	  calibrator.	   	   	  Analysis	  of	   the	  expression	  of	  Fpr2	  was	  carried	  
out	  relative	  to	  untreated	  virgin	  spleen	  as	  a	  calibrator.	  	  	  
	  
4.2.4 ELISA	  
ELISAs	  were	  used	   to	  quantify	   the	   concentration	  of	  TNF-­‐α	   and	   IL-­‐10	   in	  amniotic	   fluid	  
collected	  6	  hours	  post-­‐surgery.	  	  Details	  of	  each	  assay	  are	  given	  in	  section	  2.4.	  	  	  
	  
4.2.5 Statistical	  analysis	  
Data	   are	   presented	   as	  mean	  ±	   SEM.	   	  Where	  data	  were	  not	   normally	   distributed	   they	  
was	  transformed	  prior	  to	  analysis.	  	  Time	  to	  delivery	  data	  were	  log	  transformed	  before	  
analysis;	  and	  the	  proportion	  of	  live	  born	  pups	  was	  arc-­‐sin	  transformed	  prior	  to	  analysis.	  	  
Normally	   distributed	   data	   were	   then	   analysed	   by	   one-­‐way	   ANOVA	   to	   compare	  
treatment	   groups,	   followed	  by	  Tukey’s	  multiple	   comparison	   tests	   between	   treatment	  
groups	   to	   identify	   significant	   differences.	   Preterm	   delivery	   rates	   were	   analysed	   by	  
Fisher’s	   exact	   test.	   	   Amniotic	   fluid	   cytokine	   levels	   were	   analysed	   non-­‐parametrically	  
using	   a	   Kruskal-­‐Wallis	   test	   followed	   by	   Dunn’s	  multiple	   comparison	   tests	   to	   identify	  
significant	   differences	   between	   treatment	   groups.	   	   As	   Fpr2	   expression	   was	   only	  
measured	   in	   two	  treatment	  groups,	  PBS	  and	  20µg	  LPS,	   the	  expression	  was	  compared	  
using	  unpaired	  t-­‐tests.	  	  P<0.05	  was	  considered	  statistically	  significant.	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4.3 RESULTS	  
4.3.1 Expression	   of	   the	   lipoxin	   receptor,	   Fpr2,	   in	   utero-­‐placental	   tissues	   following	  
intrauterine	  LPS	  administration	  
Uterus,	   fetal	   membranes	   and	   placenta	   were	   harvested	   from	   mice	   6	   hours	   post-­‐	  
intrauterine	   injection	   of	   PBS	   or	   20µg	   LPS	   and	   qRT-­‐PCR	   was	   performed	   to	   examine	  
whether	   mRNA	   expression	   of	   the	   lipoxin	   receptor,	   Fpr2,	   was	   altered	   in	   response	   to	  
intrauterine	  LPS.	  	  	  
Intrauterine	  LPS	  administration	  induced	  elevated	  expression	  of	  Fpr2	  in	  all	  three	  tissues	  
(Figure	  4.1).	  	  Uterine	  Fpr2	  expression	  was	  significantly	  elevated	  in	  mice	  receiving	  LPS,	  
compared	  to	  those	  receiving	  PBS	  (2.4-­‐fold	  increase;	  p<0.001;	  Figure	  4.1A).	  	  In	  the	  fetal	  
membranes,	   Fpr2,	   was	   also	   significantly	   elevated	   in	   response	   to	   intrauterine	   LPS	  
compared	  to	  the	  PBS	  control	  group	  (29-­‐fold	  increase;	  p<0.001;	  Figure	  4.1B).	  	  Placental	  
expression	  of	  Fpr2	  was	  also	  significantly	  higher	  in	  mice	  treated	  with	  LPS,	  compared	  to	  
those	  receiving	  PBS	  (3.6-­‐fold	  increase;	  p<0.001;	  Figure	  4.1C).	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Figure	  4.1	   -­‐	  Expression	  of	  Fpr2	  mRNA	   in	  uterus,	   fetal	  membranes	  and	  placenta.	  	  	  
Uterus,	   fetal	  membranes	  and	  placenta	  were	  collected	  6	  hours	  post-­‐surgery	   from	  mice	  
receiving	  intrauterine	  PBS	  (n=7)	  or	  20µg	  LPS	  (n=10)	  and	  the	  mRNA	  expression	  of	  Fpr2	  
was	   investigated	   using	   qRT-­‐PCR.	   	   (A)	   Fpr2	   expression	   in	   the	   uterus	   	   (B)	   Fpr2	  
expression	  in	  the	  fetal	  membranes.	   	  (C)	  Placental	  Fpr2	  expression.	   	  Data	  presented	  as	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4.3.2 Effect	  of	  pre-­‐treatment	  with	  epi-­‐lipoxin	  on	   time	  to	  delivery	  and	  proportion	  of	   live	  
born	  pups	  
Given	   that	  many	   studies	  have	  demonstrated	   that	   epi-­‐lipoxins	  have	   anti-­‐inflammatory	  
and	   pro-­‐resolution	   actions	   in	   other	   animal	   models	   of	   inflammation-­‐associated	  
pathologies	  (Levy	  et	  al.	  2002,	  Conte	  et	  al.	  2010,	  Borgeson	  et	  al.	  2011);	  and	  that	  lipoxin	  
receptor	   expression	   in	   the	   utero-­‐placental	   tissues	   was	   increased	   in	   response	   to	  
intrauterine	  LPS,	  we	  wanted	  to	  investigate	  the	  potential	  of	  epi-­‐lipoxin	  to	  delay	  delivery	  
and	   improve	  pup	   survival	   in	  our	  model.	   	   	  Mice	  were	  pre-­‐treated	  with	  epi-­‐lipoxin	  1-­‐2	  
hours	   prior	   to	   intrauterine	   LPS	   or	   PBS	   administration.	   	   As	   controls,	   mice	   were	   pre-­‐
treated	  with	  vehicle	  prior	  to	  intrauterine	  LPS	  or	  PBS	  injection.	  	  
	  
4.3.2.1 Time	  to	  delivery	  
Pre-­‐treatment	   with	   125ng	   epi-­‐lipoxin	   had	   no	   effect	   on	   time	   to	   delivery	   in	   mice	  
receiving	   PBS,	   compared	   with	   the	   vehicle	   control	   group	   (Mean	   time	   to	   delivery	   of	  
125ng	  epi-­‐lipoxin	  group	  50.2	  hours	  ±	  SEM	  5.0	  vs.	  vehicle	  mean	  55.4	  hours	  ±	  SEM	  6.4;	  
Figure	   4.2).	   	   Mice	   receiving	   intrauterine	   LPS	   delivered	   significantly	   earlier	   than	   the	  
vehicle	  control	  group	  (LPS	  mean	  time	  to	  delivery	  27.54	  hours	  ±	  SEM	  6.3;	  p<0.001	  vs.	  
vehicle).	  	  Mice	  pre-­‐treated	  with	  either	  12.5ng	  or	  125ng	  epi-­‐lipoxin	  prior	  to	  intrauterine	  
LPS	   still	   delivered	   significantly	   earlier	   compared	   to	   the	   vehicle	   control	   group	   (mean	  
time	   to	   delivery	   in	   12.5ng	   epi-­‐lipoxin+LPS	   group	   27.02	   ±	   SEM	   4.57;	   mean	   time	   to	  
delivery	   in	  125ng	  epi-­‐lipoxin+LPS	  group	  26.82	  ±	  SEM	  2.62;	  p<0.01	  vs.	  vehicle).	   	  Mice	  
receiving	   intrauterine	   LPS	   administration,	   either	   alone	   or	   with	   epi-­‐lipoxin	   pre-­‐
treatment,	  also	  delivered	  significantly	  earlier	  than	  the	  125ng	  epi-­‐lipoxin	  control	  group	  
(LPS	  group	  p<0.01,	  12.5ng	  epi-­‐lipoxin+LPS	  group	  p<0.05,	  125ng	  epi-­‐lipoxin+LPS	  group	  
p<0.05).	  	  
To	   investigate	   further	   whether	   epi-­‐lipoxin	   had	   any	   effect	   on	   preterm	   delivery,	   the	  
preterm	  delivery	  rates	  in	  each	  group	  were	  calculated	  (Table	  4.1).	  	  The	  preterm	  delivery	  
rates	  were	  defined	  as	   the	  proportion	  of	  dams	   in	  which	   there	  was	  delivery	  of	   the	   first	  
pup	  within	  36	  hours	  of	  intrauterine	  injection.	  	  All	  groups	  receiving	  intrauterine	  LPS	  had	  
higher	   rates	   of	   preterm	   delivery	   compared	   with	   the	   vehicle	   and	   125ng	   epi-­‐lipoxin	  
groups.	   	   Compared	   to	   the	   LPS	   group,	   the	   risk	   of	   preterm	   delivery	   was	   significantly	  
lower	   in	   the	   vehicle	   (p<0.05)	   and	   125ng	   epi-­‐lipoxin	   (p<0.01)	   groups.	   	   Pre-­‐treatment	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with	   epi-­‐lipoxin	   prior	   to	   intrauterine	   LPS	   administration	   did	   not	   have	   a	   significant	  
effect	  on	  the	  rate	  of	  preterm	  delivery,	  compared	  to	  mice	  treated	  with	  LPS	  alone.	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Figure	   4.2	   -­‐	   Effect	   of	   epi-­‐lipoxin	   pre-­‐treatment	   on	   time	   to	   delivery.	   	   	   Time	   to	  
delivery	  was	  monitored	   in	  mice	  pre-­‐treated	  with	  vehicle	   (n=12)	  or	  125ng	  epi-­‐lipoxin	  
(n=9),	   prior	   to	   intrauterine	  PBS;	   and	   in	  mice	  pre-­‐treated	  with	  vehicle	   (n=12),	   12.5ng	  
epi-­‐lipoxin	   (n=11)	   or	   125ng	   epi-­‐lipoxin	   (n=11),	   prior	   to	   intrauterine	   LPS	  
administration.	  Data	  are	  presented	  as	  mean	  ±	  SEM	  (error	  bars).	  	  **p<0.01,	  ***p<0.001,	  
compared	  to	  vehicle.	  	  	  
	  
	  
Table	  4.1	  -­‐	  Effect	  of	  epi-­‐lipoxin	  pre-­‐treatment	  on	  LPS-­‐induced	  preterm	  delivery.	  	  	  
Time	  to	  delivery	  was	  monitored	  in	  mice	  pre-­‐treated	  with	  vehicle	  or	  125ng	  epi-­‐lipoxin	  
prior	   to	   intrauterine	   PBS	   and	   in	  mice	   pre-­‐treated	  with	   vehicle,	   12.5ng	   epi-­‐lipoxin	   or	  
125ng	   epi-­‐lipoxin	   prior	   to	   intrauterine	   LPS	   administration.	   	   Preterm	   delivery	   was	  
defined	   as	   delivery	   within	   36	   hours	   of	   intrauterine	   injection.	   	   Relative	   risk	   ratios	  
calculated	  using	  Fisher’s	  exact	  test.	  *p<0.05,	  **p<0.01,	  compared	  to	  LPS.	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4.3.2.2 Proportion	  of	  live	  born	  pups	  
Mice	  pre-­‐treated	  with	  125ng	  epi-­‐lipoxin	  prior	  to	  intrauterine	  PBS	  administration	  had	  a	  
greater	  proportion	  of	   live	  born	  pups	  compared	  with	  the	  vehicle	  control	  group	  (125ng	  
epi-­‐lipoxin	  mean	  proportion	  of	  live	  born	  pups	  0.87	  ±	  SEM	  0.05	  vs.	  vehicle	  mean	  0.58	  ±	  
SEM	  0.1;	  Figure	  4.3A),	  however	  this	  difference	  was	  not	  statistically	  significant	  (p=0.2).	  	  
Mice	   in	   the	   LPS	   group	   had	   a	   significantly	   reduced	   proportion	   of	   live	   born	   pups	  
compared	  with	  both	  the	  groups	  treated	  with	  intrauterine	  PBS,	  either	  those	  which	  had	  
pre-­‐treatment	   with	   vehicle	   (p<0.01)	   or	   those	   pre-­‐treated	   with	   epi-­‐lipoxin	   (p<0.001;	  
mean	  proportion	  of	  live	  born	  pups	  in	  LPS	  group	  0.16	  ±	  SEM	  0.09).	  	  Pre-­‐treatment	  with	  
125ng	  epi-­‐lipoxin	  prior	  to	  intrauterine	  LPS	  appeared	  to	  increase	  the	  proportion	  of	  live	  
born	  pups	  (mean	  0.45	  ±	  SEM	  0.11)	  compared	  to	  LPS	  treatment	  alone,	  but	  this	  did	  not	  
reach	  statistical	  significance	  (p=0.18;	  Figure	  4.3A).	  	  Compared	  to	  the	  125ng	  epi-­‐lipoxin	  
control	   group,	  mice	   pre-­‐treated	  with	   epi-­‐lipoxin	   prior	   to	   intrauterine	   LPS	   still	   had	   a	  
significantly	  reduced	  proportion	  of	   live	  born	  pups	   in	  both	   the	  12.5ng	  epi-­‐lipoxin+LPS	  
group	   (mean	  proportion	  of	   live	  born	  pups	  0.23	  ±	   SEM	  0.09;	  p<0.001)	   and	   the	  125ng	  
epi-­‐lipoxin+LPS	  group	  (p<0.05).	  	  
To	   further	   investigate	   whether	   epi-­‐lipoxin	   was	   having	   an	   effect	   on	   pup	   survival,	  
particularly	   in	   mice	   delivering	   early,	   the	   proportion	   of	   live	   born	   pups	   was	   also	  
investigated	  in	  mice	  delivering	  preterm	  (which	  we	  defined	  as	  delivery	  within	  36	  hours	  
of	   intrauterine	   injection).	   	   Mice	   delivering	   prematurely	   in	   the	   vehicle	   group	   had	   a	  
greater	  proportion	  of	   live	  born	  pups	  compared	  to	  LPS	  alone	  (mean	  proportion	  of	   live	  
born	  pups	  in	  vehicle	  group	  0.52	  ±	  SEM	  0.29	  vs.	  LPS	  mean	  0.03	  ±	  SEM	  0.02;	  Figure	  4.3B),	  
however	   this	  difference	  was	  not	  statistically	  significant	   (p=0.08).	   	  Pre-­‐treatment	  with	  
125ng	  epi-­‐lipoxin	  prior	  to	  LPS	  treatment	  significantly	  increased	  the	  proportion	  of	  live	  
born	  pups,	   compared	   to	  LPS	  alone	   (mean	  proportion	  of	   live	  born	  pups	   in	  125ng	  epi-­‐
lipoxin+LPS	   group	   0.45	   ±	   SEM	   0.12;	   p<0.05,	   Figure	   4.3B).	   	   Although	   a	   greater	  
proportion	  of	   live	  born	  pups	  were	  born	   to	  mice	   receiving	  12.5ng	   epi-­‐lipoxin	  prior	   to	  
intrauterine	  LPS	  (mean	  0.12	  ±	  SEM	  0.09),	   this	  was	  not	  significantly	  greater	  compared	  
to	  LPS	  alone.	  	  Only	  two	  mice	  in	  the	  125ng	  epi-­‐lipoxin	  control	  group	  delivered	  preterm,	  
therefore,	  they	  were	  excluded	  from	  analysis;	  however	  both	  mice	  delivered	  litters	  with	  a	  
high	  proportion	  of	  live	  born	  pups	  (0.78	  and	  1.0).	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Figure	  4.3	  -­‐	  Effect	  of	  pre-­‐treatment	  with	  epi-­‐lipoxin	  on	  the	  proportion	  of	  live	  born	  
pups.	   	   	   The	   proportion	   of	   live	   born	   pups	   was	   determined	   in	   mice	   pre-­‐treated	   with	  
vehicle	  (n=12)	  or	  125ng	  epi-­‐lipoxin	  (n=9),	  prior	  to	   intrauterine	  PBS;	  and	  in	  mice	  pre-­‐
treated	   with	   vehicle	   (n=12),	   12.5ng	   epi-­‐lipoxin	   (n=11)	   or	   125ng	   epi-­‐lipoxin	   (n=11),	  
prior	  to	   intrauterine	  LPS	  administration.	   	  (A)	  Proportion	  of	   live	  born	  pups	  in	  all	  mice	  
(B)	   The	  proportion	  of	   pups	  delivered	  prematurely	   (within	  36	  hours	  of	   surgery)	  who	  
were	  born	   live;	   [vehicle	   (n=3),	   LPS	   (n=10),	   12.5ng	   epi-­‐lipoxin+LPS	   (n=7),	   125ng	  Epi-­‐
lipoxin+LPS	   (n=10)].	   	  Data	  presented	   as	  mean	  ±	   SEM	   (error	  bars).	   *p<0.05,	   **p<0.01	  
compared	  to	  vehicle;	  #p<0.05	  compared	  to	  LPS.	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4.3.3 Expression	  of	  inflammatory	  mediators	  in	  the	  utero-­‐placental	  tissues	  following	  intra-­‐
peritoneal	  pre-­‐treatment	  with	  epi-­‐lipoxin	  
Given	   the	   results	   described	   in	   chapter	   3,	   which	   demonstrated	   intrauterine	   LPS	  
treatment	  induced	  a	  robust	  inflammatory	  response	  in	  the	  intrauterine	  tissues,	  resulting	  
in	  the	   increased	  expression	  of	  a	  number	  of	   inflammatory	  genes,	   in	  a	  second	  cohort	  of	  
mice,	  vehicle,	  epi-­‐lipoxin,	  PBS	  and	  LPS	  were	  given	  as	  before,	  but	  mice	  were	  sacrificed	  6	  
hours	   after	   intrauterine	   injection	   and	   utero-­‐placental	   tissues	  were	   then	   analysed	   for	  
the	   expression	   of	   the	   same	   inflammatory	   mediators	   using	   qRT-­‐PCR	   to	   examine	  
whether	   pre-­‐treatment	   with	   epi-­‐lipoxin	   affected	   LPS-­‐induced	   inflammatory	   gene	  
expression.	  	  As	  before,	  the	  genes	  examined	  were	  Tnf-­‐α,	  Il-­‐1β,	  Il-­‐6,	  Il-­‐10,	  Cox-­‐2,	  15-­‐Hpgd,	  
Cxcl1,	  Cxcl2,	  Cxcl5	  and	  Ccl2.	  	  To	  investigate	  the	  anti-­‐inflammatory	  actions	  of	  epi-­‐lipoxin,	  
we	  administered	  higher	  doses	  of	  epi-­‐lipoxin	  to	  try	  to	  maximise	  the	  anti-­‐inflammatory	  
effects,	   with	   0.25µg	   and	   2.5µg	   being	   used	   as	   the	   low	   and	   high	   doses	   in	   these	  
experiments.	  	  	  
	  
4.3.3.1 Inflammatory	  gene	  expression	  in	  the	  uterus	  
Compared	   to	   the	   vehicle	   control	   group,	   uterine	   Tnf-­‐α	   expression	   was	   significantly	  
elevated	  in	  mice	  treated	  with	  LPS	  (6.4-­‐fold	  greater	  expression;	  p<0.001;	  Figure	  4.4A).	  	  
Pre-­‐treatment	   with	   0.25µg	   and	   2.5µg	   epi-­‐lipoxin,	   prior	   to	   intrauterine	   LPS,	   did	   not	  
significantly	   alter	   LPS-­‐induced	   Tnf-­‐α	   expression,	   with	   mice	   in	   the	   0.25µg	   epi-­‐
lipoxin+LPS	  and	  2.5µg	  epi-­‐lipoxin+LPS	  groups,	  still	  having	  significantly	  elevated	  Tnf-­‐α	  
expression	  compared	  to	  vehicle	  (4.9-­‐fold	  and	  6.8-­‐fold	  greater	  expression	  respectively;	  
p<0.001).	   	   Pre-­‐treatment	   with	   2.5µg	   epi-­‐lipoxin	   prior	   to	   intrauterine	   PBS	   did	   not	  
significantly	  affect	  Tnf-­‐α	  expression,	  compared	  to	  the	  vehicle	  control	  group.	  	  
Expression	   of	   Il-­‐1β	   in	   the	   uterus	  was	   significantly	   elevated	   in	  mice	   treated	  with	   LPS,	  
compared	  to	  the	  vehicle	  control	  group	  (p<0.05;	  Figure	  4.4B),	  with	  LPS	  inducing	  a	  2.6-­‐
fold	  increase	  in	  expression.	  	  	  Again,	  mice	  pre-­‐treated	  with	  0.25µg	  and	  2.5µg	  epi-­‐lipoxin,	  
prior	  to	  intrauterine	  LPS,	  still	  had	  significantly	  elevated	  Il-­‐1β	  expression,	  compared	  to	  
the	   vehicle	   control	   group	   (3.1-­‐fold	   and	   3.4-­‐fold	   greater	   expression	   respectively;	  
p<0.01).	   	  No	   significant	  difference	   in	   Il-­‐1β	  expression	  was	  observed	  when	   comparing	  
mice	  pre-­‐treated	  with	  2.5µg	  epi-­‐lipoxin	  prior	  to	  intrauterine	  PBS	  to	  the	  vehicle	  control	  
group.	  	  	  	  
	   	   	   Chapter	  4	  
	   141	  
Compared	   to	   the	   vehicle	   group,	   Il-­‐6	   expression	   was	   significantly	   elevated	   in	   mice	  
receiving	   LPS	   (7.7-­‐fold	   greater	   expression;	   p<0.001).	   	   Pre-­‐treatment	  with	   epi-­‐lipoxin	  
prior	   to	   intrauterine	   LPS	   did	   not	   significantly	   alter	   Il-­‐6	  expression	   compared	   to	   LPS	  
alone,	   and	   mice	   in	   these	   groups	   still	   had	   significantly	   greater	   expression	   of	   Il-­‐6	  
compared	   to	   vehicle	   (0.25µg	   epi-­‐lipoxin+LPS:	   7.9-­‐fold	   greater	   expression;	   p<0.001;	  
2.5µg	   epi-­‐lipoxin+LPS	   group	   12.3-­‐fold	   greater	   expression;	   p<0.001;	   Figure	   4.4C).	  	  
Treatment	  with	  epi-­‐lipoxin	  alone	  did	  not	  significantly	  affect	  Il-­‐6	  expression,	  compared	  
to	  the	  vehicle	  group.	  	  
Expression	  of	  Il-­‐10	  was	  significantly	  elevated	  in	  the	  LPS	  treatment	  group	  compared	  to	  
the	   vehicle	   group	   (2.2-­‐fold	   greater	   expression;	   p<0.05;	   Figure	   4.4D).	   	   	   Whilst	   pre-­‐
treatment	  with	  epi-­‐lipoxin	  did	  not	  result	   in	  any	  significant	  effect	  on	  LPS-­‐induced	  Il-­‐10	  
expression	  in	  the	  uterus,	  compared	  to	  either	  LPS	  alone	  or	  vehicle.	  	  
Compared	  to	  the	  vehicle	  group,	  Cox-­‐2	  expression	  was	  significantly	  elevated	  in	  response	  
to	   intrauterine	   LPS,	   in	   mice	   treated	   with	   LPS	   alone	   (9.2-­‐fold	   greater	   expression,	  
p<0.01)	  and	  in	  mice	  pre-­‐treated	  with	  0.25µg	  and	  2.5µg	  epi-­‐lipoxin	  prior	  to	  intrauterine	  
LPS	  (16.1-­‐fold	  and	  20.8-­‐fold	   increased	  expression	  respectively,	  p<0.001;	  Figure	  4.4E).	  	  
Interestingly,	   pre-­‐treatment	   with	   2.5µg	   epi-­‐lipoxin	   prior	   to	   intrauterine	   PBS	   also	  
significantly	  increased	  uterine	  Cox-­‐2	  expression,	  compared	  to	  the	  vehicle	  group	  (6-­‐fold	  
greater	  expression,	  p<0.05).	  	  
Uterine	  expression	  of	  15-­‐Hpgd	  was	  significantly	  reduced	  in	  mice	  pre-­‐treated	  with	  2.5µg	  
epi-­‐lipoxin	   prior	   to	   intrauterine	   PBS	   administration,	   compared	   to	   vehicle	   (2.8-­‐fold	  
reduced	   expression,	   p<0.05;	   Figure	   4.4F).	   	   LPS	   treatment	   alone	   did	   not	   significantly	  
alter	  15-­‐Hpgd	  expression,	   compared	   to	  vehicle,	  however	  mice	  pre-­‐treated	  0.25µg	  and	  
2.5µg	   epi-­‐lipoxin	   prior	   to	   intrauterine	   LPS	   also	   had	   significantly	   reduced	   15-­‐Hpgd	  
expression	   compared	   to	   the	   vehicle	   group	   (3.6-­‐fold	   decrease	   (p<0.001)	   and	   3.4-­‐fold	  
decrease	   (p<0.01)	   respectively).	   	   Mice	   in	   the	   0.25µg	   epi-­‐lipoxin+LPS	   and	   2.5µg	   epi-­‐
lipoxin+LPS	  group	  also	  had	  significantly	  decreased	  expression	  of	  15-­‐Hpgd	  compared	  to	  
mice	  receiving	  LPS	  alone,	  with	  a	  mean	  3.2-­‐fold	  (p<0.001)	  and	  3-­‐fold	  (p<0.01)	  decrease,	  
respectively.	  	  
Expression	  of	  the	  neutrophil	  chemokines	  Cxcl1,	  Cxcl2	  and	  Cxcl5	   in	  the	  uterus,	  were	  all	  
significantly	   elevated	   in	   the	   LPS	   treatment	   group,	   compared	  with	   the	   vehicle	   control	  
group.	  	  Cxcl1	  expression	  was	  18.2-­‐fold	  higher	  in	  the	  LPS	  treatment	  group	  compared	  to	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mice	   in	   the	   vehicle	   group	   (p<0.001;	   Figure	   4.5A).	   	   Intrauterine	   LPS	   administration	  
induced	   a	  mean	  16.8-­‐fold	  upregulation	   in	  Cxcl2	   compared	  with	   the	   vehicle	   (p<0.001;	  
Figure	   4.5B).	   	   Expression	   of	   Cxcl5	   was	   8.8-­‐fold	   greater	   in	   the	   LPS	   treatment	   group	  
compared	  to	  mice	  in	  the	  vehicle	  group	  (p<0.001;	  Figure	  4.5C).	  	  Pre-­‐treatment	  with	  epi-­‐
lipoxin,	   at	   either	   dose,	   prior	   to	   intrauterine	   LPS	   administration	   did	   not	   significantly	  
alter	   LPS-­‐induced	   expression	   of	   Cxcl1,	   Cxcl2	   or	   Cxcl5,	   with	   mice	   in	   these	   treatment	  
groups	   still	   having	   significantly	   elevated	   expression	   of	   Cxcl1,	   Cxcl2	   and	   Cxcl5	  when	  
compared	  to	  the	  vehicle	  group	  (p<0.001).	  	  	  	  	  
Although	   expression	   of	   the	   macrophage	   chemokine,	   Ccl2,	   was	   elevated	   2.3-­‐fold	   in	  
response	   to	   intrauterine	   LPS,	   compared	   to	   the	   vehicle	   group,	   this	   difference	  was	   not	  
found	   to	   be	   statistically	   significant	   (p=0.07;	   Figure	   4.5D).	   	   Similarly,	   epi-­‐lipoxin	   pre-­‐
treatment	  had	  no	  significant	  effect	  on	  Ccl2	  expression	  in	  the	  uterus.	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Figure	   4.4	   -­‐	   Effect	   of	   i.p.	   epi-­‐lipoxin	   pre-­‐treatment	   on	   inflammatory	   gene	  
expression	   in	   the	  uterus.	   	   	   	  Uterine	  tissue	  was	  harvested	  6	  hours	  post	  surgery	  from	  
mice	   pre-­‐treated	  with	   vehicle	   (n=3)	   or	   2.5µg	   epi-­‐lipoxin	   (n=4),	   prior	   to	   intrauterine	  
PBS;	  and	  in	  mice	  pre-­‐treated	  with	  vehicle	  (n=5),	  0.25µg	  epi-­‐lipoxin	  (n=5)	  or	  2.5µg	  epi-­‐
lipoxin	   (n=5),	   prior	   to	   intrauterine	   LPS	   administration,	   and	   the	   expression	   of	  
inflammatory	   genes	   was	   assessed	   by	   qRT-­‐PCR.	   (A)	   Tnf-­‐α	   expression.	   (B)	   Il-­‐1β	  
expression.	  (C)	  Il-­‐6	  expression	  (D)	  Il-­‐10	  expression.	  	  (E)	  Cox-­‐2	  expression	  	  (F)	  15-­‐Hpgd	  
expression.	  	  Data	  presented	  as	  mean	  fold	  change	  ±	  SEM	  (error	  bars);	  *p<0.05,	  **p<0.01,	  
***p<0.001,	  compared	  to	  vehicle;	  ##p<0.01,	  ###p<0.001,	  compared	  to	  LPS.	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Figure	   4.5	   -­‐	   Effect	   of	   i.p.	   epi-­‐lipoxin	   treatment	   on	   inflammatory	   chemokine	  
expression	   in	   the	   uterus.	   	   	  Uterine	   tissue	  was	  harvested	  6	  hours	  post	  surgery	   from	  
mice	   pre-­‐treated	  with	   vehicle	   (n=3)	   or	   2.5µg	   epi-­‐lipoxin	   (n=4),	   prior	   to	   intrauterine	  
PBS;	  and	  in	  mice	  pre-­‐treated	  with	  vehicle	  (n=5),	  0.25µg	  epi-­‐lipoxin	  (n=5)	  or	  2.5µg	  epi-­‐
lipoxin	   (n=5),	   prior	   to	   intrauterine	   LPS	   administration,	   and	   the	   expression	   of	  
inflammatory	   genes	   was	   assessed	   by	   qRT-­‐PCR.	   	   (A)	   Cxcl1	   expression.	   (B)	   Cxcl2	  
expression	   (C)	   Cxcl5	   expression.	   (D)	   Ccl2	   expression.	   	   Data	   presented	   as	   mean	   fold	  
fold-­‐change	  ±	  SEM	  (error	  bars);	  ***p<0.001,	  compared	  to	  vehicle.	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4.3.3.2 Inflammatory	  gene	  expression	  in	  the	  fetal	  membranes	  
Expression	  of	  Tnf-­‐α	   in	   the	   fetal	  membranes	  was	   significantly	   elevated	   in	   response	   to	  
intrauterine	   LPS	   administration,	   with	   48-­‐fold	   increased	   expression	   in	   the	   fetal	  
membranes	   of	   mice	   receiving	   intrauterine	   LPS	   compared	  with	   the	   vehicle	   (p<0.001;	  
Figure	   4.6A).	   	   Pre-­‐treatment	  with	   0.25µg	   and	   2.5µg	   epi-­‐lipoxin,	   prior	   to	   intrauterine	  
LPS	  did	  not	  significantly	  affect	  LPS-­‐induced	  Tnf-­‐α	  expression,	  compared	  to	  LPS	  alone,	  
with	  Tnf-­‐α	  expression	  in	  these	  groups	  still	  significantly	  greater	  compared	  to	  the	  vehicle	  
control	   (58.9-­‐fold	   and	   60.4-­‐fold	   increase,	   respectively,	   p<0.001).	   	   Pre-­‐treatment	  with	  
epi-­‐lipoxin	   prior	   to	   intrauterine	   PBS	   administration	   did	   not	   significantly	   affect	  Tnf-­‐α	  
expression	  in	  the	  fetal	  membranes,	  compared	  to	  the	  vehicle	  control	  group.	  	  	  
Intrauterine	   administration	   of	   LPS	   resulted	   in	   significantly	   elevated	   Il-­‐1β	   expression	  
compared	   with	   the	   vehicle	   (29.5-­‐fold	   increase;	   p<0.001;	   Figure	   4.6B).	   	   	   Again	   pre-­‐
treatment	  with	  epi-­‐lipoxin	  prior	  to	  intrauterine	  LPS	  administration	  did	  not	  significantly	  
alter	   expression	   of	   Il-­‐1β,	   compared	   to	   LPS	   alone,	   with	   mice	   in	   the	   epi-­‐lipoxin+LPS	  
groups	   still	   having	   significantly	   greater	   Il-­‐1β	   expression,	   compared	   to	   the	   vehicle	  
control	   group	   (0.25µg	   epi-­‐lipoxin+LPS	  29.5-­‐fold	   greater	   expression;	   50.9-­‐fold	   greater	  
expression;	  p<0.001).	  
Compared	  to	  vehicle,	  LPS	  alone	  did	  not	  significantly	   increase	   Il-­‐6	  expression	  (9.9-­‐fold	  
increase,	  p=0.08;	  Figure	  4.6C).	  	  Pre-­‐treatment	  with	  epi-­‐lipoxin	  at	  both	  0.25µg	  and	  2.5µg	  
epi-­‐lipoxin	   prior	   to	   intrauterine	   LPS	   significantly	   increased	   expression	   of	   Il-­‐6	   in	   the	  
fetal	   membranes	   compared	   to	   the	   vehicle	   control	   group	   (16.9-­‐fold	   and	   33.2-­‐fold	  
greater	   expression	   respectively,	   p<0.01);	   however	   these	   increases	   were	   not	  
significantly	  greater	  when	  compared	  to	  LPS	  alone.	  	  
Il-­‐10	   expression	   was	   significantly	   elevated	   in	   response	   to	   intrauterine	   LPS	  
administration	  compared	  with	  vehicle	  (15.8-­‐fold	  increase;	  p<0.001;	  Figure	  4.6D).	  	  Mice	  
pre-­‐treated	  with	  epi-­‐lipoxin	  at	  both	  0.25µg	  and	  2.5µg	  epi-­‐lipoxin	  prior	  to	  intrauterine	  
LPS	   also	   had	   significantly	   elevated	   Il-­‐10	   expression	   compared	   to	   the	   vehicle	   control	  
group	  (9-­‐fold	  (p<0.01)	  and	  24.2-­‐fold	  (p<0.001)	  greater	  expression,	  respectively);	  	  these	  
differences	   were	   not	   statistically	   significant	   compared	   to	   LPS	   alone.	   	   Pre-­‐treatment	  
with	  epi-­‐lipoxin	  prior	  to	  intrauterine	  PBS	  administration	  did	  not	  significantly	  alter	  Il-­‐10	  
expression,	  compared	  to	  vehicle.	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Intrauterine	   LPS	   treatment	   alone,	   did	   not	   significantly	   alter	   Cox-­‐2	   expression	   in	   the	  
fetal	  membranes;	  however	  mice	  pre-­‐treated	  with	  epi-­‐lipoxin	  prior	  to	  intrauterine	  LPS	  
administration	  had	  increased	  Cox-­‐2	  expression	  compared	  to	  both	  vehicle	  and	  LPS	  alone.	  	  
In	   response	   to	   2.5µg	   epi-­‐lipoxin+LPS,	   Cox-­‐2	   expression	   in	   the	   fetal	   membranes	   was	  
significantly	  greater,	  compared	  to	  the	  vehicle	  control	  group	  (14.3-­‐fold	  increase,	  p<0.05;	  
Figure	  4.6E),	  and	  4.4-­‐fold	  higher	  expression	  was	  observed,	  compared	  to	  LPS	  alone,	  but	  
this	  increase	  did	  not	  reach	  statistical	  significance	  (p=0.07).	  	  	  	  
Intrauterine	   administration	   of	   LPS	   reduced	   the	   expression	   of	   15-­‐Hpgd,	   compared	   to	  
vehicle	   (2.2-­‐fold	  decrease;	  p<0.01;	  Figure	  4.6F).	   	  Similarly,	  mice	  pre-­‐treated	  with	  epi-­‐
lipoxin	  prior	  to	  intrauterine	  LPS	  administration	  had	  significantly	  reduced	  expression	  of	  
15-­‐Hpgd	   compared	   to	   vehicle	   control	   (0.25µg	   epi-­‐lipoxin+LPS:	   2.5-­‐fold	   decrease,	  
p<0.01;	   2.5µg	   epi-­‐lipoxin+LPS:	   3-­‐fold	   decrease,	   p<0.001).	   	   Pre-­‐treatment	   with	   epi-­‐
lipoxin	   prior	   to	   intrauterine	   PBS	   did	   not	   alter	   15-­‐Hpgd	   expression	   in	   the	   fetal	  
membranes.	  	  	  	  
Compared	  to	  the	  vehicle	  control	  group,	  LPS	  treatment	  alone	  induced	  a	  9.2-­‐fold	  increase	  
in	  Cxcl1	  expression,	  however	  this	  was	  not	  statistically	  significant	  (p=0.08;	  Figure	  4.7A).	  	  
Pre-­‐treatment	  with	  0.25µg	  and	  2.5µg	  epi-­‐lipoxin,	  prior	  to	  intrauterine	  LPS,	  resulted	  in	  
significantly	  greater	  Cxcl1	  expression,	  compared	  to	  the	  vehicle	  control	  group	  (15.9-­‐fold,	  
p<0.01	  and	  18-­‐fold,	  p<0.001,	  greater	  expression,	  respectively);	  however	  there	  were	  no	  
significant	   differences	   when	   comparing	   pre-­‐treatment	   with	   epi-­‐lipoxin	   to	   LPS	   alone.	  
Cxcl2	   expression	   in	   the	   fetal	   membranes	   was	   significantly	   elevated	   in	   all	   groups	  
receiving	  intrauterine	  LPS,	  with	  and	  without	  pre-­‐treatment	  with	  epi-­‐lipoxin,	  compared	  
to	  the	  vehicle	  group	  (LPS:	  13.7-­‐fold	  increase,	  p<0.05;	  0.25µg	  epi-­‐lipoxin+LPS:	  20.7-­‐fold	  
increase,	   p<0.01;	   and	  2.5µg	   epi-­‐lipoxin+LPS:	   23.7-­‐fold	   increase,	   p<0.01;	   Figure	  4.7B).	  	  
Again	   pre-­‐treatment	   with	   epi-­‐lipoxin	   prior	   to	   intrauterine	   LPS	   did	   not	   significantly	  
alter	   Cxcl2	   expression,	   compared	   to	   LPS	   alone.	   	   Similarly,	   all	   groups	   receiving	  
intrauterine	  LPS	  had	  significantly	  greater	  Cxcl5	  expression,	  compared	  to	  vehicle	  (LPS:	  
87.5-­‐fold	  increase;	  0.25µg	  epi-­‐lipoxin+LPS:	  285.9-­‐fold	  increase;	  2.5µg	  epi-­‐lipoxin+LPS:	  	  
154.8-­‐fold	  increase;	  p<0.001;	  Figure	  4.7C).	  	  	  Again,	  pre-­‐treatment	  with	  epi-­‐lipoxin	  prior	  
to	  intrauterine	  LPS	  did	  not	  significantly	  alter	  Cxcl5	  expression,	  compared	  to	  LPS	  alone.	  	  	  
As	  with	   the	   other	   chemokines,	  Ccl2	   expression	  was	   significantly	   elevated	   in	   the	   fetal	  
membranes	   of	   all	   groups	   of	   mice	   receiving	   intrauterine	   LPS,	   compared	   the	   vehicle	  
group	   (LPS:	   11-­‐fold	   increase,	   p<0.05;	   0.25µg	   epi-­‐lipoxin+LPS:	   15.2-­‐fold	   increase,	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p<0.01;	   2.5µg	   epi-­‐lipoxin+LPS:	   15-­‐fold	   increase;	   p<0.01;	   Figure	   4.7D).	   Pre-­‐treatment	  
with	  epi-­‐lipoxin,	  at	  either	  dose,	  did	  not	  significantly	  alter	  Ccl2	  expression	  compared	  to	  
LPS	  alone.	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Figure	   4.6	   -­‐	   Effect	   of	   i.p.	   epi-­‐lipoxin	   pre-­‐treatment	   on	   inflammatory	   gene	  
expression	  in	  the	  fetal	  membranes.	  	  	  	  Fetal	  membranes	  were	  harvested	  6	  hours	  post	  
surgery	   from	  mice	  pre-­‐treated	  with	  vehicle	   (n=3)	  or	  2.5µg	  epi-­‐lipoxin	   (n=4),	  prior	   to	  
intrauterine	  PBS;	  and	  in	  mice	  pre-­‐treated	  with	  vehicle	  (n=5),	  0.25µg	  epi-­‐lipoxin	  (n=5)	  
or	  2.5µg	  epi-­‐lipoxin	  (n=5),	  prior	  to	  intrauterine	  LPS	  administration,	  and	  the	  expression	  
of	   inflammatory	   genes	   was	   assessed	   by	   qRT-­‐PCR.	   (A)	   Tnf-­‐α	   expression.	   (B)	   Il-­‐1β	  
expression.	  (C)	  Il-­‐6	  expression	  (D)	  Il-­‐10	  expression.	  	  (E)	  Cox-­‐2	  expression	  	  (F)	  15-­‐Hpgd	  
expression.	  	  Data	  presented	  as	  mean	  fold	  change	  ±	  SEM	  (error	  bars);	  *p<0.05,	  **p<0.01,	  
***p<0.001,	  compared	  to	  vehicle.	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Figure	   4.7	   -­‐	   Effect	   of	   i.p.	   epi-­‐lipoxin	   treatment	   on	   inflammatory	   chemokine	  
expression	  in	  the	  fetal	  membranes.	   	   	  Fetal	  membranes	  were	  harvested	  6	  hours	  post	  
surgery	   from	  mice	  pre-­‐treated	  with	  vehicle	   (n=3)	  or	  2.5µg	  epi-­‐lipoxin	   (n=4),	  prior	   to	  
intrauterine	  PBS;	  and	  in	  mice	  pre-­‐treated	  with	  vehicle	  (n=5),	  0.25µg	  epi-­‐lipoxin	  (n=5)	  
or	  2.5µg	  epi-­‐lipoxin	  (n=5),	  prior	  to	  intrauterine	  LPS	  administration,	  and	  the	  expression	  
of	   inflammatory	   genes	   was	   assessed	   by	   qRT-­‐PCR.	   	   (A)	   Cxcl1	   expression.	   (B)	   Cxcl2	  
expression	  (C)	  Cxcl5	  expression.	  (D)	  Ccl2	  expression.	  Data	  presented	  as	  mean	  fold	  fold-­‐
change	  ±	  SEM	  (error	  bars);	  *p<0.05,	  **p<0.01,	  ***p<0.001,	  compared	  to	  vehicle.	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4.3.3.3 Inflammatory	  gene	  expression	  in	  the	  placenta	  
As	  was	   observed	   in	   the	   uterus	   and	   fetal	  membranes,	   placental	  Tnf-­‐α	   expression	  was	  
significantly	  up-­‐regulated	  in	  mice	  receiving	  intrauterine	  LPS	  compared	  with	  the	  vehicle	  
group	   (7.4-­‐fold	   increase;	  p<0.001;	  Figure	  4.8A).	   	   Similarly,	  mice	  pre-­‐treated	  with	  epi-­‐
lipoxin,	   at	   both	   0.25µg	   and	   2.5µg,	   prior	   to	   intrauterine	   LPS,	   had	   significantly	   greater	  
Tnf-­‐α	  expression,	  compared	  to	  the	  vehicle	  control	  group	  (7.4-­‐fold	  and	  8.9-­‐fold	  greater	  
expression,	  respectively,	  p<0.001).	  	  
Expression	   of	   Il-­‐1β	   in	   the	   placenta	   was	   also	   significantly	   elevated	   in	   the	   LPS	   group	  
compared	   to	   the	  vehicle	  control	  group,	  with	  an	  8.4-­‐fold	   increase	  compared	   to	  vehicle	  
(p<0.001;	  Figure	  4.8B).	  	  Again,	  pre-­‐treatment	  with	  epi-­‐lipoxin	  prior	  to	  intrauterine	  LPS	  
administration	  did	  not	   significantly	   attenuate	  LPS-­‐induced	   Il-­‐1β	  expression,	   and	  mice	  
in	  these	  groups	  still	  had	  significantly	  elevated	  expression,	  compared	  to	  vehicle	  (0.25µg	  
epi-­‐lipoxin+LPS:	  8.6-­‐fold	  increase;	  2.5µg	  epi-­‐lipoxin+LPS:	  15.5-­‐fold	  increase;	  p<0.001).	  	  	  
Il-­‐6	   expression	   was	   significantly	   increased	   in	   response	   to	   intrauterine	   LPS	  
administration	  compared	  to	  vehicle	  (7.7-­‐fold	  increase,	  p<0.001;	  Figure	  4.8C).	  	  Mice	  pre-­‐
treated	   with	   0.25µg	   and	   2.5µg	   epi-­‐lipoxin	   prior	   to	   intrauterine	   LPS,	   also	   had	  
significantly	  greater	  expression	  of	  Il-­‐6	  compared	  to	  the	  vehicle	  control	  group	  (8.9-­‐fold	  
and	  20.2-­‐fold	  increase,	  respectively;	  p<0.001).	  	  	  
Similarly,	  placental	  Il-­‐10	  expression	  was	  elevated	  in	  the	  LPS	  group	  compared	  with	  the	  
vehicle	  group	  (4.5-­‐fold	  increase;	  p<0.05;	  Figure	  4.8D);	  and	  expression	  of	  Il-­‐10	  was	  also	  
significantly	   greater	   in	   mice	   pre-­‐treated	   with	   epi-­‐lipoxin,	   prior	   to	   intrauterine	   LPS,	  
compared	   to	   vehicle	   (0.25µg	   epi-­‐lipoxin+LPS:	   4.2-­‐fold	   increase,	   p<0.05;	   2.5µg	   epi-­‐
lipoxin+LPS:	  5.9-­‐fold	  increase;	  p<0.01).	  	  
The	  expression	  of	  Cox-­‐2	  was	   increased	   in	   the	  placenta	  of	  mice	  pre-­‐treated	  with	  2.5µg	  
epi-­‐lipoxin	   prior	   to	   intrauterine	   PBS,	   compared	   to	   vehicle,	   however	   this	   was	   not	  
statistically	  significant	  (2.3-­‐fold	  greater,	  p=0.17;	  Figure	  4.8E).	  	  LPS	  treatment	  alone	  did	  
not	   significantly	   affect	   Cox-­‐2	   expression,	   but	   pre-­‐treatment	   with	   epi-­‐lipoxin	   at	   both	  
0.25µg	  and	  2.5µg	  prior	  to	  intrauterine	  LPS	  administration	  significantly	  increased	  Cox-­‐2	  
expression,	  compared	  to	  the	  vehicle	  control	  group	  (5.4-­‐fold	  increase,	  p<0.01;	  and	  6.9-­‐
fold	   increase,	   p<0.001,	   respectively).	   	   Additionally,	   pre-­‐treatment	  with	   epi-­‐lipoxin,	   at	  
both	   doses,	   prior	   to	   intrauterine	   LPS	   also	   significantly	   increased	   LPS-­‐induced	   Cox-­‐2	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expression,	   compared	   to	   LPS	   alone	   (0.25µg	   epi-­‐lipoxin+LPS:	   5.2-­‐fold	   increase;	   and	  
2.5µg	  epi-­‐lipoxin+LPS:	  6.7-­‐fold	  increase;	  p<0.001).	  	  
Conversely,	   pre-­‐treatment	   with	   2.5µg	   epi-­‐lipoxin	   prior	   to	   intrauterine	   PBS	  
administration	  resulted	  in	  significantly	  reduced	  expression	  of	  15-­‐Hpgd	  in	  the	  placenta,	  
compared	  to	  vehicle	  (3.2-­‐fold	  decrease;	  p<0.001;	  Figure	  4.8F).	  	  LPS	  treatment	  alone	  did	  
not	   significantly	   affect	   placental	   15-­‐Hpgd	  expression,	   however	  mice	   pre-­‐treated	  with	  
0.25µg	   epi-­‐lipoxin	   prior	   to	   intrauterine	   LPS	   had	   significantly	   reduced	   15-­‐Hpgd	  
expression,	  compared	  to	  the	  vehicle	  control	  group	  (2.3-­‐fold	  decrease,	  p<0.01).	  	  
Placental	   expression	   of	   the	   neutrophil	   chemokines	   Cxcl1,	   Cxcl2	   and	   Cxcl5	   was	  
significantly	  elevated	  in	  response	  to	  intrauterine	  LPS	  administration.	  	  Cxcl1	  expression	  
was	   significantly	   higher	   in	   the	   LPS	   treatment	   group	   compared	   to	   vehicle	   (4.2-­‐fold	  
increase,	   p<0.001;	   Figure	   4.9A);	   and	   pre-­‐treatment	   with	   epi-­‐lipoxin	   prior	   to	  
intrauterine	  LPS	  injection	  did	  not	  attenuate	  LPS-­‐induced	  Cxcl1	  expression,	  with	  mice	  in	  
these	  groups	  still	  having	  significantly	  elevated	  Cxcl1expression	  compared	  to	  the	  vehicle	  
control	   group	   (p<0.001).	   	   Placental	   expression	   of	   Cxcl2	   was	   similarly	   elevated	   in	  
response	   to	   intrauterine	   LPS	   administration	   compared	   with	   the	   vehicle	   (14-­‐fold,	  
p<0.001;	  Figure	  4.9B);	  and	  again	  mice	  receiving	  pre-­‐treatment	  with	  epi-­‐lipoxin	  prior	  to	  
intrauterine	  LPS	  still	  had	  significantly	  elevated	  Cxcl2	  expression,	   compared	   to	  vehicle	  
(p<0.001).	  	  Cxcl5	  expression	  was	  also	  significantly	  elevated	  in	  response	  to	  intrauterine	  
LPS	   administration	   compared	   to	   the	   vehicle	   group	   (24-­‐fold,	   p<0.001;	   Figure	   4.9C);	  
however	   pre-­‐treatment	  with	   epi-­‐lipoxin	   prior	   to	   intrauterine	   LPS	   administration	   did	  
not	   affect	   LPS-­‐induced	  Cxcl5	   expression	   in	   the	   placenta,	   compared	   to	   treatment	  with	  
LPS	  alone,	  with	  mice	  in	  these	  groups	  still	  having	  significantly	  elevated	  Cxcl5	  expression,	  
compared	  to	  the	  vehicle	  control	  group	  (p<0.001).	  	  	  
Similarly,	   the	  macrophage	   chemokine,	   Ccl2,	   was	   found	   to	   have	   significantly	   elevated	  
expression	   in	   response	   to	   intrauterine	   LPS	   administration,	   compared	   to	   vehicle	   (6.7-­‐
fold,	   p<0.001;	   Figure	   4.9D).	   	   As	   observed	   with	   the	   other	   chemokines,	   pre-­‐treatment	  
with	  epi-­‐lipoxin	  did	  not	  significantly	  attenuate	  LPS-­‐induced	  Ccl2	  expression,	  and	  these	  
mice	   were	   found	   to	   still	   have	   significantly	   greater	   Ccl2	   expression	   compared	   to	   the	  
vehicle	  control	  group	  (p<0.001).	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Figure	   4.8	   -­‐	   Effect	   of	   i.p.	   epi-­‐lipoxin	   pre-­‐treatment	   on	   inflammatory	   gene	  
expression	   in	   the	   placenta.	   	   	   	   Placental	   tissue	  was	  harvested	  6	  hours	  post	   surgery	  
from	   mice	   pre-­‐treated	   with	   vehicle	   (n=3)	   or	   2.5µg	   epi-­‐lipoxin	   (n=4),	   prior	   to	  
intrauterine	  PBS;	  and	  in	  mice	  pre-­‐treated	  with	  vehicle	  (n=5),	  0.25µg	  epi-­‐lipoxin	  (n=5)	  
or	  2.5µg	  epi-­‐lipoxin	  (n=5),	  prior	  to	  intrauterine	  LPS	  administration,	  and	  the	  expression	  
of	   inflammatory	   genes	   was	   assessed	   by	   qRT-­‐PCR.	   (A)	   Tnf-­‐α	   expression.	   (B)	   Il-­‐1β	  
expression.	  (C)	  Il-­‐6	  expression	  (D)	  Il-­‐10	  expression.	  	  (E)	  Cox-­‐2	  expression	  	  (F)	  15-­‐Hpgd	  
expression.	  	  Data	  presented	  as	  mean	  fold	  change	  ±	  SEM	  (error	  bars);	  *p<0.05,	  **p<0.01,	  
***p<0.001,	  compared	  to	  vehicle;	  ###p<0.001,	  compared	  to	  LPS.	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Figure	   4.9	   -­‐	   Effect	   of	   i.p.	   epi-­‐lipoxin	   treatment	   on	   inflammatory	   chemokine	  
expression	   in	   the	   placenta.	   	   	   Placental	   tissue	  was	   harvested	   6	   hours	   post	   surgery	  
from	   mice	   pre-­‐treated	   with	   vehicle	   (n=3)	   or	   2.5µg	   epi-­‐lipoxin	   (n=4),	   prior	   to	  
intrauterine	  PBS;	  and	  in	  mice	  pre-­‐treated	  with	  vehicle	  (n=5),	  0.25µg	  epi-­‐lipoxin	  (n=5)	  
or	  2.5µg	  epi-­‐lipoxin	  (n=5),	  prior	  to	  intrauterine	  LPS	  administration,	  and	  the	  expression	  
of	   inflammatory	   genes	   was	   assessed	   by	   qRT-­‐PCR.	   (A)	   Cxcl1	   expression.	   (B)	   Cxcl2	  
expression	   (C)	   Cxcl5	   expression.	   (D)	   Ccl2	   expression.	   	   Data	   presented	   as	   mean	   fold	  
fold-­‐change	  ±	  SEM	  (error	  bars);	  *p<0.05,	  **p<0.01,	  ***p<0.001.	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4.3.4 Effect	  of	  pre-­‐treatment	  with	  epi-­‐lipoxin	  on	  amniotic	  fluid	  cytokine	  levels	  	  
As	  described	  in	  chapter	  3,	   intrauterine	  LPS	  administration	  also	   induced	  inflammatory	  
cytokine	   production	   in	   the	   amniotic	   fluid,	   therefore,	   to	   investigate	   whether	   pre-­‐
treatment	   with	   epi-­‐lipoxin	   was	   able	   to	   alter	   amniotic	   fluid	   cytokine	   levels,	   amniotic	  
fluid	  was	  collected	  6	  hours	  post-­‐surgery	  and	  the	  concentration	  of	  TNF-­‐α	  and	  IL-­‐10	  was	  
measured	  by	  ELISA.	  	  Where	  the	  concentration	  of	  cytokines	  was	  too	  low	  to	  be	  detected	  
by	   the	  ELISAs,	   the	  value	  of	   the	   limit	  of	  detection	  of	   the	  specific	  ELISA	  was	  entered	   to	  
give	   a	   value	   for	   analysis	   and	   the	   data	   was	   analysed	   by	   non-­‐parametric	   ANOVA	  
(Kruskal-­‐Wallis).	  	  	  
TNF-­‐α	   was	   undetectable	   in	   the	   vehicle	   and	   2.5µg	   epi-­‐lipoxin	   groups,	  which	   received	  
intrauterine	  PBS;	  and	  also	  in	  one	  LPS	  sample.	  	  The	  concentration	  of	  TNF-­‐α	  was	  elevated	  
in	  mice	  receiving	  intrauterine	  LPS	  (97.63	  pg/ml	  ±	  SEM	  61.26),	  however	  this	  difference	  
was	   not	   significantly	   greater	   compared	   to	   mice	   receiving	   intrauterine	   PBS.	   	   Pre-­‐
treatment	  with	  epi-­‐lipoxin	  prior	  to	  intrauterine	  LPS	  administration	  did	  not	  significantly	  
affect	  LPS-­‐induced	  TNF-­‐α	  production,	  although	  levels	  were	  higher	  in	  mice	  pre-­‐treated	  
with	  epi-­‐lipoxin,	  compared	  to	  LPS	  alone	  (0.25µg	  epi-­‐lipoxin+LPS	  mean	  194.8	  pg/ml	  ±	  
SEM	  32.76;	  2.5µg	  epi-­‐lipoxin	  mean	  299.3	  pg/ml	  ±	  SEM	  100.8;	  Figure	  4.10A).	  	  	  
IL-­‐10	  was	  also	  undetectable	  in	  the	  vehicle	  and	  2.5µg	  epi-­‐lipoxin	  groups,	  which	  received	  
intrauterine	   PBS;	   and	   also	   in	   two	   LPS	   samples.	   	   LPS	   treatment	   did	   not	   significantly	  
increase	  amniotic	   fluid	  IL-­‐10	   levels	  (mean	  20.18	  pg/ml	  ±	  SEM	  4.97),	  compared	  to	  the	  
vehicle	   and	   2.5µg	   epi-­‐lipoxin	   groups.	   	   Pre-­‐treatment	   with	   epi-­‐lipoxin	   again	   did	   not	  
significantly	  affect	  LPS-­‐induced	  IL-­‐10	  production	  compared	  to	  LPS	  alone,	  although	  the	  
mean	  concentrations	  were	  slightly	  higher	  (mean	  0.25µg	  epi-­‐lipoxin+LPS	  36.21	  pg/ml	  ±	  
8.62;	  mean	  2.5µg	  epi-­‐lipoxin+LPS	  34.63	  pg/ml	  ±	  SEM	  5.81;	  Figure	  4.10B).	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Figure	  4.10	   -­‐	  Effect	  of	  pre-­‐treatment	  with	  epi-­‐lipoxin	  on	   inflammatory	  cytokine	  
production	  in	  the	  amniotic	  fluid.	  	   	  Amniotic	  fluid	  was	  collected	  6	  hours	  post-­‐surgery	  
from	   mice	   pre-­‐treated	   with	   vehicle	   (n=3)	   or	   2.5µg	   epi-­‐lipoxin	   (n=4),	   prior	   to	  
intrauterine	  PBS;	  and	  in	  mice	  pre-­‐treated	  with	  vehicle	  (n=5),	  0.25µg	  epi-­‐lipoxin	  (n=5)	  
or	  2.5µg	  epi-­‐lipoxin	   (n=5),	  prior	   to	   intrauterine	  LPS	  administration,	  and	  ELISAs	  were	  
used	   to	   quantify	   the	   concentration	   of	   TNF-­‐α	   and	   IL-­‐10	   in	   the	   amniotic	   fluid.	   	   (A)	  
Amniotic	   fluid	   TNF-­‐α	   concentration.	   	   (B)	   Amniotic	   fluid	   IL-­‐10	   concentration.	   	   Data	  
presented	  as	  mean	  ±	  SEM	  (error	  bars).	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4.3.5 Expression	   of	   inflammatory	   mediators	   in	   the	   utero-­‐placental	   tissues	   following	  
intrauterine	  administration	  of	  epi-­‐lipoxin	  
Several	   studies	   have	   demonstrated	   that	   lipoxin	   administration	   locally,	   at	   the	   site	   of	  
inflammation,	  can	  also	  have	  strong	  anti-­‐inflammatory	  actions	  (Menezes-­‐de-­‐Lima	  et	  al.	  
2006,	  Conte	  et	  al.	  2010).	  	  Therefore,	  given	  that	  intra-­‐peritoneal	  pre-­‐treatment	  with	  epi-­‐
lipoxin	   largely	   did	   not	   affect	   inflammatory	   gene	   expression	   in	   the	   utero-­‐placental	  
tissues,	  we	  administered	  epi-­‐lipoxin	  directly	  into	  the	  uterus	  at	  the	  same	  time	  as	  either	  
intrauterine	   LPS	   or	   PBS	   administration.	   	   As	   described	   before,	   utero-­‐placental	   tissues	  
were	   collected	   6	   hours	   post-­‐surgery	   and	   examined	   for	   the	   expression	   of	   the	   same	  
inflammatory	   genes	   using	   qRT-­‐PCR.	   	   In	   this	   series	   of	   experiments	   epi-­‐lipoxin	   was	  
administered	  at	  lower	  doses	  compared	  to	  the	  i.p.	  epi-­‐lipoxin	  6	  hour	  experiments,	  with	  
doses	   of	   25ng	   and	   250ng	   as	   the	   low	   and	   high	   doses.	   The	   doses	   of	   epi-­‐lipoxin	   were	  
reduced	   because	   previous	   studies	   using	   local	   administration	   gave	   lower	   doses,	  
compared	  to	  those	  given	  systemically.	  
	  
4.3.5.1 Inflammatory	  gene	  expression	  in	  the	  uterus	  
As	   before,	   expression	   of	  Tnf-­‐α	   was	   significantly	   elevated	   in	   response	   to	   intrauterine	  
LPS	   administration,	   with	   4.7-­‐fold	   higher	   expression	   compared	   to	   the	   vehicle	   group	  
(p<0.001;	  Figure	  4.11A).	  	  Co-­‐treatment	  of	  epi-­‐lipoxin	  and	  LPS	  did	  not	  significantly	  alter	  
LPS-­‐induced	  Tnf-­‐α	  expression	  in	  the	  uterus,	  compared	  to	  LPS	  alone,	  with	  expression	  of	  
Tnf-­‐α	   still	   significantly	   increased	   compared	   to	   the	   vehicle	   control	   group	   (25ng	   epi-­‐
lipoxin+LPS:	  7.3-­‐fold	  increase;	  250ng	  epi-­‐lipoxin+LPS	  4.9-­‐fold	  increase;	  p<0.001).	  	  	  
Similarly,	   Il-­‐1β	   expression	   was	   also	   significantly	   greater	   in	   mice	   treated	   with	  
intrauterine	   LPS,	   compared	  with	   the	   vehicle	   group	   (2.9-­‐fold	   increase;	   p<0.05;	   Figure	  
4.11B).	   	   Compared	   to	   LPS	   alone,	   co-­‐treatment	   with	   epi-­‐lipoxin	   did	   not	   significantly	  
affect	   LPS-­‐induced	   Il-­‐1β	   expression	   in	   the	   uterus;	   mice	   in	   the	   epi-­‐lipoxin+LPS	   co-­‐
treatment	   groups	   still	   had	   significantly	   greater	   Il-­‐1β	   expression,	   compared	   to	   the	  
vehicle	   control	   group	   (25ng	   epi-­‐lipoxin+LPS:	   4.7-­‐fold	   increase,	   p<0.01;	   250ng	   epi-­‐
lipoxin+LPS:	  3.3-­‐fold	  increase,	  p<0.005).	  	  	  
Uterine	   Il-­‐6	   expression	  was	  also	   significantly	  elevated	   in	   the	  presence	  of	   intrauterine	  
LPS,	   compared	   to	   vehicle	   (p<0.05;	   6.5-­‐fold	   increase;	   Figure	   4.11C).	   	   Again,	   co-­‐
administration	   of	   epi-­‐lipoxin	   and	   LPS	   did	   not	   affect	   Il-­‐6	   expression	   compared	   to	   LPS	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alone;	  and	  mice	   treated	  with	  25ng	  or	  250ng	  epi-­‐lipoxin	  prior	   to	   intrauterine	  LPS	  still	  
had	   significantly	   elevated	   Il-­‐6	   expression,	   compared	   to	   the	   vehicle	   control	   (10-­‐fold	  
increase,	  p<0.05;	  and	  5.5-­‐fold	  greater	  expression,	  p<0.01,	  respectively).	  	  	  	  
In	  this	  cohort	  of	  mice,	  expression	  of	  Il-­‐10	   in	  the	  uterus	  was	  not	  significantly	  increased	  
in	  response	  to	  intrauterine	  LPS	  administration,	  compared	  to	  the	  vehicle	  control	  group	  	  
(Figure	   4.11D).	   	   Similarly,	   compared	   to	   LPS	   treatment	   alone,	   co-­‐treatment	   with	   epi-­‐
lipoxin	  had	  no	  significant	  effect	  on	  uterine	  Il-­‐10	  expression.	  	  
Expression	   of	   Cox-­‐2	   was	   significantly	   elevated	   in	   response	   to	   intrauterine	   LPS	  
administration,	   compared	   with	   the	   vehicle	   control	   group,	   with	   5.9-­‐fold	   higher	  
expression	   in	   LPS-­‐treated	   mice	   (p<0.05;	   Figure	   4.11E).	   	   Mice	   that	   received	   co-­‐
treatment	   of	   epi-­‐lipoxin	   and	   LPS	   also	   had	   significantly	   greater	   expression	   of	   Cox-­‐2,	  
compared	   to	   the	   vehicle	   control	   group	   (25ng	   epi-­‐lipoxin+LPS:	   18.2-­‐fold	   increase;	  
250ng	   epi-­‐lipoxin+LPS:	   14.5-­‐fold	   increase;	   p<0.001).	   	   Additionally,	   co-­‐treatment	  with	  
either	  25ng	  or	  250ng	  epi-­‐lipoxin	  at	   the	  same	   time	  as	   intrauterine	  LPS	  administration	  
appeared	  to	  increase	  uterine	  Cox-­‐2	  expression,	  compared	  to	  LPS	  alone	  (3-­‐fold	  and	  2.5-­‐
fold	  increase,	  respectively);	  however	  these	  differences	  were	  not	  statistically	  significant.	  	  	  
Intrauterine	   administration	   of	   LPS	   alone	   did	   not	   significantly	   affect	   uterine	   15-­‐Hpgd	  
expression.	   However,	   co-­‐treatment	   with	   epi-­‐lipoxin	   at	   either	   25ng	   or	   250ng,	   at	   the	  
same	  time	  as	  LPS	  significantly	  reduced	  15-­‐Hpgd	  expression,	  inducing	  a	  2.3-­‐fold	  and	  2.5-­‐
fold	  decrease,	  compared	  to	  the	  vehicle	  control	  group	  (p<0.05;	  Figure	  4.11F).	  	  
As	  observed	  previously,	   intrauterine	  administration	  of	  LPS	  significantly	   increased	  the	  
expression	   of	   the	   three	   neutrophil	   chemokines,	   Cxcl1,	   Cxcl2,	   and	   Cxcl5.	   	   Cxcl1	  
expression	  was	  17.7-­‐fold	  higher	  in	  LPS-­‐treated	  mice,	  compared	  with	  the	  vehicle	  control	  
group	  (p<0.001;	  Figure	  4.12A).	  	  The	  LPS-­‐induced	  expression	  of	  Cxcl1	  was	  unaffected	  by	  
co-­‐treatment	  with	   epi-­‐lipoxin,	  with	  mice	   co-­‐treated	  with	   25ng	   and	   250ng	   epi-­‐lipoxin	  
still	   found	   to	   have	   significantly	   elevated	   Cxcl1	   expression,	   compared	   to	   the	   vehicle	  
control	  group	  (p<0.001).	  	  Similarly	  expression	  of	  Cxcl2	  was	  significantly	  elevated	  in	  the	  
LPS	  group	  compared	  with	  the	  vehicle	  group	  (15.5-­‐fold	  increase,	  p<0.01;	  Figure	  4.12B);	  
and	  co-­‐treatment	  of	  25ng	  or	  250ng	  plus	  LPS	  was	  not	   found	   to	   significantly	  attenuate	  
LPS-­‐induced	   Cxcl2	   expression,	   with	   Cxcl2	   expression	   still	   found	   to	   be	   significantly	  
greater	   in	   the	   25ng	   epi-­‐lipoxin+LPS	   (p<0.01)	   and	   250ng	   epi-­‐lipoxin+LPS	   (p<0.001)	  
groups,	   compared	   to	   the	   vehicle	   control.	   	   Cxcl5	   expression	   was	   also	   significantly	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increased	   in	   the	  LPS	  group	  compared	  with	  vehicle	  (12.2-­‐fold	   increase;	  p<0.01;	  Figure	  
4.12C);	   and	   was	   still	   significantly	   elevated	   in	   the	   groups	   co-­‐treated	   with	   25ng	   epi-­‐
lipoxin+LPS	   (p<0.05),	   and	   250ng	   epi-­‐lipoxin+LPS	   (p<0.01),	   compared	   to	   the	   vehicle	  
group.	  .	  	  
In	   this	   cohort	   of	   mice,	   although	   intrauterine	   LPS	   induced	   a	   2.4-­‐fold	   increase	   in	   Ccl2	  
expression,	   this	  was	  not	  statistically	  significant	   (p=0.17;	  Figure	  4.12D).	   	  Co-­‐treatment	  
with	  epi-­‐lipoxin,	  either	  before	   intrauterine	  PBS	  or	  LPS,	  was	  not	   found	   to	  significantly	  
alter	  uterine	  Ccl2	  	  expression.	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Figure	   4.11	   -­‐	   Effect	   of	   co-­‐treatment	   with	   epi-­‐lipoxin	   on	   inflammatory	   gene	  
expression	   in	   the	   uterus.	   	   	  Uterine	   tissue	  was	  harvested	  6	  hours	  post	  surgery	   from	  
mice	   co-­‐treated	   with	   vehicle	   (n=4)	   or	   250ng	   epi-­‐lipoxin	   (n=4),	   at	   the	   same	   time	   as	  
intrauterine	  PBS;	  and	  in	  mice	  co-­‐treated	  with	  vehicle	  (n=5),	  25ng	  epi-­‐lipoxin	  (n=6)	  or	  
250ng	  epi-­‐lipoxin	  (n=6),	  at	   the	  same	  time	  as	   intrauterine	  LPS	  administration,	  and	  the	  
expression	  of	  inflammatory	  genes	  was	  assessed	  by	  qRT-­‐PCR.	  	  (A)	  Tnf-­‐α	  expression.	  (B)	  
Il-­‐1β	  expression.	  (C)	  Il-­‐6	  expression	  (D)	  Il-­‐10	  expression.	  	  (E)	  Cox-­‐2	  expression	  	  (F)	  15-­‐
Hpgd	   expression.	   Data	   presented	   as	   mean	   fold	   change	   ±	   SEM	   (error	   bars);	   *p<0.05,	  
**p<0.01,	  ***p<0.001,	  compared	  to	  vehicle.	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Figure	  4.12	  -­‐	  Effect	  of	  co-­‐treatment	  with	  epi-­‐lipoxin	  on	  chemokine	  expression	  in	  
the	  uterus.	   	   	  Uterine	  tissue	  was	  harvested	  6	  hours	  post	  surgery	  from	  mice	  co-­‐treated	  
with	   vehicle	   (n=4)	   or	   250ng	   epi-­‐lipoxin	   (n=4),	   at	   the	   same	   time	   as	   intrauterine	   PBS;	  
and	  in	  mice	  pre-­‐treated	  with	  vehicle	  (n=5),	  25ng	  epi-­‐lipoxin	  (n=6)	  or	  250ng	  epi-­‐lipoxin	  
(n=6),	   at	   the	   same	   time	   as	   intrauterine	   LPS	   administration,	   and	   the	   expression	   of	  
inflammatory	   genes	   was	   assessed	   by	   qRT-­‐PCR.	   (A)	   Cxcl1	   expression.	   (B)	   Cxcl2	  
expression	   (C)	   Cxcl5	   expression.	   (D)	   Ccl2	   expression.	   Data	   presented	   as	   mean	   fold	  
change	  ±	  SEM	  (error	  bars);	  *p<0.05,	  ***p<0.001,	  compared	  to	  vehicle.	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4.3.5.2 Inflammatory	  gene	  expression	  in	  the	  fetal	  membranes	  
Expression	  of	  Tnf-­‐α	  in	  the	  fetal	  membranes	  was	  significantly	  increased	  in	  mice	  treated	  
with	   LPS,	   compared	   to	   the	   vehicle	   (28.4-­‐fold	   increase;	   p<0.001;	   Figure	   4.13A).	  	  
Intrauterine	  administration	  of	  epi-­‐lipoxin	  at	  the	  same	  time	  as	  LPS	  did	  not	  significantly	  
effect	  LPS-­‐induced	  Tnf-­‐α	  expression,	  compared	  with	  LPS	  alone;	  and	  mice	  treated	  with	  
25ng	  epi-­‐lipoxin+LPS	  and	  250ng	  epi-­‐lipoxin+LPS	  still	  had	  significantly	  elevated	  Tnf-­‐α,	  
compared	  to	  the	  vehicle	  control	  group	  (p<0.001).	  	  	  
Similarly,	   expression	  of	   Il-­‐1β	  was	  significantly	  elevated	   in	  mice	   receiving	   intrauterine	  
LPS	   compared	   to	   the	   vehicle	   group	   (24.9-­‐fold	   increase,	   p<0.001;	   Figure	   4.13B).	   	   Co-­‐	  
treatment	   with	   epi-­‐lipoxin	   did	   not	   affect	   LPS-­‐induced	   Il-­‐1β	   expression	   in	   the	   fetal	  
membranes,	   compared	   to	   LPS	   alone;	   Il-­‐1β	   expression	   in	   these	   groups	   was	   still	  
significantly	  greater	  than	  the	  vehicle	  control	  (p<0.001).	  	  	  
In	   this	   cohort	   of	   mice,	   Il-­‐6	   expression	   in	   the	   fetal	   membranes	   was	   not	   significantly	  
altered	  in	  response	  to	  any	  treatments	  given	  (Figure	  4.13C),	  although	  intrauterine	  LPS	  
induced	  a	  3.9-­‐fold	   increase	   in	   Il-­‐6	   expression	  compared	  with	   the	  vehicle	  group,	   these	  
differences	  were	  not	  statistically	  significant.	  	  
As	   before,	   intrauterine	   LPS	   administration	   resulted	   in	   significantly	   increased	  
expression	   of	   Il-­‐10	   compared	   to	   the	   vehicle	   group	   (5.6-­‐fold	   increase	   p<0.05;	   Figure	  
4.13D).	   	  Mice	  co-­‐treated	  with	  epi-­‐lipoxin	  and	  LPS	   	  also	  had	  significantly	  elevated	  Il-­‐10	  
expression	  compared	  with	   the	  vehicle	   control	  group	   (25ng	  epi-­‐lipoxin+LPS:	  14.1-­‐fold	  
increase,	  p<0.001;	  250ng	  epi-­‐lipoxin+LPS:	  9-­‐fold	  increase,	  p<0.01).	  	  	  
Intrauterine	  LPS	  administration	  alone	  did	  not	  significantly	  alter	  expression	  of	  Cox-­‐2	  in	  
the	   fetal	   membranes,	   compared	   to	   vehicle	   (Figure	   4.13E).	   	   Co-­‐treatment	   of	   25ng	   or	  
250ng	   epi-­‐lipoxin	   at	   the	   same	   time	   as	   intrauterine	   LPS,	   significantly	   increased	  
expression	  of	  Cox-­‐2,	  compared	  to	  the	  vehicle	  control	  group	  (7-­‐fold	  and	  6.7-­‐fold	  greater	  
expression,	  respectively;	  p<0.05).	  	  In	  mice	  treated	  with	  both	  epi-­‐lipoxin	  and	  LPS,	  Cox-­‐2	  
expression	  appeared	  to	  also	  be	  increased	  compared	  to	  LPS	  alone	  (2.8-­‐fold	  increase	  in	  
the	  25ng	  epi-­‐lipoxin+LPS	  group;	  2.6-­‐fold	  increase	  in	  the	  250ng	  epi-­‐lipoxin+LPS	  group),	  
however	  these	  differences	  were	  not	  statistically	  significant.	  	  	  
In	   this	   cohort	   of	   mice,	   expression	   of	   15-­‐Hpgd	   in	   the	   fetal	   membranes	   was	   not	  
significantly	  altered	  by	  either	  intrauterine	  LPS	  or	  epi-­‐lipoxin	  treatment	  (Figure	  4.13E).	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As	  previously	  described,	  expression	  of	  Cxcl1	  was	  significantly	  increased	  in	  response	  to	  
intrauterine	   LPS	   administration,	   compared	   to	   the	   vehicle	   group	   (12.6-­‐fold	   increase,	  
p<0.05;	   Figure	   4.14A);	   and	   co-­‐treatment	   with	   epi-­‐lipoxin+LPS	   also	   resulted	   in	  
increased	   Cxcl1	   expression,	   compared	   to	   the	   vehicle	   control	   group	   (p<0.01).	  
Intrauterine	   LPS	   administration	   also	   significantly	   increased	   expression	   of	   Cxcl2	  
compared	   to	   vehicle	   (15-­‐fold	   increase,	   p<0.01;	   Figure	  4.14B);	   and	   again	   LPS-­‐induced	  
Cxcl2	   expression	   was	   not	   significantly	   affected	   by	   co-­‐treatment	   with	   epi-­‐lipoxin,	  
compared	  to	  LPS	  alone,	  with	  mice	  co-­‐treated	  with	  epi-­‐lipoxin+LPS	  still	  being	  found	  to	  
have	   significantly	   elevated	   Cxcl2	   expression	   compared	   to	   the	   vehicle	   control	   group	  
(p<0.001).	   Similarly,	   Cxcl5	   expression	   was	   significantly	   elevated	   in	   response	   to	  
intrauterine	   LPS	   compared	   to	   the	   vehicle	   group	   (60.9-­‐fold	   increase,	   p<0.001;	   Figure	  
4.14C).	   	   	   Co-­‐treatment	   with	   epi-­‐lipoxin	   did	   not	   significantly	   alter	   LPS-­‐induced	   Cxcl5	  
expression	   in	   the	   fetal	  membranes,	   compared	   to	   LPS	   alone,	  with	  Cxcl2	  expression	   in	  
these	   groups	   still	   significantly	   elevated	   compared	   to	   the	   vehicle	   control	   group	  
(p<0.001).	  	  	  
Expression	   of	   the	   macrophage	   chemokine,	   Ccl2	   was	   also	   increased	   in	   response	   to	  
intrauterine	  LPS	  administration,	  compared	  with	  the	  vehicle	  (10.1-­‐fold	  increase,	  p<0.05;	  
Figure	  4.14D).	  	  Again,	  compared	  to	  LPS	  alone,	  co-­‐treatment	  of	  epi-­‐lipoxin	  with	  LPS	  did	  
not	  significantly	  affect	  LPS-­‐induced	  Ccl2	  expression,	  and	  co-­‐treatment	  of	  LPS	  and	  epi-­‐
lipoxin	   (at	   25ng	   or	   250ng)	   still	   resulted	   in	   significantly	   greater	   Ccl2	   expression,	  
compared	   to	   the	   vehicle	   control	   group	   (25ng	   epi-­‐lipoxin+LPS:	   15.5-­‐fold	   increase,	  
p<0.01;	  250ng	  epi-­‐lipoxin+LPS:	  11.6-­‐fold	  increase,	  p<0.05).	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Figure	   4.13	   -­‐	   Effect	   of	   co-­‐treatment	   with	   epi-­‐lipoxin	   on	   inflammatory	   gene	  
expression	  in	  the	  fetal	  membranes.	   	   	  Fetal	  membranes	  were	  harvested	  6	  hours	  post	  
surgery	   from	   mice	   co-­‐treated	   with	   vehicle	   (n=4)	   or	   250ng	   epi-­‐lipoxin	   (n=4),	   at	   the	  
same	   time	   as	   intrauterine	   PBS;	   and	   in	  mice	   co-­‐treated	  with	   vehicle	   (n=5),	   25ng	   epi-­‐
lipoxin	   (n=6)	   or	   250ng	   epi-­‐lipoxin	   (n=6),	   at	   the	   same	   time	   as	   intrauterine	   LPS	  
administration,	   and	   the	   expression	   of	   inflammatory	   genes	  was	   assessed	  by	  qRT-­‐PCR.	  	  
(A)	  Tnf-­‐α	  expression.	  (B)	  Il-­‐1β	  expression.	  (C)	  Il-­‐6	  expression	  (D)	  Il-­‐10	  expression.	  	  (E)	  
Cox-­‐2	  expression	  	  (F)	  15-­‐Hpgd	  expression.	  Data	  presented	  as	  mean	  fold-­‐change	  ±	  SEM	  
(error	  bars);	  **p<0.01;	  ***p<0.001,	  compared	  to	  vehicle.	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Figure	  4.14	  -­‐	  Effect	  of	  co-­‐treatment	  with	  epi-­‐lipoxin	  on	  chemokine	  expression	  in	  
the	   fetal	  membranes.	   	   	  Fetal	  membranes	  were	  harvested	  6	  hours	  post	  surgery	  from	  
mice	   co-­‐treated	   with	   vehicle	   (n=4)	   or	   250ng	   epi-­‐lipoxin	   (n=4),	   at	   the	   same	   time	   as	  
intrauterine	  PBS;	  and	  in	  mice	  co-­‐treated	  with	  vehicle	  (n=5),	  25ng	  epi-­‐lipoxin	  (n=6)	  or	  
250ng	  epi-­‐lipoxin	  (n=6),	  at	   the	  same	  time	  as	   intrauterine	  LPS	  administration,	  and	  the	  
expression	  of	  inflammatory	  genes	  was	  assessed	  by	  qRT-­‐PCR.	  	  (A)	  Cxcl1	  expression.	  (B)	  
Cxcl2	  expression	   (C)	   Cxcl5	  expression.	   (D)	   Ccl2	   expression.	   Data	   presented	   as	   mean	  
fold	  change	  ±	  SEM	  (error	  bars);	  *p<0.05,	  **p<0.01,	  ***p<0.001,	  compared	  to	  vehicle.	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4.3.5.3 Inflammatory	  gene	  expression	  in	  the	  placenta	  
As	   in	  previous	  cohorts,	   intrauterine	  LPS	  administration	   induced	  a	  significant	   increase	  
in	   placental	   Tnf-­‐α	   expression,	   compared	   with	   the	   vehicle	   control	   group	   (6.8-­‐fold	  
increase;	   p<0.001;	   Figure	   4.15A).	   	   Intrauterine	   administration	   of	   epi-­‐lipoxin	   did	   not	  
significantly	   affect	   LPS-­‐induced	  Tnf-­‐α	   expression	   compared	   to	   LPS	   alone,	   with	  Tnf-­‐α	  
expression	   still	   significantly	   elevated	   in	  mice	   receiving	   epi-­‐lipoxin+LPS,	   compared	   to	  
the	  vehicle	  control	  (p<0.001).	  	  	  
Similarly,	   Il-­‐1β	   expression	  was	   also	   significantly	   elevated	   in	   response	   to	   intrauterine	  
LPS	  compared	  to	  the	  vehicle	  group	  (10.9-­‐fold	  increase;	  p<0.001;	  Figure	  4.15B).	  	  Again,	  
co-­‐treatment	  with	  epi-­‐lipoxin	  did	  not	  alter	  LPS-­‐induced	  Il-­‐1β	  expression,	  compared	  to	  
LPS	   alone,	   and	   mice	   in	   these	   groups	   still	   had	   significantly	   greater	   Il-­‐1β	   expression	  
compared	  to	  the	  vehicle	  control	  group	  (p<0.001).	  	  	  
Placental	  expression	  of	  Il-­‐6	  was	  significantly	  increased	  in	  response	  to	  intrauterine	  LPS	  
compared	   to	   the	   vehicle	   control	   group	   (5.9-­‐fold	   increase;	   p<0.001;	   Figure	   4.15C).	  	  
Again,	   mice	   co-­‐treated	   with	   25ng	   and	   250ng	   epi-­‐lipoxin+LPS,	   still	   had	   significantly	  
elevated	  Il-­‐6	  expression,	  compared	  to	  the	  vehicle	  group	  (12-­‐fold	  and	  8.5-­‐fold	  increase,	  
respectively,	  p<0.001).	  	  	  
Il-­‐10	   expression	   was	   also	   significantly	   greater	   in	   response	   to	   intrauterine	   LPS	  
administration	   compared	  with	   to	   the	  vehicle	   group	   (2.7-­‐fold	   increase;	  p<0.01;	  Figure	  
4.15D).	  	  Compared	  to	  LPS	  treatment	  alone,	  intrauterine	  administration	  of	  epi-­‐lipoxin	  at	  
the	   same	   time	   as	   LPS	   did	   not	   affect	   LPS-­‐induced	   Il-­‐10	   expression;	   and	  mice	   in	   these	  
groups	  still	  had	  significantly	  elevated	  Il-­‐10	  expression	  compared	  to	  the	  vehicle	  control	  
group	  (p<0.001).	  	  	  
LPS	  alone	  did	  not	  significantly	  alter	  placental	  Cox-­‐2	  expression,	  compared	  to	  the	  vehicle	  
control	  group.	  	  However	  co-­‐treatment	  of	  epi-­‐lipoxin,	  at	  both	  25ng	  and	  250ng,	  and	  LPS	  
significantly	   increased	   Cox-­‐2	   expression,	   compared	   to	   the	   vehicle	   group	   (25ng	   epi-­‐
lipoxin+LPS:	  3-­‐fold	  increase,	  p<0.05;	  250ng	  epi-­‐lipoxin+LPS:	  3.9-­‐fold	  increase,	  p<0.01;	  
Figure	   4.15E).	   	   Additionally,	   co-­‐treatment	   with	   epi-­‐lipoxin+LPS	   also	   significantly	  
increased	  Cox-­‐2	  expression	  compared	  to	  LPS	  alone,	  with	  25ng	  epi-­‐lipoxin+LPS	  inducing	  
3.8-­‐fold	   higher	   expression	   (p<0.01)	   and	   250ng	   epi-­‐lipoxin+LPS	   inducing	   4.9-­‐fold	  
greater	  expression	  (p<0.001).	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Administration	  of	  250ng	  epi-­‐lipoxin	  prior	   to	   intrauterine	  PBS	  administration	  reduced	  
placental	   15-­‐Hpgd	   expression	   by	   2.2-­‐fold	   compared	   to	   the	   vehicle	   control	   group,	  
however	   this	   difference	   did	   not	   reach	   statistical	   significance	   (p=0.07;	   Figure	   4.15F).	  
LPS	  treatment,	  either	  alone	  or	  with	  epi-­‐lipoxin,	  did	  not	  significantly	  affect	  placental	  15-­‐
Hpgd	  expression.	  	  
As	  described	  earlier,	  intrauterine	  LPS	  injection	  significantly	  elevated	  expression	  of	  the	  
three	   neutrophil	   chemokines	   Cxcl1,	   Cxcl2	   and	   Cxcl5.	   	   Expression	   of	   Cxcl1	   was	  
significantly	  greater	   in	  mice	  treated	  with	  LPS	  compared	  to	  the	  vehicle	  group	  (4.5-­‐fold	  
increase;	   p<0.001;	   Figure	   4.16A).	   	   Intrauterine	   administration	   of	   epi-­‐lipoxin	   did	   not	  
significantly	   affect	   LPS-­‐induced	   Cxcl1	   expression	   compared	   to	   LPS	   alone,	   and	   these	  
mice	   still	   had	   significantly	   elevated	  Cxcl1	  expression	   compared	   to	   the	   vehicle	   control	  
group	  (p<0.001).	  	  Cxcl2	  was	  also	  significantly	  elevated	  in	  mice	  receiving	  LPS	  compared	  
with	   the	   vehicle	   (13.5-­‐fold	   increase;	   p<0.001;	   Figure	   4.16B).	   	   Again,	   co-­‐treatment	   of	  
epi-­‐lipoxin+LPS	  did	  not	  significantly	  alter	  Cxcl2	  expression	  compared	  to	  LPS	  alone,	  and	  
Cxcl2	  expression	  was	   still	   significantly	  greater	   compared	   to	   the	  vehicle	   control	   group	  
(p<0.001).	   	   Similarly,	  LPS	   induced	  a	   significant	   increase	   in	  placental	  Cxcl5	   expression	  
compared	   to	   the	   vehicle	   group	   (22.8-­‐fold	   increase;	   p<0.001;	   Figure	   4.16C);	   however	  
LPS-­‐induced	   Cxcl5	   expression	   was	   unaffected	   by	   co-­‐treatment	   with	   epi-­‐lipoxin,	  
compared	   to	   LPS	   alone,	   and	   mice	   receiving	   both	   epi-­‐lipoxin	   and	   LPS	   still	   had	  
significantly	  increased	  Cxcl5	  expression	  compared	  to	  the	  vehicle	  control	  group.	  	  
Ccl2	   expression	   was	   also	   significantly	   increased	   in	   response	   to	   intrauterine	   LPS	  
administration	   compared	   to	   the	   vehicle	   (5.2-­‐fold	   increase;	   p<0.001;	   Figure	   4.16D).	  	  
Again,	  intrauterine	  administration	  of	  epi-­‐lipoxin	  at	  the	  same	  time	  as	  LPS	  did	  not	  affect	  
LPS-­‐induced	  Ccl2	  expression	  in	  the	  placenta	  compared	  to	  LPS	  alone,	  and	  these	  mice	  still	  
had	   significantly	   greater	   expression	   of	   Ccl2	  when	   compared	   to	   the	   vehicle	   control	  
group	  (p<0.001).	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Figure	   4.15	   -­‐	   Effect	   of	   co-­‐treatment	   with	   epi-­‐lipoxin	   on	   inflammatory	   gene	  
expression	   in	   the	   placenta.	   	   	   Placental	   tissue	  was	   harvested	   6	   hours	   post	   surgery	  
from	  mice	  co-­‐treated	  with	  vehicle	  (n=4)	  or	  250ng	  epi-­‐lipoxin	  (n=4),	  at	  the	  same	  time	  as	  
intrauterine	  PBS;	  and	  in	  mice	  co-­‐treated	  with	  vehicle	  (n=5),	  25ng	  epi-­‐lipoxin	  (n=6)	  or	  
250ng	  epi-­‐lipoxin	  (n=6),	  at	   the	  same	  time	  as	   intrauterine	  LPS	  administration,	  and	  the	  
expression	  of	  inflammatory	  genes	  was	  assessed	  by	  qRT-­‐PCR.	  (A)	  Tnf-­‐α	  expression.	  (B)	  
Il-­‐1β	  expression.	  (C)	  Il-­‐6	  expression	  (D)	  Il-­‐10	  expression.	  	  (E)	  Cox-­‐2	  expression	  	  (F)	  15-­‐
Hpgd	   expression.	   	   Data	   presented	   as	  mean	   fold-­‐change	   ±	   SEM	   (error	   bars);	   *p<0.05;	  
**p<0.01;	  ***p<0.001,	  compared	  to	  vehicle;	  ##p<0.01,	  ###p<0.001,	  compared	  to	  LPS.	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Figure	  4.16	  -­‐	  Effect	  of	  co-­‐treatment	  with	  epi-­‐lipoxin	  on	  chemokine	  expression	  in	  
the	   placenta.	   	   	   Placental	   tissue	   was	   harvested	   6	   hours	   post	   surgery	   from	  mice	   co-­‐
treated	  with	  vehicle	  (n=4)	  or	  250ng	  epi-­‐lipoxin	  (n=4),	  at	  the	  same	  time	  as	  intrauterine	  
PBS;	   and	   in	  mice	   co-­‐treated	  with	  vehicle	   (n=5),	   25ng	  epi-­‐lipoxin	   (n=6)	  or	  250ng	  epi-­‐
lipoxin	  (n=6),	  at	  the	  same	  time	  as	  intrauterine	  LPS	  administration,	  and	  the	  expression	  
of	   inflammatory	   genes	   was	   assessed	   by	   qRT-­‐PCR.	   	   (A)	   Cxcl1	   expression.	   (B)	   Cxcl2	  
expression	   (C)	   Cxcl5	   expression.	   (D)	   Ccl2	   expression.	   Data	   presented	   as	   mean	   fold	  
change	  ±	  SEM	  (error	  bars);	  *p<0.05,	  **p<0.01,	  ***p<0.001,	  compared	  to	  vehicle.	  	  	  
	  
	   	   	   Chapter	  4	  
	   169	  
4.3.6 Effect	  of	  intrauterine	  epi-­‐lipoxin	  administration	  on	  amniotic	  fluid	  cytokine	  levels	  
To	  determine	  whether	   co-­‐treatment	  with	  epi-­‐lipoxin	  and	  LPS	  directly	   into	   the	  uterus	  
could	   affect	   inflammatory	   cytokine	   levels	   in	   the	   amniotic	   fluid,	   ELISAs	  were	   used	   to	  
quantify	  the	  concentration	  of	  TNF-­‐α	  and	  IL-­‐10	  in	  amniotic	  fluid	  collected	  6	  hours	  post	  
surgery.	  	  As	  before,	  where	  the	  concentration	  of	  cytokines	  was	  too	  low	  to	  be	  detected	  by	  
the	  ELISAs,	  the	  value	  of	  the	  lower	  limit	  of	  detection	  of	  the	  specific	  ELISA	  was	  entered	  to	  
give	   a	   value	   for	   analysis	   and	   the	   data	   was	   analysed	   by	   non-­‐parametric	   ANOVA	  
(Kruskal-­‐Wallis).	  	  	  
TNF-­‐α	   was	   undetectable	   in	   three	   vehicle	   samples	   and	   all	   250ng	   epi-­‐lipoxin	   samples.	  	  
Intrauterine	  LPS	  administration	  resulted	  in	  greater	  TNF-­‐α	  concentration	  compared	  to	  
the	   vehicle	   control	   group,	   however	   this	   difference	   was	   not	   statistically	   significant	  
(mean	  vehicle	   concentration	  12.75	  pg/ml	  ±	  SEM	  1.85;	  mean	  LPS	  concentration	  91.73	  
pg/ml	  ±	  SEM	  27.22).	   	   	   	  Co-­‐treatment	  with	  epi-­‐lipoxin	  at	  the	  same	  time	  as	  intrauterine	  
LPS	   appeared	   to	   further	   increase	   amniotic	   fluid	   TNF-­‐α	   levels,	   although	   again	   these	  
differences	  were	  not	  statistically	  significant	  (25ng	  epi-­‐lipoxin+LPS	  mean	  203.5	  pg/ml	  ±	  
SEM	  60.23;	  250ng	  epi-­‐lipoxin+LPS	  mean	  231.5	  pg/ml	  ±	  SEM	  44.01;	  Figure	  4.17A).	  	  
IL-­‐10	  was	   also	   undetectable	   in	   three	   vehicle	   samples,	   all	   250ng	   epi-­‐lipoxin	   samples,	  
one	  LPS	  sample	  and	  one	  25ng	  epi-­‐lipoxin+LPS	  sample.	  	  Intrauterine	  LPS	  administration	  
did	   not	   significantly	   increase	   the	   concentration	   of	   IL-­‐10	   compared	   to	   the	   vehicle	  
control	   group	   (vehicle	  mean	  15.93	  pg/ml	  ±	   SEM	  0.33;	   LPS	  mean	  19.25	  pg/ml	  ±	   SEM	  
2.03).	  	  Similarly,	  co-­‐treatment	  with	  epi-­‐lipoxin	  had	  no	  significant	  effect	  on	  the	  amniotic	  
fluid	   IL-­‐10	   concentration	   compared	   to	   LPS	   alone	   (25ng	   epi-­‐lipoxin+LPS	   mean	   24.3	  
pg/ml	  ±	  SEM	  3.5;	  250ng	  epi-­‐lipoxin+LPS	  mean	  18.45	  pg/ml	  ±	  SEM	  1.56;	  Figure	  4.17B).	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Figure	   4.17	   -­‐	   Effect	   of	   co-­‐treatment	   with	   epi-­‐lipoxin	   on	   inflammatory	   cytokine	  
production	  in	  the	  amniotic	  fluid.	   	   	  Amniotic	  fluid	  was	  collected	  6	  hours	  post	  surgery	  
from	  mice	  co-­‐treated	  with	  vehicle	  (n=4)	  or	  250ng	  epi-­‐lipoxin	  (n=4),	  at	  the	  same	  time	  as	  
intrauterine	  PBS;	  and	  in	  mice	  co-­‐treated	  with	  vehicle	  (n=5),	  25ng	  epi-­‐lipoxin	  (n=6)	  or	  
250ng	   epi-­‐lipoxin	   (n=6),	   at	   the	   same	   time	   as	   intrauterine	   LPS	   administration,	   and	  
ELISAs	  were	   used	   to	   quantify	   the	   concentration	   of	   TNF-­‐α	   and	   IL-­‐10	   in	   the	   amniotic	  
fluid.	   	  (A)	  Amniotic	  fluid	  TNF-­‐α	  concentration.	  (B)	  Amniotic	  fluid	  IL-­‐10	  concentration.	  	  
Data	  presented	  as	  mean	  ±	  SEM	  (error	  bars).	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4.3.7 Effect	  of	  pre-­‐treatment	  with	  BML-­‐111	  on	  time	  to	  delivery	  and	  the	  proportion	  of	  live	  
born	  pups	  
Lipoxins	  are	  rapidly	  inactivated	  and	  broken	  down	  by	  the	  actions	  of	  15-­‐HPGD,	  therefore,	  
a	   number	   of	   stable	   synthetic	   analogues	   have	   been	   developed	   which	   have	   a	   longer	  
biological	   half-­‐life	   (Serhan	   et	   al.	   1995,	   Maddox	   et	   al.	   1997).	   	   BML-­‐111	   is	   a	   stable	  
synthetic	  analogue	  of	  lipoxin,	  which	  has	  been	  found	  to	  improve	  outcome	  in	  a	  number	  of	  
animal	  models	   of	   inflammation-­‐associated	   pathologies	   (Zhang	   et	  al.	   2007,	   Chen	   et	  al.	  
2010,	   Gong	   et	   al.	   2012),	   therefore,	   the	   potential	   of	   BML-­‐111	   to	   delay	   delivery	   and	  
improve	  the	  proportion	  of	  live	  born	  pups	  was	  also	  investigated	  in	  our	  model.	  	  	  	  As	  with	  
epi-­‐lipoxin,	  mice	  received	  pre-­‐treatment	  with	  BML-­‐111	  1-­‐2	  hours	  prior	  to	  intrauterine	  
LPS	   or	   PBS	   administration.	   	  Mice	  were	   pre-­‐treated	  with	   vehicle	   prior	   to	   intrauterine	  
PBS	  or	  LPS	  administration	  as	  controls.	  	  	  
4.3.7.1 Time	  to	  delivery	  
Pre-­‐treatment	   with	   BML-­‐111	   prior	   to	   intrauterine	   PBS	   administration	   did	   not	   affect	  
time	  to	  delivery	  compared	  to	  the	  vehicle	  control	  group	  (mean	  time	  to	  delivery	  in	  BML	  
group	  47.5	  hours	  ±	  SEM	  7.3	  vs.	  vehicle	  mean	  48.48	  ±	  SEM	  7.6;	  Figure	  4.18).	  	  Mice	  in	  the	  
LPS	  treatment	  group	  delivered	  significantly	  earlier	  compared	  with	  the	  vehicle	  control	  
group	   (mean	   time	   to	   delivery	   in	   LPS	   group	   27.6	   hours	   ±	   SEM	   4.8,	   p<0.01).	   	   Pre-­‐
treatment	  with	  1mg/kg	  or	  10mg/kg	  BML-­‐111	  prior	  to	  intrauterine	  LPS	  administration	  
did	   not	   significantly	   affect	   time	   to	   delivery	   compared	   to	   LPS	   alone,	   although	   time	   to	  
delivery	   appeared	   to	   be	   increased	   in	  mice	   pre-­‐treated	  with	   1mg/kg	  BML-­‐111	   (mean	  
time	  to	  delivery	  42.0	  hours	  ±	  SEM	  6.5);	  however	  this	  was	  not	  significantly	  different	  to	  
the	  LPS	  group	  (p=0.24;	  Figure	  4.18).	  	  Mice	  pre-­‐treated	  with	  10mg/kg	  BML-­‐111	  prior	  to	  
intrauterine	   LPS,	   still	   delivered	   significantly	   earlier	   compared	   to	   the	   vehicle	   control	  
group	  (mean	  time	  to	  delivery	  26.2	  hours	  ±	  SEM	  4.6,	  p<0.05).	  	  There	  were	  no	  significant	  
differences	  when	  comparing	  time	  to	  delivery	   in	  mice	  pre-­‐treated	  with	  BML-­‐111	  prior	  
to	  LPS	  administration	  with	  the	  BML-­‐111	  control	  group.	  
To	   investigate	   further	   the	   effect	   of	   pre-­‐treatment	   with	   BML-­‐111	   on	   LPS-­‐induced	  
preterm	  delivery,	  the	  preterm	  delivery	  rates	  in	  each	  group	  were	  calculated	  (Table	  4.2).	  	  
This	  was	  defined	  as	  the	  proportion	  of	  dams	  in	  which	  there	  was	  delivery	  of	  the	  first	  pup	  
within	  36	  hours	  of	   intrauterine	   injection.	   	  All	   treatment	  groups	  receiving	   intrauterine	  
LPS	  had	  higher	   preterm	  delivery	   rates	   compared	   to	   those	   receiving	   intrauterine	  PBS	  
injection	  (LPS	  preterm	  delivery	  rate	  0.86;	  vehicle	  preterm	  delivery	  rate	  0.3;	  BML-­‐111	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preterm	  delivery	  rate	  0.36).	  	  Compared	  to	  the	  LPS	  treatment	  group,	  the	  relative	  risk	  of	  
preterm	   delivery	  was	   significantly	   reduced	   in	   both	   the	   vehicle	   and	   BML-­‐111	   groups	  
(p<0.01).	   	  Additionally	  pre-­‐treatment	  with	  1mg/kg	  BML-­‐111	  prior	  to	  intrauterine	  LPS	  
administration	  significantly	  reduced	  the	  risk	  of	  preterm	  delivery	  (0.55;	  RR	  0.64,	  [95%	  
CI	  0.41	  –	  0.98];	  p<0.05),	  compared	  to	  LPS	  alone.	  	  Perhaps	  surprisingly,	  higher	  doses	  of	  
BML-­‐111	  failed	  to	  attenuate	  the	  adverse	  effects	  of	  LPS	  on	  the	  preterm	  delivery	  rate.	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Figure	   4.18	   -­‐	   Effect	   of	   pre-­‐treatment	   with	   BML-­‐111	   on	   LPS-­‐induced	   time	   to	  
delivery.	   	   	  Time	  to	  delivery	  was	  monitored	  in	  mice	  pre-­‐treated	  with	  vehicle	  (n=10)	  or	  
BML-­‐111	  (n=11),	  prior	  to	  intrauterine	  PBS;	  and	  in	  mice	  pre-­‐treated	  with	  vehicle	  (n=22)	  
1mg/kg	   BML-­‐111	   (n=20)	   or	   10mg/kg	   BML-­‐111	   (n=9),	   prior	   to	   intrauterine	   LPS	  
administration.	   Data	   are	   presented	   as	   mean	   ±	   SEM	   (error	   bars);	   *p<0.05,	   **p<0.01,	  
compared	  to	  vehicle.	  
	  
	  
Table	  4.2	  -­‐	  Effect	  of	  pre-­‐treatment	  with	  BML-­‐111	  on	  preterm	  delivery	  rate.	  	  Time	  
to	   delivery	   was	   monitored	   in	   mice	   pre-­‐treated	   with	   vehicle	   or	   BML-­‐111	   prior	   to	  
intrauterine	   PBS	   or	   LPS	   administration.	   Preterm	   delivery	   was	   defined	   as	   delivery	  
within	  36	  hours	  of	  intrauterine	  injection.	  	  Relative	  risk	  ratios	  calculated	  using	  Fisher’s	  
exact	  text.	  *p<0.05;	  **p<0.01.	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4.3.7.2 Proportion	  of	  live	  born	  pups	  
The	   proportion	   of	   live	   born	   pups	   was	   reduced	   in	   the	   LPS	   group,	   compared	   to	   the	  
vehicle	  control	  group	  (LPS	  mean	  proportion	  of	  live	  born	  pups	  0.21	  ±	  SEM	  0.06;	  vehicle	  
mean	   proportion	   of	   live	   born	   pups	   0.55	   ±	   SEM	   0.11;	   Figure	   4.19A);	   however	   this	  
difference	  was	  not	  statistically	  significant	  (p=0.1).	  	  Mice	  in	  the	  BML-­‐111	  control	  group	  
did	   have	   a	   significantly	   greater	   proportion	   of	   live	   born	   pups	  when	   compared	   to	   LPS	  
alone	  (mean	  proportion	  of	  live	  born	  pups	  in	  BML-­‐111	  group	  0.66	  ±	  SEM	  0.12;	  p<0.05).	  	  
Pre-­‐treatment	   with	   BML-­‐111	   at	   1mg/kg	   and	   10mg/kg	   prior	   to	   intrauterine	   LPS	  
administration	  appeared	  to	  induce	  a	  dose-­‐dependent	  increase	  in	  the	  proportion	  of	  live	  
born	   pups	   (1mg/kg	   BML-­‐111+LPS	   mean	   0.31	   ±	   SEM	   0.08;	   10mg/kg	   BML-­‐111+LPS	  
mean	   0.48	   ±	   SEM	   0.15),	   however	   these	   differences	   were	   not	   statistically	   significant	  
when	  compared	  to	  the	  LPS	  alone	  group	  (Figure	  4.19A).	  	  	  	  
In	  mice	  delivering	  preterm	  a	  similar	  trend	  was	  observed,	  where	  LPS	  treatment	  resulted	  
in	  a	  significantly	  reduced	  proportion	  of	   live	  born	  pups	  compared	  to	  mice	  in	  the	  BML-­‐
111	  group	  (LPS	  mean	  proportion	  of	  live	  born	  pups	  0.13	  ±	  SEM	  0.05,	  vs.	  BML-­‐111	  mean	  
0.64	  ±	  SEM	  0.22;	  p<0.05,	  Figure	  4.19B).	  	  Mice	  pre-­‐treated	  with	  1mg/kg	  BML-­‐111	  prior	  
to	   intrauterine	  LPS	  administration	  also	  had	  a	   significantly	   reduced	  proportion	  of	   live	  
born	   pups	   compared	   to	   the	   BML	   control	   group	   (1mg/kg	   BML-­‐111+LPS	   mean	  
proportion	  of	   live	  born	  pups	  0.03	  ±	  SEM	  0.03;	  p<0.05).	   	  Pre-­‐treatment	  with	  10mg/kg	  
BML-­‐111	   prior	   to	   intrauterine	   LPS	   administration	   again	   appeared	   to	   increase	   the	  
proportion	  of	  live	  born	  pups	  compared	  to	  mice	  receiving	  LPS	  alone	  (mean	  proportion	  
of	   live	   born	  pups	   in	   10mg/kg	  BML-­‐111+LPS	   group	  0.36	   ±	   SEM	  0.17),	   however	   again	  
this	   was	   not	   statistically	   significant	   when	   compared	   to	   mice	   receiving	   LPS	   alone	  
(p=0.57;	  Figure	  4.19B).	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Figure	  4.19	  -­‐	  Effect	  of	  pre-­‐treatment	  with	  BML-­‐111	  on	  the	  proportion	  of	  live	  born	  
pups.	   	   	   The	   proportion	   of	   live	   born	   pups	   was	   determined	   in	   mice	   pre-­‐treated	   with	  
vehicle	  (n=10)	  or	  BML-­‐111	  (n=11),	  prior	  to	   intrauterine	  PBS;	  and	  in	  mice	  pre-­‐treated	  
with	   vehicle	   (n=22)	   1mg/kg	   BML-­‐111	   (n=20)	   or	   10mg/kg	   BML-­‐111	   (n=9),	   prior	   to	  
intrauterine	  LPS	  administration.	  (A)	  Proportion	  of	   live	  born	  pups	   in	  all	  mice	  (B)	  The	  
proportion	  of	  pups	  delivered	  prematurely	  (within	  36	  hours	  of	  surgery)	  who	  were	  born	  
live;	   [vehicle	   (n=3),	   BML-­‐111	   (n=4)	   LPS	   (n=19),	   1mg/kg	   BML-­‐111+LPS	   (n=11),	  
10mg/kg	   BML-­‐111+LPS	   (n=7)].	   Data	   are	   presented	   as	   mean	   ±	   SEM	   (error	   bars);	  
#p<0.05,	  compared	  to	  LPS.	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4.3.8 Effect	   of	   pre-­‐treatment	  with	   IL-­‐10	   on	   time	   to	   delivery	   and	   the	   proportion	   of	   live	  
pups	  born	  
Administration	  of	   the	  classical	  anti-­‐inflammatory	  cytokine,	   IL-­‐10,	  has	  previously	  been	  
reported	  to	  delay	  infection-­‐induced	  preterm	  labour	  and	  improve	  pup	  survival	  in	  rodent	  
models	   (Terrone	   et	   al.	   2001,	   Rodts-­‐Palenik	   et	   al.	   2004,	   Robertson	   et	   al.	   2006).	  	  
Therefore,	  we	  wanted	  to	  investigate	  whether	  pre-­‐treatment	  with	  IL-­‐10	  was	  capable	  of	  
reversing	  the	  negative	  effects	  of	  LPS	  in	  our	  model.	  	  Mice	  were	  pre-­‐treated	  with	  IL-­‐10	  1-­‐
2	  hours	  prior	  to	  intrauterine	  LPS	  or	  PBS	  administration;	  control	  mice	  were	  pre-­‐treated	  
with	  vehicle	  prior	  to	  intrauterine	  LPS	  or	  PBS	  administration.	  	  	  
	  
4.3.8.1 Time	  to	  delivery	  
Pre-­‐treatment	  with	  IL-­‐10	  prior	  to	  intrauterine	  PBS	  administration	  did	  not	  significantly	  
alter	  time	  to	  delivery,	  compared	  to	  the	  vehicle	  control	  group	  (mean	  time	  to	  delivery	  in	  
10µg	  IL-­‐10	  group	  43.73	  hours	  ±	  SEM	  3.2	  vs.	  vehicle	  mean	  42.73	  ±	  SEM	  3.6;	  Figure	  4.20).	  	  
Mice	   receiving	   intrauterine	   LPS	   delivered	   significantly	   earlier	   than	   mice	   receiving	  
intrauterine	  PBS	   in	   the	  10µg	   IL-­‐10	  group	   (mean	   time	   to	  delivery	   in	  LPS	  group	  28.46	  
hours	   ±	   SEM	   9.7;	   p<0.05);	   although	   time	   to	   delivery	   in	   the	   LPS	   group	   was	   also	  
decreased	  compared	   to	   the	  vehicle	  control	  group,	   this	  was	  not	  statistically	  significant	  
(p=0.1).	   	   Pre-­‐treatment	   with	   either	   2.5µg	   or	   10µg	   IL-­‐10	   prior	   to	   intrauterine	   LPS	  
administration	   did	   not	   significantly	   alter	   time	   to	   delivery,	   compared	   with	   mice	  
receiving	   LPS	   alone;	   and	   mice	   receiving	   10µg	   IL-­‐10	   prior	   to	   intrauterine	   LPS	   still	  
delivered	  significantly	  earlier	  compared	  to	  the	  10µg	  IL-­‐10	  control	  group	  (mean	  time	  to	  
delivery	  in	  10µg	  IL-­‐10+LPS	  group	  23.63	  hours	  ±	  SEM	  3.04;	  p<0.05).	  	  	  	  
The	  rate	  of	  preterm	  delivery	  was	  also	  determined	  in	  each	  treatment	  group	  (Table	  4.3).	  	  
Preterm	   delivery	   rates	  were	   higher	   in	   all	   groups	   receiving	   intrauterine	   LPS,	   with	   all	  
mice	  in	  the	  2.5µg	  IL-­‐10+LPS	  and	  10µg	  IL-­‐10+LPS	  groups	  delivering	  preterm;	  however	  
in	   this	  cohort	  of	  mice,	  no	  statistically	  significant	  differences	   in	  preterm	  delivery	  rates	  
were	  observed	  between	  treatment	  groups.	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Figure	  4.20	  -­‐	  Effect	  of	  pre-­‐treatment	  with	  IL-­‐10	  on	  LPS-­‐induced	  time	  to	  delivery.	  	  	  
Time	  to	  delivery	  was	  monitored	  in	  mice	  pre-­‐treated	  with	  vehicle	  (n=11)	  or	  10µg	  IL-­‐10	  
(n=10),	  prior	  to	  intrauterine	  PBS;	  and	  in	  mice	  pre-­‐treated	  with	  vehicle	  (n=6)	  2.5µg	  IL-­‐
10	   (n=5)	   or	   10µg	   IL-­‐10	   (n=6),	   prior	   to	   intrauterine	   LPS	   administration.	   Data	   are	  




Table	  4.3	   -­‐	  Effect	  of	  pre-­‐treatment	  with	  IL-­‐10	  on	  preterm	  delivery	  rate.	   	  Time	  to	  
delivery	  was	  monitored	  in	  mice	  pre-­‐treated	  with	  vehicle	  or	  IL-­‐10	  prior	  to	  intrauterine	  
PBS	  or	  LPS	  administration.	  Preterm	  delivery	  was	  defined	  as	  delivery	  within	  36	  hours	  of	  
intrauterine	  injection.	  Relative	  risk	  ratios	  calculated	  using	  Fisher’s	  exact	  text.	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4.3.8.2 Proportion	  of	  live	  born	  pups	  
As	  previously	  observed	  in	  other	  experiments,	  LPS	  treatment	  resulted	  in	  a	  significantly	  
reduced	  proportion	  of	   live	  born	  pups,	   compared	   to	   the	  10µg	   IL-­‐10	   group	   (LPS	  mean	  
proportion	  of	   live	  born	  pups	  0.26	  ±	   SEM	  0.08	   vs.	   10µg	   IL-­‐10	  mean	  0.77	  ±	   SEM	  0.09;	  
p<0.05,	  Figure	  4.21A).	   	  The	  proportion	  of	  live	  born	  pups	  in	  LPS	  treated	  mice	  was	  also	  
reduced	   compared	   to	   the	   vehicle	   control	   group,	   however	   this	   was	   not	   statistically	  
significant	  (mean	  proportion	  of	  live	  born	  pups	  in	  vehicle	  group	  0.64	  ±	  SEM	  0.12;	  p=0.18	  
vs.	   LPS).	   	   Pre-­‐treatment	   with	   10µg	   IL-­‐10	   prior	   to	   intrauterine	   LPS	   administration	  
appeared	   to	   increase	   the	  proportion	  of	   live	  born	  pups	   compared	   to	  LPS	  alone	   (mean	  
proportion	  of	  live	  born	  pups	  in	  10µg	  IL-­‐10+LPS	  group	  0.59	  ±	  SEM	  0.17),	  however	  this	  
was	  not	  statistically	  significant	  (Figure	  4.21A).	  	  	  
In	  mice	  delivering	  preterm,	  a	  similar	  trend	  was	  observed,	  with	  a	  greater	  proportion	  of	  
live	  pups	  born	   to	  mice	  pre-­‐treated	  with	  10µg	   IL-­‐10	  prior	   to	  both	   intrauterine	  PBS	  or	  
LPS	  administration,	  compared	  to	  LPS	  alone	  (10µg	  IL-­‐10	  mean	  proportion	  of	   live	  born	  
pups	  0.48	  ±	  SEM	  0.1;	  10µg	   IL-­‐10+LPS	  mean	  proportion	  of	   live	  born	  pups	  0.59	  ±	  SEM	  
0.17	  vs.	  LPS	  mean	  0.23	  ±	  0.09;	  Figure	  4.21B);	  however	  these	  differences	  were	  again	  not	  
found	  to	  be	  statistically	  significant.	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Figure	   4.21	   -­‐	   Effect	   of	   pre-­‐treatment	  with	   IL-­‐10	   on	   the	   proportion	   of	   live	   born	  
pups.	   	   The	   proportion	   of	   live	   born	   pups	   was	   determined	   in	   mice	   pre-­‐treated	   with	  
vehicle	  (n=11)	  or	  10µg	  IL-­‐10	  (n=10),	  prior	  to	  intrauterine	  PBS;	  and	  in	  mice	  pre-­‐treated	  
with	   vehicle	   (n=6)	   2.5µg	   IL-­‐10	   (n=5)	   or	   10µg	   IL-­‐10	   (n=6),	   prior	   to	   intrauterine	   LPS	  
administration.	   (A)	   Proportion	   of	   live	   born	   pups	   in	   all	   mice.	   	   (B)	   The	   proportion	   of	  
pups	  delivered	  prematurely	  (within	  36	  hours	  of	  surgery)	  who	  were	  born	  live;	  [vehicle	  
(n=5),	   10µg	   IL-­‐10	   	   (n=3)	   LPS	   (n=5),	   2.5µg	   IL-­‐10+LPS	   (n=5),	   10µg	   IL-­‐10+LPS	   (n=6)].	  
Data	  are	  presented	  as	  mean	  ±	  SEM	  (error	  bars);	  #p<0.05,	  compared	  to	  LPS.	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4.4 DISCUSSION	  
The	   presence	   of	   an	   intrauterine	   infection	   is	   thought	   to	   be	   an	   important	   cause	   of	  
preterm	  labour	  in	  many	  cases,	  which	  prematurely	  activates	  the	  inflammatory	  pathways	  
normally	  initiated	  at	  term,	  resulting	  in	  the	  premature	  induction	  of	  labour	  (Goldenberg	  
et	  al.	  2000).	  	  Given	  this	  hypothesis,	  there	  is	  growing	  interest	  in	  examining	  whether	  anti-­‐
inflammatory	   treatments	   may	   be	   useful	   novel	   therapeutic	   agents	   to	   delay	   infection-­‐
induced	  preterm	  delivery	  and	   improve	  neonatal	  outcome.	   	  Therefore,	   the	  aims	  of	   the	  
work	   in	   this	   chapter	   were	   to	   investigate	   whether	   the	   anti-­‐inflammatory	   agents,	   epi-­‐
lipoxin,	   BML-­‐111	   and	   IL-­‐10,	   could	   delay	   LPS-­‐induced	   preterm	   labour	   and	   improve	  
survival	   rates	   in	   our	   model	   of	   infection-­‐induced	   preterm	   labour;	   and	   to	   examine	  
whether	   epi-­‐lipoxin	   could	   regulate	  LPS-­‐induced	   inflammatory	   signalling	   in	   the	  utero-­‐
placental	  tissues.	  	  	  
	  
Intrauterine	   LPS	   administration	   increased	   lipoxin	   receptor	   expression	   in	   the	   utero-­‐
placental	  tissues	  
In	  humans,	   lipoxins	  have	  been	  shown	  to	  act	  via	  a	  specific	  G-­‐protein	  coupled	  receptor,	  
FPR2/ALX,	   which	   belongs	   to	   the	   formyl	   peptide	   receptor	   family	   (Ye	   et	   al.	   2009).	  	  
Expression	  of	  FPR2/ALX	  has	  been	  described	  in	  a	  variety	  of	  cells	  and	  tissues	  including	  
monocytes,	  macrophages,	  neutrophils,	  lymphocytes,	  microglial	  cells,	  fibroblasts,	  spleen,	  
brain,	   lung	   and	   placenta	   (Migeotte	   et	   al.	   2006).	   	   Whilst	   only	   three	   human	   formyl	  
peptide	   receptors	   have	   been	   identified,	   the	   situation	   is	  more	   complex	   in	   the	  mouse,	  
where	  to	  date,	  eight	  genes	  have	  been	  identified	  belonging	  to	  the	  mouse	  Fpr	  family	  (Gao	  
et	  al.	  1998,	  Ye	  et	  al.	  2009).	   	  Two	  highly	   related	  mouse	  receptors,	  mFpr2	   (encoded	  by	  
the	  Fpr2	  gene)	  and	  mFpr3	  (encoded	  by	  the	  Fpr-­‐rs2	  gene),	  which	  have	  been	  reported	  to	  
share	  high	  sequence	  homology	  with	  FPR2/ALX,	  have	  both	  been	  shown	  to	  be	  capable	  of	  
binding	   lipoxin	  A4	   (Takano	  et	  al.	   1997,	  Vaughn	  et	  al.	   2002).	   	  Therefore,	   it	   is	  not	   clear	  
whether	  both	  mFpr2	  and	  mFpr3	  are	  murine	  orthologs	  of	   the	  human	  lipoxin	  receptor,	  
FPR2/ALX.	   	   The	   complexity	   of	   differentiating	   between	   mFpr2	   and	   mFpr3	   was	  
highlighted	  in	  a	  recent	  study	  using	  Fpr2	  knockout	  mice,	  where	  Dufton	  et	  al.	  originally	  
believed	   they	   had	   generated	   an	   Fpr2	   specific	   knockout	  mouse,	   only	   to	   later	   identify	  
that	   both	   mFpr2	   and	   mFpr3	   were	   deleted	   (Dufton	   et	   al.	   2010).	   	   Interestingly,	   this	  
knockout	  study	  demonstrated	  that	  the	  anti-­‐inflammatory	  and	  pro-­‐resolution	  actions	  of	  
lipoxin	  A4	  were	  severely	  attenuated	  providing	  further	  support	  that	  these	  receptors	  are	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key	   lipoxin	   receptors	   in	   the	   mouse	   (Dufton	   et	   al.	   2010).	   	   Similar	   to	   FPR2/ALX,	  
expression	  of	  mFpr2	  and	  mFpr3	  have	  been	  reported	   in	  mouse	   leukocytes,	  spleen	  and	  
lung	  tissue	  (Gao	  et	  al.	  1998).	  	  The	  expression	  of	  both	  the	  human	  FPR2/ALX	  and	  mouse	  
mFpr2	   have	   been	   shown	   to	   be	   up-­‐regulated	   by	   inflammatory	   cytokines	   and	   LPS	  
(Gronert	   et	   al.	   1998,	   Sodin-­‐Semrl	   et	   al.	   2000,	   Iribarren	   et	   al.	   2003,	   Chen	   et	   al.	   2007,	  
Zheng	  et	  al.	  2011,	  Mou	  et	  al.	  2012).	  	  	  
In	  reproductive	  tissues,	  FPR2/ALX	  expression	  has	  been	  identified	  during	  the	  menstrual	  
cycle	   in	   the	  endometrium	  and	   in	   first	   trimester	  decidua	   (Macdonald	  et	  al.	  2011);	  and	  
has	  also	  been	  reported	  in	  myometrial	  biopsies	  obtained	  from	  pregnant	  women	  at	  term,	  
where	   FPR2/ALX	   expression	   was	   increased	   in	   myometrial	   samples	   obtained	   from	  
women	   in	   labour,	   compared	   to	  non-­‐labouring	  women	   (Maldonado-­‐Perez	  et	  al.	   2010);	  
suggesting	   lipoxins	  may	  play	  an	   important	  role	   in	  regulating	  the	   inflammatory	  events	  
surrounding	  the	  reproductive	  processes	  of	  menstruation	  and	  labour.	  
Therefore,	   given	   these	   data,	   we	   wanted	   to	   investigate	   whether	   lipoxin	   receptor	  
expression	  was	  elevated	   in	  response	  to	   intrauterine	  LPS	  administration,	   to	  determine	  
whether	   exogenous	   lipoxin	   administration	  may	   be	   a	   useful	   therapeutic	   option	   in	   the	  
treatment	   of	   infection-­‐induced	   preterm	   labour.	   In	   agreement	   with	   these	   previous	  
studies	  demonstrating	  LPS	  can	  regulate	  Fpr2	  expression	  (Iribarren	  et	  al.	  2003,	  Mou	  et	  
al.	  2012),	  qRT-­‐PCR	  analysis	  on	  tissues	  harvested	  6	  hours	  post-­‐surgery	  confirmed	  that	  
intrauterine	   LPS	   administration	   increased	   the	   expression	   of	   Fpr2	   in	   the	   uterus,	   fetal	  
membranes	   and	   placenta,	   suggesting	   that	   either	   endogenous	   or	   exogenous	   lipoxins	  
may	   play	   an	   important	   role	   in	   regulating	   the	   LPS-­‐induced	   inflammatory	   response	  
within	  the	  utero-­‐placental	  tissues.	  	  	  
Unfortunately,	  due	   to	   the	   lack	  of	   availability	  of	   a	   suitable	  mFpr2	  antibody,	   it	  was	  not	  
possible	  to	  localise	  mFpr2	  expression	  in	  the	  utero-­‐placental	  tissues.	  	  Therefore,	  it	  is	  not	  
clear	   whether	   this	   increased	   Fpr2	   expression	   is	   largely	   due	   to	   the	   LPS-­‐induced	  
infiltration	   of	   immune	   cells	   expressing	   Fpr2,	   or	   whether	   the	   utero-­‐placental	   tissues	  
themselves	  express	  mFpr2.	  	  Furthermore,	  only	  the	  expression	  of	  Fpr2	  was	  examined,	  as	  
the	  majority	  of	  studies	  examining	  the	  role	  of	  lipoxin	  in	  animal	  models	  of	  inflammation-­‐
associated	   pathologies	   focus	   on	   Fpr2;	   however	   as	   both	   Fpr2	   and	   Fpr3	   encode	   for	  
receptors	  which	  can	  respond	  to	  lipoxin	  in	  the	  mouse,	   further	  studies	  to	  examine	  Fpr3	  
expression	  should	  be	  carried	  out.	  	  There	  is	  evidence	  that	  lipoxins	  can	  also	  interact	  with	  
other	  receptors	  including	  the	  cysteinyl	  leukotriene	  receptors	  (CysLT)	  (Badr	  et	  al.	  1989,	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McMahon	   et	   al.	   2000,	   Gronert	   et	   al.	   2001)	   and	   nuclear	   aryl	   carbon	   receptor	   (AhR)	  
(Schaldach	   et	   al.	   1999,	   Machado	   et	   al.	   2006,	   McBerry	   et	   al.	   2012),	   which	   may	   also	  
mediate	   their	   anti-­‐inflammatory	   effects.	   	  Whether	   these	   receptors	   play	   a	   role	   in	   our	  
model	  has	  not	  been	  examined.	  	  
	  
Effect	  of	  epi-­‐lipoxin	  pre-­‐treatment	  on	  LPS-­‐induced	  PTL	  and	  neonatal	  outcome	  
In	   recent	  years,	   the	   therapeutic	  potential	  of	   lipoxins	   to	   improve	  disease	  outcome	  has	  
been	  demonstrated	  in	  animal	  models	  of	  a	  range	  of	  inflammation-­‐associated	  pathologies,	  
such	   as,	   asthma	   (Levy	   et	   al.	   2002),	   ulcerative	   colitis	   (Gewirtz	   et	   al.	   2002),	   ischemia-­‐
reperfusion	   injury	   (Ye	   et	  al.	   2010)	   and	   arthritis	   (Conte	   et	  al.	   2010).	   	   This	   is	   the	   first	  
study	   to	   investigate	   the	   potential	   of	   lipoxin	   as	   therapeutic	   agents	   in	   a	   model	   of	  
infection-­‐induced	   preterm	   labour.	   	   The	   role	   of	   lipoxins	   in	   regulating	   inflammatory	  
events	   in	   the	   reproductive	   tissues,	   and	   in	  particular	  during	   labour,	  have	  been	   largely	  
unexplored,	   however	   as	   discussed	   earlier,	   recent	   work	   from	   our	   laboratory	  
demonstrated	  that	  pre-­‐treatment	  with	  lipoxin	  A4	  was	  capable	  of	  down-­‐regulating	  LPS-­‐
induced	   inflammatory	   gene	   expression	   in	   myometrial	   explants	   in	   vitro	   (Maldonado-­‐
Perez	  et	  al.	  2010),	   showing	   lipoxins	  can	  regulate	  LPS-­‐induced	   inflammatory	  signalling	  
in	   the	  myometrium.	   	  Therefore,	  using	  our	  mouse	  model	  of	   infection-­‐induced	  preterm	  
labour,	  we	  wanted	   to	   investigate	  whether	  pre-­‐treatment	  with	   epi-­‐lipoxin	   could	  delay	  
LPS-­‐induced	   preterm	   labour	   and/or	   improve	   neonatal	   outcome.	   	   As	   lipoxins	   are	  
relatively	  unstable	  and	  rapidly	  broken	  down	  by	  the	  actions	  of	  15-­‐HPGD	  (Serhan	  et	  al.	  
1995),	  we	  chose	  to	  use	  the	  more	  stable	  15-­‐epi-­‐lipoxin	  A4	  in	  this	  study.	  	  Previous	  reports	  
have	   found	   that	   epi-­‐lipoxins	  are	   inactivated	  by	  15-­‐HPGD	  at	   a	   slower	   rate	   than	  native	  
lipoxins	   (Serhan	   et	   al.	   1995),	   therefore,	   they	   display	   a	   longer	   half-­‐life	   in	   vivo.	  	  
Furthermore,	  several	  studies	  have	  shown	  that	  epi-­‐lipoxin	  A4	  is	  more	  potent	  than	  native	  
lipoxin	  A4	  in	  preventing	  neutrophil	  adhesion	  (Serhan	  1997)	  and	  regulating	  production	  
of	   the	  chemokine,	   IL-­‐8,	   in	   intestinal	  epithelial	  cells	   (Gewirtz	  et	  al.	  1998),	   thus	  making	  
15-­‐epi-­‐lipoxin	   A4	  more	   useful	   in	   in	  vivo	  models	   examining	   the	   anti-­‐inflammatory	   and	  
pro-­‐resolution	  potential	  of	  lipoxin	  administration.	  	  
In	  our	  model,	   pre-­‐treatment	  with	   epi-­‐lipoxin,	   at	   the	  doses	  used	   in	   this	   study,	  did	  not	  
delay	  LPS-­‐induced	  preterm	   labour,	  or	  have	  any	  significant	   impact	  on	   the	   rate	  of	  LPS-­‐
induced	  preterm	  delivery.	   	  However,	   interestingly	  pre-­‐treatment	  with	  epi-­‐lipoxin	  at	  a	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dose	  of	  125ng,	  prior	  to	  either	  intrauterine	  PBS	  or	  LPS	  administration	  did	  increase	  the	  
proportion	  of	  live	  born	  pups.	   	  Although	  not	  a	  significant	  increase,	  the	  finding	  that	  epi-­‐
lipoxin	   pre-­‐treatment	   increased	   the	   proportion	   of	   live	   born	   pups	   even	   in	   mice	   just	  
receiving	  intrauterine	  PBS,	  compared	  to	  the	  vehicle	  control	  group	  was	  unexpected	  and	  
suggests	  the	  surgery	  itself	  may	  be	  having	  a	  negative	  effect	  on	  pup	  survival,	  which	  can	  
be	   reversed	   by	   epi-­‐lipoxin.	   	   Unfortunately,	   it	   was	   not	   possible	   to	   compare	   the	  
proportion	  of	   live	  born	  pups	  with	  that	  of	  a	  no	  surgery	  control	  group,	  as	   the	  uterus	  of	  
mice	   in	   the	   latter	  group	  was	  not	  opened	  up.	   	  Hence	   the	  number	  of	  pups	   in	  each	  dam	  
prior	  to	  delivery	  in	  the	  “no	  surgery	  control”	  group	  was	  unknown,	  therefore,	  it	  was	  not	  
possible	  to	  calculate	  the	  proportion	  of	  live	  born	  pups	  in	  these	  mice.	  	  	  
Pre-­‐treatment	   with	   epi-­‐lipoxin	   prior	   to	   intrauterine	   LPS	   administration	   significantly	  
increased	   the	   proportion	   of	   live	   born	   pups	   in	  mice	   delivering	   preterm	   following	   LPS	  
treatment.	   	   The	   fact	   that	   the	   same	   effect	   was	   not	   observed	   when	   examining	   the	  
proportion	  of	  live	  born	  pups	  in	  the	  cohort	  as	  a	  whole	  could	  either	  be	  due	  to	  a	  selective	  
effect	  of	  lipoxins	  on	  mortality	  in	  preterm	  pups,	  or	  is	  likely	  due	  to	  the	  fact	  that	  2	  mice	  in	  
the	   LPS	   treatment	   group	  went	   to	   term	   and	   delivered	   a	   high	   proportion	   of	   live	   born	  
pups	  (time	  to	  delivery	  in	  these	  mice	  was	  68.75	  and	  75.75	  hours	  with	  82%	  and	  77%	  of	  
their	   pups	   born	   live,	   respectively),	   therefore,	   increasing	   the	  mean	   proportion	   of	   live	  
born	  pups	  in	  the	  mice	  receiving	  intrauterine	  LPS	  in	  this	  cohort.	  	  Therefore,	  analysis	  was	  
carried	  out	  on	  mice	  delivering	  preterm	  to	  determine	  whether	  pre-­‐treatment	  with	  epi-­‐
lipoxin	  had	  an	  effect	  on	  the	  proportion	  of	  live	  born	  pups	  delivered	  prematurely.	  	  These	  
data	  suggest	  that	  administration	  of	  epi-­‐lipoxin	  may	  be	  protecting	  the	  fetus	  in	  some	  way	  
from	  the	  negative	  effects	  of	  LPS,	  because	  even	  when	  mice	  pre-­‐treated	  with	  epi-­‐lipoxin	  
delivered	  early,	  they	  had	  a	  greater	  proportion	  of	  live	  born	  pups.	  	  
Previous	   studies	  have	   also	  demonstrated	   the	   ability	   of	   anti-­‐inflammatory	   treatments,	  
such	  as	  an	  anti-­‐TLR-­‐4	  antibody	  (Li	  et	  al.	  2010),	  an	  anti-­‐TNF	  antibody	  (Holmgren	  et	  al.	  
2008),	   IL-­‐10	   (Robertson	   et	  al.	   2006)	   and	   15d-­‐PGJ2	   (Pirianov	   et	  al.	   2009),	   to	   improve	  
pup	  survival	   rates	   in	  mouse	  models	  of	   infection-­‐induced	  preterm	   labour;	  however,	   in	  
each	  case,	   the	   incidence	  of	  LPS-­‐induced	  preterm	   labour	  was	  also	   reduced,	  which	  was	  
not	  observed	  with	  epi-­‐lipoxin	  treatment.	  	  This	  difference	  may	  be	  related	  to	  the	  fact	  that	  
unlike	  other	   anti-­‐inflammatory	   treatments	  used	  previously,	   epi-­‐lipoxin	   is	   also	  known	  
to	   have	   important	   pro-­‐resolution	   actions	   (Serhan	   et	   al.	   2008),	   therefore,	   epi-­‐lipoxin	  
could	  be	  promoting	  the	  resolution	  of	  the	  inflammatory	  intrauterine	  environment	  to	  an	  
extent	   which	   protects	   the	   fetus	   from	   the	   negative	   effects	   of	   being	   born	   prematurely	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and/or	   the	  LPS	   treatment,	  but	  cannot	  halt	   the	   inflammatory	  cascade	  which	  results	   in	  
preterm	  labour.	  	  How	  epi-­‐lipoxin	  is	  acting	  to	  increase	  the	  proportion	  of	  live	  born	  pups	  
in	  this	  model	  is	  not	  clear	  at	  present,	  but	  possible	  mechanisms	  will	  be	  discussed	  in	  the	  
next	   section	   examining	   the	   effect	   of	   epi-­‐lipoxin	   on	   the	   expression	   of	   inflammatory	  
mediators	  in	  the	  utero-­‐placental	  tissues.	  	  
In	  this	  study,	  all	  assessments	  of	  live	  born	  pups	  were	  made	  within	  the	  first	  24	  hours	  of	  
delivery.	   	   Therefore,	   to	   examine	   further	   whether	   epi-­‐lipoxin	   treatment	   ultimately	  
improves	   long-­‐term	  survival,	   pups	   could	  be	   examined	  at	   later	   time-­‐points	   to	   confirm	  
whether	  survival	   is	   improved,	  or	  whether	  epi-­‐lipoxin	  merely	  delays	  LPS-­‐induced	  fetal	  
death.	  	  	  
	  
Effect	  of	  epi-­‐lipoxin	  on	  the	  LPS-­‐induced	  inflammatory	  response	  in	  utero-­‐placental	  tissues	  
Previous	  studies	  have	  reported	  that	  treatment	  with	   lipoxin,	  epi-­‐lipoxin	  or	  their	  stable	  
analogues	  can	  reduce	   the	  expression	  of	   inflammatory	  mediators,	   such	  as	  TNF-­‐α,	   IL-­‐6,	  
IL-­‐1β,	   IL-­‐8	  and	  MMPs,	  whilst	   increasing	  expression	  of	   the	  anti-­‐inflammatory	  cytokine	  
IL-­‐10,	  both	   in	  models	  of	   inflammation	   in	  vitro	   and	   in	  animal	  models	  of	   inflammation-­‐
associated	  pathologies	   in	  vivo	   (Hachicha	  et	  al.	  1999,	  Sodin-­‐Semrl	  et	  al.	  2000,	  Wu	  et	  al.	  
2008,	  Baker	  et	  al.	  2009,	  Kure	  et	  al.	  2009,	  Maldonado-­‐Perez	  et	  al.	  2010,	  Borgeson	  et	  al.	  
2011,	  Macdonald	  et	  al.	  2011,	  Chen	  et	  al.	  2013).	  	  The	  mechanisms	  underlying	  these	  anti-­‐
inflammatory	   actions	   of	   lipoxins	   are	   thought	   to	   involve	   inhibition	   of	  NFκB	   signalling	  
(Gewirtz	  et	  al.	  2002,	  Wu	  et	  al.	  2008,	  Kure	  et	  al.	  2009,	  Wang	  et	  al.	  2011);	  activation	  of	  
PPAR-­‐γ	  (Sobrado	  et	  al.	  2009)	  and	  increased	  SOCS3	  expression	  via	  STAT3	  activation	  (Li	  
et	  al.	  2011).	  	  	  
Therefore,	   given	   the	   increased	   proportion	   of	   live	   born	   pups	   observed	   in	   mice	   pre-­‐
treated	   with	   epi-­‐lipoxin,	   we	   hypothesised	   that	   administration	   of	   epi-­‐lipoxin	   in	   our	  
model	   would	   alter	   LPS-­‐induced	   inflammatory	   signalling	   within	   the	   utero-­‐placental	  
tissues	   and	   amniotic	   fluid,	   thus	   providing	   a	  mechanism	   by	  which	   epi-­‐lipoxin	  may	   be	  
acting.	  	  	  
However,	   in	   contrast	   to	   these	   previous	   studies,	   we	   found	   that	   treatment	   with	   epi-­‐
lipoxin,	  either	  prior	  to	  or	  at	  the	  same	  time	  as	  intrauterine	  LPS	  administration,	  did	  not	  
significantly	  reduce	   the	  LPS-­‐induced	  expression	  of	  Tnf-­‐α,	  Il-­‐1β,	  Il-­‐6,	  IL-­‐10,	  Cxcl1,	  Cxcl2,	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Cxcl5	  or	  Ccl2,	  with	  the	  expression	  of	  these	  genes	  still	  found	  to	  be	  significantly	  elevated	  
in	   mice	   treated	   with	   epi-­‐lipoxin+LPS,	   when	   compared	   to	   the	   vehicle	   control	   group.	  	  
Indeed,	   compared	   to	   vehicle,	   Il-­‐6	   and	   Cxcl1	   in	   the	   fetal	   membranes	   were	   only	   up-­‐
regulated	   in	  response	  to	  epi-­‐lipoxin+LPS,	  and	  were	  not	  significantly	   increased	  by	  LPS	  
treatment	   alone.	   	   Rather	   than	   suggesting	   epi-­‐lipoxin	   is	   having	   a	   pro-­‐inflammatory	  
effect,	   these	   results	   more	   likely	   reflect	   the	   variable	   responses	   observed	   between	  
animals,	   which	   are	   more	   apparent	   with	   smaller	   sample	   sizes.	   	   Whilst	   the	   results	  
described	   in	   chapter	  3	  demonstrated	  a	   robust	   inflammatory	   response	   to	   intrauterine	  
LPS,	  these	  data	  in	  this	  chapter	  highlight	  that	  when	  examining	  small	  numbers	  of	  animals	  
in	   each	   group,	   the	   response	   can	   be	   variable,	   such	   that	   although	   LPS	   increased	   the	  
expression	   of	   the	   majority	   of	   inflammatory	   genes	   examined,	   due	   to	   the	   variability	  
between	  animals	  this	  was	  not	  always	  statistically	  significant.	   	  Furthermore,	  whilst	  the	  
expression	  of	  these	  two	  genes	  was	  significantly	  greater	  than	  the	  vehicle	  control	  group,	  
the	  expression	  was	  not	  found	  to	  be	  significantly	  different	  to	  LPS	  alone,	  again	  suggesting	  
this	  observed	  difference	  is	  likely	  due	  to	  a	  variable	  response	  to	  LPS	  between	  animals.	  	  	  
The	   reasons	   why	   epi-­‐lipoxin	   administration	   in	   our	   model	   did	   not	   have	   similar	   anti-­‐
inflammatory	   effects	   to	   those	   reported	   in	   other	   models	   are	   not	   clear.	   	   Comparisons	  
with	   other	   inflammatory	   models	   is	   complicated	   by	   the	   fact	   that	   the	   nature	   of	   an	  
inflammatory	  response,	  in	  terms	  of	  its	  timing,	  magnitude	  and	  the	  specific	  inflammatory	  
mediators	  involved,	  can	  be	  altered	  depending	  on	  the	  site	  of	  inflammation	  (Bannenberg	  
2010);	  and	  this	  is	  the	  first	  study	  to	  investigate	  the	  potential	  of	  lipoxins	  to	  regulate	  LPS-­‐
induced	   inflammatory	   signalling	   in	   the	   utero-­‐placental	   tissues	   in	   a	   mouse	   model	   of	  
preterm	   labour.	   	   It	   is	   possible	   that	   differences	   in	   the	   doses	   and	   timing	   of	   epi-­‐lipoxin	  
administration	  may	   in	  part	  explain	  why	  we	  did	  not	  observe	   inhibitory	  effects	  on	  pro-­‐
inflammatory	   signals.	   	   However,	   the	   doses	   used	   here	  were	  within	   the	  wide	   range	   of	  
doses	  shown	   to	  be	  effective	   in	  other	  animal	  models	  administering	   lipoxin	   (Levy	  et	  al.	  
2002,	  El	  Kebir	  et	  al.	  2009,	  Kure	  et	  al.	  2009,	  Conte	  et	  al.	  2010,	  Borgeson	  et	  al.	  2011,	  Zhou	  
et	  al.	  2011).	  	  	  
Lipoxins	   have	   been	   shown	   to	   have	   potent	   anti-­‐inflammatory	   actions	   when	  
administered	   both	   locally	   at	   the	   site	   of	   inflammation	   (Clish	   et	   al.	   1999,	  Menezes-­‐de-­‐
Lima	  et	  al.	  2006,	  Conte	  et	  al.	  2010)	  or	  systemically	  (Clish	  et	  al.	  1999,	  El	  Kebir	  et	  al.	  2009,	  
Kure	   et	  al.	   2009,	   Conte	   et	  al.	   2010,	   Borgeson	   et	  al.	   2011).	   	   In	   this	   study	   the	   route	   of	  
administration	   of	   epi-­‐lipoxin,	   either	   systemically	   via	   i.p.	   injection	   or	   directly	   into	   the	  
uterus,	   did	   not	   appear	   to	   alter	   its	   anti-­‐inflammatory	   actions.	   	  However,	   it	   is	   possible	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that	  alternative	  timings	  of	  lipoxin	  administration	  may	  have	  had	  a	  different	  effect.	  	  Pre-­‐
treatment	   with	   lipoxins	   prior	   to	   the	   inflammatory	   insult	   is	   a	   common	   protocol	   in	  
animal	  studies	  using	  lipoxins	  (Levy	  et	  al.	  2002,	  Kure	  et	  al.	  2009,	  Borgeson	  et	  al.	  2011),	  
but	  several	  studies	  also	  give	  repeated	  doses	  of	  lipoxin	  after	  the	  inflammatory	  insult	  as	  
well	   (Conte	   et	   al.	   2010,	   Levy	   et	   al.	   2011).	   	   This	   may	   be	   particularly	   important	   to	  
consider	  given	  that	  although	  more	  stable	  than	  the	  native	  lipoxin,	  15-­‐epi-­‐lipoxin	  is	  still	  
rapidly	  metabolised	   in	  vivo	   (Serhan	  et	  al.	   1995),	   	   and	  many	  of	   the	   studies	  mentioned	  
above	  actually	  use	  synthetic	  lipoxin	  or	  epi-­‐lipoxin	  analogues,	  which	  are	  more	  resistant	  
to	   metabolism.	   	   Additionally,	   given	   that	   increased	   Fpr2	   expression	   in	   the	   utero-­‐
placental	   tissues	   is	   observed	   in	   mice	   6	   hours	   after	   LPS	   treatment,	   giving	   additional	  
exogenous	  lipoxins	  at	  this	  later	  time	  point	  may	  have	  a	  greater	  impact	  on	  inflammatory	  
signalling.	  	  
Having	  observed	  that	  epi-­‐lipoxin	  treatment	  did	  not	  appear	  to	  alter	  inflammatory	  gene	  
expression	   in	   the	   utero-­‐placental	   tissues,	   we	   hypothesised	   that	   another	   potential	  
mechanism	  which	  may	  explain	  the	  increased	  proportion	  of	  live	  born	  pups	  was	  that	  epi-­‐
lipoxin	  administration	  could	  be	  protecting	  the	   fetuses	  by	  either	  reducing	  the	   levels	  of	  
inflammatory	  cytokines,	  such	  as	  TNF-­‐α,	  or	  increasing	  the	  level	  of	  the	  anti-­‐inflammatory	  
cytokine,	   IL-­‐10,	   in	   the	   amniotic	   fluid.	   	   Pre-­‐treatment	   with	   epi-­‐lipoxin	   prior	   to	  
intrauterine	   LPS	   administration	   did	   not	   reduce	   LPS-­‐induced	   amniotic	   fluid	   TNF-­‐α	  
levels;	  however,	  although	  in	  chapter	  3,	  TNF-­‐α	   levels	  were	  significantly	  elevated	  in	  the	  
amniotic	  fluid	  of	  mice	  receiving	  20µg	  LPS,	  compared	  to	  mice	  receiving	  intrauterine	  PBS,	  
the	  same	  result	  was	  not	  observed	  in	  the	  cohort	  of	  mice	  used	  for	  the	  epi-­‐lipoxin	  studies,	  
although	   TNF-­‐α	   levels	   were	   still	   greater	   in	   mice	   receiving	   intrauterine	   LPS,	   the	  
difference	   was	   not	   statistically	   significant	   when	   compared	   with	   mice	   receiving	  
intrauterine	  PBS.	  	  	  In	  terms	  of	  amniotic	  fluid	  IL-­‐10	  levels,	  again	  there	  was	  no	  significant	  
difference	  observed	  between	  any	  treatment	  groups,	  and	  no	  trend	  that	  treatment	  with	  
epi-­‐lipoxin	  was	  altering	  LPS-­‐induced	  IL-­‐10	  production.	  	  
Interestingly,	   pre-­‐treatment	  with	   epi-­‐lipoxin,	   prior	   to	   either	   intrauterine	   PBS	   or	   LPS	  
administration,	   induced	   increased	  expression	  of	  Cox-­‐2	   in	   the	  uterus,	   fetal	  membranes	  
and	   placenta;	   and	   decreased	   expression	   of	   15-­‐Hpgd	   in	   the	   uterus	   and	   placenta.	   	   As	  
discussed	   in	   chapter	   3,	   a	   change	   in	   the	   expression	   of	   these	   genes	   suggests	   increased	  
prostaglandin	  synthesis	  and	  activity	  within	  the	  intrauterine	  tissues,	  which	  is	  commonly	  
thought	   to	   be	   a	   pro-­‐inflammatory	   event.	   	   However,	   there	   is	   now	   a	   large	   body	   of	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evidence	   that	   suggests	   increased	   expression	   of	   COX-­‐2,	   and	   subsequent	   prostaglandin	  
production,	   as	   an	   important	   initial	   step	   in	   the	   resolution	  of	   inflammation.	   	   Studies	   in	  
animal	   models	   have	   demonstrated	   anti-­‐inflammatory	   roles	   for	   COX-­‐2	   and	  
prostaglandins	  in	  the	  resolution	  of	  inflammation	  in	  the	  lung	  (Gilroy	  et	  al.	  1999,	  Hodges	  
et	   al.	   2004,	   Fukunaga	   et	   al.	   2005,	   Bonnans	   et	   al.	   2006,	   Zheng	   et	   al.	   2011)	   and	   colon	  
(Reuter	   et	   al.	   1996),	   where	   increased	   COX-­‐2	   expression	   and	   subsequently	   increased	  
PGE2,	   PGD2	   and	   15d-­‐PGJ2	   production	   was	   associated	   with	   the	   resolution	   phase,	   and	  
inhibition	  of	  COX-­‐2	  led	  to	  exacerbated	  inflammation.	  	  Therefore,	  COX-­‐2	  is	  proposed	  to	  
play	  opposing	   roles	   in	   the	  different	  phases	  of	   an	   inflammatory	   response.	   	  During	   the	  
early	   phase	   of	   acute	   inflammation,	   elevated	   COX-­‐2	   expression	   is	   thought	   to	   be	   pro-­‐
inflammatory,	  whilst	  during	  the	   latter	  phase	  of	   the	   inflammatory	  response	  COX-­‐2	  has	  
important	   anti-­‐inflammatory	   and	   pro-­‐resolution	   actions	   (Gilroy	   et	   al.	   1999).	   	   	   The	  
concept	   that	   prostaglandins	   can	   have	   dual	   roles	   in	   an	   inflammatory	   response	   is	   not	  
novel,	  previous	  studies	  have	  demonstrated	  that	  depending	  on	  their	  dose,	  site	  of	  action	  
and	  route	  of	  administration,	  prostaglandins	  can	  have	  either	  pro-­‐	  or	  anti-­‐inflammatory	  
effects	  (Rampart	  and	  Williams	  1986,	  Pons	  et	  al.	  1994).	  	  	  
Lipoxins	   are	   proposed	   to	   be	   involved	   in	   mediating	   the	   anti-­‐inflammatory	   actions	   of	  
COX-­‐2	  and	  prostaglandins	  during	  the	  resolution	  phase.	   	  Studies	   in	  human	  neutrophils	  
demonstrated	   that	   PGE2	   and	   PGD2	   are	   involved	   in	   a	   process	   termed	   ‘lipid	   mediator	  
class	   switching’,	   whereby	   they	   can	   stimulate	   lipoxin	   production	   by	   activating	  
transcription	   of	   15-­‐lipoxygenase	   resulting	   in	   neutrophils	   switching	   from	   the	  
production	  of	  pro-­‐inflammatory	  leukotrienes,	  to	  synthesis	  of	  lipoxins	  (Levy	  et	  al.	  2001).	  	  
Furthermore,	   in	   models	   of	   acute	   lung	   injury,	   increased	   COX-­‐2	   expression	   was	  
associated	   with	   increased	   LXA4	  production,	   which	   was	   blocked	   when	   animals	   were	  
treated	   with	   COX-­‐2	   inhibitors,	   resulting	   in	   exacerbated	   inflammation	   and	   longer	  
recovery	   times	   (Fukunaga	   et	   al.	   2005,	   Scully	   et	   al.	   2012).	   	   PGE2	   has	   been	   shown	   to	  
directly	  increase	  expression	  of	  the	  lipoxin	  receptor	  in	  bronchial	  epithelial	  cells	  in	  vitro,	  
thus	   promoting	   lipoxin	   signalling,	   and	   this	  was	   again	   shown	   to	   be	   COX-­‐2	   dependent	  
(Bonnans	  et	  al.	  2006).	  	  Interestingly	  a	  recent	  study	  by	  Zheng	  et	  al,	  described	  a	  biphasic	  
role	   of	   lipoxin	   A4	   in	   regulating	   LPS-­‐induced	   COX-­‐2	   expression	   in	   rat	   pulmonary	  
fibroblasts	  (Zheng	  et	  al.	  2011).	   	  Their	  work	  demonstrated	  that	  LPS	  treatment	  induced	  
increased	  COX-­‐2	  expression	  at	  6	  hours,	  with	  a	  second	  increase	  observed	  after	  24	  hours,	  
where	  maximal	  COX-­‐2	   levels	  were	   reached.	   	   	  Treatment	  with	   lipoxin	  A4	   inhibited	   the	  
initial	   LPS-­‐induced	   increase	   in	   COX-­‐2	   production	   at	   6	   hours,	   but	   dose-­‐dependently	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increased	   COX-­‐2	   expression	   and	   PGD2	   after	   24	   hours	   (Zheng	   et	   al.	   2011);	   again	  
highlighting	   the	   diverse	   role	   COX-­‐2	   plays	   in	   the	   progression	   of	   an	   inflammatory	  
response	  and	  how	  it	  can	  be	  regulated	  by	  lipoxin.	  	  Similar	  to	  the	  mechanisms	  proposed	  
to	  mediate	  the	  anti-­‐inflammatory	  actions	  of	  lipoxins,	  both	  PGD2	  and	  its	  metabolite,	  15d-­‐
PGJ2	   have	   been	   found	   to	   have	   anti-­‐inflammatory	   actions	   via	   inhibition	   of	   NFκB	  
signalling	  and	  increased	  activation	  of	  PPAR-­‐γ	  in	  immune	  cells	  (Ricote	  et	  al.	  1998,	  Rossi	  
et	  al.	  2000,	  Ward	  et	  al.	  2002);	  and	  in	  reproductive	  tissues	  both	  in	  vitro	  (Ackerman	  et	  al.	  
2005,	   Lindstrom	   and	   Bennett	   2005,	   Lappas	   et	   al.	   2006)	   and	   in	   vivo	   (Pirianov	   et	   al.	  
2009).	  	  	  
Therefore,	   it	   is	   possible	   that	   the	   epi-­‐lipoxin-­‐induced	   increase	   in	   both	   basal,	   and	   LPS-­‐
induced	   Cox-­‐2	   expression	   observed	   in	   our	   model	   is	   a	   sign	   of	   the	   initiation	   of	   the	  
resolution	  of	  the	  inflammatory	  response.	  	  The	  decreased	  15-­‐Hpgd	  expression	  may	  be	  a	  
mechanism	   to	   prolong	   lipoxin	   and	   prostaglandin	   action,	   since	   15-­‐HPGD	   is	   the	   main	  
enzyme	   involved	   in	   the	   inactivation	   and	   breakdown	   of	   both	   lipoxins	   and	  
prostaglandins.	   	   As	   observed	   in	   the	   studies	   discussed	   above,	   this	   may	   result	   in	  
increased	  production	  of	  anti-­‐inflammatory	  prostaglandins,	  such	  as	  PGD2	  and	  15d-­‐PGJ2,	  
which	  may	   act	   to	   resolve	   the	   inflammatory	   environment	   surrounding	   the	   fetus,	   thus	  
leading	  to	  the	  observed	  increase	  in	  the	  proportion	  of	  live	  born	  pups.	   	  Support	  for	  this	  
hypothesis	   comes	   from	  a	   recent	   study	   that	  demonstrated	   that	  administration	  of	  15d-­‐
PGJ2	   was	   associated	   with	   increased	   pup	   survival	   in	   a	   mouse	   model	   of	   LPS-­‐induced	  
preterm	  labour	  (Pirianov	  et	  al.	  2009).	  	  However,	  to	  confirm	  whether	  this	  mechanism	  is	  
involved	   in	   our	   model,	   further	   work	   would	   need	   to	   be	   carried	   out	   to	   investigate	  
prostaglandin	  production	  within	  the	  utero-­‐placental	  tissues	  and	  amniotic	  fluid.	   	  Given	  
that	   evidence	   suggests	   biphasic	   roles	   of	   COX-­‐2	   and	   prostaglandins	   during	   an	  
inflammatory	  response,	  analysis	  at	  multiple	  time	  points,	  particularly	  later	  than	  6	  hours,	  
will	   be	   important	   in	   future	   work	   to	   fully	   understand	   the	   role	   of	   COX-­‐2	   and	   the	  
prostaglandins	   in	   the	   intrauterine	   inflammatory	  response	   to	  LPS	  and	  how	  epi-­‐lipoxin	  
administration	  may	  affect	  their	  expression.	  	  	  
Interestingly	  (as	  discussed	  in	  chapter	  3),	  at	  6	  hours,	  LPS	  treatment	  is	  associated	  with	  a	  
neutrophil	   influx	   into	   the	   uterus,	  with	   no	   significant	   effect	   on	  macrophage	   numbers.	  	  
Again	  this	  finding	  supports	  the	  idea	  that	  perhaps	  by	  looking	  at	  6	  hours,	  we	  are	  looking	  
early	   in	   the	   inflammatory	   response,	   because	   typically	   in	   the	   initial	   acute	   stage,	  
neutrophils	  are	   the	  predominant	   immune	  cell	  present,	  whereas	  during	   the	  resolution	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phase,	  monocytes	  and	  macrophages	  are	  the	  predominant	  cell	  type	  (Serhan	  et	  al.	  2007).	  	  
These	   data	   again	   suggest	   that	   looking	   at	   later	   time	   points	   may	   be	   more	   useful	   in	  
understanding	   lipoxin	   actions.	   	   To	   further	   investigate	   whether	   COX-­‐2	   is	   involved	   in	  
mediating	   the	   effect	   of	   epi-­‐lipoxin	   in	   improving	   the	   proportion	   of	   live	   born	   pups,	   a	  
selective	   COX-­‐2	   inhibitor,	   such	   as	   meloxicam	   (Cella	   et	   al.	   2010)	   or	   nimesulide	  
(Westover	  et	  al.	  2012),	  could	  be	  given	  at	  different	  time	  points	  following	  epi-­‐lipoxin	  and	  
LPS	   administration	   to	   determine	   if	   inhibiting	   the	   actions	   of	   COX-­‐2	   reversed	   the	  
beneficial	   effects	   of	   epi-­‐lipoxin	   pre-­‐treatment.	   	   However,	   the	   outcome	   of	   such	   an	  
experiment	   may	   be	   difficult	   to	   interpret,	   given	   that	   COX	   inhibitors	   have	   been	  
independently	  associated	  with	  adverse	  effects	  on	  the	  fetus.	  	  COX-­‐2	  deficient	  mice	  have	  
a	   high	   rate	   of	   neonatal	   death,	   which	   has	   been	   linked	   to	   a	   patent	   ductus	   arteriosis	  
(Loftin	   et	   al.	   2001).	   	   Furthermore,	   evidence	   from	   a	   sheep	   model	   of	   intra-­‐amniotic	  
infection	   suggests	   that	   prostaglandins	  may	  play	   an	   important	   role	   in	   promoting	   fetal	  
lung	   development,	   as	   inhibition	   of	   COX-­‐2	   was	   associated	   with	   decreased	   surfactant	  
protein	  expression	  in	  the	  fetal	  lung	  (Westover	  et	  al.	  2012).	  	  Thus	  it	  would	  be	  difficult	  to	  
separate	  out	  an	  effect	  of	  COX-­‐2	  inhibitors	  on	  epi-­‐lipoxin	  action,	   from	  a	  direct	  effect	  of	  
COX-­‐2	  inhibitors	  themselves.	  	  	  	  	  
Aside	  from	  only	  looking	  at	  one	  time	  point,	  another	  limitation	  of	  our	  study	  here	  is	  that	  
we	   focussed	   on	   examining	   the	   anti-­‐inflammatory	   effects	   of	   epi-­‐lipoxin	   and	   did	   not	  
investigate	  its	  pro-­‐resolution	  effects.	   	  In	  terms	  of	  their	  pro-­‐resolution	  actions,	  lipoxins	  
have	  been	   reported	   to	  have	   contrasting	   effects	   on	  different	   immune	   cell	   populations,	  
including:	  inhibition	  of	  neutrophil	  activation,	  adhesion	  and	  chemotaxis	  (Lee	  et	  al.	  1989,	  
Colgan	  et	  al.	  1993,	  Papayianni	  et	  al.	  1996,	  Filep	  et	  al.	  2005);	  stimulation	  of	  neutrophil	  
apoptosis	   (El	   Kebir	   et	   al.	   2007);	   stimulation	   of	   monocyte	   adhesion	   and	   migration	  
(Maddox	   and	   Serhan	   1996,	   Maddox	   et	   al.	   1997);	   inhibition	   of	   monocyte	   apoptosis	  
(Simoes	   et	   al.	   2010);	   and	   promoting	   the	   non-­‐phlogistic	   phagocytosis	   of	   apoptotic	  
neutrophils	  by	  macrophages	  (Godson	  et	  al.	  2000).	  	  Therefore,	  to	  further	  investigate	  the	  
mechanisms	   by	   which	   epi-­‐lipoxin	   may	   be	   acting,	   it	   would	   be	   important	   to	   examine	  
whether	   epi-­‐lipoxin	   administration	   in	   our	   model	   is	   associated	   with	   any	   of	   these	  
inhibitory	   actions	   on	   neutrophils,	   or	   stimulation	   of	   monocytes	   and	   macrophages.	  
Identification	   of	   the	   predominant	   immune	   cell	   population	   in	   mice	   treated	   with	   epi-­‐
lipoxin	   would	   help	   us	   to	   determine	   whether	   epi-­‐lipoxin	   administration	   was	   indeed	  
promoting	  resolution.	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Additionally,	   to	   investigate	   whether	   the	   actions	   of	   epi-­‐lipoxin	   in	   the	   utero-­‐placental	  
tissues	  are	  mediated	  by	  the	  lipoxin	  receptor,	  Fpr2,	  the	  experiments	  could	  be	  repeated	  
using	  Fpr2	  knockout	  mice	   (Dufton	  et	  al.	   2010)	  or	  mice	   could	  be	  pre-­‐treated	  with	   the	  
specific	   lipoxin	   receptor	   antagonist	   butoxycarbonyl-­‐Phe-­‐Leu-­‐Phe-­‐Leu-­‐Phe	   (Boc-­‐2)	  
(Menezes-­‐de-­‐Lima	  et	  al.	  2006,	  Wang	  et	  al.	  2011),	   to	  examine	  whether	   inhibiting	  Fpr2	  
signalling	  alters	  the	  effects	  of	  epi-­‐lipoxin	  treatment	  in	  our	  model.	  	  	  	  
It	  should	  also	  be	  noted,	  that	  the	  doses	  of	  epi-­‐lipoxin	  administered	  in	  the	  6	  hour	  analysis	  
studies,	  were	  different	  to	  the	  original	  doses	  of	  lipoxin	  administered	  in	  the	  initial	  time	  to	  
delivery	   experiments.	   	   The	   rationale	   behind	   increasing	   our	   doses	   of	   lipoxin	   was	   to	  
maximise	   the	   potential	   anti-­‐inflammatory	   actions	   of	   lipoxin.	   	   Similarly,	   when	   lipoxin	  
was	   administered	  directly	   into	   the	  uterus,	   the	  doses	  were	   reduced	   as	   lower	  doses	  of	  
lipoxin	  have	  been	  administered	  locally	  in	  other	  animal	  models,	  compared	  to	  the	  doses	  
used	  for	  systemic	  administration	  (Clish	  et	  al.	  1999,	  Conte	  et	  al.	  2010).	  	  	  As	  stated	  earlier,	  
all	   doses	  of	   epi-­‐lipoxin	  administered	   in	   the	   course	  of	   this	   study	  were	  well	  within	   the	  
range	  of	  doses	  which	  have	  been	  proved	  to	  be	  effective	  in	  other	  models	  (Levy	  et	  al.	  2002,	  
El	  Kebir	  et	  al.	  2009,	  Kure	  et	  al.	  2009,	  Conte	  et	  al.	  2010,	  Borgeson	  et	  al.	  2011,	  Zhou	  et	  al.	  
2011).	   	  Therefore,	  although	  the	  doses	  of	   lipoxin	  are	  not	  directly	  comparable	  between	  
the	   different	   experiments,	   it	   is	   unlikely	   that	   this	   had	   a	  major	   impact	   on	   the	   results;	  
however,	  it	  may	  be	  easier	  to	  elucidate	  the	  effects	  of	  lipoxin	  action	  if	  the	  same	  doses	  are	  
used	  throughout	  future	  experiments.	  	  	  
	  
Effect	  of	  BML-­‐111	  pre-­‐treatment	  on	  LPS-­‐induced	  PTL	  and	  neonatal	  outcome	  
As	  previously	  discussed,	   lipoxins	   are	   rapidly	  metabolised	   and	  have	   a	   short	   biological	  
half-­‐life	   in	  vivo,	   therefore,	  research	  has	   focused	  on	  developing	  stable	  synthetic	   lipoxin	  
and	  epi-­‐lipoxin	  analogues	  which	  are	  more	  resistant	  to	  metabolism	  (Serhan	  et	  al.	  1995,	  
Maddox	   et	   al.	   1997).	   	   BML-­‐111	   (5(S),6(R),7-­‐trihydroxymethyl	   heptanoate)	   is	   a	  
commercially	  available	  truncated	  analogue	  of	  lipoxin	  A4	  which	  is	  an	  FPR2	  agonist	  and	  
has	   been	   shown	   to	   be	   as	   potent	   as	   lipoxin	   A4	   in	   inhibiting	   leukotriene-­‐induced	  
neutrophil	  migration	  in	  vitro	  (Lee	  et	  al.	  1991)	  and	  has	  been	  found	  to	  have	  potent	  anti-­‐
inflammatory	   actions	   when	   administered	   in	   vivo	   in	   a	   number	   of	   animal	   models	   of	  
inflammation-­‐associated	   pathologies	   such	   as	   acute	   liver	   injury	   (Zhang	   et	   al.	   2007),	  
arthritis	   (Zhang	   et	  al.	   2008,	   Conte	   et	  al.	   2010),	   hepatocellular	   carcinoma	   (Chen	   et	  al.	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2010,	  Hao	  et	  al.	  2011),	  acute	  lung	  injury	  (Gong	  et	  al.	  2012)	  and	  in	  a	  model	  of	  low-­‐dose	  
endotoxin	  induced	  pre-­‐eclampsia	  (Lin	  et	  al.	  2012).	  	  Therefore,	  we	  wanted	  to	  investigate	  
whether	  administration	  of	  this	  stable	  lipoxin	  analogue	  in	  our	  model	  would	  delay	  LPS-­‐
induced	  preterm	  labour	  and	  improve	  the	  proportion	  of	  live	  born	  pups.	  	  	  	  
We	   found	   that	   pre-­‐treatment	  with	  BML-­‐111	  prior	   to	   intrauterine	  PBS	   administration	  
had	   no	   effect	   on	   the	   time	   to	   delivery	   compared	   to	   the	   vehicle	   control	   group.	   	   Pre-­‐
treatment	   with	   BML-­‐111	   prior	   to	   intrauterine	   LPS	   administration	   also	   did	   not	  
significantly	  affect	  LPS-­‐induced	  time	  to	  delivery,	  although	  the	  mean	  time	  to	  delivery	  in	  
mice	   receiving	  1mg/kg	  BML-­‐111	  prior	   to	  LPS	  was	  14	  hours	   later,	   compared	   to	   those	  
mice	  receiving	  LPS	  alone,	  however	   this	  was	  not	  statistically	  significant.	   	   Interestingly,	  
when	  examining	  the	  preterm	  delivery	  rates	  in	  the	  different	  treatment	  groups,	  we	  found	  
that	   pre-­‐treatment	   with	   1mg/kg	   BML-­‐111	   significantly	   reduced	   the	   rate	   of	   preterm	  
delivery	   from	  86%	   to	  55%	   (RR	  0.64,	   95%	  CI	  0.41-­‐0.98);	   thus	   although	  BMl-­‐111	  pre-­‐
treatment	  was	  not	  associated	  with	  an	  overall	   reduction	   in	   the	   time	  to	  delivery,	   fewer	  
mice	  in	  this	  group	  delivered	  preterm.	  	  	  	  
Similar	   to	   the	   effect	   of	   epi-­‐lipoxin	   pre-­‐treatment,	   we	   observed	   that	  mice	   pre-­‐treated	  
with	   the	  higher	  dose	  of	  BML-­‐111,	  10mg/kg,	  had	  an	   increased	  proportion	  of	   live	  born	  
pups,	   compared	  with	   LPS	   treatment	   alone,	   but	   this	  was	  not	   found	   to	   be	   a	   significant	  
increase.	   	  However,	   the	  reduction	   in	  the	  proportion	  of	   live	  born	  pups	  associated	  with	  
LPS	  treatment,	  was	  no	  longer	  significantly	  different	  compared	  to	  the	  BML-­‐111	  control	  
group	   in	   mice	   pre-­‐treated	   with	   BML-­‐111	   prior	   to	   intrauterine	   LPS,	   suggesting	   that	  
BML-­‐111	  may	   be	   reducing	   the	   effects	   of	   LPS	   on	   pup	   death,	   however	   it	   is	   difficult	   to	  
draw	   a	   firm	   conclusion	   from	   the	   current	   data.	   	   Similarly	   when	   examining	   the	  
proportion	   of	   live	   born	   pups	   in	  mice	   delivery	   preterm,	  we	   found	   that	   pre-­‐treatment	  
with	  10mg/kg	  BML-­‐111	  prior	  to	  intrauterine	  LPS	  administration	  appeared	  to	  increase	  
the	  proportion	  of	  live	  born	  pups	  to	  a	  level	  which	  was	  no	  longer	  significantly	  different	  to	  
the	  BML-­‐111	  control	  group.	  	  However,	  again	  this	  was	  not	  significantly	  greater	  than	  the	  
proportion	   of	   live	   born	   pups	   in	   the	   LPS	   alone	   group,	   so	  whilst	   this	  may	   support	   the	  
hypothesis	   that	  BML-­‐111	   is	  attenuating	   the	  LPS-­‐induced	  effects	  on	  pup	  mortality,	   the	  
data	  is	  currently	  not	  conclusive.	  	  	  
Given	   that	  BML-­‐111	  has	  been	   found	   to	  have	   similar	   actions	   to	   lipoxins	   in	  vivo	   and	   in	  
vitro,	   as	   discussed	   above,	   it	   is	   possible	   that	   any	   beneficial	   effect	   of	   BML-­‐111	   on	   the	  
proportion	  of	  live	  born	  pups	  may	  be	  occurring	  via	  the	  same	  mechanisms	  hypothesised	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above	  for	  epi-­‐lipoxin.	  	  These	  results	  require	  confirmation	  in	  other	  studies,	  but	  they	  do	  
suggest	  that,	  similar	  to	  epi-­‐lipoxin,	  pre-­‐treatment	  with	  BML-­‐111	  may	  be	  protecting	  the	  
pups	  from	  the	  negative	  effects	  of	  being	  born	  prematurely;	  and	  additionally	  appears	  to	  
reduce	  the	  rate	  of	  LPS-­‐induced	  preterm	  delivery.	  	  To	  better	  understand	  how	  BML-­‐111	  
may	   be	   acting,	   tissue	   collection	   and	   analysis	   at	   a	   fixed	   time-­‐point	   would	   need	   to	   be	  
performed.	   	   Support	   for	   the	   therapeutic	   potential	   of	   BML-­‐111	   in	   treating	   infection-­‐
induced	   preterm	   labour,	   comes	   from	   a	   rat	   model	   of	   low-­‐dose	   LPS-­‐induced	   pre-­‐
eclampsia	   (Lin	   et	   al.	   2012),	   which	   demonstrated	   that	   BML-­‐111	   administration	   can	  
attenuate	  another	  inflammation-­‐associated	  pregnancy	  pathology,	  that	  of	  pre-­‐eclampsia.	  	  
Interestingly	   Lin	   et	   al.	   also	   used	   repeated	   BML-­‐111	   administration,	   therefore,	   again	  
highlighting	   repeat	   administration	   of	   lipoxins	   as	   a	   possible	   alteration	   of	   the	   study	  
design	  used	  here.	  	  	  	  
	  
Effect	  of	  IL-­‐10	  pre-­‐treatment	  on	  LPS-­‐induced	  PTL	  and	  neonatal	  outcome	  
IL-­‐10	  is	  a	  classical	  anti-­‐inflammatory	  cytokine	  that	  has	  been	  previously	  shown	  to	  play	  
an	  important	  role	  in	  protecting	  mice	  from	  LPS-­‐induced	  preterm	  labour	  (Robertson	  et	  al.	  
2006).	   	   Robertson	   et	   al	   demonstrated	   that	   IL-­‐10	   knockout	   mice	   required	   a	   ten-­‐fold	  
lower	  dose	  of	  LPS	  to	  induce	  50%	  preterm	  fetal	  loss	  compared	  to	  wild-­‐type	  animals;	  and	  
LPS	   treatment	   induced	   significantly	   greater	   production	   of	   inflammatory	   cytokines	   in	  
the	  serum,	  uterus,	  placenta	  and	  fetus	  in	  IL-­‐10	  knockout	  animals,	  compared	  to	  wild-­‐type	  
animals	   receiving	   LPS.	   	   Exogenous	   administration	   of	   recombinant	   IL-­‐10	   to	   both	  
knockout	  and	  wild-­‐type	  animals	   reduced	   the	  negative	  effects	  of	  LPS	  on	   fetal	   loss	  and	  
reduced	  LPS-­‐induced	   inflammatory	  signalling.	   	  Also	  previous	  work	   in	  a	   rat	  models	  of	  
infection-­‐induced	  preterm	  birth	  demonstrated	  that	  administration	  of	  exogenous	  IL-­‐10	  
significantly	   delayed	   LPS-­‐induced	   preterm	   delivery	   and	   improved	   pup	   survival	   rates	  
(Terrone	  et	  al.	  2001);	  and	  inhibited	  E.Coli-­‐induced	  white	  matter	  damage	  in	  pup	  brains	  
(Rodts-­‐Palenik	  et	  al.	  2004,	  Pang	  et	  al.	  2005).	  	  Furthermore,	  evidence	  from	  a	  non-­‐human	  
primate	   model	   showed	   that	   IL-­‐10	   treatment	   attenuated	   IL-­‐1β-­‐induced	   uterine	  
contractions	   and	   reduced	   leukocyte	   influx	   and	   inflammatory	  mediator	   production	   in	  
the	  amniotic	  fluid	  (Sadowsky	  et	  al.	  2003).	  	  Collectively,	  these	  studies	  suggest	  that	  IL-­‐10	  
treatment	   could	   be	   a	   useful	   therapeutic	   option	   in	   the	   treatment	   of	   infection-­‐induced	  
preterm	   labour.	  Therefore,	  we	  wanted	   to	   investigate	  whether	   IL-­‐10	  administration	   in	  
our	  model	  had	  similar	  effects	  in	  reducing	  time	  to	  delivery	  and	  improving	  pup	  survival.	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In	  contrast	   to	   these	  previous	  studies,	  we	  did	  not	  observe	  any	  beneficial	  effect	  of	  pre-­‐
treatment	  with	   IL-­‐10	  on	  LPS-­‐induced	  preterm	  delivery	  or	   the	  proportion	  of	   live	  born	  
pups.	  	  Similar	  to	  the	  results	  described	  above,	  administration	  of	  the	  higher	  dose	  of	  IL-­‐10,	  
10µg,	  prior	  to	  intrauterine	  LPS	  treatment,	  did	  increase	  the	  proportion	  of	  live	  born	  pups	  
to	   a	   level	  more	   similar	   to	   the	   10µg	   IL-­‐10	   control	   group,	   compared	   to	   LPS	   treatment	  
alone;	  however,	  the	  difference	  was	  not	  statistically	  significant.	  	  The	  reasons	  why	  IL-­‐10	  
has	   not	   worked	   in	   our	   model,	   in	   comparison	   with	   previously	   published	   data,	   are	  
unclear.	  	  However,	  we	  had	  problems	  with	  our	  vehicle	  control	  mice	  in	  the	  cohort	  of	  mice	  
used	   in	  these	  experiments,	  where	  a	  higher	  than	  normal	  number	  of	  mice	   in	  this	  group	  
delivered	  prematurely	   (45%),	   and	  we	  also	  observed	   increased	  variability	   in	   terms	  of	  
the	  effectiveness	  of	  LPS	  to	  induce	  preterm	  labour	  as	  well,	  thus	  resulting	  in	  no	  treatment	  
significantly	   affecting	   the	   preterm	   delivery	   rate	   in	   this	   cohort.	   The	   doses	   of	  
recombinant	  IL-­‐10	  used	  were	  based	  on	  the	  dose	  used	  in	  the	  work	  by	  Robertson	  et	  al,	  
where	   they	   demonstrated	   an	   effect	   of	   2.5µg	   in	   the	   effects	   of	   LPS-­‐induced	   preterm	  
labour.	   	   However,	   our	   model	   differs	   from	   theirs,	   in	   that	   they	   administer	   LPS	  
systemically,	  via	  i.p.	  injection;	  and	  also	  use	  a	  different	  type	  of	  LPS,	  which	  could	  explain	  
some	  of	  the	  differences	  we	  have	  observed.	   	  Another	  possibility	   is	   that	  perhaps	  higher	  
doses	  of	   IL-­‐10	   are	   required	   to	   attenuate	  LPS-­‐induced	  preterm	  delivery	   in	  our	  model.	  	  
Although	  there	  appears	  to	  be	  no	  effect	  on	  time	  to	  delivery,	  there	  is	  a	  trend	  towards	  an	  
increased	   proportion	   of	   live	   born	   pups	   in	  mice	   pre-­‐treated	  with	   10µg	   IL-­‐10	   prior	   to	  
intrauterine	  LPS,	  so	  it	  would	  be	  interesting	  to	  test	  whether	  increasing	  the	  does	  of	  IL-­‐10	  
may	   further	   increase	   the	   proportion	   of	   live	   born	   pups.	   	   The	   2.5µg	   dose	   was	   chosen	  
based	  on	  the	  work	  by	  Robertson	  et	  al	  (Robertson	  et	  al.	  2006),	  and	  the	  10µg	  dose	  was	  
chosen	   based	   a	   model	   demonstrating	   it	   as	   a	   suitable	   dose	   to	   protect	   mice	   from	  
endotoxin-­‐induced	  death	  (Howard	  et	  al.	  1993),	  where	  they	  used	  the	  same	  strain	  of	  LPS	  
as	  we	  have	  used	  in	  our	  study.	  	  	  	  
Although	   no	   significant	   effects	   of	   IL-­‐10	   treatment	  were	   observed	   in	   our	   study,	   IL-­‐10	  
warrants	   further	   investigation	   as	   a	   potential	   therapeutic	   agent	   in	   the	   treatment	   of	  
preterm	   labour	   as	   it	   appears	   capable	   of	   reducing	   the	   negative	   affects	   of	   LPS	   on	   pup	  
mortality.	   The	   experiments	   would	   need	   to	   be	   repeated	   in	   another	   cohort	   of	   mice,	  
perhaps	  using	  a	  new	  batch	  of	  LPS	  and	  examining	  a	  higher	  dose	  of	  IL-­‐10	  pre-­‐treatment.	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Summary	  
This	   chapter	   has	   investigated	   and	   discussed	   the	   potential	   of	   three	   anti-­‐inflammatory	  
agents	   to	   delay	   LPS-­‐induced	   preterm	   delivery	   and	   improve	   pup	   survival	   in	   a	  mouse	  
model	  of	  preterm	  labour.	  	  This	  is	  the	  first	  study	  to	  investigate	  the	  potential	  of	  the	  dual	  
acting	   anti-­‐inflammatory	   and	   pro-­‐resolution	   mediators,	   lipoxins,	   and	   their	   stable	  
analogue,	   BML-­‐111	   in	   a	   mouse	   model	   of	   infection-­‐induced	   preterm	   labour.	  	  
Interestingly	   although	   pre-­‐treatment	   with	   epi-­‐lipoxin	   prior	   to	   intrauterine	   LPS	  
administration	   did	   not	   delay	   LPS-­‐induced	   preterm	   labour,	   the	   mice	   that	   delivered	  
prematurely	  had	  a	  significantly	  increased	  proportion	  of	  live	  born	  pups,	  compared	  with	  
mice	   receiving	   LPS	   alone;	   suggesting	   that	   epi-­‐lipoxin	   is	   in	   some	   way	   protecting	   the	  
fetuses	   from	   the	   negative	   effects	   of	   preterm	   birth	   and/or	   LPS	   treatment.	   	   The	  
mechanisms	  by	  which	  epi-­‐lipoxin	  may	  be	  acting	  to	  improve	  pup	  survival	  in	  our	  model	  
are	   not	   currently	   clear,	   as	   we	   only	   investigated	   one	   (early)	   time	   point	   after	   lipoxin	  
administration,	  but	  since	  epi-­‐lipoxin	   increases	  expression	  of	  Cox-­‐2,	  which	  is	  known	  to	  
be	   important	   in	   initiation	   the	   resolution	   phase	   of	   an	   inflammatory	   response,	   we	  
propose	  that	  it	  may	  involve	  increased	  production	  of	  anti-­‐inflammatory	  prostaglandins,	  
such	  as	  PGD2	  and	  15d-­‐PGJ2,	  which	  may	  attenuate	  LPS-­‐induced	  inflammatory	  signalling.	  	  
Similarly,	   the	   data	   presented	   here	   suggest	   that	   BML-­‐111	  may	   be	   another	   potentially	  
useful	  anti-­‐inflammatory	  therapeutic	  option,	  given	  that	  we	  observed	  a	  reduction	  in	  the	  
preterm	  delivery	   rate	  of	  mice	  pre-­‐treated	  with	  BML-­‐111	   compared	   to	  mice	   receiving	  
LPS	  alone,	  and	  again	  we	  saw	  a	  trend	  for	  a	  greater	  proportion	  of	  live	  pups	  being	  born	  to	  
mice	  pre-­‐treated	  with	  BML-­‐111	  prior	  to	  intrauterine	  LPS,	  compared	  to	  mice	  receiving	  
LPS	   alone.	   	   Finally,	   in	   our	   model,	   pre-­‐treatment	   with	   IL-­‐10	   was	   not	   found	   to	  
significantly	   attenuate	   LPS-­‐induced	   preterm	   delivery	   or	   significantly	   improve	   the	  
proportion	  of	  live	  born	  pups,	  however	  there	  was	  a	  similar	  trend	  as	  observed	  with	  both	  
epi-­‐lipoxin	  and	  BML-­‐111,	  whereby	  a	  greater	  proportion	  of	  live	  pups	  were	  born	  to	  mice	  
pre-­‐treated	  with	  IL-­‐10	  prior	  to	  intrauterine	  LPS.	  	  Therefore,	  taken	  together,	  these	  data	  
suggest	   that	   anti-­‐inflammatory	   agents,	   in	   particular	   lipoxins,	   may	   be	   useful	   novel	  
therapeutic	   options	   in	   the	   treatment	   of	   preterm	   labour,	  which	  may	   protect	   the	   fetus	  
from	   the	   adverse	   effects	   of	   infection-­‐induced	  preterm	  birth,	   thus	   improving	  neonatal	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5.1 INTRODUCTION	  
Parturition,	   both	   at	   term	   and	   preterm,	   is	   associated	   with	   an	   immune	   cell	   influx,	  
particularly	  of	  neutrophils	  and	  macrophages,	  into	  the	  intrauterine	  tissues	  (Thomson	  et	  
al.	  1999,	  Osman	  et	  al.	  2003,	  Gomez-­‐Lopez	  et	  al.	  2010).	   	   In	  women,	  macrophages	  have	  
been	  reported	  to	  influx	  into	  the	  myometrium,	  fetal	  membranes,	  decidua,	  placenta	  and	  
cervix	   during	   spontaneous	   term	   labour	   (Thomson	   et	   al.	   1999,	   Osman	   et	   al.	   2003,	  
Gomez-­‐Lopez	  et	  al.	   2009,	  Gomez-­‐Lopez	  et	  al.	   2010),	   and	  also	   into	   the	  decidua	  during	  
preterm	  labour	  (Hamilton	  et	  al.	  2012).	  	  Neutrophils	  are	  proposed	  to	  play	  an	  important	  
role	   in	   stimulating	   cervical	   ripening	   in	  women	   (Bokström	  et	  al.	   1997)	  and	  have	  been	  
shown	   to	   infiltrate	   into	   both	   the	  myometrium	   and	   cervix	   in	   association	  with	   normal	  
term	   labour	   (Thomson	   et	  al.	   1999,	   Osman	   et	  al.	   2003).	   	   Interestingly,	  Hamilton	   et	  al.	  
recently	  reported	  that	  neutrophil	  numbers	  were	  increased	  in	  the	  decidua	  of	  women	  in	  
infection-­‐associated	  preterm	  labour,	  when	  compared	  with	  women	  in	  either	  idiopathic	  
preterm	  or	  normal	  term	  labour	  (Hamilton	  et	  al.	  2012).	  
What	  role	  these	  immune	  cells	  play	  in	  the	  induction	  of	  labour,	  either	  in	  the	  presence	  of	  
an	   intrauterine	   infection	  or	  normally	  at	   term	   is	  unclear;	  however,	  previous	  work	  has	  
shown	   that	   infiltrating	   leukocytes	   are	   a	   major	   source	   of	   inflammatory	   mediator	  
production,	  including	  IL-­‐1β,	  TNF-­‐α,	  IL-­‐8,	  IL-­‐6	  and	  MMP-­‐9	  in	  the	  utero-­‐placental	  tissues	  
during	   labour	  (Roh	  et	  al.	  2000,	  Helmig	  et	  al.	  2002,	  Young	  et	  al.	  2002),	  suggesting	   that	  
immune	   cells	   are	   likely	   to	   contribute	   to	   the	   inflammatory	   response	   surrounding	  
parturition.	  	  
Therefore,	  using	  antibody-­‐mediated	  immune	  cell	  depletion	  in	  our	  mouse	  model	  of	  LPS-­‐
induced	   preterm	   labour,	   the	  work	   described	   in	   this	   chapter	   aimed	   to	   investigate	   the	  
role	  of	  neutrophils	  and	  macrophages	  in	  infection-­‐induced	  preterm	  labour.	  	  Specifically,	  
this	  work	  aimed	  to	  investigate	  whether	  neutrophils	  or	  macrophages	  were	  required	  for	  
the	   induction	   of	   preterm	   labour	   in	   response	   to	   intrauterine	   LPS;	   and	   to	   examine	  
whether	   these	   immune	  cell	  populations	  contributed	  to	   the	  LPS-­‐induced	   inflammatory	  
response	  observed	  in	  the	  utero-­‐placental	  tissues.	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5.2 METHODS	  
5.2.1 Mouse	  model	  of	  PTL	  
To	   investigate	   the	   role	   of	   specific	   immune	   cell	   populations	   in	   LPS-­‐induced	   preterm	  
labour,	  antibody-­‐based	  depletion	  strategies	  were	  used	  to	  deplete	  either	  neutrophils	  or	  
macrophages	   and	   to	   examine	   the	   effect	   of	   such	   depletion	   on	   LPS-­‐induced	   preterm	  
labour	  and	  the	  inflammatory	  response	  within	  the	  utero-­‐placental	  tissues.	  	  Neutrophils	  
were	   depleted	   using	   two	   different	   antibodies,	   either	   anti-­‐Gr-­‐1	   or	   anti-­‐Ly-­‐6G,	   and	  
macrophages	  were	  depleted	  using	  anti-­‐F4/80.	  	  	  
5.2.1.1 Anti-­‐Gr-­‐1	  experiments	  
On	   D16	   of	   gestation,	   mice	   received	   an	   intra-­‐peritoneal	   injection	   of	   either	   a	   rat	   anti-­‐
mouse	  anti-­‐Gr-­‐1	  antibody	  (clone	  RB6-­‐8C5;	  n=5)	  or	  a	  rat	  IgG2b	  isotype	  control	  antibody	  
n=5),	   at	   a	   dose	   of	   250µg	   in	   a	   volume	   of	   500µl.	   	   The	   following	   day,	  mice	   underwent	  
surgery	  as	  detailed	  in	  section	  2.1	  and	  received	  an	  intrauterine	  injection	  of	  20µg	  LPS.	  	  	  
5.2.1.2 Anti-­‐Ly-­‐6G	  experiments	  
On	   D16	   of	   gestation,	   mice	   received	   an	   intra-­‐peritoneal	   injection	   of	   either	   a	   rat	   anti-­‐
mouse	   anti-­‐Ly-­‐6G	   antibody	   (clone	   1A8;	   n=8)	   or	   a	   rat	   IgG2a	   isotype	   control	   antibody	  
(n=8),	   at	   a	   dose	   of	   500µg	   in	   a	   volume	  of	   500µl.	   	   The	   following	   day,	  mice	   underwent	  
surgery	  as	  detailed	  in	  section	  2.1	  and	  received	  an	  intrauterine	  injection	  of	  20µg	  LPS.	  	  	  
5.2.1.3 Anti-­‐F4/80	  experiments	  
On	   D17	   of	   gestation,	   mice	   received	   an	   intra-­‐peritoneal	   injection	   of	   either	   rat	   anti-­‐
mouse	   anti-­‐F4/80	   antibody	   (n=6)	   or	   a	   rat	   IgG2a	   isotype	   control	   antibody	   (n=5),	   at	   a	  
dose	  of	  300µg	  in	  a	  volume	  of	  600µl.	  	  After	  4	  hours	  mice	  underwent	  surgery	  as	  detailed	  
in	  section	  2.1	  and	  received	  an	  intrauterine	  injection	  of	  20µg	  LPS.	  	  
In	   each	   experiment,	   time	   to	   delivery	   and	   the	   proportion	   of	   live	   born	   pups	   were	  
recorded	  following	  surgery,	  as	  detailed	  in	  sections	  2.1.1.	  and	  2.1.2	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5.2.2 Tissue	  collection	  
In	  separate	  cohorts	  of	  mice,	  utero-­‐placental	  tissues	  and	  maternal	  blood	  were	  collected	  
6	   hours	   post-­‐surgery,	   as	   detailed	   in	   section	   2.1.3,	   for	   confirmation	   of	   immune	   cell	  
depletion	   and	   analysis	   of	   the	   inflammatory	   response	   following	   neutrophil	   or	  
macrophage	  depletion.	   	   Some	  mice	  delivered	  before	   the	  6	  hour	   collection	   time	  point,	  
therefore	   it	   was	   not	   possible	   to	   collect	   utero-­‐placental	   tissues	   from	   these	   mice,	   but	  
maternal	  blood,	  spleen,	  liver,	  lung	  and	  cervix	  were	  still	  collected	  to	  confirm	  depletion	  in	  
these	  mice.	  
5.2.2.1 Anti-­‐Gr-­‐1	  experiments	  
Utero-­‐placental	   tissues	   were	   collected	   6	   hours	   post-­‐surgery	   from	   mice	   treated	   with	  
either	  the	  IgG	  control	  antibody+LPS	  (n=5)	  or	  anti-­‐Gr-­‐1+LPS	  (n=5)	  for	  qRT-­‐PCR	  analysis	  
and	   immunohistochemistry.	   	  Maternal	   blood	  was	   also	   collected	  6	   hours	   post-­‐surgery	  
from	  mice	   treated	   with	   either	   the	   IgG	   control	   antibody+LPS	   (n=6)	   or	   anti-­‐Gr-­‐1+LPS	  
(n=7)	  for	  flow	  cytometric	  and	  ELISA	  analysis.	  	  	  
5.2.2.2 Anti-­‐Ly-­‐6G	  experiments	  
Maternal	  blood	  and	  utero-­‐placental	   tissues	  were	   collected	  6	  hours	  post-­‐surgery	   from	  
mice	  treated	  with	  either	  the	  IgG	  control	  antibody+LPS	  (n=7)	  or	  anti-­‐Ly-­‐6G+LPS	  (n=5)	  
for	  analysis.	  	  
5.2.2.3 Anti-­‐F4/80	  experiments	  
Utero-­‐placental	   tissues	   were	   collected	   6	   hours	   post-­‐surgery	   from	   mice	   treated	   with	  
either	   the	   IgG	  control	  antibody+LPS	  (n=4)	  or	  anti-­‐F4/80+LPS	  (n=6).	   	  Maternal	  blood,	  
spleen,	   liver,	   lung	   and	   cervix	   were	   also	   collected	   6	   hours	   post-­‐surgery	   from	   mice	  
treated	  with	   either	   the	   IgG	   control	   antibody+LPS	   (n=5)	   or	   anti-­‐F4/80+LPS	   (n=7)	   for	  
analysis.	  	  	  	  	  
	  
5.2.3 Flow	  cytometry	  
Flow	  cytometry	  was	  used	  to	  confirm	  neutrophil	  depletion	  following	  anti-­‐Gr-­‐1	  and	  anti-­‐
Ly-­‐6G	  treatment,	  as	  detailed	  in	  section	  2.7.	  Maternal	  blood	  was	  collected	  6	  hours	  post-­‐
surgery	  and	  stained	  with	  anti-­‐CD45	  and	  anti-­‐Ly-­‐6G	  to	  identify	  circulating	  neutrophils.	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5.2.4 Immunohistochemistry	  
Immunohistochemistry	   was	   used	   to	   localise	   neutrophils	   in	   the	   uterus,	   and	  
macrophages	   in	   the	   uterus,	   cervix,	   spleen,	   liver	   and	   lung	   to	   examine	   whether	  
administration	   of	   the	   immune-­‐cell	   specific	   antibodies	   resulted	   in	   depletion	   of	   tissue-­‐
resident	  immune	  cells.	  	  To	  confirm	  depletion	  following	  anti-­‐Gr-­‐1	  treatment,	  neutrophils	  
were	   localised	   with	   anti-­‐Gr-­‐1	   in	   the	   uterus	   of	   mice	   treated	   with	   either	   IgG	   control	  
antibody+LPS	  (n=5)	  or	  anti-­‐Gr-­‐1+LPS	  (n=5).	  	  To	  confirm	  depletion	  following	  anti-­‐Ly-­‐6G	  
treatment,	   neutrophils	   were	   localised	   with	   anti-­‐Ly-­‐6G	   in	   the	   uterus	   of	   mice	   treated	  
with	   either	   IgG	   control	   antibody+LPS	   (n=7)	   or	   anti-­‐Ly-­‐6G+LPS	   (n=5).	   Macrophages	  
were	   localised	   using	   anti-­‐F4/80	   in	   uterine	   tissue,	   spleen,	   liver,	   lung	   and	   cervix	  
harvested	   from	  mice	   treated	  with	   IgG+LPS	   (n=4)	   or	   anti-­‐F4/80+LPS	   (n=6).	   	   Staining	  
protocols	  are	  detailed	  in	  section	  2.5.2.	  	  	  
	  
5.2.5 qRT-­‐PCR	  
The	  mRNA	  expression	  of	  several	  inflammatory	  genes	  was	  examined	  using	  qRT-­‐PCR	  as	  
described	  in	  section	  2.3.	  	  Expression	  of	  the	  following	  genes	  was	  quantified	  in	  the	  uterus,	  
fetal	  membranes	  and	  placenta	  of	  mice	  6	  hours	  post-­‐surgery:	  Tnf-­‐α,	  Il-­‐1β,	  Il-­‐6,	  Il-­‐10,	  Cox-­‐
2,	  Cxcl1,	  Cxcl2,	  Cxcl5	  and	  Ccl2.	  	  
As	  described	   in	  section	  2.3.3,	  expression	  of	   the	  gene	  of	   interest	  was	  normalised	   to	  β-­‐
actin	   as	   the	   endogenous	   control	   gene	   in	   each	   sample	   and	   all	   samples	   were	   then	  
compared	  relative	  to	  a	  calibrator	  tissue,	  which	  was	  untreated	  D18	  uterus.	  	  
	  
5.2.6 ELISA	  
The	  concentration	  of	  TNF-­‐α	  in	  maternal	  serum	  following	  treatment	  with	  either	  the	  IgG	  
control	  antibodies+LPS	  or	  the	  immune	  cell	  specific	  antibodies+LPS	  was	  determined	  by	  
ELISA.	  	  Details	  of	  the	  TNF-­‐α	  ELISA	  kit	  are	  given	  in	  section	  2.4.	  	  
	  
5.2.7 Statistical	  analysis	  
Data	  are	  presented	  as	  mean	  ±	  SEM.	   	   	  Where	  data	  were	  not	  normally	  distributed,	   they	  
were	  transformed	  prior	  to	  analysis.	  	  Time	  to	  delivery	  data	  were	  log	  transformed	  before	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analysis,	  and	  the	  proportion	  of	  live	  pups	  born	  was	  arc-­‐sin	  transformed	  prior	  to	  analysis.	  	  
Normally	   distributed	   data	   were	   then	   analysed	   by	   unpaired	   t-­‐tests	   between	   the	   IgG	  
control	   group	   and	   the	   group	   treated	  with	   the	   immune	   cell-­‐specific	   antibody.	   	   P<0.05	  
was	  considered	  statistically	  significant.	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5.3 RESULTS	  
5.3.1 Administration	  of	  anti-­‐Gr-­‐1	  to	  deplete	  neutrophils	  on	  day	  16	  of	  gestation	  
To	   investigate	   whether	   neutrophils	   were	   involved	   in	   LPS-­‐induced	   preterm	   labour	  
and/or	   the	   LPS-­‐induced	   inflammatory	   response	   in	   the	   utero-­‐placental	   tissues	   in	   our	  
model,	   neutrophils	   were	   depleted	   prior	   to	   intrauterine	   LPS	   administration	   using	   an	  
antibody-­‐based	   depletion	   strategy.	   	   The	   anti-­‐Gr-­‐1	   antibody	   (RB6-­‐8C5	   clone)	   is	  
commonly	   used	   to	   deplete	   neutrophils	   in	   in	   vivo	   mouse	   models	   (Kaitu'u-­‐Lino	   et	   al.	  
2007,	   Tate	   et	   al.	   2008,	   Gong	   and	   Koh	   2010).	   	   In	   our	  model,	   mice	   received	   an	   intra-­‐
peritoneal	   injection	   with	   either	   anti-­‐Gr-­‐1	   or	   an	   IgG	   control	   antibody	   on	   D16	   of	  
gestation,	   followed	   on	  D17	   of	   gestation	  with	   intrauterine	   LPS	   administration	   to	   both	  
groups.	  
To	   confirm	   that	   administration	   of	   the	   anti-­‐Gr-­‐1	   antibody	   successfully	   depleted	  
neutrophils	   in	   our	   model,	   circulating	   neutrophil	   numbers	   were	   assessed	   using	   flow	  
cytometry	  and	  LPS-­‐induced	  neutrophil	  recruitment	  to	  the	  uterus	  was	  examined	  using	  
immunohistochemistry.	  	  	  	  
	  
5.3.1.1 Depletion	  of	  circulating	  neutrophils	  
Blood	  samples	  were	  collected	  6	  hours	  post-­‐intrauterine	  LPS	  administration	  and	  stained	  
with	   anti-­‐CD45	   and	   anti-­‐Ly-­‐6G	   to	   assess	   the	   number	   of	   circulating	   neutrophils.	  	  
Representative	   flow	   cytometry	   plots	   from	   two	   control	   mice	   that	   received	   the	   IgG	  
control	   antibody	   and	   two	  mice	   that	   received	   anti-­‐Gr-­‐1	   are	   shown	   in	   Figure	   5.1.	   	   The	  
flow	   cytometry	   plots	   confirmed	   that	   blood	   harvested	   from	   mice	   receiving	   the	   IgG	  
control	   antibody	   contained	   a	   high	   percentage	   of	   circulating	   neutrophils	   (Figure	   5.1A	  
and	  Figure	  5.1B),	  while	  blood	  harvested	   from	  mice	   treated	  with	  anti-­‐Gr-­‐1	  had	  a	  very	  
low	  percentage	  of	  circulating	  neutrophils	  (Figure	  5.1C	  and	  Figure	  5.1D).	   	  Additionally,	  
quantification	   of	   the	   neutrophils	   confirmed	   that	   administration	   of	   anti-­‐Gr-­‐1	   antibody	  
significantly	  reduced	  the	  number	  of	  circulating	  neutrophils	  compared	  to	  the	  IgG	  control	  
group	  (mean	  number	  of	  neutrophils/ml	  of	  blood	  in	  IgG	  control	  group:	  3.67x106	  ±	  SEM	  
0.21	  vs.	  mean	  number	  of	  neutrophils/ml	  of	  blood	  in	  anti-­‐Gr-­‐1	  group:	  0.0063x106	  ±	  SEM	  
0.0018,	  p<0.001;	  Figure	  5.1E).	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Figure	   5.1-­‐	   Effect	   of	   anti-­‐Gr-­‐1	   administration	   on	   circulating	   blood	   neutrophils.	  	  
Flow	  cytometric	  analysis	  of	  maternal	  blood	  collected	  6	  hours	  post-­‐surgery	   from	  mice	  
treated	  with	  either	  anti-­‐Gr-­‐1	  antibody	  (n=7)	  or	  an	  IgG	  control	  antibody	  (n=6)	  prior	  to	  
intrauterine	  LPS	  administration.	  	  Cells	  were	  gated	  based	  on	  expression	  of	  CD45	  and	  Ly-­‐
6G.	  	  Representative	  flow	  plots	  from	  two	  mice	  treated	  with	  the	  IgG	  control	  antibody	  (A)	  
and	  (B);	  and	  from	  2	  mice	  treated	  with	  the	  anti-­‐Gr-­‐1	  antibody	  (C)	  and	  (D).	  	  The	  number	  
given	  beside	  each	  gated	  region	  indicates	  the	  percentage	  of	  neutrophils	  counted	  out	  of	  
the	   total	   number	   of	   live	   cells.	   (E)	   The	   number	   of	   neutrophils	   per	  ml	   of	   blood.	   	   Data	  
presented	  as	  mean	  ±	  SEM;	  ***p<0.001.	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5.3.1.2 Effect	   of	   neutrophil	   depletion	   using	   anti-­‐Gr-­‐1	   on	   LPS-­‐induced	   neutrophil	  
recruitment	  to	  the	  uterus	  	  
To	  confirm	  that	  depletion	  of	  neutrophils	  using	  anti-­‐Gr-­‐1	  also	  blocked	  the	  LPS-­‐induced	  
recruitment	   of	   neutrophils	   into	   the	   uterus,	   uterine	   tissues	   was	   harvested	   on	   D17	   of	  
gestation	   6	   hours	   post-­‐intrauterine	   LPS	   administration	   from	   mice	   that	   received	   an	  
intra-­‐peritoneal	   injection	   of	   either	   an	   IgG	   control	   antibody,	   or	   anti-­‐Gr-­‐1	   on	   D16	   of	  
gestation.	  	  Immunohistochemistry	  using	  the	  anti-­‐Gr-­‐1	  antibody	  was	  then	  performed	  on	  
the	  fixed	  uterine	  tissue	  to	  localise	  Gr-­‐1	  positive	  cells	  within	  the	  uterus.	  	  
In	  mice	   treated	  with	   the	   IgG	  control	  antibody,	   intrauterine	  LPS	   treatment	   induced	  an	  
influx	  of	  Gr-­‐1	  positive	  cells	  into	  the	  myometrial	  tissue	  (Figure	  5.2A),	  and	  the	  decidua	  of	  
these	  mice	   (Figure	   5.2B).	   	   In	   contrast,	   no	  Gr-­‐1	   positive	   neutrophils	  were	   localised	   in	  
uterine	   tissue	   harvested	   from	   mice	   treated	   with	   anti-­‐Gr-­‐1	   prior	   to	   intrauterine	   LPS	  
administration,	  with	  both	  the	  myometrium	  (Figure	  5.2C)	  and	  the	  decidua	  (Figure	  5.2D)	  
clear	   of	   positive	   staining	   cells.	   	   Also,	   no	   positive	   staining	   was	   observed	   in	   negative	  
control	   sections	  of	  myometrium,	  which	  were	  not	   treated	  with	   the	  anti-­‐Gr-­‐1	  antibody,	  
thus	  confirming	  specificity	  of	  the	  staining	  observed	  (Figure	  5.2E)	  and	  decidua	  (Figure	  
5.2F).	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Figure	  5.2	  –	  Effect	  of	  anti-­‐Gr-­‐1	  treatment	  on	  neutrophil	  localisation	  in	  the	  uterus.	  	  	  
Uterine	  tissue	  was	  collected	  6	  hours	  post-­‐LPS	  treatment	  from	  mice	  treated	  with	  either	  
anti-­‐Gr-­‐1	  (n=5)	  or	  the	  IgG	  control	  antibody	  (n=5).	  	  Representative	  images	  of	  neutrophil	  
localisation	   by	   immunohistochemical	   staining	   for	   Gr-­‐1.	   	   Gr-­‐1	   positive	   cells	   were	  
localised	  to	  the	  myometrium	   (A)	  and	  decidua	   (B)	  of	  mice	  treated	  with	  the	  IgG	  control	  
antibody+LPS.	   	  No	  Gr-­‐1	  positive	  cells	  were	  present	   in	  mice	   treated	  with	  the	  anti-­‐Gr-­‐1	  
antibody+LPS	   (C)	  and	  (D).	   	  No	  positive	  staining	  was	  observed	  in	  the	  negative	  control	  
sections	  (E)	  and	  (F).	  	  Scale	  bars	  show	  50µm.	  	  All	  images	  taken	  with	  a	  x20	  objective	  lens.	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5.3.2 Effect	  of	  neutrophil	  depletion	  using	  anti-­‐Gr-­‐1	  on	  LPS-­‐induced	  preterm	  labour	  
To	   investigate	   whether	   the	   observed	   LPS-­‐induced	   neutrophil	   recruitment	   into	   the	  
uterus	  of	  mice	  was	  required	  for	  the	  induction	  of	  LPS-­‐induced	  preterm	  labour,	  on	  D16	  of	  
gestation	  mice	  received	  an	  intra-­‐peritoneal	   injection	  of	  either	  an	  IgG	  control	  antibody	  
or	  anti-­‐Gr-­‐1,	  followed	  on	  D17	  with	  an	  intrauterine	  injection	  of	  20µg	  LPS.	  	  The	  effect	  of	  
neutrophil	  depletion	  on	  LPS-­‐induced	  preterm	  labour	  was	  monitored.	  	  	  
	  
5.3.2.1 Time	  to	  delivery	  
There	  was	   no	   statistically	   significant	   difference	   in	   time	   to	   delivery	   between	   the	   two	  
treatment	   groups.	   	   If	   anything,	   a	   trend	   towards	   earlier	   delivery	   in	   the	   anti-­‐Gr-­‐1+LPS	  
group	  (mean	  time	  to	  delivery	  in	  anti-­‐Gr-­‐1	  group	  8.95	  hours	  ±	  SEM	  1.91;	  mean	  time	  to	  
delivery	   in	   IgG	   control	   group:	   33.3	   hours	   ±	   SEM	   7.99;	   p=0.12;	   Figure	   5.3A)	   was	  
observed.	  	  	  	  
	  
5.3.2.2 Proportion	  of	  live	  born	  pups	  
Similarly,	  mice	  treated	  with	  anti-­‐Gr-­‐1+LPS	  had	  a	  reduced	  proportion	  of	  live	  born	  pups	  
compared	  to	  the	  IgG+LPS	  control	  group	  (no	  live	  pups	  were	  born	  to	  mice	  treated	  with	  
anti-­‐Gr-­‐1+LPS,	  vs.	  mean	  proportion	  of	  live	  born	  pups	  in	  IgG+LPS	  group:	  0.3	  ±	  SEM	  0.13;	  
Figure	   5.3B);	   however	   this	   difference	   did	   not	   quite	   reach	   statistical	   significance	  
(p=0.051).	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Figure	  5.3	  –	  Effect	  of	  neutrophil	  depletion	  with	  anti-­‐Gr-­‐1	  on	  LPS-­‐induced	  preterm	  
delivery	  and	  the	  proportion	  of	  live	  born	  pups.	  	  	  Time	  to	  delivery	  and	  the	  proportion	  
of	   live	   born	   pups	   was	   monitored	   in	   mice	   treated	   with	   either	   the	   IgG	   control	  
antibody+LPS	   (n=5)	   or	   the	   anti-­‐Gr-­‐1	   antibody+LPS	   (n=5).	   (A)	   Time	   to	   delivery.	   	   (B)	  
Proportion	  of	  live	  born	  pups.	  	  Data	  are	  presented	  as	  mean	  ±	  SEM	  (error	  bars).	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5.3.3 LPS-­‐induced	   expression	   of	   inflammatory	   mediators	   in	   the	   utero-­‐placental	   tissues	  
following	  neutrophil	  depletion	  with	  anti-­‐Gr-­‐1	  
To	  investigate	  whether	  neutrophil	  depletion	  using	  the	  anti-­‐Gr-­‐1	  antibody	  affected	  LPS-­‐
induced	   inflammatory	   gene	   expression	   in	   the	   utero-­‐placental	   tissues,	   treated	   mice	  
were	   sacrificed	   6	   hours	   after	   intrauterine	   LPS	   injection.	  Utero-­‐placental	   tissues	  were	  
harvested	  and	  analysed	  by	  qRT-­‐PCR	  to	  measure	  the	  expression	  of	  Tnf-­‐α,	  Il-­‐1β,	  Il-­‐6,	  Il-­‐10,	  
Cox-­‐2,	  Cxcl1,	  Cxcl2,	  Cxcl5	  and	  Ccl2.	  	  	  
	  
5.3.3.1 Inflammatory	  gene	  expression	  in	  the	  uterus	  
There	  was	  no	  difference	  in	  Tnf-­‐α	  expression	  in	  the	  uterine	  tissue	  harvested	  from	  anti-­‐
Gr-­‐1+LPS	  mice,	  when	  compared	  to	  the	  IgG	  control+LPS	  group	  (Figure	  5.4A).	  	  
Expression	   of	   Il-­‐1β	   was	   significantly	   reduced	   in	   mice	   treated	   with	   anti-­‐Gr-­‐1+LPS,	  
compared	  to	  the	  IgG+LPS	  group	  (2.9-­‐fold	  lower	  expression,	  p<0.01;	  Figure	  5.4B).	  	  	  
Uterine	   expression	  of	   Il-­‐6	  (Figure	  5.4C),	   Il-­‐10	  (Figure	  5.4D),	  Cox-­‐2	  (Figure	  5.4E)	  Cxcl1	  
(Figure	  5.5A),	  Cxcl2	  (Figure	  5.5B),	  Cxcl5	  (Figure	  5.5C)	  and	  Ccl2	  (Figure	  5.5D)	  were	  also	  
not	   significantly	   different	   when	   comparing	   the	   anti-­‐Gr-­‐1	   treated	   mice	   with	   the	   IgG	  
control	  mice.	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Figure	   5.4	   –	   Effect	   of	   anti-­‐Gr-­‐1	   treatment	   on	   LPS-­‐induced	   inflammatory	   gene	  
expression	   in	   the	   uterus.	   	   	  Uterine	   tissue	  was	  harvested	  6	  hours	  post-­‐surgery	   from	  
mice	   treated	   with	   either	   the	   IgG	   control	   antibody+LPS	   (n=5)	   or	   the	   anti-­‐Gr-­‐1	  
antibody+LPS	   (n=5)	  and	   the	  expression	  of	   inflammatory	  genes	  was	  assessed	  by	  qRT-­‐
PCR.	   	   (A)	   Tnf-­‐α	   expression.	   (B)	   Il-­‐1β	   expression.	   (C)	   Il-­‐6	   expression	   (D)	   Il-­‐10	  
expression.	   	  (E)	  Cox-­‐2	  expression.	   	  Data	  presented	  as	  mean	   fold	  change	  ±	  SEM	  (error	  
bars);	  **p<0.01.	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Figure	   5.5	   –	   Effect	   of	   anti-­‐Gr-­‐1	   treatment	   on	   LPS-­‐induced	   inflammatory	  
chemokine	   expression	   in	   the	   uterus.	   	   	  Uterine	   tissue	  was	  harvested	  6	  hours	  post-­‐
surgery	  from	  mice	  treated	  with	  either	  the	  IgG	  control	  antibody+LPS	  (n=5)	  or	  the	  anti-­‐
Gr-­‐1	   antibody+LPS	   (n=5)	   and	   the	   expression	   of	   inflammatory	   chemokines	   was	  
assessed	  by	  qRT-­‐PCR.	  	  (A)	  Cxcl1	  expression.	  	  (B)	  Cxcl2	  expression.	  	  (C)	  Cxcl5	  expression.	  	  
(D)	  Ccl2	  expression.	  	  Data	  presented	  as	  mean	  fold-­‐change	  ±	  SEM	  (error	  bars).	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5.3.3.2 Inflammatory	  gene	  expression	  in	  the	  fetal	  membranes	  
In	   the	   fetal	   membranes,	   there	   was	   no	   difference	   in	   the	   expression	   of	   Tnf-­‐α	   (Figure	  
5.6A)	   or	   Il-­‐1β	   (Figure	   5.6B)	   when	   comparing	   mice	   treated	   with	   anti-­‐Gr-­‐1+LPS	   and	  
those	  treated	  with	  IgG+LPS.	  	  	  
Il-­‐6	   expression	  was	   significantly	   greater	   in	   the	   anti-­‐Gr-­‐1+LPS	   group	   compared	   to	   the	  
IgG	  control+LPS	  (3.0-­‐fold	  greater	  expression;	  p<0.05;	  Figure	  5.6C).	  	  
Expression	  of	   Il-­‐10	  was	  not	   altered	  by	  anti-­‐Gr-­‐1	   treatment,	   compared	   to	   the	   IgG+LPS	  
control	  group	  (Figure	  5.6D).	  	  	  
Cox-­‐2	   expression	   was	   significantly	   up-­‐regulated	   in	   mice	   treated	   with	   anti-­‐Gr-­‐1+LPS	  
compared	  to	  the	  IgG	  control+LPS	  (2.1-­‐fold	  greater	  expression;	  Figure	  5.6E).	  	  
The	  expression	  of	  Cxcl1,	  Cxcl2,	  Cxcl5	  and	  Ccl2	   in	  the	  fetal	  membranes	  was	  significantly	  
elevated	   in	   response	   to	   anti-­‐Gr-­‐1+LPS	   compared	   to	   the	   IgG	   control+LPS	   group.	  	  
Expression	  of	  Cxcl1	  was	  3.7-­‐fold	  greater	   (p<0.01;	  Figure	  5.7A).	   	  Cxcl2	  expression	  was	  
3.2-­‐fold	  higher	  in	  the	  anti-­‐Gr-­‐1	  group	  compared	  to	  the	  IgG	  group	  (p<0.01;	  Figure	  5.7B).	  	  
Expression	  of	  Cxcl5	  was	  3.6-­‐fold	  greater	   in	   the	  anti-­‐Gr-­‐1	  group	   (p<0.05;	  Figure	  5.7C).	  	  
Ccl2	  expression	  was	  3.3-­‐fold	  greater	  in	  the	  anti-­‐Gr-­‐1	  treatment	  group	  compared	  to	  the	  
IgG	  control	  group	  (p<0.05;	  Figure	  5.7D).	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Figure	   5.6	   –	   Effect	   of	   anti-­‐Gr-­‐1	   treatment	   on	   LPS-­‐induced	   inflammatory	   gene	  
expression	  in	  the	  fetal	  membranes.	  	  	  Fetal	  membranes	  were	  harvested	  6	  hours	  post-­‐
surgery	  from	  mice	  treated	  with	  either	  the	  IgG	  control	  antibody+LPS	  (n=5)	  or	  the	  anti-­‐
Gr-­‐1	   antibody+LPS	   (n=5)	   and	   the	   expression	  of	   inflammatory	   genes	  was	   assessed	  by	  
qRT-­‐PCR.	   	   (A)	   Tnf-­‐α	   expression.	   (B)	   Il-­‐1β	   expression.	   (C)	   Il-­‐6	   expression	   (D)	   Il-­‐10	  
expression.	   	  (E)	  Cox-­‐2	  expression.	   	  Data	  presented	  as	  mean	   fold	  change	  ±	  SEM	  (error	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Figure	   5.7	   -­‐	   Effect	   of	   anti-­‐Gr-­‐1	   treatment	   on	   LPS-­‐induced	   inflammatory	  
chemokine	  expression	  in	  the	  fetal	  membranes.	  	  	  Fetal	  membranes	  were	  harvested	  6	  
hours	  post-­‐surgery	  from	  mice	  treated	  with	  either	  the	  IgG	  control	  antibody+LPS	  (n=5)	  
or	   the	  anti-­‐Gr-­‐1	  antibody+LPS	   (n=5)	  and	   the	  expression	  of	   inflammatory	   chemokines	  
was	   assessed	   by	   qRT-­‐PCR.	   	   (A)	   Cxcl1	   expression.	   	   (B)	   Cxcl2	   expression.	   	   (C)	   Cxcl5	  
expression.	   	   (D)	  Ccl2	  expression.	   	   Data	   presented	   as	  mean	   fold-­‐change	   ±	   SEM	   (error	  
bars);	  *p<0.05,	  **p<0.01.	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5.3.3.3 Inflammatory	  gene	  expression	  in	  the	  placenta	  
There	   was	   no	   significant	   difference	   in	   Tnf-­‐α	   expression	   in	   the	   placental	   tissue	  
harvested	   from	   anti-­‐Gr-­‐1+LPS	   mice,	   when	   compared	   to	   the	   IgG	   control+LPS	   group	  
(Figure	  Figure	  5.8A).	  	  
Expression	   of	   Il-­‐1β	   was	   significantly	   reduced	   in	   mice	   treated	   with	   anti-­‐Gr-­‐1+LPS,	  
compared	  to	  the	  IgG+LPS	  group	  (1.7-­‐fold	  lower	  expression,	  p<0.01;	  Figure	  5.8B).	  	  	  
As	  was	   observed	   in	   the	   uterus,	   the	   expression	   of	   the	   remaining	   genes	   examined,	   Il-­‐6	  
(Figure	  5.8C),	  Il-­‐10	  (Figure	  5.8D),	  Cox-­‐2	  (Figure	  5.8E),	  Cxcl1	  (Figure	  5.9A),	  Cxcl2	  (Figure	  
5.9B),	  Cxcl5	  (Figure	  5.9C)	  and	  Ccl2	  (Figure	  5.9D)	  was	  unaffected	  by	  anti-­‐Gr-­‐1	  treatment	  
prior	  to	  intrauterine	  LPS,	  compared	  to	  those	  mice	  receiving	  IgG.	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Figure	   5.8	   –	   Effect	   of	   anti-­‐Gr-­‐1	   treatment	   on	   LPS-­‐induced	   inflammatory	   gene	  
expression	   in	   the	   placenta.	   	   	   Placental	   tissue	   was	   harvested	   6	   hours	   post-­‐surgery	  
from	   mice	   treated	   with	   either	   the	   IgG	   control	   antibody+LPS	   (n=5)	   or	   the	   anti-­‐Gr-­‐1	  
antibody+LPS	   (n=5)	  and	   the	  expression	  of	   inflammatory	  genes	  was	  assessed	  by	  qRT-­‐
PCR.	   	   (A)	   Tnf-­‐α	   expression.	   (B)	   Il-­‐1β	   expression.	   (C)	   Il-­‐6	   expression	   (D)	   Il-­‐10	  
expression.	   	  (E)	  Cox-­‐2	  expression.	   	  Data	  presented	  as	  mean	   fold	  change	  ±	  SEM	  (error	  
bars);	  *p<0.05.	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Figure	   5.9	   -­‐	   Effect	   of	   anti-­‐Gr-­‐1	   treatment	   on	   LPS-­‐induced	   inflammatory	  
chemokine	  expression	  in	  the	  placenta.	  	  	  Placental	  tissue	  was	  harvested	  6	  hours	  post-­‐
surgery	  from	  mice	  treated	  with	  either	  the	  IgG	  control	  antibody+LPS	  (n=5)	  or	  the	  anti-­‐
Gr-­‐1	   antibody+LPS	   (n=5)	   and	   the	   expression	   of	   inflammatory	   chemokines	   was	  
assessed	  by	  qRT-­‐PCR.	  	  (A)	  Cxcl1	  expression.	  	  (B)	  Cxcl2	  expression.	  	  (C)	  Cxcl5	  expression.	  	  
(D)	  Ccl2	  expression.	  	  Data	  presented	  as	  mean	  fold-­‐change	  ±	  SEM	  (error	  bars).	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5.3.4 Effect	  of	  anti-­‐Gr-­‐1	  administration	  on	  LPS-­‐induced	  serum	  TNF-­‐α 	  levels	  
As	   it	   has	   previously	   been	   reported	   that	   neutrophil	   depletion	   using	   the	   anti-­‐Gr-­‐1	  
antibody	   followed	  by	  LPS	  treatment	  resulted	   in	  elevated	  circulating	  TNF-­‐α	   levels	   in	  a	  
mouse	  model	  of	   endotoxaemia	   (Daley	  et	  al.	   2008),	  we	   investigated	  whether	  a	   similar	  
effect	  operated	  in	  our	  model.	  Blood	  was	  collected	  from	  mice	  6	  hours	  post-­‐intrauterine	  
LPS	  injection	  from	  mice	  treated	  with	  either	  the	  IgG	  control	  antibody	  or	  anti-­‐Gr-­‐1,	  and	  
the	  serum	  concentration	  of	  TNF-­‐α	  was	  measured	  by	  ELISA.	  	  	  
There	   was	   no	   statistically	   significant	   difference	   in	   the	  mean	   serum	   concentration	   of	  
TNF-­‐α	   in	   mice	   treated	   with	   anti-­‐Gr-­‐1+LPS	   compared	   to	   the	   IgG+LPS	   group	   (mean	  
concentration	  anti-­‐Gr-­‐1	   group:	  47.6	  pg/ml	  ±	   SEM	  18.5	  vs.	   IgG+LPS	  group:	  mean	  28.5	  
pg/ml	  ±	  SEM	  7.4;	  p=0.36;	  	  Figure	  5.10).	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Figure	  5.10	  –	  Effect	  of	  anti-­‐Gr-­‐1	  treatment	  on	  serum	  TNF-­‐α 	  levels.	  	  	  Maternal	  blood	  
was	   collected	   6	   hours	   post-­‐surgery	   from	   mice	   treated	   with	   either	   the	   IgG	   control	  
antibody+LPS	   (n=5)	   or	   the	   anti-­‐Gr-­‐1	   antibody+LPS	   (n=7)	   and	   ELISA	   was	   used	   to	  
quantify	   the	   serum	   concentration	   of	   TNF-­‐α.	   	   Data	   presented	   as	   mean	   ±	   SEM	   (error	  
bars).	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5.3.5 Administration	  of	  anti-­‐Ly-­‐6G	  to	  deplete	  neutrophils	  on	  day	  16	  of	  gestation	  
Whilst	  anti-­‐Gr-­‐1	   is	   commonly	  used	   to	  deplete	  neutrophils	   in	   in	  vivo	  models,	   it	   is	  now	  
understood	  that	  as	  this	  antibody	  recognises	  both	  Ly-­‐6G	  and	  Ly-­‐6C	  antigens	  (Fleming	  et	  
al.	  1993).	  	  Anti-­‐Gr-­‐1	  therefore	  not	  only	  depletes	  neutrophils,	  but	  may	  also	  deplete	  other	  
cells	  expressing	  Ly-­‐6C,	  such	  as	  some	  subsets	  of	  monocytes,	  T	  cells	  and	  dendritic	  cells	  
(Jutila	  et	  al.	  1988,	  Hestdal	  et	  al.	  1991,	  Kung	  et	  al.	  1991,	  Shortman	  and	  Naik	  2007,	  Daley	  
et	  al.	  2008).	  	  In	  order	  to	  further	  investigate	  the	  specific	  role	  of	  neutrophils	  in	  our	  model	  
of	   infection-­‐induced	   preterm	   labour,	   we	   repeated	   the	   depletion	   experiments	   using	   a	  
specific	  anti-­‐Ly-­‐6G	  antibody	  (1A8	  clone),	  which	  has	  been	  shown	  to	  successfully	  remove	  
neutrophils	  without	  altering	  other	   immune	  cell	  populations	   in	  vivo	   (Daley	  et	  al.	  2008,	  
Tate	   et	   al.	   2009,	   Wojtasiak	   et	   al.	   2010,	   Shi	   et	   al.	   2011).	   	   	   Mice	   received	   an	   intra-­‐
peritoneal	   injection	   with	   either	   anti-­‐Ly-­‐6G	   or	   an	   IgG	   control	   antibody	   on	   D16	   of	  
gestation,	   followed	   on	  D17	   of	   gestation	  with	   intrauterine	   LPS	   administration	   to	   both	  
groups.	  
To	   confirm	   that	   administration	   of	   the	   anti-­‐Ly-­‐6G	   antibody	   successfully	   depleted	  
neutrophils	   in	   our	  model,	   circulating	   neutrophil	   numbers	  were	   quantified	   using	   flow	  
cytometry	  and	  LPS-­‐induced	  neutrophil	  recruitment	  to	  the	  uterus	  was	  examined	  using	  
immunohistochemistry.	  	  	  	  
5.3.5.1 Depletion	  of	  circulating	  neutrophils	  
Blood	  samples	  were	  collected	  6	  hours	  post-­‐intrauterine	  LPS	  administration	  and	  stained	  
with	   anti-­‐CD45	   and	   anti-­‐Ly-­‐6G	   to	   assess	   the	   number	   of	   circulating	   neutrophils.	  	  
Representative	   flow	   cytometry	   plots	   from	   two	   control	   mice	   that	   received	   the	   IgG	  
control	  antibody	  and	  two	  mice	  that	  received	  anti-­‐Ly-­‐6G	  are	  shown	  in	  Figure	  5.11.	  	  Flow	  
cytometry	  analysis	  confirmed	  that	  blood	  harvested	  from	  mice	  receiving	  IgG	  contained	  a	  
high	  percentage	  of	  circulating	  neutrophils	  (Figure	  5.11A	  and	  Figure	  5.11B),	  while	  blood	  
harvested	  from	  mice	  treated	  with	  anti-­‐Ly-­‐6G	  had	  a	  very	  low	  percentage	  of	  circulating	  
neutrophils	   (Figure	   5.11C	   and	   Figure	   5.11D).	   	   Additionally,	   quantification	   of	   the	  
neutrophils	   present	   in	   the	   blood	   sample	   confirmed	   that	   administration	   of	   anti-­‐Ly-­‐6G	  
significantly	  reduced	  the	  number	  of	  circulating	  neutrophils	  compared	  to	  the	  IgG	  control	  
group	  (mean	  number	  of	  neutrophils/ml	  of	  blood	  in	  IgG	  control	  group:	  2.95x106	  ±	  SEM	  
0.35	  vs.	  mean	  number	  of	  neutrophils/ml	  of	  blood	  in	  anti-­‐Ly-­‐6G	  group:	  0.04x106	  ±	  SEM	  
0.02,	  p<0.001;	  Figure	  5.11E).	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Figure	  5.11	  -­‐	  Effect	  of	  anti-­‐Ly-­‐6G	  administration	  on	  circulating	  blood	  neutrophils.	  	  
Flow	  cytometric	  analysis	  of	  maternal	  blood	  collected	  6	  hours	  post-­‐surgery	   from	  mice	  
treated	  with	  either	  anti-­‐Ly-­‐6G	  antibody	  (n=7)	  or	  an	  IgG	  control	  antibody	  (n=7)	  prior	  to	  
intrauterine	  LPS	  administration.	  	  Cells	  were	  gated	  based	  on	  expression	  of	  CD45	  and	  Ly-­‐
6G.	  	  Representative	  flow	  plots	  from	  two	  mice	  treated	  with	  the	  IgG	  control	  antibody	  (A)	  
and	   (B);	   and	   from	   2	   mice	   treated	   with	   the	   anti-­‐Ly-­‐6G	   antibody	   (C)	   and	   (D).	   	   The	  
number	  given	  beside	  each	  gated	  region	  indicates	  the	  percentage	  of	  neutrophils	  counted	  
out	   of	   the	   total	   number	  of	   live	   cells.	   (E)	  The	  number	  of	   neutrophils	   per	  ml	   of	   blood.	  	  
Data	  presented	  as	  mean	  ±	  SEM;	  ***p<0.001.	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5.3.5.2 Effect	   of	   neutrophil	   depletion	   with	   anti-­‐Ly-­‐6G	   on	   LPS-­‐induced	   neutrophil	  
recruitment	  to	  the	  uterus	  	  
As	   in	   the	   anti-­‐Gr-­‐1	   experiments,	   immunohistochemistry	   was	   performed	   on	   uterine	  
tissue	  harvested	  6	  hours	  post-­‐intrauterine	  LPS	  administration,	  from	  mice	  treated	  with	  
either	  the	  IgG	  control	  antibody	  or	  anti-­‐Ly-­‐6G,	  to	  confirm	  that	  depletion	  of	  neutrophils	  
using	   anti-­‐Ly-­‐6G	   also	   blocked	   the	   LPS-­‐induced	   recruitment	   of	   neutrophils	   into	   the	  
uterus.	  	  Neutrophils	  were	  localised	  using	  the	  anti-­‐Ly-­‐6G	  antibody.	  	  
In	  mice	   treated	  with	   the	   IgG	   control	   antibody	   intrauterine	  LPS	   treatment	   induced	   an	  
influx	  of	  Ly-­‐6G	  positive	  neutrophils	  into	  the	  myometrium	  (Figure	  5.12A),	  and	  decidua	  
of	  these	  mice	  (Figure	  5.12B).	  	  In	  contrast,	  no	  Ly-­‐6G	  positive	  neutrophils	  were	  localised	  
in	  uterine	  tissue	  harvested	  from	  mice	  treated	  with	  anti-­‐Ly-­‐6G	  prior	  to	  intrauterine	  LPS	  
administration,	   with	   both	   the	   myometrium	   (Figure	   5.12C)	   and	   the	   decidua	   (Figure	  
5.12D)	   clear	   of	   positive	   staining	   cells.	   	   Also	   no	   positive	   staining	   was	   observed	   in	  
negative	  control	  sections	  of	  myometrium	  (Figure	  5.12E)	  and	  decidua	  (Figure	  5.12F).	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Figure	   5.12	   -­‐	   Effect	   of	   anti-­‐Ly-­‐6G	   treatment	   on	   neutrophil	   localisation	   in	   the	  
uterus.	   	   	  Uterine	   tissue	  was	   collected	  6	  hours	  post-­‐LPS	   treatment	   from	  mice	   treated	  
with	  either	  anti-­‐Ly-­‐6G	  (n=6)	  or	  the	  IgG	  control	  antibody	  (n=7).	  	  Representative	  images	  
of	  neutrophil	   localisation	  by	   immunohistochemical	  staining	   for	  Ly-­‐6G.	   	  Ly-­‐6G	  positive	  
cells	  were	   localised	  to	  the	  myometrium	   (A)	  and	  decidua	   (B)	  of	  mice	  treated	  with	  the	  
IgG	  control	  antibody+LPS.	   	  No	  Ly-­‐6G	  positive	  cells	  were	  present	   in	  mice	   treated	  with	  
the	   anti-­‐Ly-­‐6G	   antibody+LPS	   (C)	   and	   (D).	   	  No	   positive	   staining	  was	   observed	   in	   the	  
negative	  control	  sections	  (E)	  and	  (F).	   	  Scale	  bars	  show	  50µm.	  	  All	  images	  taken	  with	  a	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5.3.6 Effect	  of	  neutrophil	  depletion	  using	  anti-­‐Ly-­‐6G	  on	  LPS-­‐induced	  preterm	  labour	  
To	   further	   investigate	   the	   specific	   role	   neutrophils	   may	   play	   in	   infection-­‐induced	  
preterm	   labour	   we	   determined	   the	   effect	   of	   anti-­‐Ly-­‐6G	   on	   LPS-­‐induced	   preterm	  
delivery.	   	  On	  D16	  of	  gestation	  mice	  received	  an	   intra-­‐peritoneal	   injection	  of	  either	  an	  
IgG	  control	   antibody	  or	  anti-­‐Ly-­‐6G,	   followed	  on	  D17	  with	  an	   intrauterine	   injection	  of	  
20µg	  LPS,	   and	   the	   effect	   of	   neutrophil	   depletion	  on	  LPS-­‐induced	  preterm	   labour	  was	  
monitored.	  	  	  
	  
5.3.6.1 Time	  to	  delivery	  
There	   was	   no	   statistically	   significant	   difference	   when	   comparing	   the	   mean	   time	   to	  
delivery	  between	  mice	  treated	  with	  anti-­‐Ly-­‐6G+LPS	  and	  those	  treated	  with	  IgG+LPS,	  if	  
anything	   there	  was	  a	   trend	   towards	  a	   reduced	   time	   to	  delivery	   in	   those	  mice	   treated	  
with	  anti-­‐Ly-­‐6G	  (mean	  time	  to	  delivery	  in	  anti-­‐Ly-­‐6G	  group:	  19.25	  hours	  ±	  SEM	  9.35	  vs.	  
IgG	  group	  mean	  time	  to	  delivery:	  33.47	  hours	  ±	  9.58;	  p=0.14	  Figure	  5.13A).	  	  	  
	  
5.3.6.2 Proportion	  of	  live	  born	  pups	  	  
As	   was	   observed	   with	   anti-­‐Gr-­‐1	   treatment,	   mice	   treated	   with	   anti-­‐Ly-­‐6G+LPS	   had	   a	  
reduced	  proportion	  of	   live	  born	  pups	  compared	   to	   the	   IgG+LPS	  control	  group,	   (mean	  
proportion	  of	  live	  born	  pups	  anti-­‐Ly-­‐6G	  group:	  0.06	  ±	  SEM	  0.05	  vs.	  mean	  proportion	  of	  
live	  born	  pups	  IgG	  group:	  0.29	  ±	  0.11;	  Figure	  5.13B);	  however	  this	  difference	  was	  not	  
found	  to	  be	  statistically	  significant.	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Figure	   5.13	   -­‐	   Effect	   of	   neutrophil	   depletion	   with	   anti-­‐Ly-­‐6G	   on	   LPS-­‐induced	  
preterm	  delivery	  and	  the	  proportion	  of	   live	  born	  pups.	   	   	  Time	  to	  delivery	  and	  the	  
proportion	  of	  live	  born	  pups	  was	  monitored	  in	  mice	  treated	  with	  either	  the	  IgG	  control	  
antibody+LPS	  (n=8)	  or	   the	  anti-­‐Ly-­‐6G	  antibody+LPS	  (n=8).	  (A)	  Time	  to	  delivery.	   	  (B)	  
Proportion	  of	  live	  born	  pups.	  	  Data	  are	  presented	  as	  mean	  ±	  SEM	  (error	  bars).	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5.3.7 LPS-­‐induced	   expression	   of	   inflammatory	   mediators	   in	   the	   utero-­‐placental	   tissues	  
following	  neutrophil	  depletion	  with	  anti-­‐Ly-­‐6G	  
To	   investigate	   whether	   neutrophil	   depletion	   using	   the	   anti-­‐Ly-­‐6G	   antibody	   also	  
affected	   LPS-­‐induced	   inflammatory	   gene	   expression	   in	   the	   utero-­‐placental	   tissues,	   as	  
observed	  with	  anti-­‐Gr-­‐1	  treatment,	  mice	  were	  sacrificed	  6	  hours	  after	  intrauterine	  LPS	  
injection	   and	   utero-­‐placental	   tissues	   were	   harvested	   and	   analysed	   by	   qRT-­‐PCR	   to	  
measure	  the	  expression	  of	  Tnf-­‐α,	  Il-­‐1β,	  Il-­‐6,	  Il-­‐10,	  Cox-­‐2,	  Cxcl1,	  Cxcl2,	  Cxcl5	  and	  Ccl2.	  	  	  
	  
5.3.7.1 Inflammatory	  gene	  expression	  in	  the	  uterus	  
Expression	  of	  Tnf-­‐α	  was	  significantly	  reduced	  in	  mice	  receiving	  treatment	  with	  anti-­‐Ly-­‐
6G+LPS	   compared	   to	   the	   IgG+LPS	   control	   group	   (1.8-­‐fold	   decrease,	   p<0.05;	   Figure	  
5.14A).	  	  	  
Similarly,	  uterine	   Il-­‐1β	  expression	  was	  also	  significantly	  reduced	   in	  mice	   treated	  with	  
anti-­‐Ly-­‐6G+LPS	  compared	  to	  those	  treated	  with	  IgG+LPS,	  with	  a	  5.5-­‐fold	  decrease	  in	  Il-­‐
1β	  expression	  (p<0.001;	  Figure	  5.14B).	  	  
There	   was	   no	   significant	   differences	   in	   the	   expression	   of	   Il-­‐6	   (Figure	   5.14C),	   Il-­‐10	  
(Figure	  5.14D),	  Cox-­‐2	   (Figure	  5.14E),	  Cxcl1	  (Figure	  5.15A),	  Cxcl2	   (Figure	  5.15B),	  Cxcl5	  
(Figure	   5.15C)	   and	   Ccl2	   (Figure	   5.15D)	   in	   the	   uterus	   of	   mice	   treated	   with	   anti-­‐Ly-­‐
6G+LPS,	  compared	  to	  those	  treated	  with	  IgG+LPS.	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Figure	   5.14	   -­‐	   Effect	   of	   anti-­‐Ly-­‐6G	   treatment	   on	   LPS-­‐induced	   inflammatory	   gene	  
expression	   in	   the	   uterus.	   	   	  Uterine	   tissue	  was	  harvested	  6	  hours	  post-­‐surgery	   from	  
mice	   treated	   with	   either	   the	   IgG	   control	   antibody+LPS	   (n=7)	   or	   the	   anti-­‐Ly-­‐6G	  
antibody+LPS	   (n=6)	  and	   the	  expression	  of	   inflammatory	  genes	  was	  assessed	  by	  qRT-­‐
PCR.	   	   (A)	   Tnf-­‐α	   expression.	   (B)	   Il-­‐1β	   expression.	   (C)	   Il-­‐6	   expression	   (D)	   Il-­‐10	  
expression.	   	  (E)	  Cox-­‐2	  expression.	   	  Data	  presented	  as	  mean	   fold	  change	  ±	  SEM	  (error	  
bars);	  *p<0.05,	  ***p<0.001.	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Figure	   5.15	   -­‐	   Effect	   of	   anti-­‐Ly-­‐6G	   treatment	   on	   LPS-­‐induced	   inflammatory	  
chemokine	   expression	   in	   the	   uterus.	   	   	  Uterine	   tissue	  was	  harvested	  6	  hours	  post-­‐
surgery	  from	  mice	  treated	  with	  either	  the	  IgG	  control	  antibody+LPS	  (n=7)	  or	  the	  anti-­‐
Ly-­‐6G	   antibody+LPS	   (n=7)	   and	   the	   expression	   of	   inflammatory	   chemokines	   was	  
assessed	  by	  qRT-­‐PCR.	  	  (A)	  Cxcl1	  expression.	  	  (B)	  Cxcl2	  expression.	  	  (C)	  Cxcl5	  expression.	  	  
(D)	  Ccl2	  expression.	  	  Data	  presented	  as	  mean	  fold-­‐change	  ±	  SEM	  (error	  bars).	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5.3.7.2 Inflammatory	  gene	  expression	  in	  the	  fetal	  membranes	  
Treatment	  with	  anti-­‐Ly-­‐6G+LPS	  did	  not	  significantly	  alter	  the	  expression	  of	  any	  of	  the	  
inflammatory	   genes	   examined,	   with	   similar	   expression	   levels	   observed	   for	   Tnf-­‐α	  
(Figure	  5.16A),	  Il-­‐1β	  (Figure	  5.16B),	  Il-­‐6	  (Figure	  5.16C),	  Il-­‐10	  (Figure	  5.16D)	  and	  Cox-­‐2	  
(Figure	  5.16E),	  compared	  to	  the	  IgG+LPS	  control	  group.	  	  
Additionally,	  there	  were	  no	  significant	  differences	  in	  the	  expression	  of	  the	  chemokines	  
Cxcl1	  (Figure	  5.17A),	  Cxcl2	  (Figure	  5.17B),	  Cxcl5	  (Figure	  5.17C)	  and	  Ccl2	  (Figure	  5.17D)	  
when	  compared	  between	  anti-­‐Ly-­‐6G+LPS	  treatment	  and	  IgG	  control+LPS	  treatment.	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Figure	   5.16	   -­‐	   Effect	   of	   anti-­‐Ly-­‐6G	   treatment	   on	   LPS-­‐induced	   inflammatory	   gene	  
expression	  in	  the	  fetal	  membranes.	  	  	  Fetal	  membranes	  were	  harvested	  6	  hours	  post-­‐
surgery	  from	  mice	  treated	  with	  either	  the	  IgG	  control	  antibody+LPS	  (n=7)	  or	  the	  anti-­‐
Ly-­‐6G	  antibody+LPS	  (n=6)	  and	  the	  expression	  of	  inflammatory	  genes	  was	  assessed	  by	  
qRT-­‐PCR.	   	   (A)	   Tnf-­‐α	   expression.	   (B)	   Il-­‐1β	   expression.	   (C)	   Il-­‐6	   expression	   (D)	   Il-­‐10	  
expression.	   	  (E)	  Cox-­‐2	  expression.	   	  Data	  presented	  as	  mean	   fold	  change	  ±	  SEM	  (error	  
bars).	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Figure	   5.17	   -­‐	   Effect	   of	   anti-­‐Ly-­‐6G	   treatment	   on	   LPS-­‐induced	   inflammatory	  
chemokine	  expression	  in	  the	  fetal	  membranes.	  	  	  Fetal	  membranes	  were	  harvested	  6	  
hours	  post-­‐surgery	  from	  mice	  treated	  with	  either	  the	  IgG	  control	  antibody+LPS	  (n=7)	  
or	  the	  anti-­‐Ly-­‐6G	  antibody+LPS	  (n=7)	  and	  the	  expression	  of	  inflammatory	  chemokines	  
was	   assessed	   by	   qRT-­‐PCR.	   	   (A)	   Cxcl1	   expression.	   	   (B)	   Cxcl2	   expression.	   	   (C)	   Cxcl5	  
expression.	   	   (D)	  Ccl2	  expression.	   	   Data	   presented	   as	  mean	   fold-­‐change	   ±	   SEM	   (error	  







	   	   	   Chapter	  5	  
	   230	  
5.3.7.3 Inflammatory	  gene	  expression	  in	  the	  placenta	  
Similar	  to	  the	  gene	  expression	   levels	  observed	  in	  the	  fetal	  membranes,	   there	  were	  no	  
significant	  differences	  in	  the	  expression	  of	  Tnf-­‐α	  (Figure	  5.18A),	  Il-­‐1β	  (Figure	  5.18B),	  Il-­‐
6	  (Figure	  5.18C),	  Il-­‐10	  (Figure	  5.18D)	  or	  Cox-­‐2	  (Figure	  5.18E)	  in	  the	  placental	  tissue	  of	  
mice	  treated	  with	  anti-­‐Ly-­‐6G+LPS,	  compared	  with	  IgG	  control+LPS.	  	  
The	  expression	  of	  Cxcl1	  (Figure	  5.19A)	  and	  Cxcl2	  (Figure	  5.19B)	  was	  also	  unaffected	  by	  
anti-­‐Ly-­‐6G	   treatment.	   	  However,	  placental	  Cxcl5	   expression	  was	  significantly	  elevated	  
in	  mice	  treated	  with	  anti-­‐Ly-­‐6G+LPS,	  compared	  to	  the	  IgG+LPS	  control	  group	  (2.3-­‐fold	  
greater	   expression,	   p<0.05;	   Figure	   5.19C).	   	   Expression	   of	   Ccl2	  was	   not	   significantly	  
altered	  by	  anti-­‐Ly-­‐6G+LPS	  treatment,	  compared	  with	  the	  IgG+LPS	  group	  (Figure	  5.19D).	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Figure	   5.18	   -­‐	   Effect	   of	   anti-­‐Ly-­‐6G	   treatment	   on	   LPS-­‐induced	   inflammatory	   gene	  
expression	   in	   the	   placenta.	   	   	   Placental	   tissue	  was	   harvested	   6	   hours	   post-­‐surgery	  
from	  mice	   treated	  with	   either	   the	   IgG	   control	   antibody+LPS	   (n=7)	   or	   the	   anti-­‐Ly-­‐6G	  
antibody+LPS	   (n=6)	  and	   the	  expression	  of	   inflammatory	  genes	  was	  assessed	  by	  qRT-­‐
PCR.	   	   (A)	   Tnf-­‐α	   expression.	   (B)	   Il-­‐1β	   expression.	   (C)	   Il-­‐6	   expression	   (D)	   Il-­‐10	  
expression.	   	  (E)	  Cox-­‐2	  expression.	   	  Data	  presented	  as	  mean	   fold	  change	  ±	  SEM	  (error	  
bars).	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Figure	   5.19	   -­‐	   Effect	   of	   anti-­‐Ly-­‐6G	   treatment	   on	   LPS-­‐induced	   inflammatory	  
chemokine	  expression	  in	  the	  placenta.	  	  	  Placental	  tissue	  was	  harvested	  6	  hours	  post-­‐
surgery	  from	  mice	  treated	  with	  either	  the	  IgG	  control	  antibody+LPS	  (n=7)	  or	  the	  anti-­‐
Ly-­‐6G	   antibody+LPS	   (n=7)	   and	   the	   expression	   of	   inflammatory	   chemokines	   was	  
assessed	  by	  qRT-­‐PCR.	  	  (A)	  Cxcl1	  expression.	  	  (B)	  Cxcl2	  expression.	  	  (C)	  Cxcl5	  expression.	  	  
(D)	  Ccl2	  expression.	  	  Data	  presented	  as	  mean	  fold-­‐change	  ±	  SEM	  (error	  bars);	  *p<0.05.	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5.3.8 Effect	  of	  anti-­‐Ly-­‐6G	  treatment	  on	  LPS-­‐induced	  serum	  TNF-­‐α 	  levels	  
As	   previously	   mentioned,	   neutrophil	   depletion	   using	   anti-­‐Gr-­‐1	   followed	   by	   LPS	  
treatment	   has	   been	   shown	   to	   result	   in	   elevated	   circulating	   TNF-­‐α	   levels	   in	   a	  mouse	  
model	   of	   endotoxaemia,	   however,	   depletion	  using	   anti-­‐Ly-­‐6G	  was	  not	   found	   to	   cause	  
this	   increase	  in	  TNF-­‐α	   levels	  (Daley	  et	  al.	  2008).	   	  Therefore,	  we	  wanted	  to	   investigate	  
whether	  anti-­‐Ly-­‐6G	  treatment	  altered	  circulating	  TNF-­‐α	  levels	  in	  our	  model.	  	  As	  before,	  
blood	   was	   collected	   from	   mice	   6	   hours	   post-­‐intrauterine	   LPS	   injection	   from	   mice	  
treated	  with	  either	  the	  IgG	  control	  antibody	  or	  anti-­‐Ly-­‐6G,	  and	  the	  serum	  concentration	  
of	  TNF-­‐α	  was	  measured	  by	  ELISA.	  	  	  
There	  was	  no	  difference	  in	  the	  serum	  concentration	  of	  TNF-­‐α	  when	  samples	  obtained	  
from	  mice	   treated	  with	   anti-­‐Ly-­‐6G+LPS	  were	   compared	  with	  mice	   receiving	   IgG+LPS	  
(mean	  concentration	  anti-­‐Ly-­‐6G	  group:	  19.4	  pg/ml	  ±	  SEM	  2.9	  vs.	  mean	  concentration	  
IgG	  group:	  15.3	  ±	  1.6,	  p=0.23;	  Figure	  5.20).	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Figure	   5.20	   -­‐	   Effect	   of	   anti-­‐Ly-­‐6G	   treatment	   on	   serum	   TNF-­‐α 	   levels.	   	   	  Maternal	  
blood	  was	  collected	  6	  hours	  post-­‐surgery	  from	  mice	  treated	  with	  either	  the	  IgG	  control	  
antibody+LPS	   (n=7)	   or	   the	   anti-­‐Ly-­‐6G	   antibody+LPS	   (n=6)	   and	   ELISA	   was	   used	   to	  
quantify	   the	   serum	   concentration	   of	   TNF-­‐α.	   	   Data	   presented	   as	   mean	   ±	   SEM	   (error	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5.3.9 Administration	  of	  anti-­‐F4/80	  to	  deplete	  macrophages	  on	  day	  17	  of	  gestation	  
To	   investigate	   whether	   macrophages	   were	   involved	   in	   LPS-­‐induced	   preterm	   labour	  
and/or	   the	   LPS-­‐induced	   inflammatory	   response	   in	   the	   utero-­‐placental	   tissues	   in	   our	  
model,	  mice	  were	  treated	  with	  anti-­‐F4/80	  prior	  to	   intrauterine	  LPS	  administration	  to	  
deplete	  macrophages.	  	  Different	  methods	  of	  macrophage	  depletion	  have	  been	  found	  to	  
selectively	  deplete	  different	  tissue-­‐resident	  macrophage	  populations	  in	  the	  spleen,	  liver	  
and	   lung	  (Bedoret	  et	  al.	  2009,	  Dhaliwal	  et	  al.	  2012,	  Ferenbach	  et	  al.	  2012).	   	  Therefore	  
spleen,	   liver	   and	   lung	   tissues	   were	   collected	   to	   examine	   whether	   anti-­‐F4/80	  
administration	   in	   our	   model	   affected	   the	   macrophage	   populations	   in	   these	   tissues.	  	  
Cervix	   was	   also	   collected,	   as	   a	   previous	   study	   has	   reported	   that	   anti-­‐F4/80	  
administration	   depleted	   cervical	   macrophages	   in	   a	   mouse	   model	   of	   LPS-­‐induced	  
preterm	  labour	  (Gonzalez	  et	  al.	  2011);	  and	  finally	  uterine	  tissue	  was	  also	  examined	  to	  
determine	  if	  the	  resident	  uterine	  macrophage	  population	  was	  depleted	  following	  anti-­‐
F4/80	   treatment.	   	   	  Mice	  received	  an	   intra-­‐peritoneal	   injection	  of	  either	  anti-­‐F4/80	  or	  
an	  IgG	  control	  antibody	  on	  D17	  of	  gestation,	  followed	  4	  hours	  later	  with	  an	  intrauterine	  
LPS	   injection.	   	   All	   tissues	   were	   harvested	   6	   hours	   post-­‐LPS	   injection	   and	   fixed	   for	  
immunohistochemical	   analysis.	   	   Macrophages	   were	   localised	   using	   the	   anti-­‐F4/80	  
antibody.	  	  	  
Immunohistochemical	  analysis	  showed	  that	  anti-­‐F4/80	  treatment	  appeared	  to	  reduce	  
the	  number	  of	  F4/80	  positive	  cells	  in	  the	  spleen	  (Figure	  5.21B),	  lung	  (Figure	  5.21F)	  and	  
cervix	  (Figure	  5.21H),	  compared	  to	  the	  same	  tissues	  harvested	  from	  mice	  receiving	  the	  
IgG	  control	  antibody	  (Figure	  5.21A,	  Figure	  5.21E	  and	  Figure	  5.21G,	  respectively).	   	  The	  
number	  of	  F4/80	  positive	  cells	  appeared	  similar	  in	  liver	  tissue	  from	  mice	  treated	  with	  
the	   IgG	   antibody,	   compared	   with	   mice	   treated	   with	   anti-­‐F4/80	   (Figure	   5.21C	   and	  
Figure	  5.21D	  respectively).	  	  	  	  
Similarly,	  anti-­‐F4/80	  treatment	  did	  not	  result	  in	  an	  obvious	  reduction	  in	  the	  number	  of	  
F4/80	  positive	  cells	  with	   the	  myometrium	  (Figure	  5.22C)	  or	  decidua	   	   (Figure	  5.22D),	  
when	  compared	  to	  F4/80	  staining	   in	  uterine	  tissue	  harvested	   from	  mice	  treated	  with	  
the	  IgG	  control	  antibody	  (Figure	  5.22A	  and	  Figure	  5.22B).	  	  	   	  
	   	   	   Chapter	  5	  
	   236	  
	  
Figure	   5.21	   -­‐	   Effect	   of	   anti-­‐F4/80	   treatment	   on	  macrophage	   populations	   in	   the	  
spleen,	  liver,	  lung	  and	  cervix.	  	  	  Spleen,	  liver,	  lung	  and	  cervical	  tissue	  were	  collected	  6	  
hours	  post-­‐LPS	  treatment	  from	  mice	  treated	  with	  either	  the	  IgG	  control	  antibody	  (n=4)	  
or	   the	   anti-­‐F4/80	  antibody	   (n=6).	   	  Representative	   images	  of	  macrophage	   localisation	  
by	  immunohistochemical	  staining	  for	  F4/80.	  	  Macrophages	  were	  localised	  to	  the	  spleen	  
in	  mice	  treated	  with	  IgG+LPS	  (A)	  and	  reduced	  macrophage	  staining	  was	  seen	  in	  spleen	  
from	  mice	  treated	  with	  anti-­‐F4/80+LPS	  (B).	  	  F4/80	  positive	  cells	  present	  in	  liver	  tissue	  
from	   both	   IgG+LPS	   treated	   (C)	   and	   anti-­‐F4/80+LPS	   treated	  mice	   (D).	   	   Macrophages	  
were	  present	  in	  the	  lung	  of	  mice	  in	  the	  IgG+LPS	  group	  (E),	  but	  fewer	  positively	  stained	  
cells	  were	  present	  in	  the	  lung	  tissue	  from	  anti-­‐F4/80+LPS	  treated	  mice	  (F).	   	  Similarly,	  
macrophages	  were	  found	  in	  the	  cervical	  stroma	  of	  mice	  in	  the	  IgG+LPS	  group	  (G),	  with	  
reduced	   staining	   present	   in	   the	   cervix	   from	  mice	   treated	  with	   anti-­‐F4/80	   (H).	   	   Scale	  
bars	   show	   50µm.	   Images	   A-­‐D	  were	   taken	  with	   a	   x10	   objective	   lens,	   and	   images	   E-­‐H	  
were	  taken	  with	  a	  x20	  objective	  lens.	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Figure	   5.22	   -­‐	   Effect	   of	   anti-­‐F4/80	   treatment	   on	  macrophage	   localisation	   in	   the	  
uterus.	   	   	  Uterine	   tissue	  was	   collected	  6	  hours	  post-­‐LPS	   treatment	   from	  mice	   treated	  
with	  either	  anti-­‐F4/80	  (n=6)	  or	  the	  IgG	  control	  antibody	  (n=4).	  	  Representative	  images	  
of	  neutrophil	  localisation	  by	  immunohistochemical	  staining	  for	  F4/80.	  	  F4/80	  positive	  
cells	  were	   localised	  to	  the	  myometrium	   (A)	  and	  decidua	   (B)	  of	  mice	  treated	  with	  the	  
IgG	  control	  antibody+LPS.	   	  Similarly,	  F4/80	  postiive	  macrophage	  were	  still	  present	   in	  
the	  myometrium	  (C)	  and	  decidua	  (D)	  of	  mice	  treated	  with	  anti-­‐F4/80+LPS.	  	  No	  positive	  
staining	  was	  observed	   in	   the	  negative	   control	   sections	   (E)	   and	   (F).	   	   Scale	   bars	   show	  
50µm.	  	  All	  images	  taken	  with	  a	  x20	  objective	  lens.	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5.3.10 Effect	  of	  anti-­‐F4/80	  treatment	  on	  LPS-­‐induced	  preterm	  labour	  
Administration	   of	   anti-­‐F4/80	   antibody	   prior	   to	   intravaginal	   LPS	   administration	   has	  
previously	  been	  shown	  to	  prevent	  preterm	  delivery	  in	  a	  mouse	  model	  (Gonzalez	  et	  al.	  
2011).	   	   Therefore,	   to	   investigate	   whether	   anti-­‐F4/80	   affected	   LPS-­‐induced	   preterm	  
delivery	   in	   our	   model,	   on	   D17	   of	   gestation	   mice	   received	   either	   an	   intra-­‐peritoneal	  
injection	   of	   the	   appropriate	   IgG	   control	   antibody	   or	   anti-­‐F4/80,	   then	   4	   hours	   later	  
underwent	  surgery	  and	  received	  an	  intrauterine	  injection	  of	  20µg	  LPS	  and	  the	  effect	  of	  
anti-­‐F4/80	  depletion	  on	  LPS-­‐induced	  time	  to	  delivery	  and	  the	  proportion	  of	   live	  born	  
pups	  was	  determined.	  	  	  
	  
5.3.10.1 Time	  to	  delivery	  
Treatment	  with	   anti-­‐F4/80	  prior	   to	   intrauterine	   LPS	   administration	  had	  no	   effect	   on	  
LPS-­‐induced	   time	   to	   delivery,	   compared	   with	   mice	   treated	   with	   the	   IgG	   control	  
antibody	  (mean	  time	  to	  delivery	  in	  anti-­‐F4/80	  group:	  20.08	  hours	  ±	  SEM	  2.23	  vs.	  mean	  
time	  to	  delivery	  in	  IgG	  group:	  23.7	  hours	  ±	  SEM	  6.25;	  Figure	  5.23A).	  	  	  
	  
5.3.10.2 Proportion	  of	  live	  born	  pups	  
Similarly,	  there	  was	  no	  significant	  difference	  in	  the	  proportion	  of	  live	  born	  pups	  when	  
compared	  between	  the	  anti-­‐F4/80	  group	  and	  the	  IgG	  control	  group	  (mean	  proportion	  
of	  live	  born	  pups	  in	  anti-­‐F4/80	  group:	  0.18	  ±	  SEM	  0.13	  vs.	  mean	  proportion	  of	  live	  born	  
pups	  in	  IgG	  control	  group:	  0.23	  ±	  0.25;	  Figure	  5.23B).	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Figure	  5.23	  -­‐	  Effect	  of	  anti-­‐F4/80	  treatment	  on	  LPS-­‐induced	  preterm	  delivery	  and	  
the	  proportion	  of	   live	  born	  pups.	   	   	  Time	  to	  delivery	  and	  the	  proportion	  of	  live	  born	  
pups	  was	  monitored	  in	  mice	  treated	  with	  either	  the	  IgG	  control	  antibody+LPS	  (n=5)	  or	  
the	  anti-­‐F4/80+LPS	  (n=6).	  (A)	  Time	  to	  delivery.	  	  (B)	  Proportion	  of	  live	  born	  pups.	  	  Data	  
are	  presented	  as	  mean	  ±	  SEM	  (error	  bars).	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5.3.11 LPS-­‐induced	   expression	  of	   inflammatory	  mediators	   in	   the	  utero-­‐placental	   tissues	  
following	  treatment	  with	  anti-­‐F4/80	  
To	   examine	   wheher	   anti-­‐F4/80	   treatment	   altered	   LPS-­‐induced	   inflammatory	   gene	  
expression	   in	   the	   utero-­‐placental	   tissues,	   mice	   were	   sacrificed	   6	   hours	   after	  
intrauterine	  LPS	  injection	  and	  utero-­‐placental	  tissues	  were	  harvested	  and	  analysed	  by	  
qRT-­‐PCR	  to	  measure	  the	  expression	  of:	  Tnf-­‐α,	  Il-­‐1β,	  Il-­‐6,	  Il-­‐10,	  Cox-­‐2,	  Cxcl1,	  Cxcl2,	  Cxcl5	  
and	  Ccl2.	  	  	  
	  
5.3.11.1 Inflammatory	  gene	  expression	  in	  the	  uterus	  
Uterine	   Tnf-­‐α	   expression	   was	   significantly	   reduced	   in	   mice	   treated	   with	   anti-­‐
F4/80+LPS,	  compared	  with	  the	  IgG+LPS	  control	  group,	  with	  1.9-­‐fold	  lower	  expression	  
(p<0.01;	  Figure	  5.24A).	  	  	  
Expression	   of	   Il-­‐1β	   (Figure	   5.24B),	   Il-­‐6	   (Figure	   5.24C),	   Il-­‐10	   (Figure	   5.24D),	   Cox-­‐2	  
(Figure	  5.24E),	  Cxcl1	  (Figure	  5.25A),	  Cxcl2	  (Figure	  5.25B),	  Cxcl5	  (Figure	  5.25C)	  and	  Ccl2	  
(Figure	  5.25D)	  was	  not	  significantly	  different	  when	  comparing	  uterine	  tissue	  collected	  
from	  mice	  treated	  with	  anti-­‐F4/80+LPS	  to	  the	  IgG+LPS	  group.	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Figure	  5.24	   -­‐	   Effect	   of	   anti-­‐F4/80	   treatment	  on	  LPS-­‐induced	   inflammatory	   gene	  
expression	   in	   the	   uterus.	   	   	  Uterine	  tissue	  was	  harvested	  6	  hours	  post-­‐surgery	   from	  
mice	   treated	   with	   either	   the	   IgG	   control	   antibody+LPS	   (n=4)	   or	   the	   anti-­‐F4/80	  
antibody+LPS	   (n=6)	  and	   the	  expression	  of	   inflammatory	  genes	  was	  assessed	  by	  qRT-­‐
PCR.	   	   (A)	   Tnf-­‐α	   expression.	   (B)	   Il-­‐1β	   expression.	   (C)	   Il-­‐6	   expression	   (D)	   Il-­‐10	  
expression.	   	  (E)	  Cox-­‐2	  expression.	   	  Data	  presented	  as	  mean	   fold	  change	  ±	  SEM	  (error	  
bars);	  **p<0.01.	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Figure	   5.25	   -­‐	   Effect	   of	   anti-­‐F4/80	   treatment	   on	   LPS-­‐induced	   inflammatory	  
chemokine	   expression	   in	   the	   uterus.	   	   Uterine	   tissue	  was	   harvested	   6	   hours	   post-­‐
surgery	  from	  mice	  treated	  with	  either	  the	  IgG	  control	  antibody+LPS	  (n=4)	  or	  the	  anti-­‐
F4/80	   antibody+LPS	   (n=6)	   and	   the	   expression	   of	   inflammatory	   chemokines	   was	  
assessed	  by	  qRT-­‐PCR.	  	  (A)	  Cxcl1	  expression.	  	  (B)	  Cxcl2	  expression.	  	  (C)	  Cxcl5	  expression.	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5.3.11.2 Inflammatory	  gene	  expression	  in	  the	  fetal	  membranes	  
Anti-­‐F4/80	   treatment	   had	  no	   significant	   effect	   on	   the	   LPS-­‐induced	  mRNA	   expression	  
levels	   of	   any	   of	   the	   inflammatory	  mediators	   examined	   in	   the	   fetal	  membranes,	  when	  
compared	  with	  the	  IgG+LPS	  control	  group:	  Tnf-­‐α	  (Figure	  5.26A),	  Il-­‐1β	  (Figure	  5.26),	  Il-­‐6	  
(Figure	   5.26C),	   Il-­‐10	   (Figure	   5.26D),	   Cox-­‐2	   (Figure	   5.26E),	   Cxcl1	   (Figure	   5.27A),	   Cxcl2	  
(Figure	  5.27B),	  Cxcl5	  (Figure	  5.27C)	  and	  Ccl2	  (Figure	  5.27D).	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Figure	  5.26	   -­‐	   Effect	   of	   anti-­‐F4/80	   treatment	  on	  LPS-­‐induced	   inflammatory	   gene	  
expression	  in	  the	  fetal	  membranes.	  	  	  Fetal	  membranes	  were	  harvested	  6	  hours	  post-­‐
surgery	  from	  mice	  treated	  with	  either	  the	  IgG	  control	  antibody+LPS	  (n=4)	  or	  the	  anti-­‐
F4/80	  antibody+LPS	  (n=6)	  and	  the	  expression	  of	  inflammatory	  genes	  was	  assessed	  by	  
qRT-­‐PCR.	   	   (A)	   Tnf-­‐α	   expression.	   (B)	   Il-­‐1β	   expression.	   (C)	   Il-­‐6	   expression	   (D)	   Il-­‐10	  
expression.	   	  (E)	  Cox-­‐2	  expression.	   	  Data	  presented	  as	  mean	   fold	  change	  ±	  SEM	  (error	  
bars).	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Figure	   5.27	   -­‐	   Effect	   of	   anti-­‐F4/80	   treatment	   on	   LPS-­‐induced	   inflammatory	  
chemokine	  expression	  in	  the	  fetal	  membranes.	  	  Fetal	  membranes	  were	  harvested	  6	  
hours	  post-­‐surgery	  from	  mice	  treated	  with	  either	  the	  IgG	  control	  antibody+LPS	  (n=4)	  
or	  the	  anti-­‐F4/80	  antibody+LPS	  (n=6)	  and	  the	  expression	  of	  inflammatory	  chemokines	  
was	   assessed	   by	   qRT-­‐PCR.	   	   (A)	   Cxcl1	   expression.	   	   (B)	   Cxcl2	   expression.	   	   (C)	   Cxcl5	  
expression.	   	   (D)	  Ccl2	  expression.	   	   Data	   presented	   as	  mean	   fold-­‐change	   ±	   SEM	   (error	  
bars).	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5.3.11.3 Inflammatory	  gene	  expression	  in	  the	  placenta	  
As	   observed	   in	   the	   fetal	   membranes,	   treatment	   with	   anti-­‐F4/80	   had	   no	   significant	  
effect	   on	   LPS-­‐induced	  mRNA	   expression	   levels	   of	   any	   of	   the	   inflammatory	  mediators	  
examined,	  when	  compared	  with	  the	  IgG+LPS	  control	  group:	  Tnf-­‐α	  (Figure	  5.28A),	  Il-­‐1β	  
(Figure	   5.28B),	   Il-­‐6	   (Figure	   5.28C),	   Il-­‐10	   (Figure	   5.28D),	   Cox-­‐2	   (Figure	   5.28E),	   Cxcl1	  
(Figure	  5.29A),	  Cxcl2	  (Figure	  5.29B),	  Cxcl5	  (Figure	  5.29C)	  and	  Ccl2	  (Figure	  5.29D).	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Figure	  5.28	   -­‐	   Effect	   of	   anti-­‐F4/80	   treatment	  on	  LPS-­‐induced	   inflammatory	   gene	  
expression	   in	   the	   placenta.	   	   	   Placental	   tissue	  was	   harvested	   6	   hours	   post-­‐surgery	  
from	  mice	   treated	  with	   either	   the	   IgG	   control	   antibody+LPS	   (n=4)	   or	   the	   anti-­‐F4/80	  
antibody+LPS	   (n=6)	  and	   the	  expression	  of	   inflammatory	  genes	  was	  assessed	  by	  qRT-­‐
PCR.	   	   (A)	   Tnf-­‐α	   expression.	   (B)	   Il-­‐1β	   expression.	   (C)	   Il-­‐6	   expression	   (D)	   Il-­‐10	  
expression.	   	  (E)	  Cox-­‐2	  expression.	   	  Data	  presented	  as	  mean	   fold	  change	  ±	  SEM	  (error	  
bars).	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Figure	   5.29	   -­‐	   Effect	   of	   anti-­‐F4/80	   treatment	   on	   LPS-­‐induced	   inflammatory	  
chemokine	  expression	  in	  the	  placenta.	  	  Placental	  tissue	  was	  harvested	  6	  hours	  post-­‐
surgery	  from	  mice	  treated	  with	  either	  the	  IgG	  control	  antibody+LPS	  (n=4)	  or	  the	  anti-­‐
F4/80	   antibody+LPS	   (n=6)	   and	   the	   expression	   of	   inflammatory	   chemokines	   was	  
assessed	  by	  qRT-­‐PCR.	  	  (A)	  Cxcl1	  expression.	  	  (B)	  Cxcl2	  expression.	  	  (C)	  Cxcl5	  expression.	  	  
(D)	  Ccl2	  expression.	  	  Data	  presented	  as	  mean	  fold-­‐change	  ±	  SEM	  (error	  bars).	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5.3.12 Effect	  of	  anti-­‐F4/80	  treatment	  on	  LPS-­‐induced	  serum	  TNF-­‐α 	  levels	  
To	   examine	   whether	   anti-­‐F4/80	   treatment	   altered	   the	   LPS-­‐induced	   systemic	  
inflammatory	  response,	  serum	  TNF-­‐α	   levels	  were	  measured	  6	  hours	  post-­‐surgery.	   	  As	  
before	   blood	   was	   collected	   from	   mice	   6	   hours	   post-­‐intrauterine	   LPS	   injection	   from	  
mice	   treated	   with	   either	   the	   IgG	   control	   antibody	   or	   anti-­‐F4/80,	   and	   the	   serum	  
concentration	  of	  TNF-­‐α	  was	  measured	  by	  ELISA.	  	  	  
There	  was	  no	  statistically	  significant	  difference	  in	  the	  serum	  concentration	  of	  TNF-­‐α	  in	  
mice	   treated	   with	   anti-­‐F4/80+LPS,	   compared	   to	   the	   IgG	   control+LPS	   (mean	   TNF-­‐α	  
concentration	   in	   anti-­‐F4/80	   group:	   28.14	   pg/ml	   ±	   SEM	   6.64	   vs.	   mean	   TNF-­‐α	  
concentration	  in	  IgG	  control	  group:	  69.66	  pg/ml	  ±	  SEM	  27.24;	  p=0.13	  Figure	  5.30).	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Figure	   5.30	   -­‐	   Effect	   of	   anti-­‐F4/80	   treatment	   on	   serum	   TNF-­‐α 	   levels.	   	   	  Maternal	  
blood	  was	  collected	  6	  hours	  post-­‐surgery	  from	  mice	  treated	  with	  either	  the	  IgG	  control	  
antibody+LPS	   (n=7)	   or	   the	   anti-­‐F4/80	   antibody+LPS	   (n=7)	   and	   ELISA	   was	   used	   to	  
quantify	   the	   serum	   concentration	   of	   TNF-­‐α.	   	   Data	   presented	   as	   mean	   ±	   SEM	   (error	  
bars).	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5.4 DISCUSSION	  
Studies	   in	   women	   have	   demonstrated	   that	   labour,	   both	   at	   term	   and	   preterm,	   is	  
associated	  with	   an	   immune	   cell	   influx	   into	   the	  utero-­‐placental	   tissues,	   particularly	   of	  
neutrophils	  and	  macrophages	  (Young	  et	  al.	  2002,	  Osman	  et	  al.	  2003,	  Gomez-­‐Lopez	  et	  al.	  
2010).	  	  Additionally,	  as	  described	  in	  chapter	  3,	  we	  observed	  a	  massive	  neutrophil	  influx	  
into	   the	  decidua	  of	  mice	   treated	  with	   intrauterine	  LPS	  within	  6	  hours	  of	  surgery,	  and	  
we	   demonstrated	   that	   there	   is	   population	   of	   tissue-­‐resident	  macrophages	  within	   the	  
uterus,	   which	   we	   hypothesised	   might	   contribute	   to	   the	   LPS-­‐induced	   inflammatory	  
response.	   	   Therefore,	   the	   work	   in	   this	   chapter	   aimed	   to	   investigate	   the	   role	   of	  
neutrophils	   and	  macrophages	   in	  both	   the	   induction	  of	  preterm	   labour	   in	   response	   to	  
intrauterine	  LPS	  and	  the	  LPS-­‐induced	  inflammatory	  response,	  using	  our	  mouse	  model	  
of	  infection-­‐induced	  preterm	  labour.	  	  	  
	  
Antibody-­‐mediated	  depletion	  strategies	   to	  study	   the	   role	  of	   specific	   immune	  cells	   in	   the	  
inflammatory	  response	  	  
The	  administration	  of	  monoclonal	   antibodies	   in	  vivo	   to	  deplete	   specific	   cell	   types	  has	  
been	  used	  for	  decades	  to	  investigate	  the	  role	  of	  immune	  cells	  in	  various	  disease	  models,	  
including,	  acute	   lung	   injury	  (Tate	  et	  al.	  2009,	  Dhaliwal	  et	  al.	  2012),	  systemic	   infection	  
(Daley	   et	   al.	   2008,	   Shi	   et	   al.	   2011)	   and	   carcinogenesis	   (Tazawa	   et	   al.	   2003).	  	  
Furthermore,	  therapeutic	  antibodies	  targeting	  specific	  immune	  cells	  are	  used	  clinically	  
in	  the	  treatment	  of	  some	  types	  of	  cancer	  (Grillo-­‐Lopez	  2003)	  and	  autoimmune	  diseases,	  
such	   as	   rheumatoid	   arthritis	   (Edwards	   and	   Cambridge	   2006);	   and	   have	   also	   been	  
trialled	  as	  a	  therapeutic	  option	  for	  the	  treatment	  of	  allergic	  asthma	  (Leckie	  et	  al.	  2000,	  
Nair	   et	   al.	   2009).	   	   The	  mechanisms	   underlying	   antibody-­‐based	   depletion	   of	   immune	  
cells	   have	   been	   most	   well	   studied	   in	   the	   field	   of	   cancer	   research,	   investigating	   the	  
mechanism	   of	   action	   of	   B-­‐cell	   depleting	   antibodies,	   and	   are	   thought	   to	   involve	  
antibody-­‐dependent	   cell-­‐mediated	   cytotoxicity	   (ADCC)	   and	   complement-­‐dependent	  
cytotoxicity	  (CDC).	  	  	  In	  ADCC,	  Fcγ	  receptors	  on	  effector	  immune	  cells,	  such	  as	  NK	  cells,	  
monocytes	   or	   macrophages,	   recognise	   and	   bind	   to	   the	   Fc	   region	   on	   the	   monoclonal	  
antibody,	  which	  is	  bound	  to	  the	  target	  immune	  cell.	  	  The	  binding	  of	  the	  Fcγ	  receptors	  to	  
the	   Fc	   region	   of	   the	   antibody	   results	   in	   activation	   of	   the	   effector	   cell,	   which	   then	  
releases	  cytotoxic	  granules	  resulting	  in	  apoptosis	  of	  the	  target	  immune	  cell	  (Boross	  and	  
Leusen	  2012).	   	  CDC	   involves	   the	  C1q	  protein	  complex	  binding	   to	   the	  Fc	  region	  of	   the	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antibody,	  which	  triggers	  the	  classical	  complement	  activation	  pathway	  resulting	  in	  cell	  
destruction	  via	  formation	  of	  the	  membrane	  attack	  complex	  (Boross	  and	  Leusen	  2012).	  	  
The	   exact	   depletion	  mechanisms	  of	   the	   antibodies	   used	   in	   this	   chapter	   are	  not	   clear,	  
but	   are	   thought	   to	   involve	   the	   mechanisms	   already	   discussed,	   with	   other	   potential	  
mechanisms	  still	  being	  investigated	  (Abbitt	  et	  al.	  2009).	  	  
The	  anti-­‐Gr-­‐1	  antibody	  (clone	  RB6-­‐8C5)	  has	  been	  widely	  used	  to	  deplete	  neutrophils	  in	  
mouse	  models	   to	   investigate	   the	   role	   they	   play	   in	   the	   development	   of	   inflammatory	  
pathologies	   (Kaitu'u-­‐Lino	   et	   al.	   2007,	   Tate	   et	   al.	   2008,	   Gong	   and	   Koh	   2010).	   	   This	  
antibody	  recognises	  two	  antigens	  expressed	  on	  the	  surface	  of	  some	  immune	  cells,	  Ly-­‐
6G	   and	  Ly-­‐6C	   (Fleming	  et	  al.	   1993).	   	  Whilst	   Ly-­‐6G	   expression	   is	   restricted	   to	  murine	  
neutrophils,	   Ly-­‐6C	   is	   also	   expressed	   on	   subpopulations	   of	   monocytes,	   macrophages,	  
dendritic	   cells	   and	   T-­‐cells	   (Jutila	   et	   al.	   1988,	   Hestdal	   et	   al.	   1991,	   Kung	   et	   al.	   1991,	  
Shortman	  and	  Naik	  2007).	  	  Therefore	  administration	  of	  anti-­‐Gr-­‐1	  can	  also	  result	  in	  the	  
depletion	   of	   other	   immune	   cell	   populations	   (Han	   and	   Cutler	   1997,	   Tvinnereim	   et	   al.	  
2004,	   Daley	   et	  al.	   2008),	  making	   the	   specific	   role	   of	   neutrophils	   in	   the	   inflammatory	  
response	   difficult	   to	   interpret.	   	   For	   this	   reason,	  many	   studies	   now	   focus	   on	   using	   an	  
anti-­‐Ly-­‐6G	   specific	   monoclonal	   antibody	   (clone	   1A8)	   to	   investigate	   the	   role	   of	  
neutrophils,	  as	  this	  antibody	  has	  been	  shown	  to	  selectively	  deplete	  neutrophils	  whilst	  
preserving	  other	  immune	  cell	  populations	  (Daley	  et	  al.	  2008,	  Tate	  et	  al.	  2009,	  Wojtasiak	  
et	  al.	  2010,	  Shi	  et	  al.	  2011).	  
In	  our	  model,	  flow	  cytometric	  analysis	  confirmed	  that	  administration	  of	  either	  anti-­‐Gr-­‐
1	   or	   anti-­‐Ly-­‐6G	   on	   D16	   of	   gestation	   successfully	   depleted	   circulating	   neutrophils.	  	  
Additionally	  immunohistochemical	  studies	  demonstrated	  that	  both	  anti-­‐Gr-­‐1	  and	  anti-­‐
Ly-­‐6G	   treatment	   prior	   to	   intrauterine	   LPS	   administration	   blocked	   the	   LPS-­‐induced	  
neutrophil	  recruitment	  into	  the	  uterus,	  which	  was	  still	  observed	  in	  mice	  receiving	  the	  
IgG	   control	   antibody,	   thus	   again	   confirming	   successful	   depletion	   of	   neutrophils.	   	   A	  
limitation	  of	  our	  analysis	  is	  that	  we	  did	  not	  examine	  the	  effects	  of	  depletion	  with	  either	  
antibody	   on	   other	   immune	   cell	   populations.	   	   Given	   the	   evidence	   discussed	   above	  
regarding	  the	  ability	  of	  anti-­‐Gr-­‐1	  treatment	  to	  deplete	  other	  immune	  cell	  populations,	  it	  
would	  be	  important	  to	  fully	  characterise	  the	  effects	  on	  other	  immune	  cells	  in	  order	  to	  
understand	  any	  response	  to	  anti-­‐Gr-­‐1	  treatment	  in	  our	  model.	  
Macrophage	  depletion	  using	  the	  anti-­‐F4/80	  antibody	  has	  been	  utilised	  in	  a	  number	  of	  
animal	  models	  (Tidball	  and	  Wehling-­‐Henricks	  2007,	  Bedoret	  et	  al.	  2009,	  Thaxton	  et	  al.	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2009,	   Gonzalez	   et	   al.	   2011,	   Sun	   et	   al.	   2013).	   	   F4/80	   is	   a	   glycoprotein	   that	   is	   highly	  
expressed	  on	  the	  cell	  surface	  of	  mature	  macrophages	  and	  is	  a	  commonly	  used	  marker	  
to	   identify	   tissue-­‐resident	   macrophages	   in	   the	   mouse	   (Austyn	   and	   Gordon	   1981).	  	  
Another	   method	   of	   macrophage	   depletion	   is	   systemic	   liposomal	   clodronate	   (sLC)	  
administration,	  which	  when	  ingested	  by	  macrophages	  induces	  apoptosis	  (Van	  Rooijen	  
and	   Sanders	   1994,	   Bedoret	   et	   al.	   2009,	   Dhaliwal	   et	   al.	   2012,	   Ferenbach	   et	   al.	   2012).	  	  
Lastly,	   some	   have	   used	   diphtheria	   toxin	   administration	   to	   CD11b	   diphtheria	   toxin	  
receptor	  transgenic	  mice	  (CD11b-­‐DTR),	  which	  are	  genetically	  modified	  to	  express	  the	  
human	  diphtheria	  toxin	  receptor	  from	  the	  CD11b	  promoter	  sequence.	  	  In	  this	  scenario,	  
diphtheria	   toxin	   administration	   results	   in	   conditional	   ablation	   of	   monocytes	   and	  
macrophages	   (Duffield	   et	   al.	   2005,	   Stoneman	   et	   al.	   2007,	   Dhaliwal	   et	   al.	   2012,	  
Ferenbach	   et	   al.	   2012).	   	   In	   contrast	   to	   circulating	   neutrophils,	   which	   can	   be	   rapidly	  
depleted	   from	   the	   blood	   in	   response	   to	   antibody	   treatment,	   the	   depletion	   of	  
macrophages	  is	  complicated	  by	  the	  fact	  that	  macrophages	  are	  tissue-­‐resident	  cells	  and	  
these	  different	  methods	  of	  macrophage	  depletion	  have	  been	  reported	  to	  deplete	  some	  
tissue-­‐resident	  macrophage	  populations	  and	  not	  others.	  	  For	  example,	  a	  recent	  study	  by	  
Dhaliwal	   et	   al.	   (Dhaliwal	   et	   al.	   2012),	   investigating	   the	   role	   of	   monocytes	   in	   LPS-­‐
induced	   lung	   injury,	   reported	   that	   sLC	   administration	   depleted	   peripheral	   blood	  
monocytes	   and	   macrophages	   resident	   in	   both	   the	   liver	   and	   spleen,	   whilst	   the	   lung	  
alveolar	   macrophage	   population	   remained	   unchanged.	   	   The	   same	   study	   also	  
investigated	  the	  CD11b-­‐DTR	  mouse	  as	  a	  method	  of	  depletion	  and	  found	  that	  there	  was	  
90%	  depletion	   of	   peripheral	   blood	  monocytes,	  with	   reduced	   depletion	   in	   the	   spleen,	  
and	  with	   this	  method	  macrophage	   populations	   in	   the	   liver	   and	   lung	  were	   unaffected	  
(Dhaliwal	  et	  al.	  2012).	   	  Similar	  findings	  have	  also	  been	  reported	  by	  others	  (Bedoret	  et	  
al.	   2009,	   Ferenbach	   et	   al.	   2012),	   again	   highlighting	   the	   complexity	   of	   macrophage	  
depletion	  models.	  	  	  
Immunohistochemical	  analysis	  of	  F4/80	  positive	  cells	  in	  our	  model	  demonstrated	  that	  
anti-­‐F4/80	   treatment	   appeared	   to	   reduce	   the	   number	   of	   F4/80	   positive	   cells	   in	   the	  
spleen,	   lung	   and	   cervix,	   although	   some	   macrophages	   were	   still	   present;	   while	   the	  
macrophage	  population	  of	   the	   liver	  appeared	  unaffected.	   	   In	   the	  uterus,	  macrophages	  
were	  still	  present	   in	  both	  the	  myometrium	  and	  decidua	  of	  mice	  treated	  with	  the	  anti-­‐
F4/80	  antibody.	  	  As	  formal	  quantification	  of	  F4/80	  positive	  cells	  was	  not	  carried	  out	  in	  
these	  preliminary	  studies	  we	  cannot	  definitively	  exclude	  the	  possibility	  that	  anti-­‐F4/80	  
treatment	   did	   result	   in	   a	   small	   reduction	   in	   macrophage	   numbers	   in	   the	   uterus.	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Macrophage	  depletion	  using	  the	  anti-­‐F4/80	  antibody	  has	  been	  previously	  investigated	  
during	   pregnancy,	   where	   anti-­‐F4/80	   treatment	   has	   been	   reported	   to	   deplete	  
macrophages	   in	   the	   cervix	   (Gonzalez	   et	   al.	   2011)	   and	   in	   the	   utero-­‐placental	   tissues	  
(Thaxton	   et	   al.	   2009,	   Sun	   et	   al.	   2013).	   	   The	   reason	   why	   similar	   depletion	   of	  
macrophages	  in	  the	  uterus	  was	  not	  observed	  in	  our	  study	  is	  not	  clear,	  but	  differences	  in	  
the	   timing	   and	   duration	   of	   anti-­‐F4/80	   treatment	  may	   be	   important.	   	   In	   some	   of	   the	  
previous	   studies,	   the	   anti-­‐F4/80	   antibody	  was	   administered	   twice	   during	   pregnancy	  
(on	  D5	  and	  D7;	  or	  D13	  and	  D15),	  and	  depletion	  was	  examined	  two	  days	  later	  by	  flow	  
cytometry	  (Thaxton	  et	  al.	  2009,	  Sun	  et	  al.	  2013).	   	   In	  contrast,	   in	  our	  study	  anti-­‐F4/80	  
was	  administered	  once	  on	  D17,	  and	  tissues	  were	  harvested	  the	  same	  day.	   	  Perhaps	   if	  
repeated	  doses	  of	  anti-­‐F4/80	  had	  been	  given,	  or	  if	  the	  tissues	  had	  been	  examined	  at	  a	  
later	  time-­‐point,	  we	  may	  have	  observed	  significant	  depletion	  of	  macrophages.	  	  	  
 
Effect	  of	  immune	  cell	  depletion	  on	  LPS-­‐induced	  preterm	  labour	  
As	   it	   has	   become	   increasingly	   clear	   that	   labour,	   both	   at	   term	   and	   preterm,	   is	   an	  
inflammatory	  event	  that	  is	  associated	  with	  immune	  cell	  influx	  into	  the	  utero-­‐placental	  
tissues	   (Thomson	   et	  al.	   1999),	   there	   has	   been	   growing	   interest	   in	   understanding	   the	  
role	   these	   immune	   cells	   play	   in	   the	   induction	   of	   labour.	   	   For	   that	   reason,	   in	   vivo	  
depletion	  studies	  have	  become	  a	  useful	   tool	   in	   this	   field	  of	   research.	   	   In	   recent	  years,	  
studies	   have	   used	   antibody-­‐based	   depletion	  methods	   to	   deplete	   various	   immune	   cell	  
populations	  including:	  macrophages	  (Thaxton	  et	  al.	  2009,	  Gonzalez	  et	  al.	  2011,	  Sun	  et	  al.	  
2013),	   neutrophils	   (Timmons	   and	   Mahendroo	   2006,	   Thaxton	   et	   al.	   2009,	   Sun	   et	   al.	  
2013)	  and	  uterine	  NK	  cells	  (Murphy	  et	  al.	  2005,	  Murphy	  et	  al.	  2009,	  Thaxton	  et	  al.	  2009,	  
Sun	  et	  al.	  2013)	  to	  investigate	  their	  role	  in	  normal	  and	  adverse	  pregnancy	  outcomes.	  	  
These	   previous	   studies	   found	   that	   neutrophil	   depletion	   in	   mice	   using	   the	   anti-­‐Gr-­‐1	  
antibody	   (RB6-­‐8C5)	   had	   no	   effect	   on	   normal	   term	   labour	   (Timmons	   and	  Mahendroo	  
2006)	  or	  in	  models	  of	  CpG	  oligodeoxynucleotide	  (CpG	  ODN)-­‐induced	  preterm	  labour,	  in	  
IL-­‐10	  knockout	   (Thaxton	  et	  al.	   2009)	  and	  NK	  cell-­‐deficient	  non-­‐obese	  diabetic	   (NOD)	  
mice	   (Sun	   et	  al.	   2013).	   	   CpG	  ODN	   are	   short	  DNA	  molecules	   that	   are	   abundant	   in	   the	  
microbial	   genome	   which	   induce	   an	   inflammatory	   and	   immune	   response	   via	   TLR-­‐9	  
activation	   (Thaxton	   et	   al.	   2009).	   	   As	   we	   had	   observed	   a	   massive	   recruitment	   of	  
neutrophils	  in	  to	  the	  decidua	  of	  mice	  treated	  with	  LPS,	  but	  not	  in	  mice	  treated	  with	  PBS,	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we	  hypothesised	  that	  this	  neutrophil	  influx	  may	  play	  an	  important	  role	  in	  the	  initiation	  
of	   LPS-­‐induced	   preterm	   labour.	   	   Therefore,	   we	   sought	   to	   investigate	   this	   using	   two	  
different	  antibodies.	  	  In	  line	  with	  these	  previous	  studies	  discussed,	  we	  chose	  to	  deplete	  
neutrophils	  using	  the	  anti-­‐Gr-­‐1	  antibody,	  however	  we	  also	  used	  the	  more	  specific	  anti-­‐
Ly-­‐6G	   antibody	   to	   ensure	   any	   effects	  we	   observed	  were	   due	   to	   neutrophil	   depletion	  
and	  not	  the	  depletion	  of	  other	  subpopulations	  of	  immune	  cells.	  	  This	  is	  the	  first	  study	  to	  
examine	   the	   effect	   of	   neutrophil	   depletion	  using	   anti-­‐Gr-­‐1	   in	   a	  model	   of	   LPS-­‐induced	  
preterm	   labour,	   and	   also	   the	   first	   study	   to	   use	   the	   specific	   anti-­‐Ly-­‐6G	   antibody	   to	  
investigate	   the	   role	   of	   neutrophils	   in	   a	  model	   of	   preterm	   labour.	   	   In	   line	  with	   these	  
previous	   studies	   which	   investigated	   the	   effect	   of	   depletion	   with	   anti-­‐Gr-­‐1	   in	   other	  
models	   of	   preterm	   labour,	  we	   found	   that	  neutrophil	   depletion	  with	   anti-­‐Gr-­‐1	  did	  not	  
delay	  LPS-­‐induced	  preterm	  delivery,	  compared	  to	   the	   IgG+LPS	  control	  group.	   	   In	   fact,	  
the	  anti-­‐Gr-­‐1	  treated	  mice	  seemed	  to	  deliver	  somewhat	  earlier	  than	  the	  control	  group,	  
although	  this	  was	  not	  statistically	  significant.	  	  Depletion	  of	  neutrophils	  using	  anti-­‐Ly-­‐6G	  
also	  did	  not	  delay	  LPS-­‐induced	  preterm	  delivery,	  and	  again	  the	  mean	  time	  to	  delivery	  
was	  slightly	  lower	  in	  the	  depleted	  mice	  compared	  to	  the	  control	  group,	  however	  not	  to	  
the	   same	   extent	   as	   observed	   with	   anti-­‐Gr-­‐1	   treatment.	   	   These	   data	   suggest	   that	  
neutrophils	   are	   not	   required	   for	   the	   induction	   of	   LPS-­‐induced	   preterm	   labour	   in	   our	  
model,	   and	   in	   fact	   may	   have	   a	   role	   in	   controlling	   the	   LPS-­‐induced	   inflammatory	  
response,	   given	   that	   the	   depleted	   mice	   delivered	   earlier.	   Further	   studies	   would	   be	  
needed	  to	  confirm	  this	  hypothesis.	  	  	  
As	  discussed	  previously	  (in	  chapter	  3),	  neutrophils	  are	  proposed	  to	  play	  an	  important	  
role	   in	   the	   repair	   and	   re-­‐modelling	   of	   the	   uterus	   during	   the	   post-­‐partum	   period	  
(Timmons	  et	  al.	  2009,	  Shynlova	  et	  al.	  2013,	  Shynlova	  et	  al.	  2013),	  therefore	  it	  would	  be	  
interesting	  to	  examine	  what	  effect	  the	  neutrophil	  depletion	  has	  during	  the	  post-­‐partum	  
period,	   and	   to	   investigate	   whether	   repeated	   administration	   of	   the	   antibodies	   to	  
maintain	   neutrophil	   depletion	   may	   impact	   uterine	   remodelling	   and	   therefore	  
potentially	   hinder	   subsequent	   pregnancies.	   	   Support	   for	   this	   hypothesis	   comes	   from	  
evidence	   from	   a	   mouse	   model	   of	   menstruation	   that	   demonstrated	   that	   neutrophil	  
depletion	   (using	   the	   anti-­‐Gr-­‐1	   antibody)	   significantly	   delayed	   endometrial	   repair	  
following	  menstruation	  (Kaitu'u-­‐Lino	  et	  al.	  2007).	  	  
The	   proportion	   of	   live	   born	   pups	   was	   also	   lower	   in	   neutrophil	   depleted	   mice	   (with	  
either	   antibody),	   compared	   to	   the	   respective	   control	   groups,	   however	   again	   this	  was	  
not	  statistically	  significant.	  	  This	  could	  suggest	  that	  neutrophils	  play	  a	  role	  in	  protecting	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the	  fetus	  from	  the	  adverse	  effects	  of	  LPS	  treatment,	  but	  may	  also	  just	  reflect	  the	  shorter	  
time	  to	  delivery	  observed	  in	  the	  neutrophil	  depleted	  groups	  (particularly	  in	  the	  anti-­‐Gr-­‐
1+LPS	  group),	  resulting	  in	  preterm	  delivery	  early	  on	  D17,	  when	  the	  pups	  are	  unlikely	  
to	  be	  developmentally	  competent	  to	  survive.	  	  	  	  
Previous	   studies	   investigating	  macrophage	  depletion	   in	   adverse	  pregnancy	   outcomes	  
have	   proved	   more	   promising.	   	   Depletion	   of	   macrophages	   with	   anti-­‐F4/80	   has	   been	  
shown	   to	   rescue	   CpG	   ODN-­‐induced	   early	   pregnancy	   loss	   and	   preterm	   birth	   in	   IL-­‐10	  
knockout	   (Thaxton	   et	   al.	   2009)	   and	   NK	   cell-­‐deficient	   NOD	   mice	   (Sun	   et	   al.	   2013).	  	  
Additionally,	  Gonzalez	  et	  al.	  demonstrated	  that	  macrophage	  depletion	  prevented	  LPS-­‐
induced	   preterm	   delivery	   in	   a	   mouse	   model	   (Gonzalez	   et	   al.	   2011).	   	   	   However,	   in	  
contrast	  we	  found	  that	  anti-­‐F4/80	  treatment	  prior	   to	   intrauterine	  LPS	  administration	  
had	   no	   effect	   on	   LPS-­‐induced	   preterm	   delivery	   in	   our	   model.	   	   This	   difference	   was	  
unexpected,	  as	  we	  used	  the	  same	  dose	  and	  timing	  of	  anti-­‐F4/80	  administration	  as	  that	  
used	  by	  Gonzalez	  et	  al,	  but	  the	  different	  routes	  of	  LPS	  administration	  used	  may	  explain	  
it.	   	  Gonzalez	  et	  al.	  administered	  LPS	  intravaginally	  on	  D15	  of	  gestation	  (Gonzalez	  et	  al.	  
2011),	  while	   our	  model	   is	   of	   intrauterine	   LPS	   administration	  on	  D17.	   	   It	   is	   therefore	  
possible,	   that	   intravaginal	   LPS	   administration,	   which	   results	   in	   a	  more	   local	   cervical	  
inflammatory	   response,	   is	   more	   macrophage-­‐dependent,	   than	   the	   inflammatory	  
response	   induced	   by	   intrauterine	   LPS	   administration.	   	   It	   should	   also	   be	   noted,	   as	  
discussed	   above,	   that	   anti-­‐F4/80	   treatment	   did	   not	   appear	   to	   cause	   depletion	   of	  
macrophages	   from	   the	  body	  of	   the	  uterus,	   although	   there	  did	   appear	   to	  be	  depletion	  
from	   the	   cervix,	   as	   reported	   by	   Gonzalez	   et	   al.	   (Gonzalez	   et	   al.	   2011).	   	   Even	   if	   there	  
were	  a	  small	  number	  of	  macrophages	  depleted	  from	  the	  uterine	  tissue,	  due	  to	  the	  large	  
tissue-­‐resident	  population	  of	  macrophages,	  there	  was	  still	  a	  large	  number	  of	  cells	  that	  
could	   still	   respond	   to	   LPS.	   	   Therefore,	   although	   these	   data	   presented	   here	   suggest	  
macrophages	  are	  also	  not	  necessary	  for	  the	  induction	  of	  LPS-­‐induced	  preterm	  delivery	  
in	   our	   model,	   it	   is	   difficult	   to	   draw	   a	   firm	   conclusion	   at	   present,	   as	   anti-­‐F4/80	  
treatment	   did	   not	   appear	   to	   deplete	   the	   local	   macrophage	   population	   within	   the	  
uterine	   tissue.	   	   To	   investigate	   further	   the	   role	   of	   macrophages	   in	   our	   model	   of	  
infection-­‐induced	  preterm	  labour,	  the	  macrophage	  depletion	  protocol	  would	  need	  to	  be	  
optimised,	   either	   by	   administering	   additional	   doses	   of	   anti-­‐F4/80	   or	   by	   trying	   an	  
alternative	  method	  of	  macrophage	  depletion	   such	   as	   sLC	   administration	  or	  using	   the	  
CD11b-­‐DTR	  mouse,	  as	  described	  above.	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Effect	  of	  immune	  cell	  depletion	  on	  the	  LPS-­‐induced	  inflammatory	  response	  	  
Having	   observed	   that	   neither	   neutrophil	   nor	  macrophage	   depletion	   had	   a	   significant	  
effect	  on	  LPS-­‐induced	  preterm	  delivery	  in	  our	  model,	  we	  investigated	  whether	  either	  of	  
these	  immune	  cell	  populations	  contributed	  to	  the	  LPS-­‐induced	  inflammatory	  response	  
observed	  in	  the	  utero-­‐placental	  tissues	  and	  serum.	  	  The	  previous	  studies	  investigating	  
immune	  cell	  depletion	  in	  preterm	  labour	  models	  have	  focussed	  more	  on	  the	  outcome	  of	  
preterm	   labour,	   rather	   than	   examining	   the	   effect	   of	   immune	   cell	   depletion	   on	   the	  
inflammatory	  signalling	  of	  the	  utero-­‐placental	  tissues.	  	  Of	  the	  studies	  mentioned	  above,	  
only	   two	   have	   examined	   inflammatory	   signalling	   in	   the	   utero-­‐placental	   tissues	  
following	  depletion,	  and	   these	  studies	  only	  examined	  TNF-­‐α	  production;	  both	  studies	  
showed	  that	  depletion	  with	  anti-­‐Gr-­‐1	  had	  no	  effect	  on	  TNF-­‐α	  in	  utero-­‐placental	  tissue,	  
whereas	  anti-­‐F4/80	  treatment	  reduced	  TNF-­‐α	  production	  (Thaxton	  et	  al.	  2009,	  Sun	  et	  
al.	   2013).	   	   Therefore,	  we	   sought	   to	   examine	   the	   effect	   of	   immune	   cell	   depletion	   on	   a	  
wider	  range	  of	   inflammatory	  markers	   in	  our	  model.	   	   Interestingly,	  depletion	  with	   the	  
three	  different	  antibodies	  resulted	  in	  different	   inflammatory	  gene	  expression	  changes	  
within	  the	  utero-­‐placental	  tissues	  examined.	  	  	  
Depletion	   with	   the	   anti-­‐Gr-­‐1	   antibody	   resulted	   in	   decreased	   Il-­‐1β	   expression	   in	   the	  
uterus	   and	   placenta,	   whilst	   the	   expression	   of	   several	   inflammatory	   mediators,	  
including	   Il-­‐6,	   Cxcl1	   and	   Cxcl2	   in	   the	   fetal	   membranes	   was	   significantly	   elevated	   in	  
response	   to	  anti-­‐Gr-­‐1+LPS	  treatment,	  compared	  to	   the	   IgG+LPS	  control	  group.	   	  These	  
results	   suggest	   that	   the	   Gr-­‐1	   positive	   depleted	   cells	   contribute	   to	   the	   observed	   LPS-­‐
induced	   increase	   in	   Il-­‐1β	   expression	   in	   the	   uterus	   and	   placenta.	   	   In	   contrast,	   Gr-­‐1	  
positive	   cells	   may	   play	   a	   role	   in	   inhibiting	   inflammatory	   signalling	   in	   the	   fetal	  
membranes,	  as	  lack	  of	  Gr-­‐1	  positive	  cells	  induced	  increased	  expression	  of	  a	  number	  of	  
inflammatory	   genes.	   	   Specific	   depletion	   of	   neutrophils	   using	   the	   anti-­‐Ly-­‐6G	   antibody	  
resulted	   in	   fewer	   gene	   expression	   changes,	   with	   significantly	   reduced	   expression	   of	  
Tnf-­‐α	  and	  Il-­‐1β	  in	  the	  uterus	  and	  increased	  Cxcl5	  expression	  in	  the	  placenta;	  no	  change	  
was	   found	   in	   inflammatory	   gene	   expression	   in	   the	   fetal	  membranes	   following	   Ly-­‐6G	  
depletion.	  	  	  	  	  
The	  different	  responses	  observed	  to	  depletion	  using	  anti-­‐Gr-­‐1,	  compared	  to	  anti-­‐Ly-­‐6G	  
again	   highlights	   that	   these	   two	   antibodies	   do	   not	   target	   the	   same	   immune	   cell	  
population.	   	   It	   is	   possible	   that	   the	   large	   number	   of	   changes	   in	   inflammatory	   gene	  
expression	   observed	   with	   anti-­‐Gr-­‐1,	   which	   are	   not	   apparent	   following	   anti-­‐Ly-­‐6G	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treatment,	  are	  a	  result	  of	  depletion	  of	  the	  other	  subsets	  of	  immune	  cells	  expressing	  Ly-­‐
6C	   which	   are	   also	   depleted	   upon	   Gr-­‐1	   administration.	   	   Previous	   studies	   have	   also	  
reported	   a	   more	   pro-­‐inflammatory	   and	   more	   severe	   phenotype	   following	   Gr-­‐1	  
administration,	  compared	  with	  Ly-­‐6G	  administration,	  and	  it	   is	  proposed	  that	  the	  non-­‐
neutrophil	   Gr-­‐1	   positive	   cells	   may	   have	   an	   important	   inhibitory	   role	   in	   regulating	  
inflammatory	   signalling	   (Daley	   et	  al.	   2008,	  Wojtasiak	   et	  al.	   2010).	   	   In	   line	  with	   these	  
data	   suggesting	   anti-­‐Gr-­‐1	   depletion	   results	   in	   a	  more	   pro-­‐inflammatory	   response,	   in	  
our	  model,	  anti-­‐Gr-­‐1	  treatment	  resulted	  in	  a	  much	  shorter	  time	  to	  delivery	  compared	  to	  
anti-­‐Ly-­‐6G	   treatment	   (mean	   time	   to	   delivery	   in	   anti-­‐Gr-­‐1+LPS	   group:	   8.95	   hours	  
compared	   with	   mean	   time	   to	   delivery	   in	   anti-­‐Ly-­‐6G+LPS	   group:	   19.25	   hours)	   and	  
induced	   a	   2.5-­‐fold	   (non-­‐significant)	   increase	   in	   serum	   TNF-­‐α	   levels,	   which	   was	   not	  
observed	  following	  anti-­‐Ly-­‐6G	  treatment.	  	  Future	  work	  should	  focus	  on	  identifying	  the	  
non-­‐neutrophil	   Gr-­‐1	   positive	   cell	   populations	   that	   may	   play	   an	   important	   role	   in	  
limiting	   the	   inflammatory	   response,	   as	   understanding	  more	   about	  how	   the	   infection-­‐
induced	  inflammatory	  response	  is	  regulated	  in	  the	  utero-­‐placental	  tissues	  may	  help	  in	  
the	  identification	  of	  novel	  targets	  for	  the	  treatment	  of	  preterm	  labour.	  	  	  
As	  has	  been	  previously	  reported	  (Thaxton	  et	  al.	  2009,	  Sun	  et	  al.	  2013),	  treatment	  with	  
anti-­‐F4/80	   resulted	   in	   reduced	   expression	   of	   Tnf-­‐α	   in	   the	   uterus	   and	   a	   2-­‐fold	   (non-­‐
significant)	  reduction	  in	  serum	  TNF-­‐α	  levels.	  	  As	  macrophages	  are	  the	  major	  source	  of	  
TNF-­‐α	   (Riches	   et	   al.	   1996),	   these	   results	   suggest	   that	   although	   not	   obvious	   by	  
immunohistochemical	   analysis,	   anti-­‐F4/80	   treatment	   may	   have	   resulted	   in	   some	  
macrophage	  depletion	  in	  the	  uterus.	  	  	  
Therefore,	   whilst	   immune	   cell	   depletion	   in	   our	  model	   suggests	   that	   neutrophils	   and	  
macrophages	   are	   not	   required	   for	   the	   induction	   of	   preterm	   delivery	   in	   response	   to	  
intrauterine	  LPS,	  they	  do	  have	  a	  role	  in	  contributing	  to	  the	  LPS-­‐induced	  inflammatory	  
response	  within	  the	  utero-­‐placental	  tissues.	  	  	  
	  
Summary	  
This	  chapter	  has	  described	  the	  use	  of	  antibody-­‐mediated	  depletion	  of	  neutrophils	  and	  
macrophages	  to	  investigate	  their	  role	  in	  LPS-­‐induced	  preterm	  labour.	   	  This	  is	  the	  first	  
study	  to	  investigate	  the	  effect	  of	  neutrophil	  depletion	  in	  a	  mouse	  model	  of	  LPS-­‐induced	  
preterm	  labour,	  and	  furthermore,	  the	  first	  study	  to	  use	  the	  specific	  anti-­‐Ly-­‐6G	  antibody	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to	   investigate	   the	   role	   of	   neutrophils.	   	   Flow	   cytometry	   and	   immunohistochemical	  
analysis	   confirmed	   successful	   depletion	   of	   neutrophils	   in	   response	   to	   both	   anti-­‐Gr-­‐1	  
and	   anti-­‐Ly-­‐6G	   treatment,	   however	   neutrophil	   depletion	   did	   not	   have	   a	   significant	  
effect	  on	  LPS-­‐induced	  preterm	  delivery.	   	   	   Similarly,	  macrophage	  depletion	  using	  anti-­‐
F4/80	   treatment	   also	   did	   not	   affect	   LPS-­‐induced	   preterm	   delivery	   in	   our	   model,	  
although	  how	  effective	  the	  anti-­‐F4/80	  treatment	  was	  in	  depleting	  macrophages	  in	  our	  
model	   remains	   unclear.	   	   	   Although	   no	   effect	   on	   LPS-­‐induced	   preterm	   delivery	   was	  
observed,	   depletion	   of	   both	   neutrophils	   and	   macrophages	   altered	   the	   LPS-­‐induced	  
inflammatory	   response	   in	   the	   utero-­‐placental	   tissues,	   suggesting	   that	   whilst	   these	  
immune	   cells	   appear	   not	   to	   be	   required	   for	   LPS-­‐induced	   preterm	   delivery,	   they	   do	  
contribute	   to	   the	   inflammatory	  response	  of	   the	  utero-­‐placental	   tissues	   in	  response	   to	  
intrauterine	  LPS	  administration.	   	   Immune	  cell	  depletion	   is	  a	  useful	   tool	   to	   investigate	  
the	   role	   different	   immune	   cell	   populations	   play	   in	   infection-­‐induced	   preterm	   labour,	  
however,	   these	   data	   highlight	   the	   importance	   of	   choosing	   the	   most	   appropriate	  
depletion	   strategy	   to	   ensure	   efficient	   depletion	   in	   the	   target	   tissues,	   and	   specific	  
depletion	   of	   the	   immune	   cell	   population	   of	   interest.	   	   Using	   alternative	   depletion	  
strategies	  may	   prove	  more	   useful	   to	   investigate	   the	   role	   of	  macrophages	   in	   preterm	  
labour,	  and	  this	  work	  highlights	  that	  future	  work	  investigating	  the	  role	  of	  neutrophils	  
should	   be	   carried	   out	   using	   the	   specific	   anti-­‐Ly-­‐6G	   antibody,	   as	   different	   responses	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6.1 SUMMARY	  OF	  FINDINGS	  
Preterm	   labour	   remains	   a	   major	   clinical	   problem	   worldwide,	   with	   limited	   effective	  
treatment	   options	   available.	   	   Given	   that	   many	   cases	   of	   preterm	   labour	   occur	   in	   the	  
presence	   of	   an	   intrauterine	   infection,	   extensive	   research	   is	   being	   carried	   out	   to	  
understand	  how	  the	  presence	  of	  an	  intrauterine	  infection	  triggers	  preterm	  labour	  and	  
to	   investigate	   potential	   novel	   therapeutic	   options	   to	   stop	   preterm	   delivery	   that	   will	  
ultimately	  improve	  neonatal	  outcome.	  	  This	  thesis	  has	  investigated	  the	  role	  of	  infection	  
and	  inflammation	  in	  a	  mouse	  model	  of	  infection-­‐induced	  preterm	  labour,	  with	  specific	  
aims	   to:	   characterise	   the	   inflammatory	   and	   immune	   response	   to	   a	   bacterial	  
intrauterine	   infection;	   investigate	   the	   potential	   of	   anti-­‐inflammatory	   agents	   to	   delay	  
preterm	  delivery	  and	   improve	  neonatal	  outcome;	  and	   to	  examine	   the	  role	  of	   immune	  
cells	   in	   the	   induction	  of	   infection-­‐induced	  preterm	   labour	  and	   the	   local	   inflammatory	  
response.	  	  The	  main	  findings	  of	  this	  work	  are	  summarised	  below:	  
• Intrauterine	   administration	   of	   LPS	   at	   a	   dose	   of	   20µg	   on	   D17	   of	   gestation	  
successfully	  induced	  preterm	  labour	  in	  a	  mouse	  model.	  	  
• Intrauterine	  administration	  of	  LPS	  induced	  increased	  expression	  of	  several	  key	  
pro-­‐inflammatory	  mediators	  within	   the	   utero-­‐placental	   tissues,	   amniotic	   fluid	  
and	   serum;	   highlighting	   the	   presence	   of	   an	   intrauterine	   infection	   induces	   a	  
robust	   inflammatory	   response,	   even	   in	   response	   to	   doses	   of	   LPS	   that	   did	   not	  
induce	  preterm	  delivery.	  
• The	  increased	  inflammatory	  response	  induced	  by	  LPS	  treatment	  appears	  to	  be	  
largely	   independent	   of	   the	   actions	   of	   progesterone,	   as	   systemic	   progesterone	  
withdrawal	  was	  not	  observed.	  	  
• In	   response	   to	   intrauterine	   LPS	   administration	   there	   was	   an	   influx	   of	  
neutrophils	   into	   the	   decidua	   within	   6	   hours	   of	   LPS	   treatment,	   whilst	  
macrophage	   numbers	   remained	   stable.	   	   Surgery	   itself	   appeared	   to	   induce	  
neutrophil	   recruitment	   to	   the	   myometrium,	   even	   in	   mice	   receiving	   only	  
intrauterine	  PBS.	  	  	  
• Pre-­‐treatment	  with	  epi-­‐lipoxin	  did	  not	  delay	  LPS-­‐induced	  preterm	  delivery,	  but	  
mice	   that	  delivered	  prematurely	  who	  were	   treated	  with	  epi-­‐lipoxin	   (and	  LPS)	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had	  a	  significantly	  increased	  proportion	  of	  live	  born	  pups,	  compared	  with	  mice	  
receiving	  LPS	  alone.	  	  	  
• Epi-­‐lipoxin	  increased	  the	  expression	  of	  Cox-­‐2	  within	  the	  utero-­‐placental	  tissues,	  
and	   down-­‐regulated	   15-­‐Hpgd	   expression,	   suggesting	   that	   lipoxin	   may	   be	  
promoting	  the	  production	  of	  anti-­‐inflammatory	  prostaglandins.	  	  
• Pre-­‐treatment	   with	   BML-­‐111	   prior	   to	   intrauterine	   LPS	   administration	  
significantly	   reduced	   the	  preterm	  delivery	   rate,	   but	   did	  not	   have	   a	   significant	  
impact	  on	  the	  mean	  time	  to	  delivery	  or	  proportion	  of	  live	  born	  pups.	  
• Pre-­‐treatment	   with	   IL-­‐10	   prior	   to	   intrauterine	   LPS	   administration	   had	   no	  
significant	   effect	   on	   LPS-­‐induced	   preterm	   delivery	   or	   the	   proportion	   of	   live	  
born	  pups.	  
• Neutrophil	  depletion	  using	  either	  the	  anti-­‐Gr-­‐1	  or	  anti-­‐Ly-­‐6G	  antibody	  did	  not	  
attenuate	   LPS-­‐induced	   preterm	   delivery.	   	   Similarly,	   treatment	   with	   the	   anti-­‐
F4/80	   antibody	   to	   deplete	  macrophages	   also	   did	   not	   significantly	   affect	   LPS-­‐
induced	  preterm	  delivery	  
• Although	   immune	   cell	   depletion	   did	   not	   attenuate	   LPS-­‐induced	   preterm	  
delivery,	   the	   inflammatory	   response	   induced	   by	   intrauterine	   LPS	  
administration	   was	   altered,	   suggesting	   that	   although	   not	   required	   for	   LPS-­‐
induced	   preterm	   delivery	   neutrophils	   and	   macrophages	   are	   important	   in	  
contributing	   to	   the	   LPS-­‐induced	   inflammatory	   response	   within	   the	   utero-­‐
placental	  tissues.	  	  	  
	  
	  
6.2 MOUSE	  MODEL	  OF	  PRETERM	  LABOUR	  
Animal	   models	   have	   been	   used	   extensively	   in	   the	   field	   of	   parturition	   research	   to	  
understand	  the	  basic	  mechanisms	  underlying	  the	  onset	  of	  spontaneous	  labour	  at	  term	  
and	   to	   investigate	   potential	   novel	   therapeutic	   options	   for	   the	   treatment	   of	   preterm	  
labour.	  	  As	  previously	  discussed,	  the	  pros	  and	  cons	  of	  using	  various	  animal	  models	  for	  
parturition	   research	   have	   been	   extensively	   reviewed	   (Elovitz	   and	   Mrinalini	   2004,	  
Mitchell	  and	  Taggart	  2009,	  Ratajczak	  et	  al.	  2010).	  	  Whilst	  there	  are	  clear	  differences	  in	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the	   reproductive	   physiology	   and	   the	   mechanisms	   required	   to	   initiate	   parturition	  
between	   animal	   models	   and	   humans,	   the	   limited	   number	   of	   samples	   that	   can	   be	  
feasibly	   and	   ethically	   collected	   from	   a	   woman	   throughout	   pregnancy	   and	   the	   high	  
degree	   of	   inter-­‐patient	   variability,	   make	   animal	   models	   invaluable	   to	   this	   field	   of	  
research.	   	   A	   variety	   of	   animal	   models	   have	   been	   used	   in	   preterm	   birth	   research,	  
including	   sheep,	   rats,	  non-­‐human	  primates	  and	  guinea	  pigs,	  however	  by	   far	   the	  most	  
commonly	   used	   animal	  model	   is	   the	  mouse.	   	   Indeed	  using	   the	  mouse	   as	   a	  model	   for	  
parturition	  research	  has	  many	  advantages,	  including:	  a	  short	  gestational	  period;	  ease	  of	  
breeding;	   a	   relatively	   well	   characterised	   immune	   system;	   and	   the	   availability	   of	  
genetically	  modified	  mice	   in	  which	  a	  single	   factor	  can	  be	  either	  knocked	  out	  or	  over-­‐
expressed	  to	  investigate	  the	  role	  it	  may	  play	  in	  parturition	  (Hirsch	  and	  Wang	  2005).	  In	  
particular,	   the	  work	  presented	   in	   this	   thesis,	   and	   in	  other	  papers	  has	  highlighted	   the	  
similarities	  between	   the	   inflammatory	   responses	   to	   a	  bacterial	   intrauterine	   infection.	  	  
Limitations	   of	   using	   a	   mouse	   model	   to	   study	   parturition	   include	   physiological	  
differences	   between	   mouse	   and	   human	   pregnancy,	   such	   as	   their	   bicornuate	   uterus,	  
multiple	   pregnancies	   and	   short	   gestational	   period	   (Hirsch	   and	  Wang	   2005);	   and	   the	  
main	  issue	  often	  raised	  is	  the	  dependency	  of	  systemic	  progesterone	  withdrawal	  for	  the	  
initiation	   of	   parturition	   in	   this	   model.	   	   However,	   several	   recent	   studies	   have	   now	  
demonstrated	   that	   in	   the	   context	   of	   infection-­‐induced	   preterm	   labour,	   systemic	  
progesterone	   withdrawal	   does	   not	   appear	   to	   be	   integral	   to	   the	   induction	   of	   labour	  
(Hirsch	   and	   Muhle	   2002,	   Murphy	   et	   al.	   2009,	   Gonzalez	   et	   al.	   2011);	   similar	   to	   the	  
results	  we	  obtained	   in	  our	   study.	   	  Therefore,	  whilst	   there	  are	   clear	   limitations	   to	   the	  
use	  of	   any	  animal	  model,	   the	  mouse	  continues	   to	  provide	  a	  useful	   in	  vivo	  model	  with	  
which	  to	  investigate	  further	  the	  molecular	  mechanisms	  of	  parturition	  and	  to	  test	  novel	  
treatment	  options	  for	  preterm	  labour.	  	  
The	  model	  used	  in	  this	  thesis,	  based	  on	  the	  model	  originally	  described	  by	  Elovitz	  et	  al.	  
(Elovitz	  et	  al.	  2003),	  is	  a	  useful	  model	  to	  study	  the	  role	  of	  a	  local	  intrauterine	  infection	  
in	  the	  induction	  of	  preterm	  labour.	  	  However,	  there	  are	  clear	  limitations	  to	  this	  model	  
that	   became	   apparent	   during	   our	   work.	   	   The	   invasive	   nature	   of	   the	   surgery,	   during	  
which	   the	   entire	   uterus	   is	   externalised	   to	   receive	   an	   intrauterine	   injection,	   prior	   to	  
being	  returned	  to	  the	  abdominal	  cavity,	  resulted	  in	  a	  high	  preterm	  delivery	  rate	  even	  in	  
our	   PBS	   control	   group.	   	   Therefore,	   the	   variable	   response	   to	   surgery	   became	   a	  
confounding	  factor	  in	  the	  model.	  	  Whilst	  a	  certain	  degree	  of	  variability	  between	  animals	  
is	   to	  be	  expected,	  particularly	  when	  performing	  surgery	  on	  pregnant	  animals	  close	  to	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delivery,	   we	   feel	   that	   reducing	   the	   invasiveness	   of	   the	   surgery	   involved	   is	   key	   to	  
improving	   the	   reliability	   of	   the	   model	   for	   future	   studies.	   	   Additionally,	   such	   an	  
approach	   is	   consistent	   with	   the	   “3Rs”	   (refinement,	   reduction	   and	   replacement)	  
philosophy	  which	  should	  underpin	  all	  studies	  involving	  animals.	  	  To	  this	  end,	  we	  have	  
carried	  out	   a	  preliminary	   experiment	   investigating	   the	  potential	   of	   using	  ultrasound-­‐
guided	   intrauterine	   injection	   of	   bacterial	   agents,	   thus	   avoiding	   the	   requirement	   for	  
invasive	  surgery.	  	  Currently	  we	  have	  only	  trialled	  injecting	  methylene	  blue	  dye	  and	  an	  
ultrasound	   contrast	   agent	   as	   a	   ‘proof-­‐of-­‐principle’	   experiment	   to	   test	  whether	   it	  was	  
still	   possible	   to	   give	   a	   direct	   intrauterine	   injection	   between	   two	   gestational	   sacs,	  
without	  externalisation	  of	  the	  uterus.	  	  We	  found	  that	  using	  ultrasound	  as	  a	  guide,	  it	  was	  
possible	   to	   still	   inject	   specifically	   into	   the	   uterus,	   without	   entering	   either	   of	   the	  
amniotic	   sacs.	   	   A	   representative	   image	   of	   this	   pilot	   data	   is	   given	   in	   Figure	   6.1;	   this	  
highlights	   that	   the	   UV	   contrast	   agent	   injected	   is	   localised	   to	   the	   space	   between	   two	  
gestational	  sacs.	  	  When	  the	  uterus	  was	  opened	  up	  it	  was	  clear	  that	  the	  methylene	  blue	  
dye	  was	  localised	  to	  the	  intrauterine	  space	  and	  had	  not	  spread	  elsewhere,	  including	  in	  
the	   intra-­‐amniotic	   space.	   	  Whilst	   preliminary,	   the	   results	   are	   promising	   and	   suggest	  
that	  using	  ultrasound-­‐guided	  injection	  in	  this	  model	  could	  provide	  a	  novel	  method	  with	  
which	  to	  introduce	  LPS	  into	  the	  uterus	  in	  future	  experiments,	  which	  would	  remove	  the	  
confounding	   effect	   of	   invasive	   surgery	   and	   improve	   the	   reliability,	   reduce	   the	  
variability	   and	   ultimately	   decrease	   the	   number	   of	   animals	   required	   for	   experiments.	  	  
The	   next	   step	   will	   be	   to	   perform	   some	   further	   experiments	   with	   PBS	   and	   LPS,	   to	  
examine	   whether	   we	   still	   get	   reliable	   induction	   of	   preterm	   labour	   in	   response	   to	  
ultrasound-­‐facilitated	  LPS	  treatment,	  and	  with	  a	  reduced	   incidence	  of	  preterm	  labour	  
in	  ultrasound-­‐facilitated	  PBS-­‐treated	  mice.	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Figure	   6.1	   -­‐	   Image	   of	   ultrasound-­‐guided	   intrauterine	   injection.	   	   Ultrasound	  
contrast	   agent	   (white)	   can	   be	   seen	   localised	   to	   the	   uterine	   space	   between	   two	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6.3 ROLE	  OF	  IMMUNE	  CELLS	  IN	  PRETERM	  LABOUR	  
Whilst	   there	   is	   now	   considerable	   evidence	   that	   labour	   is	   an	   inflammatory	   event	  
associated	  with	  increased	  production	  of	   inflammatory	  cytokines	  and	  chemokines,	  and	  
an	   influx	   of	   immune	   cells	   into	   the	   utero-­‐placental	   tissues	   (Thomson	   et	   al.	   1999,	  
Sennstrom	  et	  al.	  2000,	  Young	  et	  al.	  2002,	  Osman	  et	  al.	  2003),	  their	  precise	  role	  remains	  
unclear.	  	  Work	  by	  Young	  et	  al.	  demonstrated	  that	  these	  infiltrating	  leukocytes	  produce	  
inflammatory	  cytokines,	  thus	  contributing	  to	  the	  inflammatory	  environment	  (Young	  et	  
al.	  2002),	  however	  whether	  the	  infiltration	  of	  leukocytes	  is	  a	  key	  event	  in	  triggering	  the	  
onset	   of	   parturition,	   or	   merely	   a	   consequence	   of	   the	   heightened	   inflammatory	  
signalling	  remains	  to	  be	  elucidated.	  	  	  
To	   investigate	   the	   role	   that	   specific	   immune	   cell	   populations	  play	   in	   the	   induction	  of	  
preterm	  labour,	  genetically	  modified	  mice	  that	  lack	  particular	  immune	  cell	  subsets,	  or	  
antibody-­‐based	  depletion	  of	  immune	  cells	  have	  been	  used.	  	  The	  results	  of	  these	  studies	  
to	  date	  have	  been	  mixed.	  	  Although	  a	  number	  of	  studies	  have	  reported	  that	  depletion	  of	  
some	   immune	   cell	   populations,	   including	   macrophages,	   NK	   cells	   and	   invariant	   NKT	  
(iNKT)	  cells,	  attenuates	  infection-­‐induced	  preterm	  delivery	  in	  mouse	  models	  (Murphy	  
et	  al.	  2009,	  Gonzalez	  et	  al.	  2011,	  Li	  et	  al.	  2012);	  the	  same	  result	  has	  not	  been	  observed	  
in	  other	  studies	  examining	  the	  role	  of	  T	  and	  B	  lymphocytes	  and	  neutrophils	  (Bizargity	  
et	  al.	  2009,	  Thaxton	  et	  al.	  2009).	   	  Similarly,	  the	  results	  presented	  in	  our	  study	  showed	  
no	   benefit	   of	   depleting	   either	   neutrophils	   or	   macrophages	   prior	   to	   intrauterine	   LPS	  
administration.	   	  Therefore,	  at	  present,	  it	  is	  unclear	  what	  role	  immune	  cells	  play	  in	  the	  
onset	  of	  infection-­‐induced	  preterm	  labour,	  as	  it	  appears	  that	  in	  some	  cases	  they	  are	  not	  
required	  for	  the	  induction	  of	  parturition.	  	  The	  mixed	  success	  of	  these	  studies	  highlights	  
the	   complex	   interactions	   of	   different	   immune	   cells	   and	   it	   is	   likely	   that	   different	  
inflammatory	   stimuli	   will	   induce	   different	   immune	   cells	   to	   influx,	   thus	   making	  
depletion	  of	  one	  single	  immune	  cell	  population	  difficult	  to	  interpret	  in	  each	  case.	  	  
Given	   that	   the	   primary	   role	   of	   immune	   cells	   is	   to	   defend	   the	   body	   against	   infectious	  
diseases,	  depletion	  of	  immune	  cells	  could	  result	  in	  increased	  susceptibility	  to	  infectious	  
stimuli,	  which	  may	   explain	  why	   the	   neutrophil-­‐depleted	  mice	   in	   our	   study	   showed	   a	  
trend	   for	   earlier	   delivery	   in	   response	   to	   intrauterine	   LPS	   administration,	   compared	  
with	   the	   non-­‐depleted	   mice.	   	   Interestingly,	   several	   other	   studies	   have	   reported	   that	  
depletion	   of	   neutrophils	   actually	   results	   in	   increased	   susceptibility	   to	   infection	   and	  
poorer	  outcomes	  in	  other	  models	  of	  infection-­‐induced	  pathologies	  (Jarchum	  et	  al.	  2012,	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Ribes	   et	  al.	   2013).	   	   Therefore,	  while	   the	   results	   from	   our	   study,	   alongside	   data	   from	  
previously	  published	  work,	  suggest	  that	  the	  infiltrating	  immune	  cells	  contribute	  to	  the	  
inflammatory	   response	   of	   the	   utero-­‐placental	   tissues	   by	   producing	   inflammatory	  
chemokines	  and	  cytokines,	  this	  response	  may	  be	  secondary	  to	  the	  protective	  role	  these	  
cells	  may	  initially	  play	  in	  attempting	  to	  fight	  the	  infection.	  	  	  
Currently	  the	  precise	  role	  immune	  cells	  play	  in	  the	  onset	  of	  parturition,	  in	  particular	  in	  
the	   context	   of	   an	   intrauterine	   infection	   remains	   poorly	   understood.	   	   Several	   studies	  
suggest	   targeting	   some	   specific	   immune	   cell	   populations	  may	   be	   a	   novel	   therapeutic	  
option,	  however	   these	  data	  come	   from	  mouse	  models,	   therefore	   further	   investigation	  
into	   the	   relevance	  of	   these	   findings	   to	  women	   is	   required.	   	  Better	   characterisation	  of	  
the	   immune	   cell	   populations	   that	   infiltrate	   the	   utero-­‐placental	   tissues,	   both	   at	   term	  
labour	   and	   in	   response	   to	   a	   pathological	   infection,	   and	   the	   factors	   they	  produce,	  will	  
help	  us	  to	  understand	  the	  role	  these	  cells	  play	  in	  the	  process	  of	  parturition.	  	  There	  will	  
clearly	  be	  differences	   in	  the	  role	   immune	  cells	  play	   in	  the	  presence	  of	  an	   intrauterine	  
infection,	   compared	   to	   their	   role	  during	   spontaneous	   term	   labour,	  but	   improving	  our	  
understanding	  of	  these	  roles	  will	  allow	  us	  to	  determine	  whether	  targeting	  immune	  cells	  
and/or	  their	  products	  is	  likely	  to	  be	  a	  beneficial	  novel	  treatment	  option,	  and	  if	  so	  which	  
specific	   immune	   cell	   populations	   should	   be	   targeted.	   	   The	   potential	   for	   immune	   cell	  
depletion	  to	  heighten	  the	  inflammatory	  response	  to	  an	  intrauterine	  bacterial	  infection	  
must	   also	   be	   carefully	   considered.	   	   Nevertheless,	   it	   is	   clear	   that	   continuing	   research	  
into	  the	  role	  different	   immune	  cell	  populations	  play	   in	  the	  onset	  of	  term	  and	  preterm	  
labour	  is	  required	  to	  elucidate	  the	  underlying	  mechanisms	  involved	  in	  the	  initiation	  of	  
partition	  and	  to	  identify	  novel	  targets	  for	  the	  treatment	  of	  preterm	  labour.	  	  
	  
	  
6.4 NOVEL	   TREATMENT	   OPTIONS	   FOR	   PRETERM	   LABOUR:	   WILL	   ANTI-­‐INFLAMMATORY	  
DRUGS	  BE	  THE	  ANSWER?	  	  
Despite	   considerable	   research,	   preterm	   birth	   remains	   the	   single	   biggest	   cause	   of	  
neonatal	  mortality	  worldwide.	   	  The	  currently	  available	   treatment	  options	  are	   limited,	  
and	  although	  some	  can	  be	  effective	  at	  delaying	  labour	  for	  a	  short	  period,	  there	  is	  little	  
evidence	  that	  these	  treatments	  result	  in	  an	  improved	  outcome	  for	  the	  baby.	  	  Therefore,	  
the	  search	  continues	  for	  novel,	  more	  effective	  treatment	  options.	  	  A	  poor	  understanding	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of	   the	   underlying	   causes	   of	   preterm	   labour	   has	   hindered	   the	   development	   of	   novel	  
treatments,	   as	   without	   fully	   understanding	   why	   labour	   is	   initiated	   prematurely	   it	   is	  
impossible	   to	   prevent.	   	   However,	   the	   identification	   of	   intrauterine	   infection	   and/or	  
inflammation	   as	   important	   causative	   factors	   in	   many	   cases	   has	   led	   researchers	   to	  
investigate	  whether	   targeting	   inflammatory	  signalling	  pathways	  may	  be	  a	  useful	  new	  
option.	  	  	  
Most	  current	  treatments	   focus	  on	  blocking	  the	  clinical	  signs	  of	   labour,	   i.e.	  myometrial	  
contractions,	   when	   they	   are	   already	   underway.	   	   Given	   that	   it	   now	   seems	   clear	   that	  
myometrial	  contractions,	  along	  with	  fetal	  membrane	  rupture	  and	  cervical	  ripening,	  are	  
strongly	   driven	   by	   an	   inflammatory	   signalling	   cascade,	   there	   is	   growing	   interest	   in	  
using	   anti-­‐inflammatory	   treatments.	   	   	   This	   interest	   in	   anti-­‐inflammatory	   agents	   is	  
driven	  by	  the	  hypothesis	  that	  targeting	  this	  inflammatory	  cascade	  earlier,	  prior	  to	  the	  
onset	  of	  contractions,	  may	  prove	  to	  be	  more	  effective,	  as	  it	  could	  halt	  the	  inflammatory	  
cascade	  before	  it	  has	  progressed	  too	  far.	  	  	  
An	   important	   consideration	   in	   the	   search	   for	   novel	   treatment	   options	   for	   preterm	  
labour	  is	  that	  the	  primary	  goal	  must	  be	  to	  improve	  neonatal	  outcome	  and	  not	  merely	  to	  
stop	  preterm	  delivery.	  	  For	  example,	  in	  the	  context	  of	  intrauterine	  infection,	  premature	  
delivery	  may	   remove	   the	   baby	   from	   a	   potentially	   harmful	   in	  utero	  environment,	   and	  
delaying	  this	  delivery	  could	  in	  fact	  worsen	  the	  outcome	  for	  the	  baby.	  	  However,	  another	  
potential	  advantage	  of	  using	  anti-­‐inflammatory	  treatments	  is	  the	  hope	  that	  some	  anti-­‐
inflammatory	   mediators	   that	   play	   important	   roles	   in	   driving	   the	   resolution	   of	  
inflammation,	   such	   as	   lipoxins,	   may	   be	   able	   to	   resolve	   the	   inflammatory	   in	   utero	  
environment,	  thus	  protecting	  the	  fetus	  from	  the	  adverse	  consequences	  associated	  with	  
intrauterine	  infection	  and/or	  inflammation.	  	  Indeed,	  although	  the	  work	  presented	  here	  
is	   still	   at	   an	   early	   stage,	   it	   is	   encouraging	   to	   note	   that	   treatment	  with	   epi-­‐lipoxin	  did	  
improve	  the	  survival	  of	  prematurely	  born	  pups	  in	  our	  mouse	  model.	  	  	  
Theoretically,	  the	  use	  of	  anti-­‐inflammatory	  treatments	  during	  pregnancy	  could	  result	  in	  
suppression	   of	   both	   maternal	   and	   fetal	   immune	   responses,	   which	   could	   result	   in	  
increased	  susceptibility	  to	  infection.	  	  Whether	  this	  is	  a	  real	  concern	  would	  need	  further	  
investigation,	  and	  could	  perhaps	  be	  limited	  by	  keeping	  the	  period	  of	  administration	  of	  
the	  anti-­‐inflammatory	  agent	  to	  a	  minimum.	  	  Another	  potential	  concern	  surrounding	  the	  
use	   of	   anti-­‐inflammatory	   drugs	   is	   that	  many	   of	   these	   pro-­‐inflammatory	   factors	   have	  
important	  roles	  outwith	  their	  role	  in	  the	  inflammatory	  cascade	  associated	  with	  labour,	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for	  example	  NF-­‐κB	  is	  a	  transcription	  factor	  for	  a	  large	  number	  of	  genes,	  not	  just	  those	  
involved	   in	   parturition,	   therefore	   blocking	   this	   signalling	   pathway	   may	   have	  
deleterious	   effects	   which	   would	   need	   to	   be	   investigated.	   	   Additionally,	   as	   with	   any	  
drugs	  given	  during	  pregnancy,	  extensive	  research	  would	  be	  required	  to	  investigate	  any	  
adverse	  effects	  on	  the	  fetus.	  	  	  
As	   research	   leads	   to	   a	   greater	   understanding	   of	   the	   underlying	   mechanisms	  
responsible	   for	   initiating	   the	   events	   surrounding	   the	   onset	   of	   parturition,	   more	  
potential	   targets	   will	   be	   identified;	   however,	   given	   the	   considerable	   evidence	   that	  
inflammation	  plays	  an	  integral	  role	  in	  the	  onset	  of	  parturition,	  it	  seems	  clear	  that	  anti-­‐
inflammatory	   agents	   have	   the	   potential	   to	   be	   an	   exciting	   novel	   therapeutic	   option	   in	  
the	  treatment	  of	  preterm	  birth.	  	  Although	  still	  at	  an	  early	  stage,	  there	  is	  now	  promising	  
in	  vivo	  and	  in	  vitro	  data	  that	  demonstrate	  the	  potential	  of	  anti-­‐inflammatory	  treatments.	  	  
The	   possibility	   of	   a	   combination	   therapy	   approach	   may	   hold	   promise	   in	   the	   future,	  
where	   agents	   such	   as	   lipoxin	  may	  prove	  beneficial	   as	   an	   adjuvant	   to	   classic	   tocolytic	  
therapy	   or	   progesterone	   treatment.	   	   The	   heterogeneous	   nature	   of	   preterm	   labour	  
means	  that	  it	  is	  both	  unlikely	  and	  unrealistic	  to	  believe	  that	  one	  treatment	  option	  will	  
be	   effective	   in	   all	   women,	   and	   whether	   anti-­‐inflammatory	   agents	   will	   ultimately	  
improve	   neonatal	   outcome	   remains	   to	   be	   elucidated	   at	   present.	   	   However,	   while	  
preterm	   birth	   remains	   the	   leading	   cause	   of	   neonatal	   mortality	   and	   morbidity	  
worldwide,	   claiming	   the	   lives	  of	  more	   than	  one	  million	  children	  each	  year,	   continued	  




The	  work	  presented	   in	   this	   thesis	   has	   demonstrated	   that	   in	   response	   to	   intrauterine	  
LPS,	  as	  a	  surrogate	  model	  of	  infection,	  a	  robust	  inflammatory	  and	  immune	  response	  is	  
mounted	  in	  the	  utero-­‐placental	  tissues,	  involving	  the	  increased	  production	  of	  a	  number	  
of	   inflammatory	   mediators	   and	   neutrophil	   influx	   into	   the	   decidua,	   which	   ultimately	  
results	   in	  preterm	  delivery.	   	  The	  role	   immune	  cells	  play	   in	   the	   induction	  of	   infection-­‐
induced	  preterm	  labour	  remains	  unclear,	  as	  depletion	  of	  neutrophils	  and	  macrophages	  
was	   not	   found	   to	   attenuate	   LPS-­‐induced	   preterm	   delivery.	   	   Although	   the	   anti-­‐
inflammatory	   agents	   investigated	   here	   did	   not	   delay	   LPS-­‐induced	   preterm	   delivery,	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epi-­‐lipoxin	   treatment	   did	   significantly	   improve	   pup	   survival	   in	   pups	   born	   preterm,	  
suggesting	   it	   could	   be	   useful	   in	   protecting	   the	   fetus	   from	   the	   adverse	   effects	   of	  
infection-­‐induced	  preterm	  labour.	  	  Using	  animal	  models,	  such	  as	  the	  one	  described	  here,	  
are	  vital	  to	  improving	  our	  understanding	  of	  the	  underlying	  mechanisms	  involved	  in	  the	  
induction	   of	   preterm	   labour	   and	   are	   useful	   models	   with	   which	   to	   investigate	   the	  
potential	  of	  novel	  therapeutic	   interventions.	   	   	  Collectively,	  these	  data	  confirm	  that	  the	  
presence	  of	  an	  intrauterine	  infection	  is	  associated	  with	  a	  robust	  inflammatory	  response	  
in	  the	  intrauterine	  tissues	  and	  suggest	  that	  anti-­‐inflammatory	  agents,	  such	  as	  lipoxins,	  
warrant	   further	  research	  as	  potentially	  promising	  new	  treatment	  options	  for	  preterm	  
labour.	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Appendix	  1	  -­‐	  Materials	  
MOUSE	  SURGERY	  AND	  TISSUE	  COLLECTION	   SOURCE	  





Sigma-­‐Aldrich,	  Poole,	  Dorset,	  UK	  
LPS	  (E.	  Coli	  0111:B4)	   Sigma-­‐Aldrich,	  Poole,	  Dorset,	  UK	  
	  
PBS	   Gibco,	  Life	  Technologies	  Ltd,	  Paisley,	  UK	  
	  
Mersilk	   Black	   5/0	   12mm	   3/8	   circle	  
reverse	  cutting	  needle	  sutures	  
MidMeds	  Ltd,	  Waltham	  Abbey,	  UK	  
Coated	  Vicryl	  Violet	  4/0	  16mm	  3/8	  circle	  
cutting	  needle	  sutures	  
MidMeds	  Ltd,	  Waltham	  Abbey,	  UK	  
Vetergesic	  Multidose	   Alstoe	  Ltd,	  York,	  UK	  
	  
Digital	  video	  recorder	   AVerMedia	  Technologies	  Inc,	  UK	  
	  
Mini	  Color	  IR	  Camera	  (SKC160IR)	   Sunkwang	  Electronics	  Co.,	  Ltd	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MOUSE	  SURGERY	  TREATMENTS	   SOURCE	  
15-­‐epi-­‐lipoxin	   A4	  [5(S),6(R),15(R)-­‐Lipoxin	  
A4]	  
	  
Cayman	   Chemical,	   Ann	   Arbor	   Michigan,	  
US	  
BML-­‐111	   [5(S),6(R)-­‐7-­‐trihydroxymethyl	  
Heptanoate]	  
	  
Cayman	   Chemical,	   Ann	   Arbor	   Michigan,	  
US	  
Recombinant	  Murine	  IL-­‐10	  
	  
Peprotech	  EC	  Ltd,	  London,	  UK	  
Rat	   anti-­‐mouse	   F4/80	   antigen	   purified	  
antibody	  (Clone	  BM8)	  
	  
eBioscience	  Ltd,	  Hatfield,	  UK	  
Rat	   IgG2a	   K	   Isotype	   Control	   Purified	  
antibody	  
	  
eBioscience	  Ltd,	  Hatfield,	  UK	  
Mouse	   Gr-­‐1/Ly-­‐6G	   Antibody	   (Clone	   RB6-­‐
8C5)	  
	  
R&D	  Systems,	  Abingdon,	  UK	  
Rat	  IgG2B	  Isotype	  Control	  	  antibody	  
	  
R&D	  Systems,	  Abingdon,	  UK	  
Ultra-­‐LEAF™	   Purified	   anti-­‐mouse	   Ly-­‐6G	  
(Clone	  1A8)	  
	  
BioLegend,	  Cambridge,	  UK	  
Ultra-­‐LEAF™	  Purified	  Rat	  IgG2a	  K	  Isotype	  
Control	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Sigma-­‐Aldrich,	  Poole,	  Dorset,	  UK	  
QIAzol	  Lysis	  Reagent	  
	  
Qiagen,	  Crawley,	  West	  Sussex,	  UK	  
1-­‐Bromo-­‐3-­‐chloropropane	  (BCP)	  
	  
Sigma-­‐Aldrich,	  Poole,	  Dorset,	  UK	  
RNeasy	  mini	  spin	  columns	  
	  
Qiagen,	  Crawley,	  West	  Sussex,	  UK	  
DNase	  1	  
	  
Qiagen,	  Crawley,	  West	  Sussex,	  UK	  
High	   Capacity	   cDNA	   Reverse	  
Transcription	  Kit	  
	  
Applied	   Biosystems,	   Life	   Technologies	  
Ltd,	  Paisley,	  UK	  
Taqman	  gene	  expression	  assays	   Applied	   Biosystems,	   Life	   Technologies	  
Ltd,	  Paisley,	  UK	  
β-­‐actin,	  Cox-­‐2	  and	  Il-­‐6	  probes	  
	  
Integrated	  DNA	  Technologies,	  Iowa,	  USA	  
2X	  Taqman	  mastermix	   Applied	   Biosystems,	   Life	   Technologies	  












	   	   	   	  




Quantikine	  mouse	  TNF-­‐α	  ELISA	  kit	  
	  
R&D	  Systems,	  Abingdon,	  UK	  
Quantikine	  mouse	  IL-­‐1β	  ELISA	  kit	  
	  
R&D	  Systems,	  Abingdon,	  UK	  
Quantikine	  mouse	  IL-­‐6	  ELISA	  kit	  
	  
R&D	  Systems,	  Abingdon,	  UK	  
Quantikine	  mouse	  IL-­‐10	  ELISA	  kit	   R&D	  Systems,	  Abingdon,	  UK	  





IMMUNOHISTOCHEMISTRY	   SOURCE	  
Trypsin	  (from	  bovine	  pancreas)	   Sigma-­‐Aldrich,	  Poole,	  Dorset,	  UK	  
	  
Mouse	   Gr-­‐1/Ly-­‐6G	   Antibody	   (Clone	   RB6-­‐
8C5)	  
	  
R&D	  Systems,	  Abingdon,	  UK	  
Rat	   anti-­‐mouse	   F4/80	   antigen	   purified	  
antibody	  (Clone	  BM8)	  
	  
eBioscience	  Ltd,	  Hatfield,	  UK	  
Purified	  anti-­‐mouse	  Ly-­‐6G	  (Clone	  1A8)	   BioLegend,	  Cambridge,	  UK	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WESTERN	  BLOTTING	   SOURCE	  
Bio-­‐Rad	  DC	  Protein	  Assay	   Bio-­‐Rad	   Laboratories	   Ltd,	   Hertfordshire,	  
UK	  
See	  Blue®	  Plus	  2	  Pre-­‐Stained	  Standard	   Invitrogen,	   Life	  Technologies	   Ltd,	   Paisley,	  
UK	  
NuPAGE	   Novex	   4%-­‐12%	   Bis-­‐Tris	   Mini	  
Gels	  
Invitrogen,	   Life	  Technologies	   Ltd,	   Paisley,	  
UK	  
MES	  running	  buffer	   Invitrogen,	   Life	  Technologies	   Ltd,	   Paisley,	  
UK	  
Dried	  skimmed	  milk	  powder	   Marvel,	  UK	  
Bovine	  Serum	  Albumin	   Sigma-­‐Aldrich,	  Poole,	  Dorset,	  UK	  
ECL	  Western	  Blot	  Analysis	  System	  	  
	  
GE	  Healthcare,	  Buckinghamshire,	  UK	  
Rabbit	  polyclonal	  anti-­‐TNF-­‐α	  antibody	   Cell	   Signaling	   Technology	   Inc.,	   Danvers,	  
MA,	  USA	  
Rabbit	  polyclonal	  anti-­‐β-­‐Tubulin	  antibody	   Cell	   Signaling	   Technology	   Inc.,	   Danvers,	  
MA,	  USA	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FLOW	  CYTOMETRY	   SOURCE	  
PE-­‐labelled	  rat	  anti-­‐mouse	  CD45	  antibody	   BioLegend,	  Cambridge,	  UK	  
Pacific	  Blue-­‐labelled	  rat	  anti-­‐mouse	  Ly-­‐6G	  
antibody	  
	  
BioLegend,	  Cambridge,	  UK	  
BD	  FACSLyse	  solution	   BD	  Biosciences,	  Oxford,	  UK	  
Flow-­‐check	  Fluorospheres	  	   Beckman	  Coulter,	  California,	  UK	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Appendix	  2	  –	  Publications	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